Aaron, AM, 735(ab), 835(ab)
Aaronson, RA, 766(ab)
Aarsvold, JN, 632
Abbey, SE, 936(ab)
Abbott, J, 752(ab)
Abdel-Dayem, HM, 761(ab), 825(ab), 830(ab), 834(ab), 911(ab), 914(ab), 940(ab), 945(ab)
Abdel-Nabi, H, 887(ab), 1436(le)
Abdel-Nabi, HH, 1975
Abe, M, 844(ab)
Abe, T, 881(ab)
Abeysekera, BF, 385(le)
Abide, MT, 836(ab)
Abraham, SA, 225, 1116
Abrams, M, 819(ab)
Abrams, MJ, 776(ab), 2022
Abrams, P, 725(ab), 777(ab)
Abrass, IB, 838(ab)
Aburano, T, 766(ab), 814(ab), 851(ab), 889(ab)
Abu-Zaidan, F, 761(ab)
Acharya, SA, 904(ab)
Acito, P, 743(ab)
Ackermann, RF, 835(ab)
Ackermann, RJ, 61
Adam, MJ, 737(ab), 796(ab)
Adam, W-E, 772(ab), 821(ab), 1856, 1940
Adams, BK, 106
Adams, GP, 754(ab), 755(ab), 788(ab), 823(ab)
Adams, HR, 720(ab)
Adams, R, 1723
Adatepe, MH, 731(ab)
Addison, SJ, 1257
Adelstein, SJ, 766(ab), 1358
Adiseshan, P, 753(ab)
Adler, LP, 756(ab), 884(ab)
Adler, S, 610
Adnot, S, 726(ab)
Adriaens, P, 908(ab)
Afriyie, M, 761(ab)
Aftab, N, 754(ab)
Agostini, D, 726(ab)
Ahlem, CN, 911(ab)
Ahmad, M, 834(ab)
Aicher, KP, 717(ab)
Aikens, LM, 892(ab)
Ain, K, 935(ab)
Aitken, S, 804(ab), 938(ab)
Ajani, J, 803(ab), 937(ab)
Akers, MS, 753(ab), 824(ab), 838(ab), 859(ab)
Akhtar, R, 827(ab)
Akre, CM, 519
Aksut, S, 723(ab)
Akuta, K, 844(ab)
Al-Ali, K, 825(ab)
Al-Aouar, ZR, 801(ab)
Al-Atwi, Z, 857(ab)
Alauddin, MM, 906(ab)
Alavi, A, 4, 136, 360, 573, 648, 708(ab), 727(ab), 730(ab), 731(ab), 741(ab), 751(ab), 771(ab), 782(ab), 809(ab), 822(ab), 844(ab), 845(ab), 848(ab), 849(ab), 853(ab), 876(ab), 883(ab), 890(ab), 892(ab), 1206, 1364, 1635, 1669, 1839, 2029
Alavi, JB, 360
Alazraki, N, 732(ab), 837(ab), 1240
Alazraki, NP, N26A(9), N26A(12), 1955
Alderson, PO, 46, 343, 805(ab), 830(ab), 906(ab)
Alexander, E, 826(ab)
Alexopoulos, D, 764(ab)
Alfano, B, 838(ab)
Alfred, JF, 900(ab), 906(ab)
Al-Hasani, S, 910(ab)
Ali, A, 813(ab)
Al-Kaisi, NL, 756(ab)
Allen, HC, Jr, 784(ab)
Allen, L, 850(ab)
Allison, DJ, 1980
Allwright, SJ, 893(ab)
Al-Mohanadi, S, 825(ab)
Al-Mohannadi, S, 830(ab)
Alonso, C, 1450, 1965
Alpert, NM, 1717
Al-Suhaili, AR, 830(ab)
Al-Tikriti, M, 779(ab), 883(ab)
Alvarez, V, 757(ab)
Alves, W, 741(ab), 771(ab), 876(ab)
Alves, WM, 853(ab)
Amartey, JK, 947(ab)
Amassian, V, 761(ab)
Ambrose, KR, 896(ab)
Amin, A, 754(ab)
Amir, D, 2011
Anderson, DJ, 722(ab)
Anderson, GH, Jr, 501
Anderson, JH, 274, 940(ab), 1627, 1958
Anderson, LD, 757(ab), 911(ab)
Anderson, SK, 1316
Anderson, T, 853(ab)
Anderson-Berg, WT, 824(ab)
Andreason, P, 887(ab)
Andriole, DP, 746(ab)
Anema, P, 782(ab)
Annese, ML, 793(ab)
Anno, H, 55
Ansari, A, 735(ab), 853(ab)
Ansari, M, 809(ab)
Ansari, MS, 779(ab), 786(ab), 882(ab)
Anson, CP, 728(ab), 863(ab)
Antar, MA, 890(ab), 1608
Antico, V. F., 793(ab)
Antman, KH, 794(ab)
Antuono, PG, 731(ab)
Anzai, Y, 877(ab)
Anzawa, Y, 543
Aoki, E, 1015
Apicella, A, 826(ab)
Appelbaum, FR, 724(ab), 755(ab), 1257, 1384
Appelbaum, J, 725(ab)
Applebaum, D, 818(ab)
Applegate, CN, 710(ab)
Araki, Y, 743(ab)
Araujo, LI, 736(ab), 737(ab), 778(ab)
Areeda, J, 828(ab), 1168
Argenyi, EE, 753(ab)
Arger, P, 731(ab)
Arimizu, N, 888(ab)
Armstrong, PW, 874(ab)
Armstrong, R, 906(ab)
Arnett, CD, 541
Arnold, B, 856(ab)
Aronen, HJ, 23
Aronin, N, 740(ab)
Aronson, F, 722(ab), 761(ab)
Arrington, ER, 890(ab), 679, 1099
Arsenault, A, 714(ab), 729(ab), 758(ab)
Arvieux, CC, 640
Asayama, H, 944(ab)
Ascoli, DM, 387
Ash, J, 580
Ashburn, WL, 1862
Atkner, RW, 788(ab), 1378, 1527
Atkins, FB, 855(ab)
Atkins, HL, 378
Attie, JN, 935(ab)
Augustine, SC, 741(ab)
Aulet, M, 791(ab)
Austin, M, 711(ab)
Avigad, I, 790(ab)
Awdeh, M, 940(ab), 945(ab)
Axworthy, D, 747(ab), 823(ab), 852(ab)
Azar, HA, 938(ab)
Azimizu, N, 877(ab)
Azuma, M, 813(ab)

Baas, EJ, 791(ab)
Babich, JW, 777(ab), 948(ab), 1307
Bacharach, S, 864(ab)
Bacharach, SL, 38, 736(ab), 753(ab), 777(ab), 875(ab)
Bacher, JD, 791(ab)
Badger, C, 1384
Badger, CC, 724(ab), 1257
Bahar, R, 864(ab)
Bahar, RH, 761(ab), 830(ab), 914(ab)
Baidoo, KE, 806(ab)
Bailey, R, 891(ab)
Baird, F, 715(ab)
Baker, J, 985
Baker, KL, 879(ab)
Baker, MA, 853(ab)
Baker, RJ, 1568
Baker, T, 850(ab)
Baker, TD, 852(ab)
Bakir, MA, 777(ab)
Bakker, AJ, 831(ab)
Bakker, WH, 1501
Bal, C, 1180
Balasubramanian, PN, 757(ab)
Baldwin, RM, 885(ab)
Balieu, JL, 1253(le)
Ball, ME, 1723
Ballard, JG, 866(ab)
Ballinger, J, 1892(le)
Ballinger, JR, 938(ab), 118, 1114
Balter, J, 872(ab)
Bamrah, VS, 827(ab)
Ban, T, 743(ab), 1617
Bandyopandyay, D, 890(ab)
Bangerl, I, 1007
Bannister, KM, 1568
Bannochie, CJ, 1662
Baranczuk, RA, 937(ab)
Baranczuk, RJ, 947(ab)
Baranowska-Kortylewicz, J, 766(ab), 1358
Barbagallo, S, 985
Barbaro, NM, 880(ab)
Barbet, J, 757(ab)
Bares, R, 734(ab), 751(ab)
Barest, G, 1884
Bargwanna, KA, 168
Barker, C, 935(ab)
Barker, W, 730(ab), 817(ab), 826(ab)
Barnes, D, 933(ab), 935(ab)
Barnett, A, 737(ab)
Barnhart, A. J., 910(ab), 914(ab)
Baron, D, 805(ab)
Baron, JC, 880(ab)
Barozzi, L, 913(ab)
Barrett, HH, 632, 719(ab), 769(ab), 1688
Barrett, JS, 850(ab)
Barrio, JR, 708(ab), 709(ab), 720(ab), 778(ab), 780(ab), 865(ab)
Barron, BJ, 234
Barsamian, M, 761(ab)
Bartenstein, P, 711(ab)
Bartlett, A, 728(ab)
Bartlett, JM, 946(ab)
Barton, NW, 781(ab)
Baschieri, I, 1766
Bash, S, 844(ab)
Basmadjian, GP, 727(ab), 899(ab), 908(ab)
Basmadjian, NP, 899(ab)
Bassa, P, 127(le)
Bassano, DA, 875(ab)
Bassingthwaighte, JB, 99, 909(ab)
Batchelor, JR, 851(ab)
Bateman, TM, 836(ab), 843(ab)
Battesti, JP, 839(ab)
Bauer, M, 827(ab)
Baulieu, JL, 796(ab)
Baum, R, 811(ab)
Baumeier, M, 761(ab)
Bauwens, J, 762(ab)
Bavaria, G, 839(ab)
Baxter, KG, 931(ab), 932(ab), 937(ab), 938(ab), 945(ab)
Baxter, LR, 740(ab)
Beachler, A, 722(ab)
Beatty, BG, 764(ab), 850(ab)
Beatty, JD, 764(ab), 850(ab)
Beaumier, P, 823(ab)
Beaumier, PL, 765(ab)
Beck, RN, 728(ab)
Becker, CJ, 893(ab)
Becker, D, 799(ab)
Becker, DP, 825(ab), 965
Becker, DV, 393, 784(ab)
Becker, LC, 1069, 1230
Becker, W, 758(ab)
Beckers, C, 816(ab), 847(ab)
Beckett, M, 788(ab)
Bednarczyk, E, 884(ab)
Beer, H-F, 1007
Beerbohm, D, 848(ab), 849(ab)
Beeridge, MS, 884(ab)
Behrenbeck, T, 1269
Beierwaltes, WH, 400
Beihn, B, 846(ab)
Beil, D, 789(ab)
Belisle, EH, 724(ab)
Bellani, N, 911(ab)
Bellen, JC, 1568
Beller, GA, 713(ab), 763(ab), 784(ab), 827(ab), 842(ab)
Bellil, D, 934(ab)
Bellina, CR, 1335
Bellinger, RL, 827(ab)
Bellon, EM, 931(ab)
Belloni, C, 735(ab)
Belvedere, DA, 733(ab)
Bencivelli, W, 934(ab)
Bendriem, B, 610, 719(ab), 762(ab), 780(ab), 864(ab), 866(ab)
Bengtsson, S, 902(ab)
Ben-Haim, S, 365, 1784
Ben-Harush, M, 1945
Benjamin, C, 821(ab)
Benvenuti, C, 726(ab)
Beppu, Y, 889(ab)
Ber, R, 1784
Berardi, A, 879(ab)
Berg, GW, 750(ab), 879(ab)
Berg, L, 730(ab)
Berger, H, 713(ab), 776(ab), 782(ab), 804(ab), 805(ab)

Page numbers followed by (ab) indicate abstracts.
Page numbers followed by (le) indicate letters.
N preceding a page number indicates an article appearing in *Newsline*.

Aaron, AM, 735(ab), 835(ab)
Aaronson, RA, 766(ab)
Aarsvold, JN, 632
Abbey, SE, 936(ab)
Abbott, J, 752(ab)
Abdel-Dayem, HM, 761(ab), 825(ab), 830(ab), 834(ab), 911(ab), 914(ab), 940(ab), 945(ab)
Abdel-Nabi, H, 887(ab), 1436(le)
Abdel-Nabi, HH, 1975
Abe, M, 844(ab)
Abe, T, 881(ab)
Abeysekera, BF, 385(le)
Abide, MT, 836(ab)
Abraham, SA, 225, 1116
Abrams, M, 819(ab)
Abrams, MJ, 776(ab), 2022
Abrams, P, 725(ab), 777(ab)
Abrass, IB, 838(ab)
Aburano, T, 766(ab), 814(ab), 851(ab), 889(ab)
Abu-Zaidan, F, 761(ab)
Acharya, SA, 904(ab)
Acito, P, 743(ab)
Ackermann, RF, 835(ab)
Ackermann, RJ, 61
Adam, MJ, 737(ab), 796(ab)
Adam, W-E, 772(ab), 821(ab), 1856, 1940
Adams, BK, 106
Adams, GP, 754(ab), 755(ab), 788(ab), 823(ab)
Adams, HR, 720(ab)
Adams, R, 1723
Adatepe, MH, 731(ab)
Addison, SJ, 1257
Adelstein, SJ, 766(ab), 1358
Adiseshan, P, 753(ab)
Adler, LP, 756(ab), 884(ab)
Adler, S, 610
Adnot, S, 726(ab)
Adriaens, P, 908(ab)
Afriyie, M, 761(ab)
Aftab, N, 754(ab)
Agostini, D, 726(ab)
Ahlem, CN, 911(ab)
Ahmad, M, 834(ab)
Aicher, KP, 717(ab)
Aikens, LM, 892(ab)
Ain, K, 935(ab)
Aitken, S, 804(ab), 938(ab)
Ajani, J, 803(ab), 937(ab)
Akers, MS, 753(ab), 824(ab), 838(ab), 859(ab)
Akhtar, R, 827(ab)
Akre, CM, 519
Aksut, S, 723(ab)
Akuta, K, 844(ab)
Al-Ali, K, 825(ab)
Al-Aouar, ZR, 801(ab)
Al-Atwi, Z, 857(ab)
Alauddin, MM, 906(ab)
Alavi, A, 4, 136, 360, 573, 648, 708(ab), 727(ab), 730(ab), 731(ab), 741(ab), 751(ab), 771(ab), 782(ab), 809(ab), 822(ab), 844(ab), 845(ab), 848(ab), 849(ab), 853(ab), 876(ab), 883(ab), 890(ab), 892(ab), 1206, 1364, 1635, 1669, 1839, 2029
Alavi, JB, 360
Alazraki, N, 732(ab), 837(ab), 1240
Alazraki, NP, N26A(9), N26A(12), 1955
Alderson, PO, 46, 343, 805(ab), 830(ab), 906(ab)
Alexander, E, 826(ab)
Alexopoulos, D, 764(ab)
Alfano, B, 838(ab)
Alfred, JF, 900(ab), 906(ab)
Al-Hasani, S, 910(ab)
Ali, A, 813(ab)
Al-Kaisi, NL, 756(ab)
Allen, HC, Jr, 784(ab)
Allen, L, 850(ab)
Allison, DJ, 1980
Allwright, SJ, 893(ab)
Al-Mohanadi, S, 825(ab)
Al-Mohannadi, S, 830(ab)
Alonso, C, 1450, 1965
Alpert, NM, 1717
Al-Suhaili, AR, 830(ab)
Al-Tikriti, M, 779(ab), 883(ab)
Alvarez, V, 757(ab)
Alves, W, 741(ab), 771(ab), 876(ab)
Alves, WM, 853(ab)
Amartey, JK, 947(ab)
Amassian, V, 761(ab)
Ambrose, KR, 896(ab)
Amin, A, 754(ab)
Amir, D, 2011
Anderson, DJ, 722(ab)
Anderson, GH, Jr, 501
Anderson, JH, 274, 940(ab), 1627, 1958
Anderson, LD, 757(ab), 911(ab)
Anderson, SK, 1316
Anderson, T, 853(ab)
Anderson-Berg, WT, 824(ab)
Andreason, P, 887(ab)
Andriole, DP, 746(ab)
Anema, P, 782(ab)
Annese, ML, 793(ab)
Anno, H, 55
Ansari, A, 735(ab), 853(ab)
Ansari, M, 809(ab)
Ansari, MS, 779(ab), 786(ab), 882(ab)
Anson, CP, 728(ab), 863(ab)
Antar, MA, 890(ab), 1608
Antico, V. F., 793(ab)
Antman, KH, 794(ab)
Antuono, PG, 731(ab)
Anzai, Y, 877(ab)
Anzawa, Y, 543
Aoki, E, 1015
Apicella, A, 826(ab)
Appelbaum, FR, 724(ab), 755(ab), 1257, 1384
Appelbaum, J, 725(ab)
Applebaum, D, 818(ab)
Applegate, CN, 710(ab)
Araki, Y, 743(ab)
Araujo, LI, 736(ab), 737(ab), 778(ab)
Areeda, J, 828(ab), 1168
Argenyi, EE, 753(ab)
Arger, P, 731(ab)
Arimizu, N, 888(ab)
Armstrong, PW, 874(ab)
Armstrong, R, 906(ab)
Arnett, CD, 541
Arnold, B, 856(ab)
Aronen, HJ, 23
Aronin, N, 740(ab)
Aronson, F, 722(ab), 761(ab)
Arrington, ER, 890(ab), 679, 1099
Arsenault, A, 714(ab), 729(ab), 758(ab)
Arvieux, CC, 640
Asayama, H, 944(ab)
Ascoli, DM, 387
Ash, J, 580
Ashburn, WL, 1862
Atkner, RW, 788(ab), 1378, 1527
Atkins, FB, 855(ab)
Atkins, HL, 378
Attie, JN, 935(ab)
Augustine, SC, 741(ab)
Aulet, M, 791(ab)
Austin, M, 711(ab)
Avigad, I, 790(ab)
Awdeh, M, 940(ab), 945(ab)
Axworthy, D, 747(ab), 823(ab), 852(ab)
Azar, HA, 938(ab)
Azimizu, N, 877(ab)
Azuma, M, 813(ab)

Baas, EJ, 791(ab)
Babich, JW, 777(ab), 948(ab), 1307
Bacharach, S, 864(ab)
Bacharach, SL, 38, 736(ab), 753(ab), 777(ab), 875(ab)
Bacher, JD, 791(ab)
Badger, C, 1384
Badger, CC, 724(ab), 1257
Bahar, R, 864(ab)
Bahar, RH, 761(ab), 830(ab), 914(ab)
Baidoo, KE, 806(ab)
Bailey, R, 891(ab)
Baird, F, 715(ab)
Baker, J, 985
Baker, KL, 879(ab)
Baker, MA, 853(ab)
Baker, RJ, 1568
Baker, T, 850(ab)
Baker, TD, 852(ab)
Bakir, MA, 777(ab)
Bakker, AJ, 831(ab)
Bakker, WH, 1501
Bal, C, 1180
Balasubramanian, PN, 757(ab)
Baldwin, RM, 885(ab)
Balieu, JL, 1253(le)
Ball, ME, 1723
Ballard, JG, 866(ab)
Ballinger, J, 1892(le)
Ballinger, JR, 938(ab), 118, 1114
Balter, J, 872(ab)
Bamrah, VS, 827(ab)
Ban, T, 743(ab), 1617
Bandyopandyay, D, 890(ab)
Bangerl, I, 1007
Bannister, KM, 1568
Bannochie, CJ, 1662
Baranczuk, RA, 937(ab)
Baranczuk, RJ, 947(ab)
Baranowska-Kortylewicz, J, 766(ab), 1358
Barbagallo, S, 985
Barbaro, NM, 880(ab)
Barbet, J, 757(ab)
Bares, R, 734(ab), 751(ab)
Barest, G, 1884
Bargwanna, KA, 168
Barker, C, 935(ab)
Barker, W, 730(ab), 817(ab), 826(ab)
Barnes, D, 933(ab), 935(ab)
Barnett, A, 737(ab)
Barnhart, A. J., 910(ab), 914(ab)
Baron, D, 805(ab)
Baron, JC, 880(ab)
Barozzi, L, 913(ab)
Barrett, HH, 632, 719(ab), 769(ab), 1688
Barrett, JS, 850(ab)
Barrio, JR, 708(ab), 709(ab), 720(ab), 778(ab), 780(ab), 865(ab)
Barron, BJ, 234
Barsamian, M, 761(ab)
Bartenstein, P, 711(ab)
Bartlett, A, 728(ab)
Bartlett, JM, 946(ab)
Barton, NW, 781(ab)
Baschieri, I, 1766
Bash, S, 844(ab)
Basmadjian, GP, 727(ab), 899(ab), 908(ab)
Basmadjian, NP, 899(ab)
Bassa, P, 127(le)
Bassano, DA, 875(ab)
Bassingthwaighte, JB, 99, 909(ab)
Batchelor, JR, 851(ab)
Bateman, TM, 836(ab), 843(ab)
Battesti, JP, 839(ab)
Bauer, M, 827(ab)
Baulieu, JL, 796(ab)
Baum, R, 811(ab)
Baumeier, M, 761(ab)
Bauwens, J, 762(ab)
Bavaria, G, 839(ab)
Baxter, KG, 931(ab), 932(ab), 937(ab), 938(ab), 945(ab)
Baxter, LR, 740(ab)
Beachler, A, 722(ab)
Beatty, BG, 764(ab), 850(ab)
Beatty, JD, 764(ab), 850(ab)
Beaumier, P, 823(ab)
Beaumier, PL, 765(ab)
Beck, RN, 728(ab)
Becker, CJ, 893(ab)
Becker, D, 799(ab)
Becker, DP, 825(ab), 965
Becker, DV, 393, 784(ab)
Becker, LC, 1069, 1230
Becker, W, 758(ab)
Beckers, C, 816(ab), 847(ab)
Beckett, M, 788(ab)
Bednarczyk, E, 884(ab)
Beer, H-F, 1007
Beerbohm, D, 848(ab), 849(ab)
Beeridge, MS, 884(ab)
Behrenbeck, T, 1269
Beierwaltes, WH, 400
Beihn, B, 846(ab)
Beil, D, 789(ab)
Belisle, EH, 724(ab)
Bellani, N, 911(ab)
Bellen, JC, 1568
Beller, GA, 713(ab), 763(ab), 784(ab), 827(ab), 842(ab)
Bellil, D, 934(ab)
Bellina, CR, 1335
Bellinger, RL, 827(ab)
Bellon, EM, 931(ab)
Belloni, C, 735(ab)
Belvedere, DA, 733(ab)
Bencivelli, W, 934(ab)
Bendriem, B, 610, 719(ab), 762(ab), 780(ab), 864(ab), 866(ab)
Bengtsson, S, 902(ab)
Ben-Haim, S, 365, 1784
Ben-Harush, M, 1945
Benjamin, C, 821(ab)
Benvenuti, C, 726(ab)
Beppu, Y, 889(ab)
Ber, R, 1784
Berardi, A, 879(ab)
Berg, GW, 750(ab), 879(ab)
Berg, L, 730(ab)
Berger, H, 713(ab), 776(ab), 782(ab), 804(ab), 805(ab)

Page numbers followed by (ab) indicate abstracts.
Page numbers followed by (le) indicate letters.
N preceding a page number indicates an article appearing in *Newsline*.

Berger, HJ, 795(ab), 805(ab), 833(ab)
Berger, JH, 805(ab)
Bergh, JR, 938(ab), 945(ab)
Bergin, JD, 713(ab), 784(ab)
Bergmann, SR, 713(ab), 773(ab), 794(ab), 815(ab), 841(ab), 1749, 1989, 2064
Berkovic, SF, 711(ab)
Berman, CG, 938(ab)
Berman, D, 713(ab), 744(ab), 804(ab), 805(ab), 812(ab), 828(ab), 832(ab), 836(ab), 894(ab), 934(ab)
Berman, DS, 812(ab), 1168
Berman, KF, 750(ab)
Berman, M, 948(ab)
Berná, L, 751(ab), 782(ab), 890(ab), 1450, 1965
Bernard, L, 785(ab)
Bernstein, I, 1384
Bernstein, ID, 724(ab), 1257
Bernstein, T, 536(le), 701(le), 719(ab)
Berridge, MS, 1727
Berry, JJ, 774(ab), 840(ab)
Berry, JM, 796(ab)
Bertrand, EA, 1048
Besnard, JC, 796(ab)
Besozzi, MC, 933(ab)
Besson, JAO, 1595
Best, T, 747(ab), 834(ab)
Betocchi, S, 838(ab)
Bettinardi, V, 741(ab), 748(ab), 871(ab)
Bettman, L, 1945
Beuthien-Baumann, B, 853(ab), 854(ab)
Bhadkamkar, V, 724(ab)
Bhargava, KK, 717(ab), 904(ab)
Bhatia, ML, 841(ab)
Biaglow, J, 853(ab)
Bialobzyski, PJ, 783(ab)
Bianchi, R, 876(ab)
Bianco, J, 778(ab)
Bianco, JA, 835(ab), 934(ab), 1115, 1384, 1431(le)
Bice, AN, 728(ab), 863(ab)
Bidaut, LM, 750(ab)
Biersack, F, 894(ab)
Biersack, HJ, 711(ab), 854(ab), 871(ab), 881(ab), 896(ab), 910(ab), 1740
Bigler, RE, 788(ab), 844(ab), 1884
Bigner, DD, 776(ab)
Bihl, H, 741(ab), 855(ab)
Bijvoet, OLM, 1774
Billadello, JJ, 187
Billinghurst, M, 903(ab)
Billings, J, 573, 648, 708(ab), 727(ab), 809(ab), 898(ab), 899(ab)
Billings, JJ, 1635
Bilodeau, L, 714(ab)
Bilsker, M, 934(ab)
Binney, G, 567
Bischof-Delaloye, A, 535(le), 1035
Bischoff, H, 766(ab), 771(ab), 939(ab)
Bishop, H, 933(ab)
Bishop, J, 737(ab)
Bisi, G, 821(ab)
Biskupiak, JE, 756(ab), 833(ab)
Bisunadan, MM, 768(ab)
Bitter, F, 1856
Biver, F, 750(ab)
Black, K, 799(ab)
Black, KL, 759(ab), 825(ab), 965
Black, PM, 766(ab)
Bladin, PF, 711(ab)
Blahd, WH, 881(ab), 1771
Blair, HF, 756(ab)
Blanco, R, 1450
Blasberg, R, 883(ab)
Blasberg, RG, 810(ab)
Bläuenstein, PA, 1007
Blaufox, MD, 716(ab), 717(ab), 913(ab)
Blazejewski, N, 904(ab), 905(ab)
Blend, M, 872(ab)
Blend, MJ, 1378
Blokland, JAK, 931(ab), 1774
Blomqvist, CP, 23
Blood, KMT, 887(ab)
Bloomfield, P, 943(ab)
Blower, PJ, 768(ab)
Blue, PW, 940(ab), 1211, 1627
Bluemlein, LE, 61
Blumenthal, RD, 788(ab)
Blumhardt, R, 785(ab), 806(ab)
Blystone, SL, 896(ab)
Bockisch, A, 711(ab), 854(ab), 871(ab), 910(ab), 1740
Bois-Svensson, I, 1811
Boja, JW, 720(ab)
Bol, A, 843(ab)
Bolman, RM, III, 1933
Bone, D, 1675, 1682
Bonetti, EP, 1007
Bongartz, G, 711(ab)
Boni, G, 876(ab)
Bonow, RO, 38, 736(ab), 753(ab), 777(ab)
Bonow, RO, 10
Bonte, FJ, 730(ab), 817(ab), 879(ab)
Boothe, T, 730(ab), 826(ab)
Borges-Neto, S, 820(ab), 1128
Bormans, G, 762(ab), 806(ab), 907(ab), 908(ab)
Boruchowsky, S, 790(ab)
Bosimini, E, 934(ab)
Bossuyt, A, 760(ab), 846(ab)
Botvinick, E, 752(ab), 764(ab), 812(ab), 872(ab)
Botvinick, EH, 143, 792(ab), 841(ab)
Boucher, CA, 10
Boudreau, RJ, 727(ab), 731(ab), 797(ab), 936(ab)
Bourgoignie, J, 715(ab)
Bourguignon, M, 34, 770(ab), 872(ab), 892(ab), 893(ab), 899(ab)
Bourguignon, MH, 726(ab), 875(ab), 1303
Boutin, R, 833(ab), 905(ab)
Bowsher, JE, 798(ab), 869(ab), 870(ab)
Boxen, I, 516
Boyages, J., 793(ab)
Boyers, AS, 735(ab), 808(ab), 835(ab), 870(ab)
Boysen, G, 818(ab)
Brachman, M, 721(ab)
Bradley, EW, 783(ab)
Bradley, J, 948(ab)
Bradshaw, JF, 1717
Brady, AJ, 1980
Brady, L, 849(ab)
Brady, P, 800(ab)
Brady, RO, 781(ab)
Brandau, W, 1285, 2075(le)
Brandenburg, S, 894(ab)
Brandt, J, 770(ab)
Branscheid, D, 771(ab), 939(ab)
Brar, HS, 248(le)
Braunstein, G, 744(ab)
Brechbiel, MW, 211, 824(ab), 1378, 1527
Brechner, RR, 178
Breeman, WA, 1501
Breen, SL, 2074(le)
Breitz, H, 725(ab)
Brennan, KM, 802(ab), 841(ab)
Brenner, J, 767(ab)
Bretagne, J-F, 1470
Brewer, LA, III, 594
Briandet, P, 1303
Brichon, P-Y, 640
Briele, B, 854(ab)
Brill, AB, 754(ab), 860(ab)
Bristow, D, 610
Brodack, JW, 746(ab), 910(ab)
Brodbeck, MR, 932(ab)
Brodie, J, 866(ab)
Brodie, JD, 780(ab)
Brodmerkel, GJ, 731(ab)
Broekhuizen, AH, 831(ab)
Broich, K, 1740
Brooks, K, 147
Brouillet, E, 897(ab)
Broussard, WF, 862(ab)
Brown, H, 1576(le)
Brown, J, 1980
Brown, KA, 1020
Brown, MB, 1220
Brown, ML, 292, 775(ab)
Brown, PA, 1384
Brown, SJ, 115
Brown, SL, 1257
Brownell, A-L, 764(ab)
Bruce, T, 763(ab), 836(ab)
Bruck, CE, 985
Brugge, W, 731(ab), 848(ab), 849(ab)
Bruhn, P, 818(ab)
Brunengraber, H, 1823
Bruning, PF, 1854
Brunken, RC, 773(ab), 774(ab), 840(ab), 842(ab)
Bruno, A, 839(ab)
Bruschke, AVG, 717(ab)
Brust, AS, 729(ab), 856(ab)
Bryan, RN, 816(ab)
Bryen, MJ, 106
Bubeck, B, 1285
Buchbinder, S, 90, 872(ab)
Buchegger, F, 1035
Buchsbaum, D, 852(ab)
Buchsbaum, DJ, 765(ab)
Buck, A, 777(ab), 785(ab)
Buckley, MJ, 905(ab)
Buddmeyer, U, 378
Budinger, TF, 628, 802(ab), 841(ab)
Buell, U, 734(ab)
Bugaj, J, 823(ab)
Büll, U, 751(ab)
Bunke, J, 302
Bunko, H, 792(ab)
Bunting, RW, 896(ab)
Buonocore, E, 933(ab)
Burch, L, 742(ab)
Burg, C, 1028
Burger, R, 894(ab)
Burgua, WD, 765(ab)
Burke, T, 724(ab)
Burkhardt, D, 809(ab)
Burkhardt, H, 1940
Burkholder, T, 822(ab)
Burman, KD, 52, 1958
Burn, PR, 736(ab), 831(ab)
Burnette, M, 774(ab)
Burnham, KM, 735(ab)
Burrows, L, 914(ab)
Burrows, TW, 948(ab)
Burt, RW, 936(ab)
Buscombe, JR, 811(ab), 830(ab)
Buse, MG, 1105
Bushe, H, 754(ab)
Bushnell, DL, 878(ab)
Bussy, E, 872(ab)
Busuttil, RW, 874(ab)
Butler, SP, 46, 243, 805(ab)
Buxton, DB, 713(ab), 795(ab)
Byar, A, 890(ab)
Byrd, BL, 824(ab), 849(ab), 904(ab)

Caillat-Vigneron, N, 839(ab)
Caillet, M, 796(ab)
Caldwell, JH, 99, 833(ab)
Callaghan, JJ, 274
Callahan, RJ, 736(ab), 811(ab), 831(ab), 834(ab), 896(ab), 1199, 2004, 2044
Calne, DB, 886(ab)
Camargo, EE, 732(ab), 750(ab), 771(ab), 818(ab), 878(ab), 913(ab)
Camici, P, 1335
Camilleri, M, 775(ab)
Campbell, J, 818(ab), 1240, 1761
Campini, R, 934(ab)
Camps, JAJ, 990
Camus, M, 846(ab)
Cancro, R, 864(ab)
Cannon, P, 827(ab)
Cantineau, R, 1247
Capozzi, JD, 1950
Carandente, O, 797(ab)
Caride, VJ, 296, 769(ab), 915(ab)
Carlson, C, 874(ab)
Carlson, KA, 811(ab)
Carmassi, F, 876(ab)
Carnochan, P, 1307
Carrasquillo, JA, 755(ab), 829(ab), 906(ab), 1133
Carrera, GF, 712(ab)
Carrier, L, 436
Carrió, I, 751(ab), 782(ab), 890(ab), 1450, 1965
Carroll, M, 760(ab), 846(ab)
Carson, R, 887(ab)
Carson, RE, 750(ab), 760(ab), 791(ab), 810(ab), 816(ab), 875(ab), 879(ab)
Carter, CS, 999
Carter, J, 936(ab)
Caruana, V, 112
Carvalho, P, 832(ab)
Carvalho, PA, 826(ab), 1456
Casani, A, 876(ab)
Cascella, NG, 2052
Case, T, 891(ab)
Casey, M, 862(ab)
Cassibry, AL, 879(ab)
Cassidy, EH, 884(ab), 1727
Casson, AG, 775(ab)
Castaigne, A, 34, 726(ab)
Castriotta, RJ, 1909
Castronovo, FP, 781(ab)
Castronovo, FP, Jr, 1579
Catania, TA, 296
Caufriez, A, 830(ab)
Caulin, C, 1601
Cauwe, F, 820(ab)
Cawley, M, 935(ab)
Cayla, J, 709(ab), 726(ab), 866(ab)
Cerniglia, G, 853(ab)
Cerqueira, M, 814(ab), 838(ab), 842(ab), 858(ab)
Cervoni, J, 1601
Chabriat, H, 770(ab), 880(ab)
Chaitman, BR, 733(ab)
Chakraborty, PK, 898(ab)
Chalon, S, 796(ab), 1253(le)
Chambers, CE, 723(ab)
Chan, B, 809(ab)
Chan, H-W, 1975
Chan, J, 819(ab)
Chan, SM, 903(ab)
Chan, SY, 773(ab), 774(ab), 840(ab), 842(ab)
Chang, C-H, 905(ab)
Chang, J, 826(ab)
Chang, K-H, 781(ab)
Chang, LSS, 762(ab)
Chang, W, 573, 719(ab), 769(ab)
Channing, M, 883(ab)
Channing, MA, 791(ab)
Chao, EYS, 829(ab)
Chao, S, 744(ab), 836(ab)
Chao, T-C, 1378
Chapman, D, 830(ab)
Chapman, PR, 742(ab)
Chappel, R, 831(ab)
Charalambous, A, 902(ab)
Charkes, ND, 147
Charney, DS, 779(ab), 883(ab)
Charron, M, 1575(le)
Chartrand, R, 436
Charuzi, Y, 812(ab)
Chatal, JF, 805(ab)
Chatterton, BE, 1568
Chawluk, J, 771(ab)
Chehabi, H, 764(ab)

Chen, B, 708(ab), 803(ab)
Chen, BC, 859(ab)
Chen, C-A, 902(ab)
Chen, C-T, 748(ab), 787(ab)
Chen, DCP, 735(ab), 853(ab), 876(ab)
Chen, F-M, 758(ab), 906(ab), 1059
Chen, GTY, 788(ab), 872(ab)
Chen, I, 714(ab)
Chen, I-W, 1486
Chen, K, 861(ab)
Chen, KK, 762(ab)
Chen, Z, 1294
Cheng, K, 946(ab)
Cheng, TO, 124(le)
Cherry, SR, 860(ab), 1307
Chervu, LR, 378
Chessis, PL, 192
Cheung, NKV, 742(ab)
Chiao, P, 718(ab)
Chiao, P-C, 1183
Chiariello, M, 838(ab)
Chiba, H, 763(ab)
Chierchia, SL, 797(ab), 821(ab), 839(ab)
Chin, LM, 1045
Chinol, M, 780(ab), 781(ab), 897(ab)
Chiou, P-F, 1294
Chirico, A, 760(ab)
Chiron, C, 892(ab), 893(ab)
Chiron, J, 767(ab)
Chisin, R, 2011
Chiu, ML, 736(ab), 832(ab), 1646
Cho, W, 741(ab)
Choi, Y, 778(ab), 780(ab), 803(ab)
Chopra, P, 841(ab)
Chou, J-S, 787(ab)
Chouraqui, P, 713(ab), 804(ab), 805(ab), 812(ab)
Chowdhury, SC, 243
Christiaens, L, 1247
Christian, PE, 739(ab), 770(ab), 800(ab)
Christiansen, C, 1156
Chu, TS, 735(ab), 808(ab)
Chu, YK, 762(ab)
Chua, E, 827(ab)
Chui, C, 1884
Chuman, K, 889(ab)
Chumpradit, S, 708(ab), 899(ab)
Chun, S, 717(ab), 904(ab)
Chung, C, 946(ab)
Chung, CJ, 1397
Chung, D, 936(ab)
Chung, J-K, 755(ab)
Chung, S-K, 800(ab), 803(ab), 937(ab)
Chung, W, 764(ab)
Church, CV, 716(ab)
Cianci, ML, 896(ab)
Cianflone, D, 797(ab)
Ciarmiello, A, 838(ab)
Cioloca, L, 906(ab)
Civelek, AC, 732(ab), 913(ab)
Clack, R, 770(ab)
Claessens, R, 1438(le)
Claessens, RAMJ, 403, 712(ab), 734(ab), 810(ab), 811(ab), 819(ab), 1802
Clanton, J, 933(ab)
Clanton, JA, 779(ab)
Clarke, LP, 942(ab), 945(ab)
Clarke, SEM, 768(ab)
Clausen, M, 772(ab), 821(ab), 1856, 1940
Clavo, AC, 904(ab)
Clemens, P, 807(ab)
Cleynhens, B, 806(ab)
Clinthorne, NH, 90, 718(ab), 769(ab), 798(ab)
Coakley, A, 790(ab)
Coakley, AJ, 311, 1744(le)
Coates, D, 840(ab)
Coates, DM, 944(ab)
Cobb, LM, 75, 1252(le)
Cody, R, 746(ab), 889(ab)
Coenen, HH, 281, 786(ab), 799(ab)
Cohen, AM, 857(ab)
Cohen, IJ, 755(ab)
Cohen, P, 1575(le)
Cohen, R, 887(ab)
Cohen, RM, 720(ab)
Colcher, D, 765(ab), 1133
Coleman, M, 739(ab)
Coleman, R, 858(ab)
Coleman, RE, 710(ab), 718(ab), 740(ab), 745(ab), 799(ab), 807(ab), 820(ab), 827(ab), 840(ab), 869(ab), 878(ab), 944(ab), 774(ab), 798(ab), 870(ab), 874(ab), 1128
Colletti, P, 876(ab)
Collier, BD, 712(ab), 731(ab), 745(ab), 880(ab), 1468
Collins, C, 755(ab)
Collins, J, 791(ab), 1486
Collins, R, 790(ab)
Collyer, D, 1892(le)
Colombo, F, 741(ab), 747(ab), 834(ab)
Combs, MJ, 759(ab)
Combs, RE, 897(ab)
Comerota, AJ, 1412
Comet, M, 640
Comi, G, 741(ab)
Comis, G, 739(ab)
Connett, JM, 852(ab), 909(ab)
Connor, W, 739(ab)
Consigny, M, 718(ab)
Constantinides, C, 825(ab), 945(ab)
Conversano, A, 821(ab), 839(ab)
Cook, PG, 1494
Coon, JS, 325
Coons, M, 722(ab)
Cooper, JA, 857(ab)
Cooper, M, 787(ab), 864(ab)
Cooper, MD, 761(ab)
Cooper, R, 712(ab)
Coppola, R, 707(ab)
Coralli, R, 837(ab)
Corbett, JR, 753(ab), 824(ab), 838(ab), 859(ab)
Corlija, M, 806(ab)
Corona, JF, 864(ab)
Correia, JA, 1227, 1717
Corrigan, P, 912(ab)
Corstens, F, 1438(le)
Corstens, FHM, 403, 712(ab), 734(ab), 810(ab), 811(ab), 819(ab), 1802
Corwin, LA, 767(ab)
Corwin, LA, Jr, 586, 1316
Cosgriff, P, 1576(le)
Costi, P, 821(ab), 828(ab)
Cottrill, CM, 668
Couch, MW, 385(le)
Coulston, C, 773(ab)
Counsell, RE, 332, 708(ab)
Coupal, JJ, 668, 894(ab), 897(ab)
Courey, M, 715(ab), 800(ab)
Courtney, LP, 911(ab)
Coustatin, C, 897(ab)
Covell, DG, 851(ab), 1191
Coveney, JR, 747(ab), 768(ab), 898(ab)
Coxson, PG, 802(ab)
Coyne, EP, 733(ab)
Cracco, R, 761(ab)
Cradduck, TD, 2074(le)
Crane, PD, 785(ab)
Crawford, C, 731(ab)
Crawford, JR, 1595
Crawley, JC, 231
Crispino, R, 882(ab)
Croft, BY, 759(ab), 990
Crook, JE, 824(ab), 849(ab), 904(ab)
Crosby, G, 1344
Crossman, D, 1980
Crouzel, C, 709(ab), 866(ab)
Crouzel, M, 709(ab), 866(ab)
Cuchet, P, 640
Cucolo, A, 674
Cullom, SJ, 945(ab)
Culver, CM, 845(ab)
Cunningham, J, 724(ab)
Cunningham, V, 760(ab)
Cuocolo, A, 736(ab), 777(ab)
Curien, B, 808(ab)
Currie, PJ, 773(ab)
Custer, TR, 859(ab)
Cypress, AM, 287
Czerniak, A, 790(ab)
Czernin, J, 271, 774(ab), 1431(le)

DaCosta, M, 539(le)
Daddona, PE, 905(ab)
Dadparvar, S, 115
Dae, M, 752(ab), 764(ab), 812(ab), 872(ab)
Dae, MW, 792(ab), 841(ab)
Daemen, BJG, 861(ab)
Daghighian, F, 759(ab), 764(ab), 864(ab)
Dahl, JR, 489
Dahlberg, ST, 827(ab), 828(ab)
Dahlbom, M, 749(ab), 778(ab), 780(ab), 803(ab)
Dai, S, 863(ab)
Dailey, MF, 944(ab)
Dale, S, 1675, 1682
Dalrymple, GV, 846(ab)
Daly, J, 877(ab)
D'Amato, P, 1240
Danais, S, 789(ab), 972
Daniel, CB, 900(ab)
Dannals, B, 898(ab)
Dannals, RF, 709(ab), 725(ab), 770(ab), 771(ab), 797(ab), 809(ab), 878(ab), 882(ab), 883(ab), 886(ab), 815(ab), 865(ab), 2015
Das, DK, 890(ab)
Das Gupta, TK, 1378
Dasika, V, 757(ab)
Datz, FL, 424, 684, 739(ab), 800(ab), 848(ab), 914(ab), 1847
Daube-Witherspoon, ME, 617, 816(ab), 817(ab)
Daugherty, A, 745(ab)
Davenport, KG, 847(ab)
Davey, RJ, 999
David, F, 1823
Davidson, J, 1595
Davis, M, 1658
Davison, A, 748(ab)
Dean, CJ, 777(ab)
Dean, RT, 776(ab), 833(ab), 905(ab)
Deblaton, M, 807(ab)
Debongnie, J, 814(ab)
Debrun, G, 878(ab)
De Chiara, S, 882(ab)
Decker, MJ, 884(ab)
De Coster, P, 820(ab)
Decostre, PL, 859(ab), 1702, 1710
DeFillipi, VJ, 46
DeFulvio, J, 810(ab)
De Goeij, CCJ, 746(ab)
DeGrado, T, 786(ab)
DeGrado, TR, 860(ab), 910(ab)
DeGraff, W, 815(ab)
De Groot, TJ, 746(ab)
Dehdashti, F, 746(ab)
Deiber, MP, 760(ab)
Deininger, H-K, 789(ab)
DeJesus, OT, 749(ab), 786(ab), 900(ab), 901(ab), 902(ab), 2076(le)
de Jongste, AB, 990
Delaage, M, 757(ab)
de la Barre, F, 875(ab)
Delajarte, AY, 805(ab)
Delaloye, B, 1007, 1035
Delforge, J, 709(ab), 866(ab), 897(ab)
Delmon, L, 464
Delpassand, ES, 234
Del Rosario, R, 84
del Rosario, RB, 904(ab)
Del Vecchio, S, 1252(le)
Delvenne, V, 750(ab)
Delworth, M, 791(ab)
DeMarco, T, 792(ab)
Demattos, S, 897(ab)
Demer, LL, 259
De Nardi, P, 853(ab)
DeNardo, GL, 218, 473, 724(ab), 754(ab), 788(ab), 822(ab), 823(ab), 859(ab), 1439(le)
DeNardo, SJ, 218, 473, 724(ab), 754(ab), 755(ab), 788(ab), 822(ab), 823(ab), 859(ab), 1439(le)
Dence, CS, 814(ab)
DePasquale, EE, 1761
de Paulis, T, 779(ab), 786(ab), 809(ab), 882(ab)
de Pauw, BE, 819(ab)
DePuey, EG, 839(ab), 1240, 1761
Der, M, 829(ab)
Derenzo, SE, 749(ab)
De Roo, M, 762(ab), 775(ab), 801(ab), 806(ab), 907(ab), 908(ab), 936(ab), 1490
de Roos, A, 717(ab)
Deshpande, SV, 218, 473, 823(ab)
de Silva, R, 737(ab), 778(ab)
DeSimone, PA, 897(ab)
Desmond, WJ, 911(ab)
DeSombre, ER, 1534
DeSouza, M, 580
Desplanches, G, 796(ab)
Deusch, E, 807(ab)
Deutsch, A, 830(ab)
Deutsch, E, 747(ab), 768(ab), 834(ab)
de Ville, J, 732(ab)
Devous, MD, Sr, 730(ab), 817(ab), 877(ab), 879(ab)
deVries, DJ, 729(ab)
Dew, VD, 944(ab)
Dewanjee, M, 891(ab), 934(ab)
Dewanjee, MK, 243, 820(ab), 907(ab)
Dewanjee, S, 820(ab)
Dewey, S, 719(ab), 762(ab), 866(ab)
Dewey, SH, 375
Dewey, SL, 780(ab), 787(ab), 902(ab)
Dewhirst, MW, 815(ab)
de Wit, H, 761(ab)
Dhekne, RD, 714(ab)
Diamond, M, 864(ab)
Diaz, P, 739(ab)
Di Carlo, V, 853(ab)
Dicks-Mireaux, C, 129
Diedrich, K, 910(ab)
Digby, W, 759(ab)
Dillehay, GL, 698(le), 700(le)
Dillon, WP, 880(ab)
Dilmanian, FA, 791(ab)
Dilsizian, V, 10, 736(ab), 753(ab), 777(ab)
Dimai, HP, 417
Dimitrakopoulou, A, 766(ab), 771(ab), 803(ab), 804(ab), 813(ab), 888(ab), 939(ab)
Ding, Y-S, 787(ab)
Dingler, W-H, 789(ab)
DiRocco, RJ, 1370
Divgi, CR, 845(ab)
Dobbeleir, A, 430, 840(ab)
Dobkin, JA, 770(ab), 789(ab)
Docs, J, 715(ab)
Docter, R, 1501
Doctor, DG, 46
Dodd, MG, 1595
Dodds, WJ, 1468
Doerr, RJ, 1975
Dokoh, S, 512
Dolev, E, 790(ab)

Doll, J, 771(ab), 803(ab), 939(ab)
Donato, L, 1335
Dondi, M, 913(ab)
Donohoe, K, 857(ab)
Donohoe, KJ, 857(ab)
Doornbos, J, 717(ab)
Doppelt, SH, 781(ab)
Doppman, J, 810(ab)
Dorffner, G, 825(ab)
Dosio, F, 791(ab)
Doudet, DJ, 720(ab)
Douglas, DM, 890(ab)
Douglass, KH, 866(ab)
Douillard, J-Y, 1028
Dowd, M, 864(ab)
Dowdle, SC, 1276
Dowsett, DJ, 1557
Dozio, N, 791(ab)
Drane, W, 827(ab)
Drane, WE, 716(ab), 1462
Drescher, C, 777(ab)
Drew, H, 913(ab)
Driedger, A, 526
Driedger. AA, 237, 804(ab), 2076(le)
Drum, DE, 721(ab)
Duara, R, 730(ab), 817(ab), 826(ab)
Dubois, F, 640
Dubois Rande, JL, 726(ab)
Dubovsky, EV, 716(ab), 912(ab)
duCret, RP, 731(ab), 936(ab)
Duda, RB, 725(ab), 854(ab)
Duelfer, T, 737(ab)
Duit, J, 825(ab)
Dulac, O, 892(ab), 893(ab)
Dumas, A, 715(ab)
Dumas, AS, 743(ab), 942(ab)
Duncker, C, 751(ab), 782(ab), 890(ab)
Duncker, CM, 1450
Dunn, BB, 791(ab)
Dunn, D, 735(ab), 835(ab)
Dunn, E, 722(ab), 761(ab)
Dunn, TJ, 897(ab)
Dunn, WL, 829(ab), 932(ab)
Dunning, AJ, 782(ab)
Dupont, D, 783(ab)
Dupont, RM, 1862
Dupras, G, 714(ab), 729(ab), 758(ab)
DuPree, ES, 61
Durack, L, 1384
Durack, LD, 942(ab), 1257
Duranceau, A, 775(ab), 1921
Durham, J, 1384
Durwen, HF, 711(ab), 881(ab)
Dweek, E, 1669
Dworkin, H, 941(ab)
Dworkin, HJ, 845(ab), 894(ab)
Dwyer, JP, 794(ab)
Dyer, SM, 1230
Dyve, S, 721(ab)

Earl, NL, 740(ab)
Eary, J, 1384
Eary, JF, 724(ab), 755(ab), 942(ab), 1257
Eastman, G, 878(ab), 1257
Eastman, RC, 791(ab), 879(ab)
Eber, O, 417, 1577(le)
Eberstadt, PL, 772(ab)
Eccles, SA, 754(ab), 777(ab)
Eckelman, WC, 1370, 738(ab), 747(ab)
Edgar, M, 830(ab)
Edwards, NC, 713(ab), 784(ab)
Edwards, S, 785(ab)
Efange, SMN, 727(ab), 797(ab)
Ehrenkaufer, RL, 728(ab), 901(ab)
Ehrhardt, GH, 1316
Ehrhardt, GJ, 586, 767(ab), 947(ab)
Eikman, EA, 800(ab)
Einhäupl, KM, 827(ab)
Eisen, H, 822(ab)
Eisenberg, B, 679, 890(ab), 1099
Eisler, E, 943(ab)
Eisner, RL, 735(ab), 808(ab), 835(ab), 870(ab)
Eitzman, D, 801(ab)
Ejiri, K, 55, 877(ab)
Elam, DA, 594
Eldadah, M, 914(ab)
Elgazzar, AH, 761(ab), 830(ab), 914(ab), 940(ab)
Elger, CE, 711(ab), 881(ab)
Elias, AD, 794(ab)
Ell, PJ, 811(ab), 830(ab)
Ellison, D, 692
Elmaleh, D, 1823
Elmaleh, DR, 787(ab)
Elsinga, H, 746(ab)
Elsinga, PH, 861(ab)
Emran, A, 903(ab), 1254
Endo, K, 136, 844(ab), 850(ab), 895(ab), 1077, 1632
Endo, M, 802(ab)
Endres, CJ, 709(ab), 778(ab), 786(ab)
Engdahl, JC, 719(ab), 856(ab), 870(ab), 912(ab)
Engelbrecht, DE, 931(ab)
Engelbretson, DA, 43
Engeler, CM, 731(ab)
Engelke, W, 856(ab)
Engelman, K, 1669
Engelstad, BL, 717(ab)
Engelstad, K, 820(ab)
Ennis, JT, 1557
Ensminger, WD, 784(ab)
Epelbaum, R, 365
Epenetos, AA, 1791
Epstein, A, 810(ab)
Epstein, AL, 735(ab), 758(ab), 853(ab), 906(ab), 1059
Erdman, WA, 721(ab)
Erickson, JJ, 941(ab)
Esche, B, 804(ab), 938(ab)
Escueta, A, 881(ab)
Eshima, D, 912(ab)
Essamri, B, 843(ab)
Esser, PD, 830(ab)
Esteban, J, 764(ab)
Esteban, JM, 850(ab)
Esterbrooks, D, 733(ab)
Esterhai, JL, Jr, 2029
Estorch, M, 782(ab), 751(ab), 890(ab), 1450, 1965
Etani, H, 603
Eterović, D, 382(le)
Ethier, S, 888(ab)
Ethier, SP, 1831
Ettinger, NA, 722(ab)
Evans, HJ, 43
Evans, ML, 756(ab)
Evans, NTS, 1595
Evans, RE, 733(ab)
Even-Sapir, E, 1784

Faber, TL, 753(ab), 824(ab), 838(ab), 859(ab)
Fabian, C, 937(ab)
Faggin, B, 737(ab)
Fagret, D, 640
Fahey, FH, 836(ab)
Fajman, W, 835(ab)
Falke, THM, 935(ab), 1147
Fanti, S, 913(ab)
Fantinato, L, 892(ab), 908(ab)
Farahati, J, 715(ab), 767(ab)
Farde, L, 737(ab), 796(ab), 902(ab)
Farlow, D. C., 793(ab)
Farschi, KP, 913(ab)
Fataar, A, 106
Fawwaz, RA, 805(ab), 820(ab), 906(ab)
Fazio, F, 735(ab), 741(ab), 747(ab), 748(ab), 791(ab), 821(ab), 834(ab), 853(ab), 854(ab), 871(ab), 907(ab)
Fazzini, PF, 821(ab)
Federici, M, 764(ab)
Fedida, A, 836(ab)
Fedida, AA, 843(ab)
Fedio, V, N14A(6)
Feiglin, D, 739(ab)
Feinendegen, LE, 281, 803(ab), 1608
Fejka, R, 829(ab)
Feld, T, 1370
Feldman, JM, 745(ab)
Fendel, H, 734(ab)
Fennell, RS, III, 716(ab)
Fer, M, 777(ab)
Ferency, S, 755(ab)
Fernandaz-Rubio, F, 1989
Ferroni, P, 1133
Fetterman, RC, 1400
Fettich, G, 825(ab), 914(ab)
Feuillan, P, 1474
Feyerabend, A, 884(ab)
Feyerabend, AJ, 942(ab)
Fieschi, C, 741(ab)
Fig, L, 777(ab), 852(ab)
Figueiredo, M, 781(ab)
Filesi, M, 1766
Filippone, A, 1915
Filler, RM, 516
Fine, EJ, 716(ab)
Fink, G, 771(ab)
Fink, GD, 1823
Fink-Bennett, D, 761(ab)
Finley, RJ, 775(ab)
Finn, R, 864(ab)
Finn, RT, 720(ab)
Fioravanti, C, 1494
Fiorelli, M, 880(ab)
Fiorentino, A, 1766
Fioretti, P, 782(ab)
Fischman, A, 853(ab)
Fischman, AJ, 10, 32, 736(ab), 787(ab), 795(ab), 811(ab), 819(ab), 831(ab), 833(ab), 834(ab), 896(ab), 1199, 1441(le), 2022
Fisher, D, 724(ab), 1384
Fisher, DR, 725(ab), 1257
Fisher, RS, 818(ab)
Fisher, S, 708(ab)
Fisher, SJ, 850(ab), 904(ab)
Fitzner, JN, 747(ab)
Fletcher, JE, 851(ab), 1191
Flickinger, FW, 549
Flodmark, CO, 939(ab)
Florence, S, 237
Flotte, T, 853(ab)
Flower, MA, 860(ab)
Floyd, CE, 807(ab)
Floyd, CE, Jr, 798(ab), 869(ab), 870(ab)
Foehse, MC, 936(ab)
Foisie, D, 777(ab)
Folks, R, 1240
Fordham, EW, 813(ab)
Formiconi, AR, 739(ab)
Fortenbery, EJ, 940(ab), 1627
Foster, NL, 61, 1574(le)
Fournier, D, 709(ab)
Fowler, J, 866(ab)
Fowler, JS, 719(ab), 762(ab), 780(ab), 787(ab), 886(ab)
Fox, PT, 710(ab)
Fox, RW, 938(ab)
Frackowiak, R, 760(ab)
Fragasso, G, 747(ab), 797(ab), 821(ab), 834(ab), 839(ab)
Franceschi, D, 1552
Francesconi, L, 727(ab), 1635
Francis, I, 852(ab)
Francis, IR, 872(ab)
Frangin, Y, 796(ab)
Frank, TL, 1069, 1230
Franke, C, 940(ab)
Franken, PR, 840(ab)
Franks, W, 936(ab)
Frederiksen, PB, 1121
Freedman, M, 936(ab)
Freedman, N, 777(ab)
Freeman, MR, 874(ab)
Freitas, JE, 536(le)
Frenkel, A, 1784, 1945
Frenkel, TL, 873(ab)
Frey, EC, 738(ab), 798(ab), 867(ab), 873(ab)
Frey, KA, 709(ab), 720(ab), 779(ab), 885(ab)
Frick, M, 733(ab), 891(ab)
Frick, MP, 1893(le)
Friden, A, 934(ab)
Friedland, R, 740(ab)
Friedman, A, 819(ab)
Friedman, AH, 799(ab)
Friedman, H, 878(ab)
Friedman, J, 812(ab), 836(ab), 1168
Friedmann, G, 302
Frincke, J, 844(ab)
Frincke, JM, 734(ab), 757(ab), 911(ab)
Fritz, B, 903(ab)
Fritzberg, A, 725(ab), 823(ab)
Fritzberg, AR, 747(ab), 823(ab)
Front, D, 365, 783(ab), 788(ab), 845(ab), 850(ab), 1784, 1945
Frost, JJ, 709(ab), 770(ab), 816(ab), 866(ab)
Fry, ETA, 187
Fuccello, AJ, 776(ab), 819(ab), 2022
Fujibayashi, Y, 708(ab), 895(ab), 1818
Fujii, H, 944(ab)
Fujii, R, 738(ab), 861(ab)
Fujiki, Y, 869(ab)
Fujimori, K, 851(ab), 1191
Fujita, H, 760(ab)
Fujita, N, 833(ab)
Fujita, T, 885(ab), 1015
Fujiwara, T, 1654, 1927
Fukuchi, M, 714(ab)
Fukuda, H, 1654
Fukui, H, 813(ab)
Fukuma, H, 889(ab)
Fukumura, T, 880(ab)
Fukunaga, M, 829(ab)
Fung, P, 804(ab)
Funita, T, 136
Fusani, L, 1335
Futatsuya, R, 880(ab)

Gagne, G, 892(ab)
Gagne, GM, 1048
Gagnon, A, 839(ab)
Gagnon, D, 714(ab), 729(ab), 758(ab)
Gai, M, 745(ab)
Gaillard, JF, 872(ab)
Gal, R, 723(ab), 837(ab)
Gal, RA, 450
Gallagher, K, 1352
Gallagher, KP, 1183
Galli, M, 934(ab)
Galster, J, 823(ab)
Galt, J, 837(ab)
Gambhir, SS, 944(ab)
Gansow, O, 211
Gansow, OA, 824(ab), 1378
Ganz, W, 713(ab), 715(ab), 804(ab), 805(ab), 907(ab), 943(ab)
Ganz, WI, 934(ab), 939(ab), 942(ab)
Garcia, E, 732(ab), 828(ab)
Garcia, EV, 839(ab), 1240, 1761
Garcia, J, 127(le)
Garcia, LA, 772(ab)
Garg, PK, 776(ab), 815(ab)
Garg, S, 776(ab), 815(ab)
Garmestani, K, 794(ab)
Garneau, M, 1823
Garrett, K, 877(ab), 908(ab)
Gartside, P, 393
Garty, I, 819(ab)
Garvin, AA, 842(ab)
Gassaway, SK, 877(ab), 879(ab)
Gastard, J, 1470
Gaston-Parry, D, 985

Gatley, SJ, 787(ab), 809(ab), 886(ab), 910(ab)
Gaul, FE, 776(ab), 819(ab), 2022
Gautherot, E, 757(ab)
Gee, M, 881(ab)
Gelfand, MJ, 893(ab)
Geltman, EM, 713(ab), 773(ab), 841(ab), 1749, 2064
Gemmell, HG, 1595
Genna, S, 769(ab), 1456
Gennarelli, T, 741(ab), 876(ab)
Gentili, A, 931(ab)
Genton, RE, 841(ab)
George, T, 812(ab)
Georges, L, 800(ab)
Georgi, P, 1285
Georgiou, M, 743(ab), 891(ab), 943(ab)
Georgiou, MF, 942(ab)
Gerdes, J, 737(ab)
Germá, J-R, 1450, 1965
Germano, G, 864(ab)
Gerosa, S, 839(ab)
Gertz, MA, 292
Gerundini, P, 791(ab), 797(ab), 839(ab)
Gestin, JF, 896(ab)
Geuting, B, 1608
Ghafouripour, AK, 907(ab)
Ghilardi, PL, 876(ab)
Ghosh, PR, N19A(1), N20A(2), N28A(5), N19A(6), N31A(6), N23A(7), N25A(9), N23A(10), N11A(11), N28A(12)
Gibbons, RJ, 1269
Gibbs, B, 610
Gibson, RE, 729(ab)
Gilardi, MC, 821(ab), 871(ab)
Gilbert, S, 715(ab)
Gilday, D, 580
Gilday, DL, 135
Gildersleeve, DL, 1328
Gilland, DR, 718(ab), 739(ab), 867(ab), 874(ab)
Gillespie, D, 882(ab)
Gillispie, SB, 728(ab), 863(ab)
Gilmore, M, 832(ab)
Gilyon, K, 725(ab), 854(ab)
Gindi, G, 729(ab)
Ginsberg, HN, 343
Ginsburg, I, 798(ab)
Giombetti, R, 877(ab)
Gionet, M, 903(ab)
Giraud, M, 726(ab)
Girton, M, 810(ab)
Gitler, MS, 883(ab)
Giubbini, R, 934(ab)
Gjedde, A, 721(ab), 809(ab), 861(ab), 882(ab), 884(ab)
Glantz, MJ, 799(ab)
Glaspy, J, 803(ab)
Gleason, JM, 1893(le)
Gleason, TJ, 549
Glick, SJ, 739(ab), 867(ab)
Glowniak, JV, 726(ab)
Go, RT, 722(ab), 802(ab), 1899
Goates, JJ, 424, 914(ab)
Gobuty, AH, 788(ab)
Goddard, AW, 789(ab)
Godwin, TA, 788(ab)
Goeckeler, WF, 586, 767(ab), 1316
Golberg, L, 856(ab)
Gold, J, 750(ab)
Goldberg, TE, 750(ab)
Goldenberg, DM, 508, 724(ab), 765(ab), 783(ab), 788(ab), 850(ab), 854(ab), 904(ab), 905(ab), 1510
Goldhaber, SZ, 721(ab)
Goldman, S, 744(ab), 750(ab)
Goldring, S, 710(ab)
Goldsmith, SJ, N15A(10), 109, 319, 682, 539(le), 711(ab), 712(ab), 716(ab), 780(ab), 781(ab), 819(ab), 825(ab), 860(ab), 874(ab), 890(ab), 895(ab), 897(ab), 914(ab), 941(ab), 1548, 1950
Goldstein, L, 732(ab)
Goldstein, MD 742(ab)
Goldstein, RA, 255, 259
Goldstein, S, 1839
Göller, V, 821(ab)
Gona, J, 887(ab)
Gonin, R, 794(ab)
Gonzalez, E, 834(ab)
Goodgold, HM, 733(ab)
Goodman, MM, 900(ab), 933(ab)
Goodman, WK, 750(ab)
Gopinath, PG, 841(ab)
Gordon, EE, 755(ab)
Gordon, EM, 893(ab)
Gordon, I, 129
Gordon, L, 1397
Gordon, MR, 879(ab)
Gordon, RE, 780(ab)
Gorey, JG, 707(ab)
Goris, ML, 827(ab)
Gorman, CA, 519
Gorten, RJ, 838(ab)
Gosfield, T, 741(ab)
Gotoh, E, 855(ab)
Gotoh, H, 881(ab)
Gotoh, S, 792(ab)
Gottesman, II, 751(ab)
Gottsauner-Wolf, F, 829(ab)
Gouid, KL, 610, 1894(le)
Gould, L, 259
Gould, RJ, 1494
Grady, CL, 760(ab), 879(ab)
Graf, G, 1856
Grafton, S, 965, 708(ab), 799(ab), 825(ab), 865(ab)
Grafton, ST, 740(ab), 865(ab)
Graham, M, 798(ab)
Graham, MC, 489, 864(ab)
Graham, MM, 717(ab), 762(ab), 862(ab), 903(ab), 912(ab), 941(ab), 944(ab)
Gray, B, 936(ab)
Gray, MA, 747(ab)
Greager, JA, 1378
Grebenau, R, 905(ab)
Green, CE, 836(ab)
Green, MA, 351, 727(ab), 815(ab), 909(ab), 910(ab), 914(ab), 1641, 1989
Green, MV, 38, 816(ab)
Green, S, 810(ab)
Greenberg, HE, 424
Greenberg, HM, 938(ab)
Greenberg, JH, 1364
Greenberg, M, 135
Greene, J, 912(ab)
Greenspan, RL, 46, 830(ab)
Greer, KL, 718(ab), 807(ab), 874(ab)
Grégoire, J, 714(ab), 729(ab), 758(ab)
Gregoire, MC, 872(ab), 1303
Gregor, V, 786(ab)
Greig, NH, 888(ab)
Grenier, RP, 450
Greve, J, 939(ab)
Grierson, J, 337
Grierson, JR, 756(ab), 833(ab)
Griffeth, LK, 192, 730(ab), 746(ab)
Griffin, J, 752(ab)
Griffin, TW, 754(ab)
Griffiths, GL, 905(ab)
Grimm, EA, 818(ab)
Gripenberg, J, 384(le)
Großmann, K, 1608
Gropler, RJ, 773(ab), 1749
Gross, MD, 332, 526, 708(ab), 801(ab)
Grossman, R, 1206
Grossman, ZD, 1048
Grossnickle, M, 1397
Grothe, RA, Jr, 1732
Gruaz, A, 757(ab)
Gruber, ML, 969
Gruenewald, S. M., 793(ab)
Grummon, GD, 907(ab)
Grünwald, F, 711(ab), 871(ab), 881(ab), 894(ab), 1740
Guerrero, JL, 796(ab), 805(ab)
Guerrero, T, 780(ab)
Guerrero, TM, 749(ab), 759(ab)
Guibourg, H, 1352
Guidry, GW, 754(ab), 759(ab), 843(ab), 855(ab)
Guillaume, M, 1247
Guilloteau, D, 796(ab), 1253(le)
Gulamhusein, S, 824(ab)
Gulenchyn, KY, 118, 804(ab), 938(ab)
Gullberg, GT, 738(ab), 739(ab), 770(ab), 867(ab), 868(ab)
Gulrajani, R, 895(ab)
Gunasekera, J, 837(ab)
Gunasekera, RD, 889(ab)
Gundzik, JM, 234
Gunter, DL, 728(ab)
Gupta, N, 733(ab)
Gupta, NC, 891(ab)
Gupta, RK, 717(ab)
Gupta, S, 878(ab)
Gur, R, 771(ab)
Gur, RC, 730(ab), 751(ab)
Gur, RE, 730(ab), 751(ab)
Gusella, J, 740(ab)
Gustavson, LG, 747(ab)
Guth, WR, 655
Guth-Tougelidis, B, 715(ab), 766(ab), 767(ab), 818(ab)
Gutman, A, 129
Guze, BH, 965
Guzzardi, R, 1335
Gzesh, D, 1839

Haakenstad, AO, 424, 1847
Haaparanta, M, 749(ab)
Haber, E, 841(ab)
Haberkorn, U, 766(ab), 771(ab), 803(ab), 804(ab), 813(ab), 888(ab), 939(ab)
Haden, HT, 246(le)
Haendchen, L, 744(ab)
Hagen, J, 891(ab)
Haigh, AT, 617
Haines, JL, 740(ab)
Haka, M, 726(ab), 792(ab)
Haka, MS, 707(ab), 720(ab), 738(ab), 745(ab), 831(ab), 901(ab), 1328
Haken, RKT, 872(ab)
Hakimian, E, 743(ab)
Halama, JR, 698(le), 700(le), 808(ab), 871(ab), 941(ab)
Halkar, R, 837(ab)
Hall, H, 796(ab), 902(ab)
Hall, J, 891(ab)
Hall, TC, 724(ab)
Halldin, C, 737(ab), 796(ab), 902(ab)
Halpern, SE, 1143, 1436(le), 1862
Ham, HR, 430, 830(ab)
Hamacher, K, 771(ab)
Hamamoto, K, 790(ab), 846(ab), 858(ab), 868(ab)
Hamblen, S, 840(ab)
Hamblen, SM, 944(ab)
Handa, S, 792(ab)
Handy, JE, 424, 744(ab), 800(ab), 1847
Hannesen, R, 947(ab)
Hanselarr, T, 1438(le)
Hansen, EB, 758(ab)
Hansen, HA, 795(ab)
Hansen, HJ, 724(ab), 904(ab), 905(ab)
Hansen, HW, 713(ab)
Hansen, MA, 1156
Hansen, N, 911(ab)
Hansen, RM, 745(ab)
Hanson, JM, 789(ab)
Hanson, MW, 710(ab), 740(ab), 745(ab), 774(ab), 840(ab), 878(ab), 944(ab), 799(ab), 799(ab)
Hantraye, P, 897(ab)
Haot, J, 814(ab)
Hara, M, 907(ab)
Harada, J, 881(ab)
Harada, K, 907(ab)
Haradahira, T, 332, 708(ab)
Harcke, HT, 742(ab), 1797
Hardin, JM, 852(ab)
Hardin, M, 850(ab)
Hardoff, R, 845(ab)
Hardy, M, 820(ab)
Hare, T, 723(ab)
Harkness, BA, 836(ab)
Harp, G, 842(ab), 858(ab)
Harper, PV, 1534
Harrell, C, 729(ab), 769(ab)
Harrell, CR, 830(ab)
Harris, CC, 944(ab)
Harris, GJ, 750(ab)
Harrison, C, 830(ab)
Harrison, KA, 846(ab)
Harrison, RL, 728(ab), 863(ab)
Harsch, HH, 880(ab)
Hart, J, 818(ab)
Hartley, S, 1397
Hartshorne, MF, 1099
Hartz, RK, 610
Harvey, E, 850(ab)
Hasan, A, 900(ab)
Hasbargen, JA, 1211
Hasegawa, Y, 832(ab)
Hashikawa, K, 603
Hashimoto, S, 852(ab), 894(ab)
Hashimoto, T, 713(ab)
Hasler, PH, 1007
Hassager, C, 1156
Hassan, I, 911(ab)
Hassan, IM, 825(ab), 945(ab)
Hasumi, M, 833(ab)
Hatano, K, 779(ab)
Hatano, M, 743(ab)
Hatazawa, J, 779(ab), 1654, 1927, 1997
Hattner, RH, 792(ab)
Hattner, RS, 1844
Hausen, D, 580
Hauser, H, 1084
Hauser, MF, 292
Hauser, MM, 776(ab), 819(ab), 2022
Haver, B, 844(ab)
Hawk, TC, 944(ab)
Hawkins, IF, 716(ab)
Hawkins, R, 799(ab)
Hawkins, RA, 708(ab), 749(ab), 778(ab), 780(ab), 803(ab), 825(ab), 859(ab), 874(ab), 932(ab), 965
Hawkins, WG, 873(ab)
Haxby, JV, 760(ab), 879(ab)
Hayakawa, K, 512
Hayashi, H, 944(ab)
Hayashida, K, 763(ab), 782(ab), 783(ab), 881(ab)
Hayes, AA, 519
Hayes, DF, 1835
Hayes, RL, 849(ab)
Haynie, M, 255
Haynie, TP, 724(ab), 800(ab), 803(ab), 937(ab), N22A(1)
Haynor, DR, 728(ab), 863(ab)
Haywood, L, 765(ab)
Haze, K, 763(ab), 783(ab)
Heal, A, 715(ab)
Heal, AV, 938(ab), 945(ab)
Healy, SA, 714(ab)
Heather, JD, 943(ab)
Hecht, HS, 763(ab), 836(ab)
Heelan, R, 798(ab)
Heelan, RT, 793(ab)
Hegge, J, 835(ab)
Heidenreich, P, 1856
Heikkonen, JJ, 23
Heindel, W, 302

Heiss, WD, 302, 771(ab), 799(ab)
Heller, SL, 716(ab)
Helling, DE, 748(ab)
Hellman, RS, 731(ab), 880(ab)
Hellstrom, I, 754(ab)
Hellstrom, KE, 754(ab)
Hellwig, B, 501
Heliwig, BJ, 875(ab)
Helus, F, 771(ab), 803(ab), 804(ab), 813(ab), 888(ab), 939(ab)
Heminger, L, 714(ab)
Hemingway, AP, 1980
Hendel, RC, 827(ab), 828(ab), 1851
Henderson, IC, 387
Henes, CG, 713(ab)
Heninger, GR, 779(ab), 789(ab), 883(ab)
Henkin, RE, 698(le), 700(le), 768(ab), 808(ab), 871(ab), 941(ab)
Henning, J, 948(ab)
Henrich, MM, 803(ab)
Henry, C, 888(ab)
Henry, LJ, 873(ab)
Henze, E, 772(ab), 821(ab), 1856, 1940
Heo, J, 723(ab), 763(ab), 812(ab), 837(ab), 1761
Hepner, A, 801(ab)
Herholz, K, 302, 799(ab)
Herman, KJ, 978
Herman, LW, 787(ab)
Herman, PG, 935(ab)
Herman, WH, 774(ab), 802(ab), 1876
Hermann, G, 890(ab)
Hero, AO, 798(ab)
Herold, T, 243
Herregods, P, 831(ab)
Herry, J-Y, 1470
Herscovitch, P, 710(ab), 730(ab), 760(ab), 791(ab), 810(ab), 816(ab), 817(ab), 887(ab)
Herson, G, 874(ab)
Herzog, H, 281, 803(ab)
Hester, A, 799(ab), 825(ab)
Heusman, RH, 802(ab)
Hewett, JE, 586
Hewitt, KA, 886(ab)
Heyl, B, 785(ab)
Heylen, J, 907(ab)
Heyman, S, 126(le), 742(ab)
Heymsfield, S, 791(ab)
Heyndrickx, G, 843(ab)
Hiam, J, N22A(5), N24A(9), N22A(12)
Hiasa, T, 946(ab)
Hichwa, RD, 719(ab)
Hicks, R, 1757
Hicks, RJ, 773(ab), 774(ab), 801(ab), 802(ab), 1876
Hiesiger, EM, 849(ab)
Higa, T, 240
Higashino, H, 858(ab)
Higazi, E, 830(ab)
Higgins, CB, 946(ab)
Higuchi, S, 750(ab)
Hilleman, D, 733(ab)
Himi, T, 802(ab)
Hines, JJ, 1527
Hines, RL, 789(ab)
Hinkle, G, 851(ab)
Hirano, M, 847(ab)
Hirano, T, 543
Hirasawa, Y, 855(ab)
Hirata, K, 743(ab), 1617
Hiroe, M, 793(ab), 833(ab)
Hiroishi, T, 946(ab)
Hirota, Y, 907(ab)
Hirst, AE, 594
Hisada, K, 660, 766(ab), 792(ab), 814(ab), 851(ab), 869(ab), 880(ab), 885(ab), 889(ab)
Hitchens, RE, 610
Hladik, WB, 933(ab)
Hnatowich, DJ, 754(ab), 903(ab), 1791
Hochberg, FH, 969
Hodgson, SF, 932(ab)
Hoefnagel, CA, 1854
Hoehn-Saric, R, 750(ab)
Hoffer, PB, 729(ab), 750(ab), 769(ab), 779(ab), 789(ab), 826(ab), 883(ab)
Hoffer, PF, 915(ab)
Hoffman, EJ, 749(ab), 759(ab), 778(ab), 780(ab), 803(ab), 864(ab)
Hoffman, JM, 710(ab), 720(ab), 740(ab), 799(ab), 840(ab), 878(ab), 944(ab)
Hoffman, RG, 880(ab)
Hoffman, T, 1028
Hoffman, TJ, 937(ab)
Hoffmann, RG, 731(ab)
Högberg, T, 796(ab), 902(ab)
Hogg, P, 830(ab)
Hoh, C, 749(ab), 778(ab), 780(ab), 799(ab), 803(ab)
Hoh, CK, 825(ab)
Hohlweg, R, 902(ab)
Holcomb, HH, 816(ab), 865(ab)
Holdeman, KP, 779(ab)
Holden, JE, 709(ab), 778(ab), 786(ab), 860(ab), 887(ab), 910(ab)
Holloway, EC, 824(ab), 849(ab), 904(ab)
Holman, BL, 464, 729(ab), 769(ab), 826(ab), 832(ab), 1166, 1456, 1552, 1693
Holmes, GL, 892(ab)
Holmes, RA, N20A(3), N33A(6), 767(ab), 806(ab), 937(ab)
Holohan, KM, 842(ab)
Hom, J, 730(ab)
Honda, N, 878(ab)
Hoogma, RPLM, 1147
Hoogmartens, M, 907(ab)
Hooper, HR, 945(ab), 2046
Hooper, PM, 2046
Hoory, S, 890(ab)
Hopkins, M, 777(ab)
Hori, M, 753(ab), 808(ab)
Horie, T, 833(ab)
Horii, H, 861(ab)
Horner, C, 836(ab)
Horowitz, JA, 724(ab), 783(ab), 788(ab), 850(ab)
Horwitz, B, 760(ab)
Hosain, F, 856(ab)
Hosain, P, 729(ab), 896(ab)
Hosain, PP, 707(ab)
Höschl, R, 801(ab), 847(ab)
Hoshi, H, 688
Hoskens, C, 893(ab)
Hosoda, S, 793(ab)
Hosokawa, S, 880(ab)
Hosono, M, 844(ab), 850(ab), 895(ab)
Hot, MAH, 34
Hotze, A, 711(ab), 854(ab), 871(ab)
Houghton, AL, 804(ab)
Hu, E, 735(ab), 853(ab)
Hu, X, 748(ab)
Huang, G, 769(ab)
Huang, S-C, 708(ab), 709(ab), 720(ab), 778(ab), 780(ab), 803(ab), 859(ab), 861(ab), 862(ab), 865(ab), 1431(le)
Huberty, JH, 792(ab)
Hubner, KF, 862(ab), 933(ab)
Huddleston, H, 830(ab)
Hufnagel, A, 711(ab)
Hugenholtz, EAL, 755(ab)
Hugh, J, 1797
Hughes, A, 1534
Huguet, F, 1253(le)
Human, DG, 1276
Humen, DP, 824(ab)
Humm, JL, 75, 1045, 1252(le)
Humphries, LL, 325
Hundeshagen, H, 899(ab)
Hung, G-L, 818(ab)
Hunkeler, W, 1007
Hunter, W, 891(ab)
Hurford, WE, 1344
Hurley, JR, 784(ab)
Hurm, KD, 847(ab)
Hurwitz, GA, 526
Huston, JS, 776(ab)
Hutchins, G, 746(ab), 777(ab), 792(ab), 889(ab), 1352
Hutchins, GD, 163, 718(ab), 725(ab), 745(ab), 1183, 1220, 1831
Hutchinson, RJ, 804(ab), 1479
Hutson, WR, 800(ab)
Hwang, D-R, 707(ab), 738(ab), 814(ab)
Hyun, M, 812(ab), 911(ab), 934(ab)

Ibayashi, K, 750(ab)
Ichihara, T, 792(ab), 869(ab)
Ichise, M, 936(ab)
Ichiya, Y, 880(ab), 889(ab)
Ido, T, 738(ab), 779(ab), 885(ab), 901(ab), 1654, 1927, 1997
Iervasi, G, 876(ab)
Iida, H, 736(ab), 737(ab), 760(ab), 778(ab)
Iida, Y, 885(ab)
Iio, A, 790(ab), 846(ab)
Iio, M, 778(ab), 817(ab)
Ikezaki, K, 759(ab)
Iles, S, 933(ab)
Iles, SE, 935(ab)
Imahori, Y, 738(ab), 1997
Imai, K, 743(ab)
Imakita, S, 881(ab)
Imazeki, K, 888(ab)
Inculet, R, 775(ab)
Infante-Rivard, C, 436
Ing, SJ, 594
Ingram, P, 748(ab)
Innis, RB, 769(ab), 779(ab), 883(ab)
Inokuma, S, 894(ab)
Intenzo, C, 932(ab)
Iosilevsky, G, 1784, 1945
Iqbal, A, 1358
Isaacs, GH, 731(ab)
Isaka, Y, 603
Isawa, T, 543
Ishi, N, 1520
Ishida, Y, 753(ab), 808(ab)
Ishimura, J, 714(ab)
Ishiwata, K, 779(ab), 885(ab), 901(ab), 1927, 1997
Ishiyama, N, 55, 877(ab)
Ish-Shalom, S, 845(ab), 1945
Isitman, AT, 712(ab)
Iskandrian, A, 733(ab), 763(ab), 812(ab), 837(ab)
Iskandrian, AS, 723(ab), 1761
Israel, O, 365, 845(ab), 1784, 1945
Issacher, D, 523
Itami, J, 888(ab)
Ito, M, 1927
Ito, S, 1358
Ito, T, 832(ab)
Itoh, H, 248(le), 793(ab), 846(ab)
Itoh, M, 779(ab), 1654
Iuliucci, JD, 795(ab)
Ivanovic, M, 869(ab), 875(ab), 876(ab)
Iwanaga, S, 792(ab)
Iwasaki, R, 1632
Iwasaki, T, 714(ab), 869(ab)
Iwasaki, Y, 742(ab), 743(ab), 847(ab), 885(ab)
Iwata, K, 383(le)
Iwata, R, 901(ab), 1654, 1927, 1997
Izon, D, 724(ab)
Izunaga, H, 907(ab)

Jabir, AM, 943(ab)
Jablonskyene, D, 841(ab)
Jackson, JR, 728(ab)
Jackson, S, 935(ab)
Jackson, SA, 933(ab)
Jackson, T, 852(ab)
Jacob, JH, 943(ab)
Jacobs, A, 846(ab)
Jacobson, AF, 372, 387, 814(ab)
Jacobson, KA, 791(ab)
Jadliwalla, M, 775(ab), 1921
Jaeger, N, 854(ab)
Jaeger, T, 741(ab)
Jaffe, RM, 830(ab)
Jagust, WJ, 880(ab)
Jain, D, 231, 782(ab), 841(ab), 1970
Jamal, S, 891(ab)
Jamar, F, 820(ab)
Jang, JJ, 755(ab)
Janicek, M, 892(ab)
Janier, M, 709(ab), 866(ab)
Janik, M, 815(ab)
Janjan, NA, 745(ab)
Jansons, D, 857(ab)
Janssens, J, 775(ab), 801(ab), 1490
Jantausch, B, 742(ab)
Jaszczak, R, 858(ab)
Jaszczak, RJ, 718(ab), 807(ab), 874(ab)
Jayson, HT, 721(ab)
Jeffery, PJ, 818(ab), 878(ab)
Jelinek, JJ, 1958
Jensen, MD, 829(ab)
Jeremy, RW, 1230
Jerushalmi, J, 365, 845(ab)
Jeske, J, 302
Jespers, A, 893(ab)
Jester, DW, 776(ab)
Jewell, WR, 937(ab)
Jewett, DM, 1328
Jingu, K, 889(ab)
Jinnouchi, S, 688
Jochelson, MS, 387, 793(ab), 794(ab)
John, C, 947(ab)
John, CS, 896(ab)
John, EK, 351
John, V, 896(ab)
Johns, V, 935(ab)
Johnson, A, 946(ab)
Johnson, DA, 1462
Johnson, EW, 779(ab)
Johnson, G, 943(ab)
Johnson, K, 1456
Johnson, L, 827(ab)
Johnson, MH, 1412
Johnson, MJ, 826(ab)
Johnson, RA, 990
Johnson, RF, Jr, 752(ab)
Johnson, VE, 748(ab)
Johnston, RE, 866(ab)
Joliot, F, 893(ab)
Joliot, M, 872(ab)
Jolles, PR, 853(ab)
Jones, AG, 464, 748(ab), 832(ab)
Jones, AL, 904(ab), 905(ab)
Jones, BH, 932(ab)
Jones, DW, 707(ab), 750(ab), 870(ab)
Jones, E, 791(ab)
Jones, JS, 1105
Jones, M, 732(ab), 801(ab), 847(ab)
Jones, ME, 839(ab)
Jones, R, 1344
Jones, RH, 820(ab), 1128, 1300
Jones, T, 736(ab), 737(ab), 746(ab), 756(ab), 760(ab), 778(ab)
Jouve, B, 34, 726(ab)
Joyce, J, 857(ab)
Joyce, M, 726(ab)
Joyce, MJ, 756(ab)
Joyce JM, 325
Julien, P, 721(ab)
Junaid, T, 834(ab)
Junck, L, 1220
Juneja, HS, 752(ab)

Jung, H, 734(ab)
Jung, Y-W, 738(ab), 797(ab)
Jungkind, D, 810(ab)
Juni, J, 941(ab)
Juni, JE, 698(le), 894(ab)
Juweid, M, 795(ab), 811(ab), 819(ab), 833(ab), 2022

Kabalka, GW, 900(ab)
Kader, FJ, 741(ab)
Kader, KL, 805(ab)
Kadmon, D, 707(ab)
Kagaya, A, 802(ab)
Kahn, D, 549
Kairemo, KJA, 23, 759(ab), 764(ab)
Kaiser, KP, 803(ab), 1608
Kalaigian, H, 798(ab)
Kalasinski, LA, 811(ab)
Kälble, T, 1285
Kale, NJ, 908(ab)
Kalff, V, 773(ab), 802(ab)
Kalin, NH, 887(ab)
Kalinyak, KA, 893(ab)
Kalloo, AH, 732(ab)
Kalofonos, HP, 1791
Kamada, T, 603, 753(ab), 808(ab), 813(ab)
Kamano, T, 878(ab)
Kamata, N, 894(ab)
Kamata, R, 743(ab)
Kambara, H, 742(ab), 1617
Kameyama, M, 1997
Kamholz, S, 722(ab)
Kaminski, M, 852(ab)
Kaminski, MS, 765(ab), 872(ab), 1831
Kamps, WA, 755(ab)
Kang, HS, 781(ab)
Kanno, I, 736(ab), 760(ab), 778(ab)
Kanno, T, 55, 877(ab)
Kanvinde, M, 727(ab), 899(ab)
Kanvinde, MH, 908(ab)
Kanwar, N, 874(ab)
Kao, R, 912(ab)
Kao, SCS, 549
Kao, T, 871(ab)
Kapadvanjwala, M, 820(ab), 891(ab)
Kaplan, WD, 369, 372, 387, 793(ab), 794(ab), 1746(le)
Karczewski, D, 892(ab), 908(ab)
Karesh, SM, 768(ab)
Karp, JS, 617
Karstens, HJ, 751(ab)
Karvelis, KC, 912(ab)
Karwande, SV, 848(ab)
Kashiwagi, T, 813(ab)
Kasi, L, 903(ab)
Kasi, LP, 818(ab)
Kasina, S, 747(ab)
Kasliwal, R, 884(ab)
Kaslow, S, 938(ab)
Kass, E, 761(ab)
Kassis, AI, 766(ab), 1358
Katada, K, 55, 877(ab)
Kataoka, M, 846(ab)
Katayama, H, 1116
Kato, M, 880(ab)
Katoh, Y, 1520
Katz, PG, 246(le)
Katz, RD, 932(ab)
Katzenellenbogen, JA, 746(ab), 910(ab)
Kavanagh, J, 724(ab)
Kawai, C, 136, 742(ab), 1617
Kawai, R, 772(ab), 810(ab), 883(ab)
Kawakami, K, 772(ab), 855(ab), 881(ab)
Kawamoto, M, 743(ab)
Kawamura, M, 846(ab)
Kawamura, Y, 1077
Kawana, M, 793(ab)
Kawanaka, H, 714(ab)
Kaye, JA, 740(ab)
Kazerooni, EA, 526
Keck, F, 772(ab)
Keenan, A, 782(ab)
Keenan, AM, 853(ab), 999
Keenan, JF, 910(ab)
Kegeles, LS, 825(ab), 860(ab)
Kehayias, J, 791(ab)
Kellow, J, 801(ab), 847(ab)
Kelly, BJ, 1872
Kemerink, GJ, 875(ab)
Kempner, KM, 816(ab)
Kenemans, P, 734(ab), 1438(le), 1802
Kennedy, D, 1717
Kennedy, JW, 842(ab)
Kennel, SJ, 900(ab), 906(ab)
Kenney, NP, 741(ab)
Kenzora, JL, 841(ab)
Kéromès, A, 34
Kessler, ML, 872(ab)
Kessler, RM, 779(ab), 786(ab), 809(ab), 882(ab)
Ketring, AR, 586, 1316, 767(ab), 947(ab)
Kettle, A, 790(ab)
Kettle, AG, 311, 1744(le)
Keyes, JW, 1428
Keyes, JW, Jr, 573, 836(ab)
Khalili-Varasteh, M, 897(ab)
Khalvati, S, 783(ab), 788(ab)
Khan, A, 935(ab)
Khan, I, 710(ab)
Khaw, BA, 211, 795(ab), 796(ab), 805(ab), 811(ab), 841(ab), 853(ab), 854(ab), 905(ab), 1066, 1199, 1441(le)
Khawli, LA, 906(ab)
Khazaeli, M, 850(ab)
Khazaeli, MB, 852(ab)
Khouri, M, 731(ab), 848(ab), 849(ab)
Kiat, H, 812(ab), 836(ab), 894(ab), 1168
Kijewski, MF, 729(ab), 1693
Kilbourn, M, 898(ab)
Kilbourn, MR, 720(ab), 786(ab), 901(ab)
Kim, CK, 109, 126(le), 319, 682, 711(ab), 712(ab), 716(ab), 819(ab), 890(ab), 914(ab), 941(ab), 1548, 1950
Kim, E, 903(ab)
Kim, EE, 724(ab), 800(ab), 803(ab), 862(ab), 937(ab)
Kim, HJ, 729(ab), 865(ab)
Kim, KT, 965
Kim, S, 932(ab)
Kimmel, M, 895(ab)
Kimmig, B, 813(ab)
Kimura, K, 753(ab), 808(ab), 813(ab)
Kimura, K, 603
Kimura, Y, 868(ab)
King, C, 887(ab)
King, DW, 985
King, MA, 739(ab), 867(ab)
King, P, 762(ab)
King, PT, 780(ab)
King, RB, 862(ab), 944(ab)
Kinuya, K, 660, 885(ab)
Kinuya, S, 766(ab), 814(ab), 851(ab), 889(ab)
Kippenhan, JS, 817(ab)
Kir, KM, 712(ab)
Kira, Y, 861(ab)
Kiraly, Z, 832(ab)
Kirchgebner, H, 1084
Kirchner, P, 753(ab)
Kirchner, PT, 769(ab)
Kirk, GA, 734(ab)
Kirk, KL, 791(ab)
Kirkeeide, RL, 259
Kirsch, CM, 775(ab), 827(ab), 873(ab)
Kirsh, JC, 936(ab)
Kirsh, MM, 801(ab)
Kishore, R, 728(ab)
Kita, K, 877(ab)
Kitabatake, A, 753(ab)
Kitabatake, K, 808(ab)
Kitano, T, 792(ab)
Klassen, GA, 1335
Klech, H, 441
Kleffer, U, 734(ab)
Klein, J, 744(ab), 836(ab)
Klein, JL, 823(ab), 1240
Klein, M, 1548
Klein, MJ, 780(ab)
Kleinhaus, U, 365
Klieger, P, 875(ab), 876(ab)
Klijn, JG, 1501
Kling, P, 281, 786(ab), 799(ab)
Klinkowstein, RE, 943(ab)
Klipper, R, 806(ab)
Klivényi, G, 1084
Klonecke, AS, 751(ab)
Knapp, FF, 896(ab)
Knapp, WH, 2075(le)
Knezevic, S, 880(ab)
Knight, LC, 757(ab), 776(ab)
Knopp, M, 803(ab), 804(ab), 813(ab), 888(ab)
Knopp, MV, 766(ab), 771(ab), 863(ab), 939(ab)
Knust, EJ, 766(ab)
Koch, GA, 904(ab)
Kock-Jenson, C, 1121
Koeppe, RA, 709(ab), 720(ab), 779(ab)
Koga, S, 55, 877(ab), 1433(le)
Koh, C-S, 755(ab)
Koh, WJ, 756(ab)
Kohji, T, 1520
Köhler, C, 796(ab)
Köhn, H, 441
Kohno, K, 1520
Koizumi, M, 1077
Koizumi, T, 813(ab)
Kojima, A, 907(ab)
Kojima, M, 947(ab)
Kojima, S, 808(ab)
Kollmann, M, 757(ab), 776(ab)
Kolodny, GM, 845(ab), 857(ab), 1784, 1945
Költringer, P, 417, 1577(le)
Komatsu, A, 846(ab)
Kondo, M, 861(ab)
Kong, BA, 733(ab)
König, A, 871(ab)
König, B, 441
Konishi, J, 136, 708(ab), 742(ab), 743(ab), 808(ab), 844(ab), 847(ab), 848(ab), 849(ab), 850(ab), 885(ab), 895(ab), 1015, 1077, 1617, 1632, 1818
Konno, K, 543
Konstam, MA, 723(ab)
Kooij, PP, 1501
Kopecky, RT, 501
Koper, JW, 1501
Koral, K, 852(ab)
Koral, KF, 90, 759(ab), 798(ab), 872(ab)
Kos, W, 712(ab)
Kosaka, N, 778(ab), 817(ab), 885(ab)
Kostakoglu, 793(ab)
Kosten, TR, 826(ab)
Koster, K, 1400
Kosuda, S, 894(ab)
Kotchon, TL, 2046
Kotlyarov, E, 774(ab)
Kotoura, H, 1632
Kotoura, Y, 1632
Kotzerke, J, 774(ab), 1876
Kouris, K, 825(ab), 940(ab), 945(ab)
Koutts, J., 793(ab)
Kozachuck, W, 740(ab)
Kozawa, SM, 794(ab)
Kozell, LB, 794(ab)
Kozuka, T, 603, 753(ab), 808(ab), 813(ab)
Kragh, P, 873(ab)
Kramer, E, 360
Kramer, EL, 798(ab)
Kramer, M, 826(ab)
Krasnow, AZ, 712(ab), 731(ab)
Krawczynska, E, 732(ab)
Krawczynska, EG, 837(ab)
Krebs, K, 910(ab)
Kremer, M, 805(ab)
Krenning, EP, 1501
Krivokapich, J, 773(ab), 795(ab)
Krivokapitch, J, 713(ab)
Kroger, LA, 754(ab)
Krohn, KA, 99, 337, 756(ab), 833(ab), 909(ab), 1257
Kronauge, JF, 464, 1646, 736(ab), 748(ab), 832(ab), 1646
Kropp, J, 896(ab)
Krubsack, AJ, 827(ab)
Kuang, L, 903(ab)
Kubo, A, 792(ab), 852(ab), 894(ab)
Kubo, S, 1015, 742(ab), 743(ab), 847(ab), 848(ab), 849(ab)
Kubota, K, 885(ab), 1654, 1927
Kubota, R, 885(ab)
Kucharski, AJ, 725(ab)
Kuczynski, BL, 1370
Kudryk, BJ, 1048
Kuebler, WK, 863(ab)
Kuhar, MJ, 720(ab)
Kuhl, D, 746(ab), 889(ab)
Kuhl, DE, 61, 163, 709(ab), 720(ab), 745(ab), 773(ab), 774(ab), 779(ab), 801(ab), 802(ab), 885(ab), 1220, 1876
Kuhle, W, 774(ab)
Kuhn, JA, 764(ab), 850(ab)
Kuhns, LR, 893(ab)
Kuikka, JT, 803(ab)
Kukis, DL, 473, 823(ab)
Kukumura, T, 889(ab)
Kulbertus, H, 840(ab)
Kulkarni, V, 1595
Kumar, A, 740(ab)
Kumar, K, 824(ab), 898(ab)
Kumar, R, 752(ab)
Kumar, SJ, 1797
Kumita, S, 782(ab), 783(ab), 881(ab)
Kundrat, S, 825(ab)
Kung, H, 708(ab), 899(ab)
Kung, HF, 573, 648, 668, 588(ab), 727(ab), 809(ab), 883(ab), 898(ab), 899(ab), 1635
Kung, MP, 573, 648, 708(ab), 727(ab), 809(ab), 899(ab), 1635
Kuni, CC, 731(ab), 936(ab)
Kunz, A, 905(ab)
Kunz, LL, 765(ab)
Kupfer, S, 825(ab), 860(ab), 914(ab)
Kurczak, S, 909(ab)
Kuroda, Y, 240
Kusakabe, K, 793(ab), 833(ab)
Kushner, BH, 742(ab)
Kushner, M, 741(ab), 1364
Kushner, MJ, 1574(le)
Kusić, Z, 393
Kusumoto, Y, 1520
Kuwabara, H, 721(ab), 884(ab)
Kuwabara, Y, 880(ab), 889(ab)
Kuwert, T, 281
Kuzel, T, 854(ab)
Kuzel, TM, 725(ab)
Kwiatkowski, M, 747(ab)
Kwok, CS, 783(ab)
Kyle, RA, 292

Labar, D, 816(ab), 847(ab)
L'Abbate, A, 173, 1335
Laborda, J, 1028
Lacy, JL, 754(ab), 759(ab), 843(ab), 855(ab), 1723
Lafontaine, E, 775(ab), 1921
Lahiri, A, 231, 782(ab), 841(ab)
Lai, KH, 848(ab)
Lai, YL, 773(ab)

Lambert, CR, 900(ab), 906(ab)
Lambert, R, 821(ab), 828(ab)
Lamberts, SW, 1501
Lambiotte, M, 783(ab)
Lambotte, L, 816(ab), 847(ab)
Lambrecht, R, 864(ab)
Lambrecht, RM, 777(ab), 947(ab)
Lamki, LM, 724(ab), 800(ab), 803(ab), 818(ab), 937(ab)
Lammertsma, AA, 746(ab), 756(ab), 943(ab)
Lamoureux, F, 972, 789(ab)
Lamoureux, G, 1862
Lamoureux, J, 972, 789(ab)
Lampson, LA, 766(ab)
Lançon, JP, 709(ab), 866(ab)
Landesman, AL, 632
Landoni, C, 821(ab)
Láng, JJ, 1114
Langen, K-J, 281
Langer, A, 874(ab)
Langhorst, SM, 947(ab)
Langmuir, VK, 1527
Langsteger, W, 417, 1577(le)
Lanigan, JP, 947(ab)
Lanza, RC, 729(ab)
Laor, T, 1120
Laperrière, L, 729(ab), 758(ab)
La Pidus, A, 764(ab)
LaQuaglia, M, 742(ab)
Larcos, G., 793(ab)
Larock, MP, 840(ab)
Larsen, SK, 776(ab)
Larson, DM, 888(ab)
Larson, SJ, 712(ab)
Larson, SM, 202, 742(ab), 764(ab), 793(ab), 798(ab), 845(ab), 864(ab), 879(ab), 1133
Larsson, S, 796(ab)
Lastoria, S, 794(ab), 1438(le)
Latour, Y, 821(ab), 828(ab)
Lattimer, JC, 586, 767(ab), 1316
Lattuga, S, 781(ab)
Laurin, N, 775(ab)
Laven, DL, 933(ab)
Lavender, JP, 851(ab), 1791
Lawton, RG, 904(ab)
Laxer, KD, 880(ab)
Layne, WW, 759(ab), 855(ab)
Lazewatsky, J, 785(ab), 828(ab)
Le, N, 906(ab)
Leal, JP, 816(ab)
Lear, JL, 758(ab), 835(ab), 884(ab), 942(ab)
LeBlanc, AD, 43
Lechel, U, 873(ab)
LeCloirec, J, 1470
Le Doussal, JM, 757(ab)
Lee, BCP, 936(ab)
Lee, BI, 1280
Lee, C, 801(ab)
Lee, HB, 913(ab)
Lee, K, 735(ab), 853(ab)
Lee, KJ, 711(ab), 1749, 1933
Lee, KS, 801(ab), 816(ab)
Lee, MC, 755(ab), 781(ab)
Lee, MJ, 1557
Lee, RE, 783(ab), 788(ab), 850(ab)
Lee, SO, 712(ab), 941(ab)
Lee, Y-CC, 824(ab), 849(ab), 904(ab)
Leedham, RK, 890(ab)
Lees, GS, 733(ab), 734(ab)
LeFurgey, A, 748(ab)
Legrand, V, 840(ab)
Le Gulude, D, 839(ab)
Le Guludec, D, 1303
Lehrman, H, 755(ab)
Leichner, PK, 823(ab), 873(ab)
Leichter, SB, 800(ab)
Leiderman, D, 710(ab)
Leight, GS, 745(ab)
Leinsinger, G, 873(ab)
Leisner, B, 940(ab)
Leisure, GP, 756(ab)
Lemaire, C, 1247
Lemmens, JAM, 712(ab)
Lennon, SE, 1443
Lentle, B, 1575(le)
Lentle, BC, 2046
Lenzi, GL, 741(ab)
Leon, AR, 735(ab), 835(ab)
Leonard, JC, 375
Leppo, J, 782(ab)
Leppo, JA, 67, 827(ab), 828(ab), 832(ab), 1851
Leroy, RF, 817(ab), 1851
Lesniak, MA, 791(ab)
Le-Trong, JL, 34
Lette, J, 124(le)
Levasseur, M, 770(ab), 880(ab)
Léveillé, J, 839(ab)
Levenbook, I, 1028
Lever, JR, 709(ab)
Lever, SZ, 806(ab)
Levina, T, 939(ab)
Levine, RL, 770(ab), 789(ab)
Levitt, NS, 106
Levy, AV, 864(ab)
Levy, D, 787(ab)
Levy, NB, 724(ab)
Levy, R, 1257
Levy, WC, 838(ab)
Lewellen, TK, 728(ab), 756(ab), 863(ab)
Lewis, DH, 912(ab)
Lewis, JP, 724(ab)
Li, AP, 910(ab)
Li, Q-S, 1069
Li, Z, 1059
Liang, Z, 858(ab)
Libson, K, 747(ab), 807(ab), 834(ab)
Lich, LL, 351
Lieberman, M, 748(ab)
Liege, CHU, 840(ab)
Lietzenmayer, R, 821(ab)
Liewendahl, K, 23, 384(le)
Ligon, RW, 836(ab)
Lillioja, S, 879(ab)
Lillywhite, RC, 763(ab)
Lim, K, 337
Lim, SM, 755(ab)
Lind, P, 417, 535(le), 1577(le)
Linder, KE, 747(ab)
Line, BR, 857(ab)
Link, J, 337
Link, JM, 99, 794(ab)
Links, J, 865(ab)
Links, JM, 750(ab), 862(ab), 878(ab), 1230, 2052
Lister-James, J, 776(ab), 795(ab), 833(ab), 905(ab)
Listrom, MB, 1099
Liu, B, 727(ab), 899(ab)
Liu, BL, 1635
Liu, CZ, 758(ab)
Liu, MA, 854(ab)
Liu, Q, 769(ab)
Liu, RS, 762(ab), 772(ab), 848(ab), 1294
Liu, X, 769(ab)
Liu, XJ, 782(ab)
Livni, E, 834(ab), 1823
Lizzio, EF, 1028
Ljungberg, M, 493
Ljungberg, MH, 1560
Ljunggren, K, 2058
Llaurado, JG, 594
Llewellyn, HJ, 1120
Lloyd, J, 738(ab)
Lloyd-Hontz, K., 710(ab)
Lo, JM, 947(ab)
Loats, HL, 862(ab), 865(ab)
Loats, PE, 862(ab)
LoBuglio, A, 850(ab)
LoBuglio, AF, 852(ab)
Loch, C, 770(ab), 866(ab), 897(ab), 899(ab)
Locke, E, 1199
Loeffler, J, 826(ab)
Loesch, J, 851(ab)
Loewenson, RB, 936(ab)
Loewenstein, D, 730(ab)
Logan, J, 719(ab), 809(ab), 866(ab)
Logus, JW, 856(ab), 945(ab)
Loke, JO, 789(ab)
Lollo, CP, 757(ab)
Lombroso, CT, 892(ab)
Lomsky, M, 841(ab)
London, ED, 2052
Longford, CPD, 900(ab)
Lopalco, L, 735(ab)
Loréal, O, 1470
Lorenz, WJ, 766(ab), 813(ab), 863(ab), 888(ab)
Lorimer, MK, 817(ab)
Losinno, F, 913(ab)
Losonzcy, M, 874(ab)
Lösse, B, 1608
Lotstra, F, 750(ab)
Loudenslager, DM, 873(ab)
Loutfi, I, 851(ab)
Lowe, SR, 911(ab)
Lowenstein, E, 1344
Lu, JY, 772(ab)
Lubin, E, 523, 755(ab)
Lubowski, DZ, 985
Lucignani, G, 821(ab), 834(ab)
Luckey, M, 539(le)
Ludbrook, PA, 841(ab)
Luedtke, RR, 728(ab), 901(ab)
Luh, KE, 787(ab), 864(ab)
Lui, D, 811(ab)
Lundsten, M, 783(ab)
Luo, JQ, 719(ab)
Luxen, A, 750(ab)
Lyle, LR, 747(ab)
Lynch, RE, 424
Lyons, E, 812(ab), 837(ab)
Lyons, K, 732(ab)
Lyons, NR, 985
Lyster, D, 1575(le)

Ma, GQ, 735(ab), 876(ab)
Maas, KW, 1797
Macapinlac, H., 793(ab)
Maccabee, P, 761(ab)
Macey, DJ, 788(ab), 822(ab), 859(ab)
MacGregor, D, 891(ab)
MacGregor, R, 719(ab), 866(ab)
MacGregor, RR, 780(ab), 886(ab)
Mach, J-P, 1035
Mach, RH, 728(ab), 901(ab)
Machac, J, 764(ab), 812(ab)
Machida, K, 878(ab)
Machlin, SR, 750(ab)
Machulla, H-J, 766(ab), 1608
MacIntyre, WJ, 722(ab), 802(ab), 1899
Mack, DL, 187
Mackensen, DG, 911(ab)
Mackey, DWJ, 168
Macklis, R, 1045
MacVittie, TJ, 849(ab), 904(ab)
Madajewicz, S, 762(ab)
Maddahi, J, 713(ab), 804(ab), 805(ab), 812(ab), 828(ab), 832(ab), 836(ab), 934(ab), 1168
Madden, JA, 942(ab), 945(ab)
Madsen, MT, 719(ab), 753(ab), 769(ab)
Madsen, SL, 768(ab), 1662
Maeda, H, 55, 877(ab), 1433(le)
Magata, Y, 742(ab), 848(ab), 849(ab)
Magill, HL, 287, 716(ab)
Magnani, P, 735(ab), 853(ab), 854(ab)
Magoun, S, 1486
Magoun, SL, 752(ab)
Magrath, IT, 794(ab)
Maguire, C, 237
MaGuire, RT, 724(ab)
Mahmarian, JJ, 1269, 722(ab), 751(ab), 843(ab)
Mahoney, DK, 709(ab), 865(ab), 944(ab)
Maier-Borst, W, 803(ab), 804(ab), 1084
Mailman, R, 737(ab)
Mainguet, P, 814(ab)
Majd, M, 742(ab)
Makley, JT, 756(ab)
Makrigiorgos, GM, 766(ab), 1358
Makriyannis, A, 902(ab)
Malamut, BL, 730(ab)
Malet, P, 731(ab), 848(ab), 849(ab)
Maley, BL, 1048
Malfertheiner, P, 1940
Malhotra, A, 841(ab)
Malinoff, HL, 912(ab)
Mallard, JR, 1595
Mallette, S, 777(ab)
Mallette, SA, 804(ab), 1479
Malmin, RE, 648
Maloney, PJ, 202
Mamiya, T, 878(ab)
Mamo, H, 1601
Mandelkern, M, 881(ab)
Mandell, GA, 742(ab), 1797
Mandeville, BJ, 904(ab)
Maneval, DC, 287, 716(ab), 1577(le)
Manger, R, 852(ab)
Mangili, F, 854(ab)
Manglos, SH, 875(ab)
Mangner, TJ, 163, 785(ab)
Maniawski, PJ, 718(ab)
Manjoney, D, 722(ab)
Manke, H, 766(ab)
Mankin, HJ, 781(ab)
Mankoff, D, 727(ab), 1635
Mankoff, DA, 617
Mann, MD, 1276
Mann, SJ, 716(ab)
Manning, RG, 779(ab)
Mansi, L, 882(ab), 1438(le)
Manspeaker, HF, 795(ab)
Manspeaker, P, 841(ab)
Manyari, DE, 154
Mar, LS, 632
Marcassa, C, 173
Marciano, D, 965, 799(ab), 825(ab), 874(ab)
Marciniak, G, 902(ab)
Marcus, C, 908(ab)
Marcus, CS, 1237
Margonato, A, 797(ab)
Mariani, G, 860(ab), 876(ab)
Markand, ON, 1280
Markel, MD, 829(ab)
Markl, A, 827(ab)
Marks, MA, 372
Marmion, M, 807(ab)
Marmion, ME, 748(ab)
Marsh, JD, 464
Marsh, L, 549
Marshal, P, 740(ab)
Marslew, U, 1156
Martell, AE, 768(ab), 1662, 1744(le)
Martin, B, 1105
Martin, CC, 815(ab)
Martin, E, Jr, 851(ab)
Martin, GV, 99, 833(ab)
Martin, LJ, 1723
Martin, M, 757(ab)
Martin, NL, 937(ab)
Martin, PJ, 724(ab), 1257
Martin, RH, 933(ab)
Martin, SE, 735(ab)
Martinez-Duncker, C, 1965
Martini, D, 844(ab)
Maruyama, Y, 847(ab), 897(ab)
Marwick, T, 722(ab)
Marwick, TH, 802(ab), 1899
Marzullo, P, 173
Maseri, A, 736(ab)
Mason, GR, 908(ab)
Massardo, T, 450, 837(ab)
Massuger, L, 1438(le)

Massuger, LFAG, 734(ab), 1802
Masuda, K, 880(ab), 889(ab)
Masuo, M, 778(ab)
Masure, MC, 892(ab)
Matarrese, M, 747(ab), 821(ab)
Mather, SJ, 692
Mathias, CJ, 192, 351, 707(ab), 727(ab), 738(ab), 746(ab), 814(ab), 815(ab), 909(ab), 910(ab), 1662, 1989
Mathieu, J-P, 640
Mathis, C, 737(ab)
Matley, PJ, 106
Matoba, N, 885(ab)
Matsuda, H, 660, 869(ab), 880(ab), 885(ab)
Matsudaira, M, 869(ab)
Matsumori, A, 136
Matsumoto, K, 1818
Matsumoto, M, 603
Matsumura, K, 725(ab), 886(ab)
Matsuzawa, T, 885(ab), 1654, 1927
Mattar, AG, 526
Mattera, JA, 1400
Mattheijssen, NAA, 717(ab)
Matthew, E, 887(ab)
Matys, R, 1084
Matzer, L, 836(ab)
Matzku, S, 741(ab), 855(ab), 1084
Maurer, AH, 757(ab), 776(ab), 826(ab), 1412
Mausner, LF, 909(ab)
Mayberg, HS, 709(ab), 770(ab), 816(ab)
Maynard, C, 842(ab)
Maze, M, 841(ab)
Mazess, RB, 538(le)
Mazière, B, 770(ab), 892(ab), 897(ab), 899(ab)
Mazière, M, 897(ab)
Mazoyer, B, 872(ab), 892(ab), 893(ab)
Mazoyer, BM, 709(ab), 866(ab)
Mazzière, B, 866(ab)
Mazziotta, J, 799(ab)
Mazziotta, JC, 965, 708(ab), 740(ab), 759(ab), 825(ab), 865(ab)
McAfee, J, 810(ab)
McAfee, JG, 413, 501, 892(ab), 1048
McBride, W, 885(ab)
McCall, MJ, 218, 473, 823(ab)
McCallum, RW, 759(ab), 847(ab)
McCandless, BK, 857(ab)
McCarthy, K, 715(ab), 907(ab), 943(ab)
McCarthy, KE, 743(ab), 942(ab)
McCartney, WH, 738(ab), 798(ab), 866(ab)
McClain, C, 801(ab)
McClanahan, T, 1352
McCord, M, 777(ab)
McCord, ME, 736(ab)
McCormick, L, 824(ab)
McCracken, CB, 947(ab)
McDermott, RL, 2034
McDonald, PM, 741(ab)
McDougall, IR, 751(ab)
McDougle, CJ, 750(ab), 826(ab)
McEwan, AJ, 856(ab), 2046
McGhie, AI, 753(ab), 824(ab), 838(ab), 859(ab)
McGill, JE, 741(ab)
McGillicuddy, JE, 790(ab)
McGuire, AH, 351, 707(ab), 746(ab), 909(ab), 1989
McGuire, DJ, 746(ab)
McIntosh, A, 716(ab)
McKay, WJ, 711(ab)
McKeever, PE, 784(ab), 884(ab)
McKenzie, CG, 746(ab)
McKinnon, ZA, 814(ab)
McKusick, KA, 743(ab), 781(ab)
McLean, RC, 985
McLellan, CA, 720(ab)
McNamara, D, 972
McNeill, G, 891(ab)
McShan, DL, 784(ab), 872(ab)
McSherry, BA, 827(ab), 828(ab), 1851
Meares, CF, 218, 473, 727(ab), 823(ab)
Mease, RC, 896(ab), 1534
Meerdink, DJ, 67, 832(ab)
Mehdorn, HM, 766(ab), 818(ab)
Mehr, SH, 741(ab)
Mehta, BM, 845(ab)
Meier, D, 539(le)
Meier, MJ, 936(ab)
Meigel, W, 940(ab)
Meinken, GE, 343, 896(ab)
Meldolesi, U, 821(ab)
Melega, W, 708(ab)
Melega, WP, 720(ab), 865(ab)
Melin, J, 820(ab)
Melin, JA, 843(ab)
Melis, K, 893(ab)
Meloni, C, 797(ab)
Meltzer, C, 770(ab)
Meltzer, CC, 816(ab)
Memsic, L, 767(ab)
Mena, I, 457, 877(ab), 908(ab), 1237
Mendez, GE, 718(ab)
Mendlewicz, J, 750(ab)
Meng, X, 900(ab)
Merchant, B, 734(ab)
Meredith, R, 850(ab)
Meredith, RF, 852(ab)
Merino, M, 755(ab)
Merlet, P, 34, 726(ab), 1303
Merrick, MV, 1433(le)
Merrill, JC, 910(ab)
Mesko, L, 1811
Messa, C, 871(ab)
Mester, J, 821(ab), 1856
Metherall, J, 723(ab)
Metz, CE, 748(ab)
Metz, JT, 761(ab), 864(ab)
Meury, V, 884(ab)
Meyer, E, 861(ab), 882(ab)
Meyer, GA, 712(ab)
Meyer, G-J, 899(ab)
Meyer, KL, 332
Meyer, MA, 879(ab), 937(ab), 1094
Meyers, MJ, 383(le)
Meyers, WG, 489
Michaels, E, 913(ab)
Michelson, RH, 797(ab)
Michigishi, T, 766(ab), 889(ab)
Miettinen, M, 23
Mikati, M, 892(ab)
Miki, K, 946(ab)
Miki, M, 543
Mikinski, M, 821(ab)
Milella, M, 1743(le)
Milenic, DE, 1133
Miles, S, 716(ab)
Miller, B, 877(ab)
Miller, DC, 849(ab)
Miller, DD, 785(ab)
Miller, DL, 674
Miller, GL, 721(ab)
Miller, JH, 893(ab)
Miller, KM, 747(ab), 768(ab)
Miller, R, 852(ab)
Miller, RA, 1257
Miller, S, 894(ab)
Miller, TR, 807(ab), 1421, 1732, 1933, 2064
Mills, SL, 727(ab), 899(ab), 908(ab)
Mills, SN, 724(ab)
Milne, N, 732(ab)
Milstein, D, 1784
Milster, TD, 632
Minami, C, 908(ab)
Mink, J, 830(ab)
Minkin, E, 809(ab), 882(ab)
Minoshima, K, 888(ab)
Minoshima, S, 877(ab)
Minton, J, 851(ab)
Mintun, MA, 351, 816(ab)
Mintz, A, 813(ab)
Mintz, L, 881(ab)
Mir, RN, 935(ab)
Miraldi, F, 756(ab)
Miron, SD, 931(ab)
Mirra, J, 567
Mirzadeh, S, 824(ab)
Mirzai, M, 868(ab)
Misaki, T, 512
Misra, H, 903(ab)
Mitani, I, 763(ab), 782(ab), 783(ab)
Mitchell, B, 752(ab), 791(ab)
Mitchell, D, 718(ab)
Mitchell, JB, 815(ab)
Mitsutani, N, 813(ab)
Mituyama, Y, 688
Miura, S, 760(ab)
Miyagawa, M, 858(ab), 868(ab)
Miyake, H, 720(ab)
Miyake, Y, 946(ab)
Miyaoka, R, 863(ab)
Miyaoka, RS, 728(ab), 863(ab)
Mizejewski, GJ, 910(ab)
Mlcoch, T, 878(ab)
Mochizuki, T, 858(ab), 2042
Mock, BM, 946(ab)
Modell, JG, 61, 790(ab)
Modorati, G, 854(ab)
Mody, VF, 795(ab)
Moeller, B, 715(ab)
Moen, JG, 1220
Moerlein, SM, 745(ab), 746(ab), 773(ab), 780(ab), 902(ab), 910(ab), 1749
Mogami, H, 790(ab), 858(ab)
Mogos, A, 781(ab)
Mohan, R, 1884
Mohiuddin, S, 733(ab)
Mohr, G, 972
Moi, MK, 473
Moisan, A, 1470
Mojiminiyi, SA, 381(le)
Mojzisik, C, 851(ab)
Molea, N, 876(ab)
Molina, E, 1474, 1876
Molinoff, P, 898(ab)
Molinoff, PB, 728(ab), 901(ab)
Molinolo, A, 765(ab)
Momose, T, 778(ab), 817(ab), 885(ab)
Monestier, M, 854(ab)
Monetti, N, 913(ab)
Mong, DP, 1958
Monge, JC, 187
Monroe, LA, 714(ab)
Monsein, LH, 818(ab), 878(ab)
Montes, A, 913(ab)
Mont F, G, 864(ab)
Montgomery, JA, 1823
Moolenaar, AJ, 1147
Moore, BA, 719(ab)
Moore, JG, 800(ab)
Moore, MR, 826(ab)
Moore, RH, 736(ab), 831(ab)
Moore, SC, 729(ab), 1693
Moore, WH, 714(ab), 1761
Moreno, AJ, 932(ab)
Moretti-Hop, JL, 839(ab)
Morgan, AC, Jr, 765(ab), 852(ab)
Morgan, GF, 760(ab), 807(ab)
Morgan, HT, 718(ab), 739(ab)
Morgan, WA, 1412
Mori, H, 660, 885(ab)
Mori, Y, 772(ab), 855(ab), 881(ab)
Morita, R, 829(ab)
Moriwaki, H, 603
Moriyama, H, 603
Moronoy, S, 129
Morozumi, T, 753(ab), 808(ab)
Morris, JC, 730(ab)
Morris, JH, 766(ab)
Morrison, KS, 886(ab)
Morrison, M, 874(ab)
Morrison, W, 718(ab)
Morton, KA, 424, 744(ab), 800(ab), 848(ab), 914(ab), 1847
Moser, RP, 818(ab)
Moses, WW, 749(ab)
Moskowitz, GW, 935(ab)
Mostbeck, A, 441
Motekaitis, RJ, 768(ab), 1744(le)
Motomiya, M, 543
Motta-Hennessy, C, 1510
Mountford, PJ, 311, 1744(le)
Mountz, JD, 884(ab)
Mountz, JM, 61, 790(ab), 884(ab), 1574(le)
Mousa, AR, 830(ab)
Mozley, PD, 751(ab)
Mudgett, E, 777(ab)
Mudgett, EE, 804(ab), 1479
Muehllehner, G, 617, 751(ab)
Mueller, SP, 729(ab)
Mueller-Gaertner, HW, 770(ab)
Mukai, T, 808(ab), 847(ab)
Mukherjee, J, 787(ab)
Mulder, RU, 759(ab)
Mulholland, GK, 709(ab), 779(ab), 897(ab)
Mullani, N, 803(ab), 937(ab)
Mullani, NA, 610
Müller, SP, 715(ab), 729(ab), 766(ab), 767(ab), 818(ab), 1693
Müller-Suur, R, 1811
Mulligan, JS, 1211
Mulligan, T, 246(le)
Mundy, J, 948(ab)
Munley, MT, 798(ab), 869(ab), 870(ab)
Munz, DL, 744(ab)
Murakami, M, 240, 760(ab)
Murali, D, 900(ab), 902(ab)
Muramori, A, 792(ab)
Murase, K, 858(ab), 868(ab)
Murase, M, 790(ab)
Murphy, RA, 648
Murray, IPC, 168, 1746(le)
Murray, JL, 724(ab), 1436(le)
Murthy, S, 724(ab), 783(ab), 788(ab), 850(ab)
Muzik, O, 281
Myler, RK, 763(ab), 836(ab)

Nadel, HR, 939(ab)
Nadler, LM, 793(ab)
Nagamachi, S, 688
Nagami, K, 792(ab)
Nagase, M, 881(ab)
Nagata, M, 833(ab)
Nagata, S, 782(ab)
Nagataki, S, 1520
Nagel, JS, 721(ab), 826(ab), 1552
Nair, M, 945(ab)
Nair, N, 1180
Najafi, A, 735(ab), 853(ab), 908(ab)
Nakabayashi, H, 881(ab)
Nakagawa, K, 802(ab)
Nakagawa, T, 792(ab)
Nakahashi, H, 738(ab), 861(ab)
Nakai, T, 844(ab), 850(ab), 895(ab)
Nakajima, K, 766(ab), 792(ab), 889(ab)
Nakamura, K, 852(ab)
Nakamura, Y, 808(ab)
Nakanishi, M, 895(ab)
Nakano, N, 832(ab)
Nakata, K, 1520

Nakata, S, 790(ab)
Nakayama, M, 907(ab)
Nakhleh, R, 731(ab)
Narahara, KA, 457
Nariai, T, 888(ab)
Narra, RK, 1370
Naruki, Y, 847(ab)
Narula, J, 805(ab), 841(ab), 905(ab), 1066
Narula, JL, 796(ab)
Naruse, H, 714(ab)
Nasr, F, 727(ab)
Natale, A, 765(ab)
Natarajan, TK, 809(ab)
Navarro, D, 1746(le)
Nayak, UN, 1163
Nayanar, VV, 168
Nebeling, B, 771(ab)
Neblock, DS, 805(ab)
Nedelman, M, 776(ab), 1199
Nedelman, MA, 795(ab), 805(ab), 833(ab), 905(ab)
Need, JL, 944(ab)
Neely, H, 715(ab)
Neely, HR, 1761
Nelp, WB, 724(ab), 1257
Nelson, AD, 884(ab)
Nemiroff, C, 755(ab)
Nepola, JV, 549
Neptune, M, 890(ab)
Nettekoven, F, 910(ab)
Neuman, A, 839(ab)
Neumann, DR, 802(ab), 1899
Neumann, RD, 755(ab), 794(ab), 906(ab)
Neumann, WL, 897(ab)
Neutze, J, 52
Nevin, E, 852(ab)
Newell, JB, 805(ab)
Newman, AH, 883(ab)
Newman, ES, 904(ab), 905(ab)
Newman, LG, 890(ab)
Newton, MR, 711(ab)
Newton, RH, 1595
Ng, CK, 778(ab), 860(ab), 910(ab)
Ng, MN, 762(ab)
Nguyen, BD, 731(ab)
Nguyen, D, 862(ab)
Nguyen, N, 726(ab), 785(ab), 1183
Nguyen, T, 723(ab), 763(ab), 812(ab), 837(ab)
Nichols, K, 812(ab), 828(ab), 832(ab)
Nickerson, RC, 933(ab)
Nicklaus, K, 728(ab), 901(ab)
Nickles, RJ, 749(ab), 789(ab), 815(ab), 887(ab), 900(ab), 901(ab), 902(ab)
Nicol, PD, 796(ab), 805(ab)
Nicole, M, 716(ab)
Nicosia, SV, 938(ab)
Nieroda, C, 851(ab)
Nishikawa, J, 778(ab), 817(ab), 885(ab)
Nishimura, S, 722(ab), 754(ab), 843(ab), 901(ab)
Nishimura, T, 763(ab), 782(ab), 783(ab), 881(ab)
Nishimura, Y, 1077
Nishino, H, 738(ab)
Nishino, M, 847(ab)
Nishio, Y, 743(ab)
Nishizawa, S, 240
Nissen, KF, 870(ab)
Niwayama, H, 802(ab)
Noguchi, M, 847(ab)
Nohara, R, 742(ab), 1617
Nolan, J, 801(ab), 847(ab)
Nooitgedacht, EA, 831(ab)
Norby, EH, 52
Norin, A, 722(ab)
Normolle, D, 804(ab), 1479
Normolle, DP, 765(ab)
Noronha, JG, 888(ab)
Northup, HM, 1103
Nosco, D, 806(ab), 908(ab)
Nosco, DL, 748(ab), 907(ab)
Nossiff, N, 211, 805(ab), 853(ab), 905(ab)
Nossiff, ND, 796(ab), 854(ab)
Noto, R, 573
Nowak, RD, 857(ab)
Nowotnik, DP, 747(ab)
Noz, M, 798(ab)
Nunn, AD, 747(ab), 1370
Nutt, R, 862(ab)

Oakes, J, 878(ab)
Oakes, TR, 815(ab)
Oates, E, 723(ab)
Oates, J, 808(ab)
Oba, H, 660
Oberdorfer, F, 766(ab), 888(ab)
Ochi, K, 868(ab)
O'Connell, W, 752(ab), 812(ab), 872(ab)
O'Connell, WJ, 841(ab)
O'Connor, MK, 700(le), 1872
O'Connor, W, 668
Oda, K, 944(ab)
Oda, Y, 861(ab)
Odano, I, 750(ab), 876(ab)
O'Doherty, M, 790(ab)
O'Doherty, MJ, 311, 1744(le)
O'Donnell, JK, 741(ab)
O'Donnell, SM, 796(ab), 805(ab)
Oehr, P, 854(ab)
Ogilby, D, 723(ab)
O'Grady, LF, 724(ab)
Oh, DJ, 735(ab)
O'Halloran, LR, 852(ab)
Ohashi, K, 714(ab)
Ohnishi, T, 688
Ohta, H, 1632
Ohta, S, 861(ab), 882(ab)
Ohta, Y, 793(ab), 833(ab)
Ohtake, T, 778(ab), 817(ab), 885(ab)
Ohtani, H, 136, 742(ab), 743(ab), 808(ab), 1617
Ohtani, N, 848(ab)
Ojeda, B, 1450, 1965
Okada, J, 877(ab), 888(ab)
O'Keefe, JH, Jr, 836(ab), 843(ab)
Oladiran, OB, 947(ab)
Oldfield, EH, 810(ab)
Olea, E, 825(ab), 913(ab)
Olken, NM, 708(ab)
Ollinger, JM, 617
Olsen, J, 851(ab)
Olson, J, 810(ab)
Oluwole, S, 820(ab)
Ono, K, 844(ab)
Ono, Y, 736(ab)
Onoyama, Y, 895(ab)
Onsel, C, 712(ab)
Ooya, T, 847(ab)
Ordonez, CE, 617
Orellana, P, 913(ab)
Origitano, TC, 768(ab)
Orlandi, C, 785(ab)
O'Rourke, R, 785(ab)
O'Rourke, RA, 785(ab)
Orr, R, 850(ab)
Orr, RA, 852(ab)
Orrison, WW, Jr, 679
Ortega, C, 787(ab)
Ortega, V, 751(ab), 1450
Orth, F, 899(ab)
Ortiz, SS, 893(ab)
Oskoie, SK, 880(ab)
Osman, M, 913(ab)
Ostella, F, 904(ab), 905(ab)
Oster, ZH, 832(ab), 834(ab), 886(ab), 1055
Ostertag, H, 766(ab)
Ostertag, HJ, 863(ab)
Ostrzega, E, 812(ab)
Oswald, SG, 274
Otsuka, M, 880(ab), 889(ab)
Otsuka, N, 829(ab)
Otsuka, S, 847(ab), 861(ab)
Ott, L, 801(ab)
Ott, RJ, 860(ab)
Otto, CA, 897(ab)
O'Tuama, LA, 892(ab), 2040
Ouellette, R, 789(ab)
Overgaard, K, 1156
Owen, J, 805(ab)
Owunwanne, A, 834(ab), 940(ab)
Oyen, WJG, 403, 712(ab), 810(ab), 811(ab), 819(ab)
Ozawa, Y, 743(ab)

Paans, AMJ, 746(ab), 861(ab)
Pace, L, 838(ab)
Packard, AB, 2040
Paczolt, EA, 826(ab)
Paganelli, G, 735(ab), 834(ab), 853(ab), 854(ab)
Pahl, JJ, 740(ab)
Paik, CH, 202, 896(ab), 906(ab)
Pak, KY, 795(ab), 805(ab), 905(ab)
Palatianos, G, 891(ab)
Palestro, C, 781(ab)
Palestro, CJ, 109, 319, 682, 711(ab), 712(ab), 716(ab), 819(ab), 890(ab), 895(ab), 941(ab), 1548, 1950
Palevsky, HI, 1
Palmer-Lawrence, JL, 716(ab)
Palser, R, 868(ab)
Pan, S, 573
Panza, N, 1438(le)
Panzer, D, 715(ab), 943(ab)
Panzer, DE, 942(ab)
Papadopoulis, S, 885(ab)
Papapoulos, SE, 931(ab), 1774
Pappata, S, 880(ab)
Paras, P, 393
Parekh, N, 1285
Park, C, 932(ab)
Park, CH, 810(ab)
Park, H-M, 1280
Parker, JA, 721(ab), 857(ab)
Parkey, RW, 721(ah)
Parodi, O, 173, 1335
Parviainen, S, 748(ab)
Pascal, O, 1303
Pascal, S, 730(ab), 817(ab), 826(ab)
Paserio, E, 1766
Pasini, A, 735(ab)
Passeri, A, 739(ab)
Passl, R, 417
Patchen, ML, 849(ab), 904(ab)
Patchin, D, 501
Pate, BD, 737(ab), 886(ab)
Patel, BR, 931(ab)
Patel, K, 731(ab)
Patel, RB, 1163
Patel, Y, 869(ab)
Pathria, MN, 756(ab)
Patterson, RE, 735(ab), 808(ab), 835(ab), 870(ab)
Patton, DD, 632, 719(ab), 769(ab), 772(ab)
Paugh, E, 837(ab)
Paul, S, 887(ab)
Paulesu, E, 741(ab)
Pauwels, EKJ, 931(ab), 935(ab), 1147, 1774
Pauwels, S, 732(ab), 814(ab), 816(ab), 847(ab)
Pavel, DG, 825(ab), 913(ab)
Paviá, A, 127(le)
Pavia, MS, 786(ab)
Pavlica, P, 913(ab)
Pawlik, G, 771(ab)
Pawlyk, D, 788(ab)
Pawlyk, DA, 783(ab)
Payan, JM, 1105
Payne, JK, 817(ab)
Pearlson, G, 809(ab)
Pearlson, GD, 750(ab)
Pederson, NT, 1121
Peeters, T, 1490
Pelegrin, A, 1035
Pelizzari, CA, 872(ab)
Pellerin, E, 775(ab), 1921
Pellikka, PA, 1269
Peltier, P, 805(ab)
Pemberton, JH, 775(ab)
Penalver, M, 819(ab)
Penenberg, B, 830(ab)
Peng, NJ, 772(ab), 848(ab)
Penglis, S, 1568
Penin, H, 881(ab)
Pennacchioli, L, 853(ab)
Pennell, BC, 739(ab), 867(ab)
Penney, JB, 720(ab)
Pentlow, KS, 764(ab), 864(ab)
Perani, D, 741(ab)
Peretz, A, 830(ab)
Perez, JE, 773(ab), 794(ab)
Perlman, SB, 770(ab), 778(ab), 887(ab)
Perlmutter, JS, 730(ab), 780(ab), 815(ab), 1989
Perrone-Filardi, P, 753(ab)
Perry, BD, 787(ab)
Perry, D, 1989
Perry, DJ, 746(ab), 909(ab), 1749
Perry, JR, 738(ab), 739(ab), 798(ab), 866(ab), 868(ab), 870(ab)
Peshock, RM, 721(ab)
Pesser, JW, 746(ab)
Peston, DF, 931(ab)
Peterfy, CG, 2037
Peters, AM, 129, 383(le), 1980
Peters, M, 580
Peters, PE, 711(ab)
Petersen, M, 1109
Peterson, JC, 716(ab)
Petrillo, EW, 738(ab)
Petry, NA, 61, 526, 885(ab), 1183
Petta, P, 825(ab)
Pettigrew, RI, 1240
Pfeffer, R, 779(ab)
Pfeffer, S, 1474
Phelps, M, 799(ab)
Phelps, ME, 708(ab), 709(ab), 713(ab), 720(ab), 740(ab), 749(ab), 759(ab), 773(ab), 774(ab), 778(ab), 780(ab), 795(ab), 803(ab), 840(ab), 855(ab), 865(ab), 944(ab)
Philippe, EA, 610
Phillips, R, 801(ab)
Phillips, RL, 2052
Phillips, SF, 775(ab)
Phillips, WT, 806(ab)
Philpott, GW, 852(ab)
Picard, D, 436
Picard, M, 436
Pickering, TG, 716(ab)
Pieper, K, 774(ab)
Piepsz, A, 430
Piera, C, 127(le)
Pieri, L, 1007
Pieri, P, 225, 1116, 1390
Pieri, PL, 743(ab), 805(ab)
Piers, DA, 755(ab)
Pierson, RN, Jr, 791(ab)
Pierz, DM, 849(ab)
Pietrini, P, 740(ab)
Pike, MC, 811(ab)
Pilcher, G, 748(ab)
Pilcher, GD, 768(ab), 898(ab)
Pilchowski, P, 640
Pilla, AA, 781(ab)
Pillai, KM, 784(ab)
Pillai, MRA, 947(ab)
Pinard, JM, 893(ab)
Pinczewski, L, 712(ab)
Pinsky, C, 724(ab), 850(ab)
Piotrowski, B, 715(ab), 767(ab), 818(ab)
Pipes, DW, 768(ab), 898(ab)
Pippin, JJ, 733(ab), 734(ab)
Pirotte, R, 760(ab)
Pisani, TL, 831(ab)
Piwnica-Worms, D, 464, 736(ab), 748(ab), 832(ab),

1166, 1646
Plankey, MW, 759(ab)
Platts, SH, 785(ab)
Plettenberg, A, 940(ab)
Pletzer, G, 873(ab)
Plotnick, J, 758(ab)
Plott, E, 850(ab)
Plotzke, KP, 708(ab)
Podoloff, D, 724(ab)
Podoloff, DA, 800(ab), 803(ab), 937(ab)
Poels, LG, 1802
Pohl, W, 441
Pollard, KR, 728(ab), 863(ab)
Pomper, MG, 746(ab)
Ponto, R, 941(ab)
Porenta, G, 774(ab), 825(ab)
Port, SC, 450, 723(ab), 835(ab), 837(ab)
Porter, AT, 804(ab)
Porter, B, 724(ab)
Porter, BA, 1257
Porter, WC, 894(ab)
Portlock, C, 793(ab)
Ports, T, 812(ab)
Poskitt, KJ, 939(ab)
Postiglione, A, 882(ab)
Potel, G, 805(ab)
Potts, JM, 820(ab)
Pouliot, N, 729(ab), 758(ab)
Powe, JE, 237, 775(ab), 804(ab)
Powers, WJ, 730(ab)
Pozderac, RV, 893(ab)
Pozzilli, C, 741(ab)
Pradko, J, 824(ab)
Praet, JP, 830(ab)
Pratt, JP, 758(ab), 942(ab)
Prescott, MC, 978
Preslar, J, 753(ab)
Press, OW, 724(ab), 1257
Preston, DF, 932(ab), 937(ab), 938(ab), 945(ab)
Price, DC, 717(ab)
Price, JC, 709(ab), 866(ab)
Price, LH, 750(ab), 826(ab)
Prigent, F, 744(ab), 832(ab), 836(ab), 934(ab), 1168
Primeau, M, 789(ab), 821(ab), 828(ab), 1168
Pritchard, J, 129
Pupi, A, 739(ab)
Purnell, GL, 846(ab)
Purvies, HP, 754(ab)
Pyzalski, R, 835(ab), 887(ab), 934(ab)

Quadri, SM, 823(ab), 873(ab)
Quevedo, A, 895(ab)
Quinones, N, 881(ab)
Quint, RI, 733(ab), 734(ab)
Quismorio, FP, Jr, 876(ab)

Rabito, CA, 795(ab), 2004
Radcliffe, R, 757(ab)
Radtke, R, 710(ab)
Radtke, RA, 710(ab), 799(ab)
Raferty, EB, 231
Raffel, DM, 709(ab), 778(ab), 786(ab), 860(ab), 910(ab)
Raftery, EB, 782(ab)
Raichle, ME, 351, 710(ab), 815(ab), 817(ab), 1989
Raiszadeh, M, 594
Rajagopalan, R, 907(ab)
Ralph, S, 822(ab)
Ramakrishnan, R, 343
Ramalingam, K, 747(ab)
Ramamoorthy, N, 1163
Ramanathan, P, 1163
Ramanna, L, 567, 721(ab), 744(ab), 767(ab), 830(ab), 894(ab), 911(ab)
Ramsey, G, 2042
Ranade, V, 748(ab)
Randolph, C, 750(ab)
Ranger, N, 822(ab)
Rango, M, 1364
Ranquin, R, 840(ab)
Ransohoff, J, 849(ab)
Rao, SM, 731(ab)
Rao, TN, 747(ab)
Raoul, J-L, 1470
Rapoport, SI, 740(ab), 760(ab), 879(ab), 888(ab)
Rasey, JS, 756(ab)
Rasmussen, JW, 1121
Rath, DM, 775(ab)
Rathat, C, 34
Ratliff, B, 725(ab)
Ratzlaff, NW, 792(ab)
Rauh, D, 819(ab)
Rauh, DA, 776(ab)
Rausch, A, 573
Raval, U, 782(ab)
Ravert, HT, 709(ab), 770(ab), 797(ab), 809(ab), 815(ab), 882(ab), 883(ab), 2015
Raymond, GM, 862(ab), 944(ab)
Raynaud, C, 770(ab), 872(ab), 892(ab), 893(ab)
Read, EJ, 999
Reba, R, 774(ab)
Reba, RC, 202, 707(ab), 729(ab), 827(ab), 865(ab), 883(ab), 896(ab), 906(ab)
Reddy, D, 798(ab)
Reddy, KS, 841(ab)
Redman, HC, 721(ab)
Reeves, P, 710(ab)
Reichmann, OH, 768(ab)
Reid, RH, 118, 804(ab), 938(ab)
Reilley, J, 573
Reimann, DA, 719(ab), 870(ab)
Reiners, C, 715(ab), 729(ab), 766(ab), 767(ab), 818(ab), 856(ab)
Reitelman, C, 893(ab)
Reith, J, 721(ab), 884(ab)
Reivich, M, 728(ab), 741(ab), 751(ab), 771(ab), 876(ab), 901(ab), 1364
Reno, JM, 747(ab)
Resch, PA, 911(ab)
Rescigno, A, 754(ab), 860(ab)
Reske, SN, 734(ab), 751(ab)
Resnick, L, 826(ab)
Resnick, SM, 751(ab)
Reub, [illegible]C, 1501
Reynolds, JC, 202, 755(ab), 906(ab), 935(ab), 1133, 1252(le)
Rhame, FS, 936(ab)
Rhodes, CG, 736(ab), 737(ab), 778(ab)
Ricaurte, GA, 883(ab)
Riccabona, G, 1007
Rice, KC, 810(ab)
Richalet, JP, 34
Richards, JG, 1007
Richards, RD, 847(ab)
Richter, KY, 755(ab), 1257
Riddle, MA, 750(ab)
Ridge, J, 1028
Riexinger, DJ, 776(ab)
Riffkin, M, 718(ab)
Rigo, P, 840(ab)
Riis, BJ, 1156
Rijke, AM, 990
Ritch, PS, 745(ab)
Ritchie, J, 842(ab)
Ritter-Hrncirik, CA, 1048
Rivera-Luna, H, 750(ab)
Rizzo, G, 741(ab), 748(ab), 821(ab)
Robb, S, 715(ab)
Robbins, J, 935(ab)
Robbins, WL, 1761
Roberge, E, 943(ab)
Roberson, PL, 784(ab)
Roberts, J, 777(ab)
Roberts, R, 754(ab), 759(ab), 843(ab), 855(ab)
Roberts, WS, 938(ab)
Robeson, W, 864(ab)
Robinson, RG, 931(ab), 932(ab), 937(ab), 938(ab), 945(ab), 1326, 1781
Robinson, VJB, 154
Robyn, C, 830(ab)
Rocco, TP, 10, 1623
Rockett, JF, 1554
Roddie, ME, 1980
Rodman, JH, 287, 716(ab), 1577(le)
Rodman, MS, 826(ab)
Rodwell, JD, 757(ab)
Roeda, D, 1595
Roelants, V, 820(ab)
Roeske, J, 872(ab)
Roeske, JC, 788(ab)
Rogers, SC, 719(ab)
Rogers, WL, 90, 718(ab), 759(ab), 769(ab), 798(ab), 885(ab), 1183
Rogic, MM, 897(ab)
Roland, J, 831(ab)
Roland, PE, 902(ab)
Roman, S, 890(ab)
Romhilt, DW, 733(ab), 734(ab)
Rommer, P, 870(ab)
Roney, TJ, 632, 719(ab)
Ronga, G, 1766
Roosen, N, 281
Ropchan, J, 881(ab)
Rose, MR, 978
Rose, SC, 1847
Rosebrough, SF, 1048
Roselli, M, 765(ab), 1133
Rosen, G, 567
Rosen, JM, 343
Rosen, P, 735(ab), 853(ab)
Rosen, ST, 725(ab), 854(ab)
Rosenblum, MG, 724(ab)
Rosenquist, M, 752(ab)
Rosenson, AS, 813(ab)
Rosenspire, K, 726(ab), 792(ab), 1352
Rosenspire, KC, 163, 725(ab), 738(ab), 745(ab), 831(ab), 1328
Rosenthal, MS, 873(ab)
Rosenthal, P, 1397
Rosenthall, L, 2037
Roskopf, M, 501
Ross, S, 796(ab)
Rossenwasser, R, 826(ab)
Rossetti, C, 735(ab), 821(ab), 834(ab)
Rossetti, E, 797(ab), 839(ab)
Rossleigh, M, 1746(le)
Rossleigh, MA, 168
Roth, J, 791(ab), 879(ab)
Roth, RH, 883(ab)
Rothman, C, 911(ab)
Rottman, J, 716(ab)
Roumanas, P, 819(ab), 941(ab)
Rowe, CC, 711(ab)
Rowe, JM, 884(ab)
Rowe, RK, 632, 769(ab)
Rowe, RW, 863(ab)
Rowell, LB, 160
Rowell, NP, 1307
Rowland, S, 891(ab)
Royal, HD, 722(ab), 730(ab)
Rozanski, A, 744(ab), 836(ab), 934(ab)
Rozenberg, S, 830(ab)
Rozental, JM, 789(ab)
Rubin, RH, 316, 811(ab), 819(ab), 1199, 2022
Rubin, SC, 764(ab)
Rubio, FF, 815(ab)
Rucknagel, DL, 893(ab)
Ruddy, T, 841(ab)
Rudolf, AS, 806(ab)
Rudolf, J, 771(ab), 799(ab)
Rudolph, J, 302
Ruegg, CL, 824(ab)
Ruiz, M, 713(ab), 784(ab)
Rusch, V, 798(ab)
Rusckowski, M, 754(ab), 903(ab), 1791
Rushton, HG, 742(ab)
Russell, C, 850(ab)
Russell, CD, 716(ab), 852(ab), 912(ab)
Russell, JC, 890(ab)
Ruth, TJ, 737(ab), 886(ab)
Ruttimann, UE, 856(ab)
Ryo, UY, 668, 752(ab), 791(ab), 801(ab), 857(ab), 894(ab), 897(ab), 1486
Ryo, Uy, 791(ab)
Rypins, E, 732(ab)

Sabha, M, 761(ab)
Sachdev, SS, 1163
Sacker, D, 875(ab), 876(ab)
Sacker, DF, 886(ab)
Sacks, S, 844(ab)
Sacks, W, 844(ab)
Sadek, S, 834(ab), 940(ab)
Sadoun, D, 839(ab)
Sadzot, B, 709(ab), 866(ab), 878(ab)
Saenger, EL, 393
Saga, T, 844(ab), 850(ab), 895(ab), 1077
Saha, G, 722(ab)
Saha, GB, 802(ab), 1899
Sahakian, JA, 910(ab)
Saimot, AC, 1601
Saito, S, 743(ab)
Saito, T, 796(ab)
Saji, H, 885(ab), 1015
Sakahara, H, 844(ab), 850(ab), 895(ab)
Sakai, S, 750(ab), 876(ab)
Sakaki, S, 790(ab), 868(ab)
Salaki, JS, 112
Salcedo, E, 722(ab)
Salit, IC, 936(ab)
Salmon, Y, 859(ab), 1702, 1710
Salomon, DR, 716(ab)
Salt[illegible] M, 850(ab)
Salvadori, PA, 1335
Salvatore, M, 838(ab), 882(ab), 1438(le)
Sampathkumaran, KS, 773(ab)
Samuelson, E, 725(ab), 854(ab)
Sanchez-Roa, PM, 2015
Sanderfer, E, 846(ab)
Sanders, M, 610
Sanders, TG, 1103
Sanders, VL, 911(ab)
Sanderson, JA, 747(ab)
Sandler, MP, 935(ab)
Sandmaier, B, 1384
Sandrock, D, 674, 744(ab), 794(ab)
Sano, A, 240
Santoro, GM, 821(ab)
Sanvito, F, 735(ab)
Saptogino, A, 758(ab)
Sara, R, 1743(le)
Sarkar, S, 716(ab)
Sasaki, T, 946(ab)
Sasayama, S, 743(ab), 808(ab)
Sassi, I, 735(ab)
Sato, K, 1654, 1997
Sato, N, 813(ab)
Sato, T, 1654
Satoh, A, 1520
Satter, MR, 900(ab)
Satyamurthy, N, 778(ab), 780(ab)
Saunders, RC, 707(ab), 870(ab)
Savas, V, 773(ab)
Savi, A, 839(ab), 871(ab)
Savi, AR, 791(ab)
Savola, J-M, 841(ab)
Savolainen, S, 384(le)
Savory, CG, 274
Saykin, AJ, 730(ab)
Sayle, BA, 752(ab)
Scandar, S, 943(ab)
Scesney, WA, 716(ab)
Schad, GA, 892(ab)
Schaible, T, 782(ab), 805(ab)
Schaible, TF, 795(ab)
Schapiro, MB, 740(ab), 760(ab)
Schauwecker, DS, 811(ab)
Scheffel, U, 720(ab), 725(ab), 797(ab), 806(ab), 882(ab), 883(ab), 886(ab), 2015
Schelbert, HR, 271, 713(ab), 773(ab), 774(ab), 795(ab), 840(ab), 842(ab), 862(ab), 1431(le)

Scherrer, M, 726(ab)
Schielke, E, 827(ab)
Schiepers, C, 749(ab), 778(ab), 780(ab), 803(ab)
Schijf, CPT, 734(ab), 1802
Schirrmacher, V, 855(ab)
Schlag, P, 803(ab), 888(ab)
Schlom, J, 755(ab), 765(ab), 1133
Schlyer, D, 780(ab), 866(ab)
Schlyer, DJ, 762(ab), 809(ab), 902(ab)
Schlyer, DR, 719(ab)
Schmall, B, 888(ab)
Schmarkey, LS, 735(ab)
Schmid, U, 855(ab)
Schmidt, A, 821(ab)
Schmidt, D, 779(ab), 786(ab), 882(ab)
Schmidt, DH, 450
Schmidt, KG, 1121
Schneider, RF, 892(ab), 908(ab)
Schneider, VS, 43
Schnur, W, 752(ab)
Schober, B, 1575(le)
Schober, O, 711(ab), 2075(le)
Schold, SC, 799(ab)
Schoutens, A, 750(ab)
Schroff, R, 725(ab), 777(ab)
Schröttle, W, 775(ab)
Schubiger, PA, 1007
Schuening, F, 1384
Schuhmacher, J, 1084
Schumacher, S, 1740
Schwaiger, M, 163, 725(ab), 726(ab), 745(ab), 773(ab), 774(ab), 777(ab), 785(ab), 792(ab), 801(ab), 802(ab), 831(ab), 1183, 1328, 1352, 1757, 1876
Schwartz, AN, 762(ab)
Schwartz, D, 819(ab)
Schwartz, DA, 776(ab), 2022
Schwartz, M, 890(ab)
Schwartz, RB, 826(ab)
Schwartz, RS, 838(ab)
Schwartz, Z, 2011
Schweighardt, S, 844(ab)
Schweighardt, SA, 734(ab)
Schwendner, SW, 332
Sciagrà, R, 821(ab)
Sciammarella, M, 821(ab)
Sciammerella, M, 839(ab)
Sciuk, J, 711(ab)
Scott, A, 712(ab), 801(ab), 847(ab)
Scott, JA, 1255, 1579, 1986
Scott, JW, 912(ab)
Scott, PJ, 904(ab)
Scott-Douglas, NW, 154
Scuderi, AJ, 424, 744(ab), 1847
Scully, TJ, 932(ab)
Seabold, J, 782(ab)
Seabold, JE, 549
Seacat, RH, III, 632
Seale, TW, 727(ab)
Sebree, L, 835(ab), 934(ab)
Sedvall, G, 737(ab)
Seeger, L, 780(ab)
Segall, GM, 1443
Seino, Y, 876(ab)
Sela, J, 2011
Seldin, D, 827(ab)
Seldin, DW, 830(ab)
Selikson, MH, 822(ab), 844(ab)
Selin, CE, 795(ab)
Senda, M, 944(ab), 946(ab)
Senior, R, 782(ab), 841(ab)
Senneff, MJ, 713(ab), 841(ab)
Seo, I, 895(ab)
Seo, S, 779(ab)
Serafini, A, 907(ab), 934(ab), 939(ab)
Serafini, AN, 243, 715(ab), 819(ab), 942(ab), 943(ab)
Serafini, F, 1307
Seto, M, 766(ab), 889(ab)
Sfakianakis, G, 891(ab), 907(ab), 934(ab), 939(ab)
Sfakianakis, GN, 243, 715(ab), 743(ab), 819(ab), 820(ab), 942(ab), 943(ab)
Sgouros, G, 788(ab), 844(ab), 1884
Shaffer, KA, 745(ab)
Shaffer, P, 698(le)
Shafique, I, 771(ab), 878(ab)
Shafran, B, 761(ab)
Shah, A, 938(ab)
Shah, K, 828(ab)
Shai, Y, 791(ab)
Shalmoni, J, 836(ab)
Shamlou, K, 716(ab)
Shanahan, J, 722(ab), 761(ab)
Shani, J, 2011
Shanken, J, 724(ab)
Shao, L, 769(ab), 798(ab)
Shapiro, B, 526, 745(ab), 804(ab), 1479
Shapiro, HR, 1909
Sharborough, F, 879(ab)
Sharkey, RM, 508, 724(ab), 747(ab), 765(ab), 783(ab), 788(ab), 850(ab), 854(ab), 1510
Sharma, S, 764(ab)
Sharp, PF, 1595
Shaw, LJ, 733(ab)
Shaw, RE, 763(ab), 836(ab)
Shaw, SM, 933(ab), 946(ab)
Shaya, E, 809(ab)
Shealy, D, 776(ab)
Shefer, RE, 943(ab)
Sheinin, EB, 728(ab)
Shelton, ME, 794(ab)
Shelton, SE, 887(ab)
Shen, W, 1280
Shen, YH, 723(ab), 835(ab)
Shepstone, BJ, 381(le)
Sherman, P, 884(ab)
Sherman, PS, 707(ab)
Sherrard, DJ, 1099
Shiba, K, 660, 885(ab)
Shibata, T, 1015
Shields, AF, 337, 794(ab), 909(ab)
Shih, W-J, 668, 752(ab), 773(ab), 791(ab), 857(ab), 894(ab), 897(ab), 1486
Shihab-Eldeen, A, 834(ab)
Shiku, H, 1520
Shima, M, 1520
Shimada, T, 772(ab), 855(ab)
Shimbo, S, 512
Shimizu, M, 792(ab)
Shimomura, O, 907(ab)
Shishido, F, 760(ab)
Shiue, C-Y, 902(ab)
Shiue, S-T, 1909
Shuke, N, 766(ab), 814(ab), 851(ab), 889(ab)
Shuler, S, 715(ab)
Shulkin, BL, 745(ab)
Shureigi, I, 887(ab)
Shuter, B, 801(ab), 847(ab)
Siccardi, AG, 735(ab), 853(ab)
Siddiqui, AR, 1280
Siebecker, DA, 1791
Siegel, A, 1206
Siegel, BA, N34(6), 730(ab), 746(ab), 773(ab), 1749
Siegel, JA, 775(ab), 783(ab), 788(ab), 1412
Siegel, ME, 735(ab), 853(ab), 876(ab)
Siegel, S, 759(ab)
Siegel, SB, 859(ab)
Sievers, R, 946(ab)
Signore, A, 1766
Silagan, G, 804(ab), 812(ab), 832(ab)
Silberman, A, 767(ab)
Silberstein, EB, 128(le), 752(ab)
Silbiger, ML, 938(ab), 942(ab), 945(ab)
Silfen, D, 845(ab), 2029
Silva, DA, 1370
Silverstein, EA, 856(ab)
Silvestri, M, 876(ab)
Silvestri, R, 836(ab)
Simon, H, 803(ab)
Simon, J, 586, 767(ab), 1316
Simon, TR, 674, 829(ab), 1474
Simpfendorfer, CC, 802(ab), 1899
Singer, DA, 804(ab), 1479
Singer, H, 809(ab)
Singh, J, 768(ab)
Singh, M, 178
Sinusas, AJ, 713(ab), 784(ab)
Sisson, JC, 526, 745(ab), 804(ab), 1479
Sisson, RF, III, 723(ab)
Sivolapenko, GB, 1791
Skelton, TN, 774(ab)
Skinner, RWS, 708(ab)
Slade, SK, 757(ab), 776(ab)
Slamon, D, 803(ab)
Slater, J, 844(ab)
Slater, JB, 734(ab)
Slater, JM, 594
Slinker, BK, 1020
Slizofski, WJ, 115
Sloboda, RS, 945(ab)
Sluyser, M, 746(ab)
Smabuceti, G, 173
Smart, P, 934(ab)
Smart, RC, 985
Smiseth, OA, 154
Smith, AJ, 325
Smith, AP, 769(ab), 1456
Smith, EO, 729(ab), 750(ab), 779(ab), 789(ab), 826(ab), 883(ab)
Smith, ER, 154
Smith, FW, 1595
Smith, GT, 862(ab), 933(ab)
Smith, H, 714(ab)
Smith, MF, 807(ab)
Smith, R, 732(ab)
Smith, WH, 713(ab), 763(ab), 784(ab), 827(ab), 842(ab), 858(ab), 1409
Snook, D, 1791
Snow, BJ, 886(ab)
Soares, EJ, 844(ab)
Sobel, BE, 187, 713(ab), 794(ab), 841(ab)
Sobotka, PA, 698(le), 700(le)
Sochor, H, 825(ab)
Sodoyez, JC, 791(ab)
Sodoyez-Goffaux, F, 791(ab)
Sohn, M, 751(ab)
Sokal, E, 732(ab)
Solin, O, 749(ab), 901(ab)
Solomon, HF, 1494
Solomon, RW, 109, 712(ab), 716(ab), 941(ab), 1950
Solot, G, 1069
Som, P, 832(ab), 834(ab), 886(ab), 1055
Somawardhana, CW, 947(ab)
Sonnemaker, R, 715(ab)
Sonnemaker, RE, 1761
Sonnenschein, W, 856(ab)
Sood, VK, 202, 906(ab)
Soper, ND, 381(le)
Sorenson, JA, 537(le)
Soricelli, A, 882(ab)
Sosa, A, 853(ab)
Soskolne, WA, 2011
Sostre, S, 732(ab), 750(ab), 771(ab), 818(ab), 878(ab), 913(ab)
Soucy, JP, 972, 789(ab)
Souder, E, 771(ab), 822(ab), 876(ab)
Southee, AE, 793(ab), 794(ab)
Souza, LM, 849(ab), 904(ab)
Spaccavento, LJ, 733(ab)
Spaulding, M, 887(ab)
Spaventi, S, 393
Spencer, RP, 895(ab), 1909
Sperling, M, 714(ab)
Sperling, MR, 1839
Spicer, JA, 937(ab), 947(ab)
Spicer, K, 835(ab), 946(ab)
Spiegler, EJ, 732(ab)
Spies, SM, 725(ab), 854(ab), 856(ab)
Spies, WG, 725(ab), 854(ab), 856(ab)
Spinelli, F, 1743(le)
Sprengelmeyer, JT, 2034
Srebro, J, 812(ab)
Srinivasan, A, 747(ab)
Srivastava, PC, 900(ab)
Srivastava, PD, 906(ab)
Srivastava, SC, 343, 896(ab), 909(ab)
Stabin, M, 822(ab), 844(ab)
Stadalnik, RC, 909(ab)
Stagnaro-Green, A, 890(ab)
Stains, S, 735(ab)
Staker, BL, 903(ab)
Stalnaker, CS, 841(ab)
Stamey, TA, 751(ab)
Stanley, PC, 655
Stapleton, J, 586, 1316
Stark, VL, 842(ab)
Stathis, M, 720(ab), 797(ab), 882(ab), 883(ab), 886(ab), 2015
Steen, RG, 717(ab)
Steimle, V, 788(ab)
Steimle, VS, 783(ab)
Steiner, M, 1945
Steinröder, M, 744(ab)
Stella, M, 735(ab), 853(ab)
Steplewski, Z, 824(ab), 849(ab), 896(ab), 904(ab)
Stertzer, SH, 763(ab), 836(ab)
Stevick, CD, 1443
Stewart, CA, 818(ab)
Stewart, M, 890(ab)
Stewart, RE, 785(ab), 1183
St George-Hyslop, P, 740(ab)
Stickney, D, 844(ab)
Stickney, DR, 734(ab)
Stimmler, MM, 876(ab)
Stinchcomb, TG, 845(ab)
Stinson, R, 873(ab)
Stivland, TA, 775(ab)
Stöcklin, G, 281, 771(ab), 786(ab), 799(ab)
Stokes, J, 732(ab)
Stomper, PC, 387
Stone, CK, 778(ab)
Stone-Elander, SA, 902(ab)
Storb, R, 1384
Storms, S, 732(ab)
Strand, M, 824(ab)
Strand, S-E, 493, 1560, 2058
Strange, DR, 942(ab)
Strashun, A, 722(ab), 761(ab), 948(ab)
Stratton, JR, 838(ab)
Strauss, A, 788(ab), 844(ab)
Strauss, HW, 10, 123, 736(ab), 743(ab), 781(ab), 785(ab), 787(ab), 795(ab), 796(ab), 805(ab), 811(ab), 819(ab), 831(ab), 833(ab), 834(ab), 841(ab), 853(ab), 854(ab), 896(ab), 1199, 1344, 1441(le), 1823, 2022, 2069
Strauss, LG, 766(ab), 771(ab), 803(ab), 804(ab), 813(ab), 888(ab), 939(ab)
Strickland, P, 839(ab)
Strijk, SP, 1802
Stringham, LM, 947(ab)
Stritzke, P, 716(ab)
Stritzke, PH, 825(ab), 860(ab), 874(ab), 914(ab)
Ström, P, 796(ab)
Stücker, R, 711(ab)
Stulzaft, O, 899(ab)
Styles, JM, 777(ab)
Su, F-M, 823(ab)
Subrahmanyam, N, 1163
Subramanian, G, 892(ab), 908(ab)
Subramanian, KM, 480, 1745(le)
Subramanian, R, 218, 835(ab), 934(ab)
Sucharski, LA, 885(ab)
Sud, AM, 790(ab)

Suehiro, M, 882(ab), 883(ab), 946(ab), 2015
Sugii, A, 907(ab)
Sugimoto, J, 891(ab)
Sukalac, R, 739(ab)
Sulavik, SB, 1909
Sulavik S, 895(ab)
Sullivan, BW, 757(ab)
Sumiya, H, 660
Sumiyoshi, T, 763(ab)
Summers, B, 830(ab)
Sun, B, 851(ab)
Sun, TTH, 824(ab), 849(ab), 904(ab)
Sunderland, JJ, 749(ab), 901(ab), 902(ab)
Sunderland, M, 716(ab)
Suneja, SK, 1892(le)
Susskind, H, 887(ab)
Sutorik, A, 163
Sutton, AM, 1892(le)
Suzuki, H, 946(ab)
Suzuki, K, 894(ab)
Swailem, FM, 90, 759(ab), 798(ab), 872(ab)
Swartz, BE, 881(ab)
Swayne, LC, 112, 872(ab), 1915
Swenson, ER, 909(ab)
Swyer, AJ, 682, 711(ab), 712(ab), 819(ab), 895(ab), 1548, 1950
Sy, W, 895(ab)
Sychra, JJ, 825(ab)
Syrjälä, MT, 384(le)
Syrota, A, 34, 709(ab), 726(ab), 770(ab), 866(ab), 872(ab), 875(ab), 880(ab), 892(ab), 893(ab), 897(ab), 899(ab), 1303
Szabo, Z, 771(ab), 818(ab), 878(ab), 913(ab)

Tabuchi, H, 603
Tada, M, 1654
Taddei, L, 1335
Tahara, T, 880(ab), 889(ab)
Tai, K, 895(ab)
Tai, M-S, 776(ab)
Taillefer, R, 775(ab), 782(ab), 821(ab), 827(ab), 828(ab), 839(ab), 1921
Takahashi, M, 907(ab)
Takahashi, T, 878(ab), 901(ab)
Takahashi, Y, 240
Takano, H, 808(ab)
Takayama, T, 814(ab), 889(ab)
Takeda, K, 792(ab)
Takeda, T, 895(ab)
Takehara, Y, 946(ab)
Takemura, Y, 1818
Takeshita, G, 55, 877(ab), 1433(le)
Takeuchi, A, 55, 877(ab), 1433(le)
Taki, J, 766(ab), 792(ab), 889(ab)
Takishima, T, 878(ab)
Talley, NA, 985
Tam, SH, 905(ab)
Tamaki, N, 136, 708(ab), 742(ab), 743(ab), 808(ab), 847(ab), 848(ab), 849(ab), 885(ab), 1617, 1818
Tamaki, S, 875(ab)
Tamminga, C, 865(ab)
Tanada, S, 790(ab), 846(ab), 858(ab), 868(ab)
Tandon, R, 841(ab)
Tang, J, 788(ab)
Tani, A, 753(ab), 808(ab)
Taniguchi, K, 793(ab)
Tann, LA, 896(ab)
Tansey, W, 903(ab)
Tararine, M, 875(ab)
Tarcan, Y, 837(ab)
Tateno, Y, 802(ab)
Tatsch, K, 775(ab), 827(ab)
Tatum, JL, 733(ab), 734(ab)
Tauxe, WN, 938(ab), 2042
Tavazzi, L, 934(ab)
Taylor, A, 837(ab)
Taylor, A, Jr, 912(ab)
Taylor, AT, 1240
Taylor, C, 735(ab), 853(ab)
Taylor, CJV, 736(ab), 746(ab)
Taylor, CR, 758(ab), 1059
Taylor, M, 935(ab)
Taylor, S, 885(ab)
Teal, JS, 1892(le)
Tellier, P, 839(ab)
Ten Haken, RK, 784(ab)
tenKate, CI, 2022
Tenorio, L, 800(ab)
Tenorio, LE, 938(ab)
Ter, S, 890(ab)
Terada, H, 660
Terada, Y, 848(ab)
Terahara, T, 907(ab)
Teras, M, 748(ab)
Terauchi, T, 889(ab)
Terris, AH, 1727
Terris, MK, 751(ab)
Terry, JA, 868(ab)
Terui, S, 889(ab)
Teshima, T, 543
Thakur, AK, 860(ab)
Thakur, ML, 718(ab), 810(ab)
Thakur, S, 1468
Thekkumthala, J, 1884
Theodore, W, 710(ab)
Theodoropulos, S, 897(ab)
Théroux, P, 714(ab)
Thomas, C, 713(ab), 805(ab), 832(ab)
Thomas, FD, 501, 875(ab), 892(ab), 908(ab)
Thomas, JR, 797(ab)
Thomas, SR, 378
Thomas, WC, 939(ab)
Thomforde, GM, 775(ab)
Thompson, D, 1237
Thompson, L, 724(ab)
Thonoor, CM, 385(le)
Thoolen, MJ, 785(ab)
Thornback, JR, 760(ab), 807(ab), 846(ab)
Thornton, J, 791(ab)
Thornton, K, 800(ab)
Thorsen, MK, 745(ab)
Thurston, M, 851(ab)
Tiel-van Buul, MMC, 831(ab)
Tikofsky, RS, 731(ab), 880(ab), 1254, 1255
Tilbury, R, 803(ab), 903(ab), 937(ab)
Tilbury, RS, 800(ab), 862(ab)
Tilgen, W, 804(ab)
Tilyou, SM, N13A(1), N13A(2), N13A(3), N13A(4), N22A(4), N18A(5), N25A(5), N14A(6), N13A(7), N20A(7), N11A(9), N20A(11), N15A(12)
Timmons, JH, 806(ab)
Tinco, A, 839(ab)
Tintner, R, 730(ab)
Tisselli, A, 743(ab)
Tobolski, M, 936(ab)
Tochon-Danguy, H, 736(ab)
Todd-Pokropek, A, 729(ab)
Todino, V, 1766
Tomiguchi, S, 907(ab)
Tomomitsu, T, 829(ab)
Tomura, M, 1997
Tonami, N, 766(ab), 814(ab), 851(ab), 889(ab)
Toney, MAO, 932(ab)
Topcuoglu, R, 820(ab)
Torrey EF, 751(ab)
Tourassi, GD, 798(ab), 869(ab), 870(ab)
Tow, F, 715(ab)
Toyama, H, 55, 877(ab), 944(ab), 946(ab), 1433(le)
Toyozaki, T, 833(ab)
Trambaugh, R, 722(ab)
Tran Dinh, YR, 1601
Traylor, J, 945(ab)
Trepashko, DW, 791(ab)
Treves, ST, 892(ab), 2040
Trimarco, B, 882(ab)
Troutner, DE, 767(ab), 947(ab)
Trulock, EP, 722(ab)
Trumper, J, 523
Tschudy, J, 835(ab)
Tsuchimochi, M, 856(ab)
Tsuchiya, T, 876(ab)
Tsuda, T, 846(ab)
Tsui, BMW, 90, 738(ab), 739(ab), 798(ab), 866(ab), 867(ab), 868(ab), 870(ab), 873(ab)
Tsuji, S, 660, 880(ab), 885(ab)
Tubergen, K, 806(ab)
Tuli, JK, 948(ab)
Tuli, M, 890(ab), 914(ab)
Tumeh, SS, 721(ab), 826(ab), 1456, 1746(le)
Tummarello, MA, 1766
Tune, L, 770(ab), 809(ab)
Tung, CH, 867(ab)
Turner, FE, 726(ab)
Turoglu, HT, 745(ab)
Turza, NA, 912(ab)
Tweedle, MF, 898(ab)
Tyberg, JV, 154
Tyson, DA, 912(ab)
Tyson, I, 715(ab)
Tyson, IB, 938(ab), 942(ab), 945(ab)
Tzamaloukas, AH, 1099
Tzika, AA, 717(ab)
Tzourio, N, 892(ab)
Uchida, Y, 877(ab)
Udelson, JE, 723(ab)
Ueda, R, 1077
Ueda, S, 738(ab)
Uehara, A, 603
Uehara, T, 763(ab), 782(ab), 783(ab), 881(ab)
Uematu, S, 888(ab)
Uemura, K, 760(ab)
Ueno, M, 895(ab)
Ulanski, J, 892(ab)
Underwood, DA, 802(ab), 1899
Uno, K, 877(ab), 888(ab)
Uno, Y, 725(ab), 886(ab)
Urbain, JL, 775(ab), 801(ab), 936(ab)
Urbain, JLC, 1490
Urita, Y, 847(ab)
Uzzell, B, 876(ab)

Vaalburg, W, 746(ab), 861(ab)
Vaidyanathan, G, 757(ab)
Valette, H, 726(ab), 875(ab), 899(ab)
Valette, HB, 1303
Valeyre, D, 839(ab)
Valk, PE, 880(ab)
Valkema, R, 1774
Vallabhajosula, S, 319, 716(ab), 780(ab), 781(ab), 874(ab), 897(ab), 914(ab)
Valle, G, 937(ab)
Valois, JM, 709(ab), 866(ab)
van Beek, EJR, 831(ab)
Van Billoen, H, 907(ab)
VanBrocklin, HF, 746(ab), 910(ab)
Van Cutsem, E, 1490
Vancutsem, E, 775(ab), 801(ab)
Vandecruys, A, 762(ab), 936(ab)
Van den Abbeele, AD, 766(ab), 1358
Vandenbroeck, P, 807(ab)
Vander Borght, T, 816(ab), 847(ab)
Vanderheyden, J-L, 725(ab), 823(ab)
van der Meer, JWM, 403, 810(ab), 811(ab), 819(ab)
van der Mey, AGL, 1147
Van der Wall, EE, 717(ab)
Vande Streek, PR, 733(ab)
Vandevivere, J, 831(ab), 840(ab), 893(ab)
Van Dijkman, PRM, 717(ab)
van Dongen, A, 831(ab), 1854
Van Dort, M, 797(ab)
Van Dort, ME, 707(ab), 898(ab), 1328
van Elmbt, L, 820(ab)
van Erkel, AR, 935(ab)
van Gils, APG, 935(ab), 1147
VanHeerden, BB, 878(ab)
van Hoesel, RGCM, 1802
van Horn, JR, 403, 712(ab)
van Kaick, G, 771(ab), 888(ab), 939(ab)
van Kroonenburgh, MJPG, 1147
Van Nerom, C, 762(ab), 806(ab), 908(ab)
Van Nostrand, D, 52, 274, 940(ab), 1627
Vanoli, G, 834(ab)
Vanoverschelde, J-L, 843(ab)
van Royen, EA, 782(ab), 831(ab)
Van Sickle, DC, 946(ab)
VanTrain, K, 812(ab), 828(ab), 832(ab)
Van Train, KF, 1168
Vantrappen, G, 775(ab), 801(ab), 1490
van Vlies, B, 782(ab)
Van Voorthuisen, AE, 717(ab)
Vaquer, R, 722(ab), 761(ab)
Varga, DC, 508
Vargas-Cuba, R, 819(ab)
Vassallo, M, 775(ab)
Vassiliou, MM, 875(ab)
v d Lohe, E, 803(ab)
Vega, A, 319, 682
Velchik, MG, 573, 731(ab), 845(ab), 848(ab), 849(ab), 890(ab)
Venkatesan, P, 765(ab), 823(ab)
Vera, DR, 909(ab)
Verani, MS, 722(ab), 754(ab), 759(ab), 843(ab), 855(ab), 1269
Verbruggen, A, 762(ab), 806(ab), 907(ab), 908(ab)
Verhagen, A, 746(ab)
Verheij, LF, 1774
Verheijen, RHM, 734(ab), 1802
Verhoeven, R, 840(ab)
Vessella, RL, 783(ab)
Vester, E, 803(ab), 1608
Vezina, LG, 1897
Vick, M, 948(ab)
Videen, TO, 730(ab), 817(ab)
Villa, E, 735(ab)
Villaneuva-Meyer, J, 1237
Villanueva, FS, 842(ab)
Villanueva-Meyer, J, 246(le), 457
Villari, B, 838(ab)
Villemagne, VL, 882(ab), 2015
Villeneuve, J-P, 436
Vinitsky, S, 718(ab)
Vinson, EL, 827(ab), 842(ab)
Vinter, DW, 1358
Virkkunen, PJ, 23
Virzi, F, 903(ab)
Visser, F, 896(ab)
Visser, TJ, 1501
Vitti, RA, 147, 826(ab)
Volkert, WA, 586, 767(ab), 806(ab), 1316
Volkow, N, 780(ab)
Volkow, ND, 719(ab), 762(ab), 864(ab), 875(ab), 876(ab), 886(ab)
Voorhees, W. D., 914(ab)

Vorstrup, S, 818(ab)
Votaw, JR, 779(ab), 809(ab)
Vriesendorp, HM, 873(ab)

Wackers, FJ, 718(ab)
Wackers, FJTh, 1024, 1269, 1400, 1906
Wada, K, 895(ab), 1818
Wagner, HN, 816(ab), 865(ab)
Wagner, HN, Jr, N17A(8), 709(ab), 720(ab), 725(ab), 732(ab), 750(ab), 770(ab), 771(ab), 797(ab), 806(ab), 809(ab), 815(ab), 818(ab), 862(ab), 866(ab), 878(ab), 882(ab), 883(ab), 886(ab), 913(ab), 1069, 2015
Wagner, JG, 850(ab)
Wagner, N, 761(ab)
Wagner, RH, 698(le), 700(le), 808(ab), 871(ab), 941(ab)
Wahl, R, 777(ab), 852(ab)
Wahl, RL, 84, 708(ab), 746(ab), 765(ab), 769(ab), 804(ab), 850(ab), 872(ab), 888(ab), 889(ab), 904(ab), 1479, 1831
Wahner, HW, 829(ab), 879(ab), 932(ab), 937(ab)
Wahner-Roedler, DL, 1543
Wainwright, P, 731(ab)
Wakasugi, S, 832(ab)
Wakita, K, 861(ab)
Waldemar, G, 818(ab)
Walker, AP, 745(ab)
Walker, CW, 846(ab)
Wallace, S, 903(ab)
Waller, J, 890(ab)
Wallis, JW, 807(ab), 1421, 1732, 1933, 2064
Wanek, P, 850(ab)
Wang, G-J, 832(ab)
Wang, J, 791(ab)
Wang, JK, 871(ab)
Wang, L, 769(ab)
Wang, S-J, 1294
Wang, TST, 343, 805(ab), 820(ab), 906(ab)
Wapner, K, 932(ab)
Warner-Stevenson, L, 773(ab)
Warren, DL, 325
Warren, RW, 52
Wartofsky, L, 1958
Washburn, LC, 824(ab), 849(ab), 904(ab)
Wassenaar, WG, 712(ab)
Wasserman, A, 827(ab)
Watanabe, K, 688
Watanabe, N, 880(ab)
Watanabe, R, 881(ab)
Watanabe, T, 778(ab), 817(ab), 885(ab), 1077
Watanabe, Y, 136, 766(ab), 844(ab), 850(ab), 889(ab), 895(ab), 1077
Watanuki, S, 779(ab)
Watkins, K, 735(ab), 853(ab)
Watson, DD, 713(ab), 763(ab), 784(ab), 827(ab), 842(ab), 858(ab), 1409
Watson, EE, 822(ab)
Watson, IA, 1307
Waxman, A, 567, 721(ab), 744(ab), 767(ab), 830(ab), 894(ab), 911(ab)
Waxman, S, 567
Weadock, KS, 508, 765(ab), 854(ab)
Weaver, F, 735(ab)
Webber, DI, 725(ab), 854(ab)
Weber, DA, 791(ab), 834(ab), 869(ab), 875(ab), 876(ab), 886(ab), 887(ab)
Weber, E, 1285
Weber, J, 723(ab)
Weber, RW, 833(ab), 905(ab)
Wedeking, P, 898(ab)
Weed, DA, 1909
Wegelius, U, 748(ab)
Wegener, W, 360
Wegener, WA, 125(le), 890(ab)
Wegst, AV, 941(ab)
Weichselbaum, RR, 788(ab)
Weiden, P, 725(ab), 823(ab)
Weiland, F, 722(ab)
Weiland, FL, 733(ab)
Weiler, M, 902(ab)
Weimer, DE, 870(ab)
Weinberger, DR, 707(ab), 750(ab), 870(ab)
Weiner, L, 774(ab)
Weiner, MF, 730(ab)
Weiner, R, 541
Weinheimer, CJ, 794(ab)
Weininger, J, 523
Weinkauff, RE, 725(ab)
Weinstein, JN, 851(ab), 1191
Weisman, RA, 768(ab), 910(ab)
Weiss, D, 771(ab), 890(ab)
Weiss, DW, 1
Weiss, K, 717(ab)
Welch, MJ, N34(6), 192, 351, 707(ab), 727(ab), 738(ab), 745(ab), 746(ab), 768(ab), 814(ab), 815(ab), 909(ab), 910(ab), 1662, 1744(le), 1989
Wellman, HH, 1280
Wells, C, 790(ab)
Wen, MD, 747(ab)
Wen, PYC, 766(ab)
Went, MJ, 768(ab)
Wesley, R, 729(ab)
Wessels, BW, 783(ab)
Wester, DW, 907(ab)
Westera, G, 777(ab)
Wetzel, LH, 931(ab)
Wheeler, R, 850(ab)
White, DL, 717(ab), 1844
White, JA, 1199
White, TA, 719(ab)
Whooten, WW, 424
Wible, JH, Jr, 747(ab)
Wiedermann, BL, 742(ab)
Wieland, DM, 707(ab), 725(ab), 726(ab), 738(ab), 745(ab), 792(ab), 797(ab), 804(ab), 831(ab), 898(ab), 1328, 1352, 1479
Wienhard, K, 771(ab), 799(ab)
Wierzbinski, B, 1486, 752(ab), 791(ab)
Wieshammer, S, 772(ab)
Wijns, W, 843(ab)
Wikander, R, 757(ab)
Wiklund, TA, 23
Wilbur, S, 777(ab)
Wilf, LH, 1103
Wilkinson, R, 795(ab), 833(ab)
Wilkinson, RA, 736(ab), 831(ab), 1199
Willett, CG, 601
William, C, 827(ab)
Williame, L, 831(ab)
Williams, A, 767(ab)
Williams, CM, 385(le), 939(ab)
Williams, DL, 1257
Williams, JR, 823(ab)
Williams, KA, 842(ab)
Williams, LE, 764(ab), 1433(le)
Williams, RP, 756(ab)
Williams, W, 891(ab)
Williams, WH, 772(ab)
Williamson, MR, 679
Wilmot, D, 580
Wilmot, DM, 1897
Wilson, A, 898(ab)
Wilson, AA, 385(le), 709(ab), 725(ab), 770(ab), 797(ab), 809(ab), 815(ab), 882(ab), 883(ab), 886(ab), 2015
Wilson, CB, 746(ab)
Wilson, DW, 798(ab)
Wilson, E, 905(ab)
Wilson, LA, 787(ab)
Wilson, MW, 790(ab)
Wilson, PD, 809(ab)
Wilson, RA, 726(ab)
Wimbish, WR, 847(ab)
Wissing, J, 84
Witanowski, LS, 1048
Witherspoon, L, 715(ab)
Witt, RM, 936(ab)
Witte, C, 891(ab)
Witte, M, 891(ab)
Wolf, A, 866(ab)
Wolf, AP, 719(ab), 762(ab), 780(ab), 787(ab), 886(ab), 902(ab)
Wolf, F, 758(ab)
Wolf, W, 480, 1745(le)
Wolfangel, RG, 768(ab), 898(ab), 907(ab)
Wolfe, B, 898(ab)
Wolfe, CL, 946(ab)
Wolfe, E, 774(ab), 802(ab), 1876
Wolpers, HG, 726(ab), 785(ab)
Wong, C, 804(ab)
Wong, DF, 809(ab), 882(ab)
Wong, E, 762(ab)
Wong, FC, 881(ab)
Wong, J, 894(ab)
Wong, JYC, 764(ab), 850(ab)
Wong, WH, 610, 748(ab), 864(ab)
Woo, DV, 849(ab)
Woodle, ES, 909(ab)
Woods, SW, 750(ab), 769(ab), 779(ab), 789(ab), 826(ab), 883(ab)
Woolfenden, JM, 772(ab)
Wooten, WW, 914(ab)
Worth, RM, 1280
Worthy, M, 835(ab)
Wortman, JH, 892(ab)
Woulfe, SR, 897(ab)
Wright, K, 903(ab)
Wu, LC, 762(ab), 772(ab), 848(ab), 871(ab), 1294
Wu, Y, 862(ab)
Wutz, W, 786(ab)
Wynant, G, 943(ab)

Yacoub, T, 834(ab), 940(ab)
Yagi, K, 512
Yagyu, T, 861(ab)
Yalow, RS, N17A(7)
Yamada, M, 790(ab), 869(ab)
Yamada, S, 885(ab)
Yamada, T, 136
Yamagishi, H, 861(ab)
Yamakado, K, 792(ab)
Yamamoto, I, 512
Yamamoto, K, 847(ab), 848(ab), 849(ab), 1015, 1818
Yamamoto, Y, 737(ab)
Yamamoto, YL, 738(ab)
Yamamuro, T, 1632
Yamaoka, K, 55
Yamasaki, T, 802(ab)
Yamashita, K, 742(ab), 743(ab), 848(ab)
Yamashita, M, 861(ab)
Yamazaki, M, 877(ab)
Yan, YC, 316(ab)
Yanagihara, T, 879(ab)
Yanagisawa, T, 881(ab)
Yang, D, 903(ab)
Yang, N-C, 873(ab)
Yang, SO, 781(ab)
Yang, Y, 648
Yano, J, 713(ab), 805(ab)
Yaoita, H, 795(ab), 833(ab)
Yasillo, NJ, 787(ab)
Yasuda, T, 225, 841(ab)
Yeh, SDJ, 742(ab), 793(ab)
Yeh, SH, 762(ab), 772(ab), 848(ab), 871(ab), 1294
Yin, KW, 905(ab)
Yock, P, 812(ab)
Yokoyama, A, 885(ab), 895(ab), 1015, 1818
Yokoyama, I, 778(ab)
Yokoyama, K, 202, 766(ab), 814(ab), 851(ab), 889(ab)
Yokoyama, M, 1077
Yolles, PS, 999
Yonekura, Y, 136, 708(ab), 742(ab), 743(ab), 808(ab), 847(ab), 848(ab), 849(ab), 885(ab), 895(ab), 1015, 1617, 1818
Yoon, J, 911(ab)
Yorke, ED, 783(ab)
Yoshida, A, 136
Yoshii, F, 826(ab)
Yoshikawa, K, 877(ab), 885(ab), 888(ab)
Yoshikawa, T, 792(ab)
Yoshizumi, TT, 1892(le)
Young, B, 801(ab)
Young, D, 809(ab)
Young, KC, 911(ab)
Young, LD, 880(ab)
Young, LT, 809(ab), 882(ab)
Youngerman, MJ, 862(ab)
Yu, DC, 708(ab), 861(ab), 865(ab)
Yu, D-W, 886(ab)
Yu, SK, 783(ab)
Yu, WKS, 946(ab)
Yu, X, 728(ab)
Yung, A, 800(ab), 803(ab), 937(ab)

Zabari, M, 523
Zabel, PL, 237
Zagni, P, 913(ab)
Zaizov, R, 755(ab)
Zalutsky, MR, 757(ab), 776(ab), 815(ab), 874(ab)
Zamora, PO, 832(ab)
Zanin, DEA, 1854
Zanzonico, P, 716(ab)
Zanzonico, PB, 784(ab), 788(ab), 844(ab), 1884
Zaret, BL, 1970
Zasadny, K, 852(ab)
Zasadny, KR, 84, 759(ab), 804(ab), 1479
Zasler, ND, 246(le)
Zaydenberg, I, 776(ab)
Zea Ponce, Y, 796(ab)
Zeeberg, BR, 729(ab), 758(ab), 865(ab)
Zenaqui, D, 732(ab)
Zeng, GL, 739(ab), 770(ab), 867(ab)
Zhang, CG, 716(ab)
Zhang, Y, 823(ab)
Zhang, Z, 904(ab)
Zhang, Z-M, 516
Zhao, XD, 738(ab), 867(ab)
Zhu, P, 914(ab)
Zhu, X, 852(ab), 909(ab)
Zhu, YY, 841(ab)
Zia, F, 783(ab)
Ziegler, SI, 863(ab)
Zielinski, FW, 594
Zielinski, JD, 784(ab)
Zielonka, JS, 827(ab)
Zierz, S, 1740
Ziessman, HA, 836(ab)
Zilbovicius, M, 892(ab), 893(ab)
Zimmer, AM, 725(ab), 854(ab), 856(ab)
Zimmerman, RE, 729(ab), 769(ab), 1456
Zinn, KR, 351
Zito, F, 735(ab), 747(ab), 834(ab), 854(ab), 871(ab)
Zoghbi, S, 779(ab), 883(ab)
Zubal, IG, 729(ab), 769(ab), 779(ab), 789(ab), 883(ab), 915(ab)
Zubieta, JA, 776(ab)
Zuccalà, A, 913(ab)
Zuckerman, JD, 780(ab)
Zunkeler, B, 810(ab)
Zwas, ST, 790(ab)
Zwinderman, AH, 1774

A

Abdomen, glucose utilization, thoracic and abdominal organs, 778(ab)
Abscess
brain, In-111 granulocyte scintigraphy, 1121
detection, In-111 leukocytes, Tc-99m HMPAO and Ga-67 citrate, 940(ab)
Absorptiometry
dual energy X-ray
BMC measurement of femora, titanium endoprostheses, 829(ab)
bone mineral density, lumbar spine, 1156
human transiliac bone biopsies, small animal bones, 932(ab)
dual energy X-ray and dual photon
body composition measurements, 829(ab)
cross calibration, 829(ab)
dual photon: *See* Dual-photon absorptiometry
single photon
osteoporosis in women, eating disorders, 325
reassessment for coverage, N15A(6)
Accelerator, dedicated for nuclear medicine, N13A(3)
high-current electrostatic, radionuclide production, PET, 943(ab)
Acetabulum, three-phase bone and indium white blood cell scintigraphy, porous-coated hip arthroplasty, 274
Acetate, radiolabeled, regional myocardial metabolism, quantification of patterns, 835(ab)
Acetazolamid, reversible cerebrovascular disease, Tc-99m HMPAO SPECT, 789(ab)
Achalasia, quantitative and qualitative evaluation, esophageal motility disorder, multiple swallow test, 775(ab)
Acquired immunodeficiency syndrome (AIDS)
dementia, I-123 IMP SPECT, brain, 936(ab)
distinction of patterns, radiogallium uptake, sarcoidosis, 895(ab)
PET and neuropsychologic correlates, 1584(ab)
ACS Award, Michael J. Welch, N38A(6)
Adenocarcinoma
comparison of biological activity, human/mouse chimeric antibody, original murine antibody, 754(ab)
prostate, prediction, serum PSA and PAP level, 791(ab)
radical prostatectomy, bone scans and PSA levels, 751(ab)
reactive, intravenous administration, Y-90 B72.3, 725(ab)
Adenoma
parathyroid
simultaneous dual isotope acquisition technique, 1583(ab)
technetium-thallium scintigraphy, 935(ab)
vs. hyperplasia, adrenal scintigraphy, Cushings and Conns syndrome, 845(ab)
Adenosine
comparative diagnostic efficacy, treadmill exercise SPECT thallium imaging, CAD detection, 733(ab)
-induced hyperemia, left ventricular dilatation, SPECT thallium imaging, 837(ab)
infusion, comparison, exercise Tl-201 tomography, 722(ab)
post-stenotic myocardial SQ30,217 kinetics, 785(ab)
replacement for dipyridamole, N25A(8)
-SPECT thallium-201 myocardial imaging, 723(ab)
Tl-201, stress, comparative myocardial count density, 837(ab)
treadmill exercise and, Tl-201 imaging, coronary artery disease, 733(ab)
Adenosine triphosphate
concentration, myocardial accumulation, I-125 BMIPP, 1818
inhibition of synthesis, decreased myocardial uptake, iodinated methyl-branched fatty acid, 708(ab)
Adrenal gland
I-124 NCL-6-I PET radiotracer, 947(ab)
scintigraphy, adenoma *vs.* hyperplasia, Cushings and Conns syndrome, 845(ab)
Adrenoceptors
beta, graphical method for quantification, cardiac PET, 866(ab)
MIBG and, rats, 1253(le)
Adriamycin
auger electron emitting analogues, cancer radiotherapeutic agents, 900(ab)
-induced cardiomyopathy, I-125 MIBG, 832(ab)
Advisory Committee on the Medical Uses of Isotopes (ACMUI), first meeting in two years, N23A(10)
Aebersold Award, Marcus E. Raichle, N25A(5)
Aerosol, ventilation scans, improvement with ethanol, 894(ab)
Aging
cerebral metabolic rate of glucose, 1585(ab)
dependence, alpha-fetoprotein-16α-[F-18]fluoro-estradiol interaction, 910(ab)
normal, whole brain and regional glucose metabolism, F-18 PET, 771(ab)
normal and Alzheimer's, behavioral activation, PET, 730(ab)
senescence accelerated mouse, altered glucose metabolism, brain, 895(ab)
supine exercise stroke volume, cardiac dilatation, elderly, 838(ab)
AH5183, ligand for SPECT imaging, cholinergic denervation, brain, 885(ab)
Albumin, -DTPA-In-111, molecular size and immunoreactivity, serum and supernatant, 906(ab)
Algorithms
attenuation scan misalignment, cardiac SPECT, 875(ab)
"behavioral imaging," validity study, Alzheimer's dementia, 730(ab)
deconvolution, two-phase fit, hepatic extraction efficiency, 732(ab)
3D interpolation, quantitative performance analysis, reorientation of cardiac PET images, 1590(ab)
image data compression, nuclear medicine images, 857(ab)
inflammation imaging, 1746(le)
iterative cone beam reconstruction, geometric point response correction, SPECT, 867(ab)
limited-angle tomography for the nineties, 1688
mathematical modeling, antibody distribution in man, 1589(ab)
maximum-likelihood estimation, mathematical model for quantitation, 1693
ML-EM, SPECT image reconstruction, 867(ab)
quantitation, 1986
systemic evaluation, suspected osteomyelitis, 932(ab)
temporal behavior, peripheral organ distribution volume, mammillary systems, 1710
three-dimensional assessment, myocardial oxidative metabolism, C-11 acetate PET, 1876
uniformity correction, error, brain SPECT, 700(le)
Allied Health, appropriations, N22A(3), N15A(6)
Allografts
cardiac, perfusion abnormalities, PET, 841(ab)
renal transplants, blood flow, pediatric patients, 580
Aluminum, toxicity treated with desferoxamine, altered biodistribution, Ga-67, 115
Alzheimer's disease
accuracy of PET for detection, 730(ab)
beware classic FDG-PET pattern, 740(ab)
brain perfusion patterns, HMPAO SPECT, 877(ab)
cholinergic synaptic vesicle, selective radiotracers, 797(ab)
interactive three-dimensional region of interest, HMPAO SPECT brain studies, 2046
localization of R,R-I-123 IQNB, SPECT, 729(ab)
neural-network classifier, PET scans, 817(ab)
normal aging and, behavioral activation, PET, 730(ab)
opiate *mu* receptors, C-11 carfentanil, PET, 770(ab)
-type dementia, mitochondrial encephalomyopathy, HMPAO-SPECT, 1740
validity study, "behavioral imaging" algorithm, 730(ab)
American Chemical Society (ACS), Michael J. Welch receives Nuclear Chemistry Award, N38A(6)
American College of Nuclear Physicians (ACNP), SNM/ACNP government relations update, N14A(6)
Amide thiolate, ligands, Tc-99m Fab, radioimmunodetection, 747(ab)
γ-Aminobutyric acid, reuptake, F-18 labeled inhibitors, 786(ab)
Amphetamines
cocaine and, D1 and D2 dopamine ligand uptake, rat brain, 809(ab)
regional cerebral metabolism, glucose, 761(ab)
Amyloidosis, diagnosis of primary amyloid nephrotic syndrome, utility, gallium imaging, 292
Amytal, distribution, intra-arterial sodium amytal test, Tc-99m HMPAO SPECT, 818(ab)

Page numbers followed by (ab) indicate abstracts.
Page numbers followed by (le) indicate letters.
N preceding a page number indicates an article appearing in *Newsline*.

Anemia
aplastic, bone marrow imaging, MRI and In-111 chloride scintigraphy, 752(ab)
detection of focal lesions, Ga-67 citrate, 512
Anesthesia
inhalational anesthetics, F-18-labeled, 900(ab)
norepinephrine-induced left ventricular dysfunction, 1580(ab)
Aneurysm, anterior left ventricle, improved detection, multiharmonic Fourier analysis, 1303
Anger camera, deadtime, dual-energy-window-acquisition mode, 759(ab)
Angina
during coronary angioplasty, functional significance, 843(ab)
left ventricular wall motion and myocardial perfusion, Tc-99m MIBI compared to Tl-201 SPECT, 457
Angiocardiography
first-pass, dipyridamole Tc-99m MIBI SPECT and planar imaging, 821(ab)
radionuclide, 1300
Angiography
coronary
computerized quantitative assessment, tomographic thallium reversibility, 874(ab)
vascular territory, rapid planar teboroxime, 828(ab)
wall motion analysis, 3-D surface gated radionuclide ventriculograms, 838(ab)
intraarterial injection of Tc-99m MAA, peripheral arteriovenous malformation, 1557
significance of fill-in after Tl-201 reinjection, delayed imaging, 1617
single perfusion defect and pulmonary embolism, 296
Angiography, radionuclide, multigated, left ventricular volume calculation, 450
Angioplasty
coronary
disease progression, previously normal vessels, 836(ab)
extent of restenosis, exercise Tl-201 tomography, 843(ab)
functional significance of angina, 843(ab)
restenosis after partial *vs.* total revascularization, Tl-201 exercise imaging, 763(ab)
Angiotensin converting enzyme
F-18 labeled inhibitor, synthesis and biodistribution, 738(ab)
-inhibited renal scintigraphy, renal artery stenosis, multiple renal arteries, 1847
inhibitor, 1990 Berson-Yalow Award, Dah-Ren Hwang, N19A(6)
Anorexia nervosa, osteoporosis in women, 325
Antibodies
96.5 and 9.2.27, binding site analysis, normal liver and spleen, 755(ab)
anti-idiotype second, enhanced clearance, anti-CEA monoclonal antibody, 854(ab)
bifunctional
DB III synthesis and characterization, radioimaging, 757(ab)
delivery system, imaging and therapeutic potential, 734(ab)
enhanced anti-tumor effect, multiple course radioimmunotherapy, 911(ab)
bispecific conjugates, radiolabeled tracers, tumor imaging, 757(ab)
chimeric, tumor and organ dosimetry, animal biodistribution data, 788(ab)
human anti-murine
Ca-125, mouse monoclonal antibodies, 715(ab)
cold antibody titration, radiolabeled monoclonal antibodies, 854(ab)
immunoscintigraphy, 381(le)
immunoscintigraphy, bone marrow, 751(ab)
human/mouse chimeric, comparison to original murine antibody, 754(ab)
intraperitoneal delivery, protein dose and volume effects, 850(ab)
radiolabeled, "fusion" of CT, improved mediastinal staging, 798(ab)
Anti-CEA antibodies
I-131 monoclonal antibody $F(ab')_2$ fragments, radioimmunotherapy, colon carcinoma, 1035
pharmacokinetic modeling, distribution in man, 754(ab)
Antiflammatory agents, kinetics of In-111 granulocytes, 890(ab)
Antimicrobial agents, kinetics of In-111 granulocytes, 890(ab)
Antimyosin
dual radiolabeled, documentation, reperfusion myocardial injury, 805(ab)
quantitative assessment, age of myocardial infarction, 782(ab)
uptake, stunned myocardium, 795(ab)
α-1 Antitrypsin, protein-losing gastroenteropathy and, diagnostic value, In-111 transferrin, 814(ab)
Apnea, sleep, brain perfusion patterns, HMPAO SPECT, 877(ab)
Appendicitis
acute, detection, Tc-99m HMPAO labeled WBC, 1588(ab)
hot, 316
Arteriography
coronary, SPECT perfusion imaging, Tc-99m TEBO, 1581(ab)
renal artery stenosis, captopril renal scintigraphy, echo-Doppler flowmetry, 913(ab)
Artery
carotid, *see* Carotid artery
coronary, systolic and diastolic ventricular function, transient coronary flow interruption, 754(ab)
normal coronary, impaired myocardial metabolism, PET, 713(ab)
occlusive disease in legs, exercise whole-body thallium scintigraphy, 1443
occlusive thrombi, *in vivo* visualization, Tc-99m monoclonal antibody against activated platelets, 713(ab)
peripheral arteriovenous malformation, intraarterial injection, Tc-99m MAA, 1557
renal
angiotension converting enzyme-inhibited renal scintigraphy, 1847
renovascular hypertension, renal scintigraphy, 674
Arthritis
acute gouty, In-111 leukocyte scintigraphy, 682
antigen-induced, radiation synovectomy, Ho-166-FHMA, 780(ab)
experimental, non-invasive imaging, four radiotracers, 781(ab)
Arthrography
Ga-67 citrate, painful hip prosthesis, 830(ab)
nuclear, loosening, total hip prostheses, 712(ab)
radionuclide and contrast, evaluation, total hip arthroplasty loosening, 712(ab)
Arthroplasty
hip, periprosthetic In-111 leukocyte activity, Tc-99m sulfur colloid imaging, 1950
porous-coated hip, acetabulum, three-phase bone and indium white blood cell scintigraphy, 274
ASP, high resolution tomograph for small animals, 769(ab)
ASPECT system, dedicated brain SPET system, comparison, rotating γ-camera and PET, 871(ab)
Aspirin, low dose, inhibitor, platelet aggregation, 891(ab)
Assays
chemiluminescent label, clinical sensitivity, TSH, 714(ab)
micronucleus, intravenously injected radiolabeled antibody, liver cells, 844(ab)
monoclonal immunoradiometric, malarial antigen detection, rat, 1587(ab)
radioimmunometric, liquid-phase two-site sandwich, prostate specific antigen, 714(ab)
sensitive hTG IRMA, thyroid carcinoma, 715(ab)
Astrocytoma, preoperative Tl-201 SPECT, 825(ab)
ATE method, radioiodination of monoclonal antibodies, 757(ab)
Atherosclerotic disease, lipoprotein distribution, In-111 LDL, 343
Atrophy, correction of PET data, MRI, 816(ab)
Atropine, I-125 DEX ligands, central muscarinic receptors, 886(ab)
Attenuation correction
effects in myocardium, misalignment, transmission and emission PET, 736(ab)
scatter and, SPECT, density maps and Monte Carlo simulated scatter functions, 1560
SPECT
build-up functions, 493
filter design, iterative Chang method, 739(ab)
Autoradiography
antibody uptake, liver metastases, 855(ab)
dual-tracer, Tc-99m MIBI and Tl-201, heart, 832(ab)
image digitization and analysis system, 758(ab)
intratumor localization of monoclonal antibodies, Lym-1 and TNT-1 antigens, 1059
iodoamphetamine redistribution, brain ischemia, 660
Tc-99m HM-PAO, central nervous system, murine lupus, 884(ab)
validation of 5-[I-123/I-125] iodo-2'-deoxyuridine, brain tumors, 766(ab)
Avidin
-biotin system, antibody-guided tumor detection, CEA-positive patients, 735(ab)
I-125 biotinylated monoclonal antibodies, antibody guided surgery, 853(ab)

B

Back, pain in lower region, SPECT and X-ray CT, 830(ab)
Background, correction, Tc-99m DTPA renal clearance, 430
Balloon, PTCA, myocardial ischemia, perfusion imaging, 840(ab)
Bayesian method, image restoration of PET, 748(ab)
B cells, treatment of malignancies, I-131 Lym-1, 723(ab)
BCNU, perfusion and oxygenation of rat 9L tumor, P-31 NMR metabolic activation, 717(ab)

Behavior
disorders, Tc-99m HMPAO SPECT, brain, 741(ab)
obsessive-compulsive disorder
regional cerebral blood flow, SPECT, 750(ab)
Tc-99m D,L-HMPAO SPECT, 750(ab)
treated and untreated panic disorder, cerebral blood flow, 880(ab)
Benzyl-EDTA, chelate, minimal transchelation of indium, 218
Berson-Yalow Award 1990
criteria, 34A(10)
Dah-Ren Hwang, N13A(6)
Beta-adrenergic blockade, acute myocardial infarction, radionuclide ventriculography, 557
Beta camera, static and dynamic imaging, charged-particle emitting radionuclides, biologic samples, T32
Bicarbonate, stability of gallium-transferrin complex, 903(ab)
Bile, reflux, scintigraphic cholecystokinin-induced, 248(le)
Bile duct, sphincter of Oddi dysfunction, CCK-stimulated biliary scintigraphy, 732(ab)
Biliary stenosis, efficacy of Tc-99m DISIDA for early detection, liver transplanted children, 732(ab)
Biological Effects of Ionizing Radiation (BEIR)
BEIR V report
higher risk estimates, N13A(4)
minisymposium, N16A(5)
Biotin
-avidin system, antibody-guided tumor detection, CEA-positive patients, 735(ab)
In-111-labeled, imaging of tumor, 1791
Bismuth
bifunctional DTPA's, polyazacycloalkane-N-acetic DOTA, 824(ab)
-labeled monoclonal antibody, cell survival curves, SQ20B cell irradiation, 788(ab)
Bismuth-212-NRLU-10, toxicity, I-125 NRLU-10 kinetic studies, LS174T multicell spheroids, 1527
Bladder, elimination of "hot" artifacts, pelvis, SPECT, 1872
Bleomycin, administered dose and tumor dose, cobalt-57, mice and men, 1784
Blood
human and canine, metabolic fate, N-13 ammonia, 163
human clot labeling, active-site mutant, t-PA, 187
liver and, time-activity curves, GI tract radiation dose, 844(ab)
plasma free fraction, concentration-dependence, radiopharmaceuticals, 809(ab)
time activity curves, labeled metabolites, quantitative tracer PET studies, 708(ab)
Blood-brain barrier
CMR_{O2} measurement in PET, weighted integration, CBV correction, 861(ab)
disruption, chemotherapy, malignant glioma, 1584(ab)
hyperosmotic, disruption, Rb-82 and PET, 810(ab)
permeability, error analysis, Ga-68 EDTA PET, 860(ab)
transport of 6-[F-18]fluoro-L-dopa, regiospecifically labeled [C-14]dopa, 1593(ab)
Blood flow
assessment, inter-operator errors, renal transplants, 911(ab)
brain, cerebrovascular disease, I-123 HIPDM SPECT, 879(ab)
breast tumors, exchangeable volume of water, dynamic PET, 746(ab)
cerebral
children from birth to 18 years, Xe-133, 892(ab)
chronic hypertension, brain-dedicated SPECT, 882(ab)
chronic obstructive carotid disease, SPECT, 55
CMRO2 measurement simultaneously, O-15 water and PET, 760(ab)
correction for extraction fraction, I-123 IMP and SPECT, 868(ab)
correction of overestimation, dynamic SPECT with I-123 and arterialized venous samplings, 790(ab)
crack users and controls, SPECT, 876(ab)
frontal lobe function, PET, 750(ab)
generator-produced PET tracer, Cu-PTSM, 351
1990 Hevesy Award, Neils A. Lassen, N28A(5)
mimicry, lipophilic technetium complexes, 807(ab)
naloxone effects, complex partial seizures, 710(ab)
neuropsychological test scores, dementia, 731(ab)
neutral lipophilic Tc-99m complex, 1370
N-isopropyl-P [I-123] IMP SPECT, memory task, 750(ab)
obsessive-compulsive disorder, SPECT, 750(ab)
O-15 butanol and PET, human subjects, 884(ab)
optimal reconstruction filters, PET subtraction studies, 865(ab)
postictal switch, HMPAO SPECT, 711(ab)
progressive dementia with motor neuron disease, 688
ratio to rCBV, SPECT, 1433(le)
residual O-15 activity, PET, 861(ab)
resting, reproducibility with O-15 water PET, 887(ab)
SPECT, epileptic children treated by callosotomy, 893(ab)
Tc-99m HMPAO SPECT, compared to C-15 O_2 PET, 1595
Tc-99m or Xe-133 SPECT, mild perfusion abnormalities, 817(ab)
Tc-99m RBC and Tc-99m HMPAO, SPECT, 790(ab)
test-retest comparison, face matching task, 760(ab)
threshold level, functional activation, 760(ab)
time dependency, diffusible tracer-based measurements, 884(ab)
tracer validation studies, I-123 IMP SPECT, 1364
treated and untreated panic disorder, 880(ab)
triple tracer kinetics, Tc-99m HMPAO brain SPECT, 881(ab)
uptake and retention, Tc-99m T691, 885(ab)
visually stimulated state, I-123 IMP SPECT, 875(ab)
visual stimulation effects, I-123 IMP deposition, 875(ab)
comparison of PET with bitemporal epidural electroencephalography, preoperative evaluation, partial complex epilepsy, 710(ab)
hepatic arterial and portal venous, nonlinear regression based deconvolution method, fractional distribution, 859(ab)
hypercapnic, reactivity, unilateral carotid disease, 789(ab)
kinetic model, Tc-99m HMPAO SPECT, 868(ab)
muscle, electrical stimulation, spinal cord injury, 818(ab)
myocardial
clearance kinetics, Tc-99m SQ30217, 1183
dysfunctioning collateral-dependent myocardium, 843(ab)
mitochondrial oxidative substrate flux, ischemic myocardium, 840(ab)
N-13 ammonia PET, factor analysis, 802(ab)
noninvasive quantification, collateral circulation, 271
optimal dynamic SPECT data acquisition protocols, 718(ab)
O-15 water *vs.* N-13 ammonia, 1431(le)
validation, N-13 ammonia, 1335
oxidative metabolism and systolic function, inotropic stimulation, stunned myocardium, 713(ab)
pancreatic cancer imaging by PET, 847(ab)
penile
radioisotope penile plethsymography, xenon washout, 762(ab)
Xe-133 washout, 246(le)
quantification, reproducibility, Tc-99m SESTAMIBI SPECT, 821(ab)
quantitative assessment, renal transplants, pediatric patients, 580
regional, Cu(PTSM) localization, dog kidney, 914(ab)
renal
hypertension, lithotripsy, 939(ab)
noninvasive measurement, Tc-99m DTPA, 1980
small cyclotron production, Cu-60 PTSM, 815(ab)
Tc-99m ECD, compared to I-123 QNB kinetics, SPECT, 707(ab)
tumor measurement, copper-PTSM, 909(ab)
venography, detection, deep venous thrombosis, 838(ab)
Blood pool imaging
applications, noncoronary heart disease, 10
blood flow venography and, detection, deep venous thrombosis, 838(ab)
copper-62, radiopharmaceuticals, 727(ab)
gated cardiac sequences, fixed and variable temporal resolution methods, 38
gated tomographic detection, regional ejection fraction, myocardial infarction, 842(ab)
harmonic analysis, ejection fraction, left ventricular functional parameters, 858(ab)
importance of scintigraphic measurements, splanchnic blood volume, 160
multiharmonic Fourier analysis, improved detection, anterior left ventricular aneurysm, 1303
placental localization in abdominal pregnancy, Tc-99m red blood cells, 1106
regional perfusion, bone scintigraphy, 831(ab)
scintigraphy, scrotal variocele, 911(ab)
splanchnic vascular capacity and capacitance, equilibrium blood-pool scintigraphy, 154
Blood type, anti-Gerbich, *in vivo* cross-match, Cr-51 urinary excretion from labeled erythrocytes, 2042
Bolton-Hunter method, radioiodination of monoclonal antibodies, 757(ab)
Bond, Victor P., DOE award for lifetime

achievement, N32A(9)

Bone
body composition measurements, dual photon and dual energy X-ray absorptiometry, 829(ab)
cancer
metabolically active calcific tissues, Sm-153 EDTMP, 767(ab)
simple kit for preparation, Re-186 HEDP, 898(ab)
cross calibration, dual photon and dual energy X-ray absorptiometry, 829(ab)
dual-photon absorptiometry in clinical practice, 1781
dynamics, inhaled Xe-133, 781(ab)
fracture healing, ultrasonic stimulation, scintigraphy, 781(ab)
fracture site hematoma and fracture healing, subperiosteal transplantation, 781(ab)
heterotopic uptake on scans, serendipitous findings, extraskeletal pathology, 931(ab)
imaging kits, clinical evaluation, 829(ab)
infection, scintigraphic detection, In-111 nonspecific polyclonal human IgG, 403
inflammatory lesions, double tracer subtraction/reverse subtraction imaging, 1589(ab)
In-111 leukocyte/Tc-99m MDP, MRI, osteomyelitis, 549
metabolic rates, F-18 fluoride ion and PET, 778(ab)
metastasis, samarium-153 EDTMP, clinical effects, 586
mineral content
highlights, EANM Congress, N15A(10)
precision, total-body scans, 43
QCT scanner STRATEC SCT 900, precision, 856(ab)
statistical artifact, DPA measurements, 537(le)
mineral density
anthropometric factors, 830(ab)
Colles' fractures, dual-photon absorptiometry, 1580(ab)
lumbar spine, dual-energy X-ray absorptiometry, 1156
neoplasms, Sm-153 EDTMP, 1316
painful metastases, Sr-89, prostatic and breast carcinoma, 804(ab)
"positive" scan, stress fracture and/or shin splint, basic training, 932(ab)
primary and metastatic cancer, systemic radioisotopic therapy, 1326
radionuclide imaging findings, histological Gleason grading, prostate carcinoma, 752(ab)
routine scanning, asymptomatic prostate carcinoma patients, 887(ab)
sarcoma, Tl-201 scintigraphy, 567
scan
acute and chronic brucellosis, scintigraphic patterns, 830(ab)
analog and digital, clinical comparison, 830(ab)
jaw, orthopan display technique and normal values, 871(ab)
paper-based laser images, 857(ab)
skeletal metastases, breast cancer, 387
scans in conjunction with PSA levels, adenocarcinoma recurrence, radical prostatectomy, 751(ab)
scintigraphy
accuracy, osseous spinal metastasis, 931(ab)
calcific discitis, childhood, 234
Ewing's sarcoma, 755(ab)
fractures of scaphoid, 831(ab)
hyperparathyroidism, thyrotoxicosis, 845(ab)
increased sacroiliac joint uptake, low back pain, 712(ab)
magnification, detection of talocalcaneal coalitions, 1797
regional perfusion, blood pool images, 831(ab)
secondary chondrolysis, slipped epiphysis, 742(ab)
soft tissue abnormalities, serendipitous findings, 932(ab)
-seeking radiopharmaceuticals, nonosseous uptake, 931(ab)
skeletal deposits, serum osteocalcin measurements, prostate carcinoma, 1486
spine, automatic image comparison, dual-photon absorptiometry, 931(ab)
splenic accumulation of Tc-99m methylene diphosphonate, chronic myelogenous leukemia, 1552
Tc-99m MDP
chronic recurrent multifocal osteomyelitis, 938(ab)
cold defect on scan, malignant fibrous histiocytoma, 1104
three-phase imaging
scintigraphy, plantar fasciitis, 932(ab)
stress injury, anterior iliac crest, 1554
three-phase scanning and In-111 white blood cells
acetabulum, porous-coated hip arthroplasty, 274
osteomyelitis, pedal ulcers in diabetics, 890(ab)
tibial repair, technetium uptake, mineralization, 2011
titanium endoprostheses, BMC measurement of femora, dual energy X-ray absorptiometry, 829(ab)
transiliac biopsies, small animal bones, dual-energy X-ray absorptiometry, 932(ab)

Bone marrow
acute infarction, combined scintigraphic identification, sickle cell disease, 893(ab)
breast cancer patients, radioimmunoimaging, Tc-99m NCA antibodies, 751(ab)
dosimetry, marrow-to-blood activity concentration ratio, 788(ab)
enhancement of radiation dose, backscattering, electron sources, 783(ab)
immunoscintigraphy, Tc-99m NCA-95/CEA antibodies, 751(ab)
MRI and In-111 chloride scintigraphy, myelodysplasia, aplastic anemia, 752(ab)
radioimmune imaging, suspected bone metastases, primary breast cancer, 1450
scan, Sr-89 therapy, metastatic prostate and breast cancer, 938(ab)
transplantation, lung uptake of sulfur colloid, venoocclusive disease, 372

Book reviews
A Non-Mathematical Approach to Basic MRI, 1120
A Textbook of Radiology and Imaging, 702
Edeiken's Roentgen Diagnosis of Disease of Bone, 4th Edition, 1255
Evaluation of Renal Function and Disease with Radiopharmaceuticals: The Upper Urinary Tract, 1897
Hospital Radiopharmacy Principle and Practice, 1254
Imaging 1990, 1120
Imaging of the Newborn, Infant and Young Child. Third Edition, 702
Impact of Functional Neuroimaging in Neurology and Psychiatry. Current Problems in Neurology:5, 1255
Magnetic Resonance Imaging and Computed Tomography of the Head and Spine, 1897
MRI of the Musculoskeletal System: A Teaching File, 1579
NCRP Report No. 105, Radiation Protection for Medical and Allied Health Personnel, 1579
Neuroimaging II, 1254
Pharmaceuticals in Medical Imaging: Radiologic Contrast Media, Radiopharmaceuticals, Enhancement Agents for Magnetic Resonance Imaging and Ultrasound, 703
Positron Emission Tomography in Clinical Research and Clinical Diagnosis: Tracer Modelling and Radioreceptors, 541
Scintigraphy of Inflammation with Nanometer-sized Colloidal Tracers, 541

Bowel
inflammatory disease, In-111 granulocyte splenic pooling, 1470
small, positive and negative oral contrast, MRI, 946(ab)

Brachytherapy, I-125, recurrent malignant glioma, Tl-201/Tc-99m HMPAO SPECT, 826(ab)

Brain
abscess diagnosis, In-111 granulocyte scintigraphy, 1121
altered glucose metabolism, senescence accelerated mouse, 895(ab)
amphetamine and cocaine effect, D1 and D2 dopamine ligand uptake, 809(ab)
amyotrophic lateral sclerosis, Tc-99m HMPAO SPECT, 818(ab)
ASPECT-dedicated SPECT, physical performance, 769(ab)
baboon, dopaminergic and serotonergic blockade, C-11 methyl-benztropine, 780(ab)
blood flow, cerebrovascular disease, I-123 HIPDM SPECT, 879(ab)
caudate nuclei glucose hypermetabolism, eating disorders, 750(ab)
cerebellar hypometabolism, unusual patterns, head trauma, 741(ab)
cerebellar vasoreactivity, vertebro-basilar insufficiency, 1584(ab)
cerebral blood flow, *see* Blood flow, cerebral
cerebral blood volume SPECT, DIAMOX cerebral blood flow SPECT, cerebral vascular reserve, 877(ab)
cerebral glucose metabolism, familial inverted chorea, PET, 740(ab)
cerebral hemodynamics, chronic obstructive carotid disease, SPECT, 55
cerebral infarction, dependence on SPECT/IMP results, time post onset after infarction, 878(ab)
cerebral ischemia
SPECT quantitation, carotid endarterectomy, 1412
Tc-99m RBC CBV and Tc-99m HMPAO CBF SPECT, 790(ab)
cerebral metabolic rate of glucose, effect of age, 1585(ab)
cerebral perfusion defects, vestibular disorders, 876(ab)
chemistry and mental function, N21A(8)
chemistry of the unconscious, N24A(8)
cholinergic denervation, AH5183 ligand, SPECT imaging, 885(ab)

cocaine effect, I-123 IMP distribution, 887(ab)
compartmental analysis, C-11 benztropine binding, 866(ab)
cone beam SPECT, two orbits, 770(ab)
constrained evaluation of dopa decarboxylase, F-18 FDOPA and PET, 884(ab)
cortical metabolism, posterolateral thalamic stroke, 880(ab)
crossed cerebellar diaschisis and stroke, I-123 IMP SPECT, F-18 FDG PET, 770(ab)
Cu-62 pyruvaldehyde *bis*(*N*⁴-methylthiosemicarbazonato)copper(II), tracer for PET, 1989
D2-dopamine receptor-specific binding, C-11 YM-09151-2 PET, 779(ab)
death determination, Tc-99m HMPAO, 2075(le), 2076(le)
determination of flow and rate constants, compartmental model, Tc-99m HMPAO, 868(ab)
developments in cerebral imaging, IOM brain symposium, N32A(9)
disturbances in cerebral perfusion, HIV-1 seropositive asymptomatic subjects, 1601
dopa decarboxylase activity *in vivo*, 720(ab)
ECT, resolution and count density requirements, 718(ab)
F-18 FDG metabolism, $GABA_A$ receptor antagonist, 878(ab)
6-[F-18]fluoro-dopa model, estimation, kinetic parameters, 865(ab)
fossa tumors, FDG-PET, pediatrics, 878(ab)
functional images
  correlation methods, alignment, 1220
  two-day symposium, N27A(1)
functional mapping, metric for activation detectability, PET scanners, 817(ab)
glucose metabolism, insulin effect, PET, 879(ab)
high resolution SPECT, accurate modeling, spatial system response, 739(ab)
high-spatial resolution SPECT, fan beam collimators, 869(ab)
HIPDM-SPECT, presurgical evaluation, intractable seizures, 1280
HMPAO SPECT
  interactive three-dimensional region of interest analysis, 2046
  localization of epileptic foci, site of temporal lobectomy, 711(ab)
hypoperfusion, orthostatic hypotension, autonomic failure, 877(ab)
I-123 IMP SPECT, clinical significance, pediatric patients, 878(ab)
I-123 iodo-*m*-tyrosine SPECT, synthesis, preliminary evaluation, 796(ab)
image analysis and observer bias, 864(ab)
imaging
  design study, stationary 3-D SPECT, 769(ab)
  new apparatus, 603
interaction of I-125 epiderpride, dopamine receptors, 809(ab)
ischemia, autoradiographic analysis, iodoamphetamine redistribution, 660
kinetics of carbon-11 cocaine, 719(ab)
labeling of dopamine D2 receptor, *N*-C-11 methyl-benperidol, 2015
lacrimal gland dosimetry, Tc-99m HMPAO, 1237
lateral view, new display for SPECT images, 872(ab)
mapping of cerebral benzodiazepine receptors, F-18 flumazenil PET, 902(ab)
mapping of supratentorial lesions, crossed cerebellar diaschisis, 789(ab)
melatonin receptor, I-125 IMEL binding, 883(ab)
mesial temporal sclerosis, PET and MRI, partial complex epilepsy, 880(ab)
metabolic activity in monkey mothers, brief separation from infants, 887(ab)
metabolic rates for glucose, program for PET image alignment, 2052
nonspecific tissue binding, opiate antagonist cyclofoxy, 883(ab)
normal perfusion, high resolution SPECT, 3-head rotating gamma camera, 880(ab)
pediatric tumor, Tc-99m HEXAMIBI SPECT, 2040
perfusion agent Tc-99m MRP20, 760(ab)
perfusion patterns, HMPAO SPECT, sleep apnea and Alzheimer's disease, 877(ab)
perfusion SPECT, annular single crystal camera, 1456
perfusion studies, focal high uptake of HM-PAO, encephalitis, 1094
PET and neuropsychologic correlates of AIDS, 1584(ab)
PET-MRI-3D-cortical surface display and analysis, 865(ab)
PET/SPECT scans, N22A(8)
pharmacokinetics and metabolism, L-[2-F-18] fluorotyrosine, 786(ab)
presynaptic cholinergic marker, I-125 iodobenzovesamicol, 797(ab)
primary and metastatic tumors, C-11 thymidine accumulation, 1585(ab)
primate
  benzodiazepine receptor, SPECT, 779(ab)
  dopamine D2 receptors, SPECT, 883(ab)
principal axes transformation, method for image registration, 1717
radiation-induced activation, pentose phosphate pathway, 844(ab)
radiopharmaceutical uptake, ultra-high resolution SPECT collimator, 870(ab)
rat and primate, slow turn-over rate pool of dopamine, 6-F-18 fluoro-L-dopa, 720(ab)
ratio of rCBV to rCBF, SPECT, 1433(le)
regional cerebral hematocrit, blood flow, canine acute stroke model, 1584(ab)
regional cerebral metabolism, glucose, drugs of abuse, 761(ab)
remote history of traumatic head injury, Tc-99m HM-PAO SPECT, 936(ab)
resting cerebral blood flow, reproducibility, O-15 water PET, 887(ab)
resting state glucose utilization, memory performance, young and old subjects, 879(ab)
reversible cerebrovascular disease, Tc-99m HMPAO SPECT, acetazolamid, 789(ab)
simultaneous SPECT, Tc-99m and I-123, PRISM scanner, 877(ab)
SPECT
  collateral circulation, trial balloon occlusion, 878(ab)
  DIAMOX and, 936(ab)
  error, uniformity correction algorithm, 700(le)
  MRI and, CNS systemic lupus erythematosus, 876(ab)
  program for quantitative analysis, 1862
  subtraction images and sector analyses, changes in tracer uptake, 874(ab)
  Tc-99m and I-123, quantitation linearity of three instruments, 769(ab)
striate cortex hypometabolism, visual field defects, post-lobectomy epileptic patients, 881(ab)
Tc-99m HMPAO
  SPECT, triple tracer kinetics, 881(ab)
  variable quality, radiopharmaceutical factors, 118
1990 Tetalman Memorial Award, Kirk A. Frey, N23A(7)
three-dimensional surface MR image, combination display, PET, 817(ab)
tumors
  early postoperative evaluation, FDG PET, 799(ab)
  FDG-PET, P-31 magnetic resonance spectroscopy, 302
  F-18 FDG PET and Tl-201 SPECT, 799(ab)
  homing patterns, adoptively transferred autologous lymphocytes, 818(ab)
  I-123 IPA SPECT, 899(ab)
  imaging by F-18 DFPA, 888(ab)
  radiation defect differentiation, FDG-PET images, 799(ab)
  recurrences, I-123 α-methyl tyrosine, 766(ab)
  residual or recurrent, FDG-PET, 800(ab)
  systemic evaluation, 969
  Tl-201 SPECT, methods and results, 965
variance in global F-18 FDG metabolism, 771(ab)
volume, distribution of Tc-99m D,L-HMPAO, neuroanatomy, 937(ab)
whole and regional glucose metabolism, normal aging, F-18 PET, 771(ab)

Breast
attenuation, inappropriate motion correction, thallium SPECT, 1591(ab)
cancer, *see* Breast cancer
differentiation of malignant from benign mass abnormalities, thallium scintigraphy, 767(ab)
milk, excretion of radioactivity, 978

Breast cancer
advanced, doxorubicin therapy, In-111 antimyosin scintigraphy, 1965
axillary lymphoscintigraphy, 1835
blood flow and exchangeable volume of water distribution, dynamic PET, 746(ab)
bone metastases, radioimmunoimaging, 1450
bone marrow metastases, radioimmunoimaging, Tc-99m NCA antibodies, 751(ab)
bone scan abnormalities, skeletal metastases, 387
CA-15-3 RIA values, 938(ab)
detection, imageable estradiol, 937(ab)
I-124 ICR12 PET, proto-oncogene expression, 777(ab)
low level ionizing radiation, N18A(7)
metastatic
  pain, Re-186, N26A(8)
  Sr-89 therapy, bone marrow scanning, 938(ab)
primary and metastatic cancer, FDG PET imaging, 889(ab)
recurrent, immunoscintigraphy, 734(ab)
regional spread, mammary lymphoscintigraphy, CT and MRI, 745(ab)
tumor perfusion, Rb-81 PET, 1307

Bremsstrahlung imaging, intraperitoneal radioimmunotherapy, Y-90 GKY-DTPA-B72.3 antibody, ovarian cancer, 724(ab)

Bromine-77 bromovinyl steroidal, triphenylethylene estrogens and, comparison of distribution, immature rat, 1534

Bronchiectasis, mucociliary clearance and transport, global and regional assessment,

543
Brucellosis, acute and chronic, scintigraphic patterns, bone scan, 830(ab)
Budd-Chiari syndrome, diagnosis, SPECT imaging, 109
Budget Reconciliation Bill, cost-containment, N18A(1)
Budinger, Thomas F., elected to Institute of Medicine, N28A(8)
Bulimia nervosa, osteoporosis in women, 325
Bulsulfan, "no-carrier-added" C-11 labeling, 1592(ab)
Buthionine sulfoximine, radiosensitizer in radioimmunotherapy, 853(ab)

C

CA-15-3, RIA, breast cancer, radiologic and clinical evaluations, 938(ab)
CA-125 antigen, different antigenic natures, apparently healthy individuals, 895(ab)
Cadmium, -telluride, Tc-99m MDP, focal maxillofacial lesions, 856(ab)
Calcium
chelated metallic radionuclides and chelating agents, endotoxin testing, limulus amoebocyte lysate, 243
cyclic phosphate and etidronate, dual-photon absorptiometry, osteoporosis, 752(ab)
technetium uptake, rat tibial bone repair, 2011
Calcium-125, HAMA in serum, mouse monoclonal antibodies, 715(ab)
CALLA: *see* Common acute lymphocytic leukemia antigen
Callosotomy, epileptic children, cerebral blood flow, SPECT, 893(ab)
Camera, *see also* specific type
annular single crystal, brain perfusion SPECT, 1456
posicam 6.5 BGO positron, design and performance, 610
Cancer, *see also* organ type
antibody guided surgery, I-125 biotinylated monoclonal antibodies, cold avidin, 853(ab)
diagnosis, *N*-[^{18}F]fluoroacetyl-D-glucosamine, 1654
mortality, radiation discharges and, no link, N11A(11)
multifocal, radioimmunotherapy, Y-90 monoclonal antibody, 911(ab)
radiotherapeutic agents, auger electron emitting Adriamycin analogues, 900(ab)
therapy, F-18 FDG, 889(ab)
Capillary, time dependency of diffusible tracer-based measurements, local cerebral blood flow, 884(ab)
Captopril
induced scintirenographic changes, hypertensives without renovascular hypertension, 715(ab)
post, diuretic therapy influences, renovascular hypertension, 913(ab)
renal scintigraphy, echo-Doppler flowmetry, renal artery stenosis, 913(ab)
renography, renovascular disease detection, renal transplant, 716(ab)
Carbon-11, "no-carrier-added" labeling of busulfan, 1592(ab)
Carbon-11 acetate
early net myocardial extraction, oxidative substrate flux, ischemic heart disease, 842(ab)
kinetics and hemodynamic performance, canine heart, 785(ab)
myocardial kinetics, compartmental model, delineation, 777(ab)
PET
metabolic performance, pressure and volume loaded heart, 773(ab)
oxidative and glucose metabolism, normal heart, 774(ab)
three-dimensional assessment, myocardial oxidative metabolism, 1876
tracer for myocardial oxidative metabolism, 1581(ab)
Carbon-11 benztropine, compartmental analysis of binding in brain, 866(ab)
Carbon-11 carfentanil, PET, opiate *mu* receptors, Alzheimer's disease, 770(ab)
Carbon-11 citalopram, C-11 fluoxetine and, ligands for serotonin uptake site, 883(ab)
Carbon-11 cocaine, human brain and heart, 719(ab)
Carbon-11 compounds, contribution of labeled carbon dioxide, PET, 909(ab)
Carbon-11 diprenorphine, binding quantification to opiate receptors, 866(ab)
Carbon-11 ethanol, PET, pancreas and liver imaging, 849(ab)
Carbon-11 flumazenil, metabolism, 897(ab)
Carbon-11 fluoxetine, C-11 citalopram and, ligands for serotonin uptake site, 883(ab)
Carbon-11 HED
I-131 MIBG comparison, ischemic neuronal injury, heart, 725(ab)
mechanistic studies of heart, 707(ab)
PET
pheochromocytoma, 745(ab)
sympathetic nervous system, cardiomyopathy, 792(ab)
sympathetic innervation in heart, distribution volume approach, 725(ab)
Carbon-11 *meta*-hydroxyephedrine, false transmitter agent, heart neuronal imaging, 1328
Carbon-11 IBZ, dopamine D2 receptors, 882(ab)
Carbon-11 methamphetamine, no-carrier-added, synthesis, analogs, 1592(ab)
Carbon-11 methionine, PET, differential diagnosis, lung tumor, 1927
Carbon-11 methyl-benperidol, labeling of dopamine D2 receptor, 2015
Carbon-11 methyl-benztropine, dopaminergic and serotonergic blockade, baboon brain, 780(ab)
Carbon-11 MHED
compared to C-11 PHED, 738(ab)
PET, metabolic studies, 831(ab)
Carbon-11 NMB, dopamine D2 receptors, 882(ab)
Carbon-11 NMSP
C-11 raclopride and, central D2-dopamine receptor characteristics, 1583(ab)
PET, dopamine and serotonin receptors, neuropsychiatric illness, 809(ab)
Carbon-11 palmitic acid, β-methyl heptadecanoic acid distribution, human liver, 848(ab)
Carbon-11 PHED, synthesis, compared with heart agent MHED, 738(ab)
Carbon-11 putrescine, PET, human prostate, 762(ab)
Carbon-11 raclopride, C-11 NMSP and, central D2-dopamine receptor characteristics, 1583(ab)
Carbon-11 Ro 15-1788, concentration of benzodiazepine receptors, 709(ab)
Carbon-11 SCH 39166
preparation of, 737(ab)
synthesis, potential D1 dopamine antagonist, PET, 737(ab)
Carbon-11 thymidine
accumulation in primary and metastatic brain tumors, 1585(ab)
DNA synthesis, 337
PET, hepatic cellular proliferation, 847(ab)
ring-2 and methyl positions, PET, 794(ab)
synthesis, cellular proliferation, 816(ab)
Carbon-11 tropanyl benzilate
binding to muscarinic cholinergic receptors, modeling alternatives, receptor ligands, 709(ab)
PET, cerebral muscarinic receptors, 779(ab)
Carbon-11 tyrosine, protein synthesis rate, four compartment model, 861(ab)
Carbon-11 YM-09151-2, PET, D2-dopamine receptor-specific binding, brain, 779
Carbon-14 deoxyglucose, accumulation in myocardial infarction, 835(ab)
Carbon-14 urea
breath test, chronic gastritis and peptic ulcer disease, 814(ab)
validation of simplified breath test, detection, *Heliobacter pylori*, 1940
Carbon-15 water, PET, compared to Tc-99m SPECT, regional cerebral blood flow, 1595
Carbon dioxide, PET imaging, C-11 compounds, 909(ab)
Carboxylate complexes, rare-earth, stability, skeletal biodistribution, 767(ab)
Carcinoembryonic antigen
enhancer, γ-interferon, colon cancer xenografts, 764(ab)
metabolism of In-111 monoclonal antibody, tumor and normal tissue, athymic mouse, 1510
-positive patients, antibody-guided tumor detection, avidin-biotin system, 735(ab)
quantitation and distribution, stomach cancer, 755(ab)
Carcinoid tumors, bronchial, increased accumulation, I-123 IMP, 240
Carcinoma
breast, tumor perfusion, Rb-81 PET, 1307
thyroid
I-131 dosimetry, 935(ab)
nasal radioiodine activity, 52
Carcinoma, breast, *see also* Breast cancer
model system, NR-LU-10 radioimmunotherapy, 852(ab)
painful bone metastases, Sr-89, 804(ab)
progestin receptors, PET, 746(ab)
sequential quantitative FDG/PET assessment, metabolic response, chemohormonotherapy, 746(ab)
serum glucose effects, tumor and normal tissue uptake, FDG, 888(ab)
Carcinoma, bronchiogenic
preoperative staging, F-18 deoxyglucose PET, 771(ab)
unresectable, optimizing therapy management, PET metabolic imaging, 766(ab)
Carcinoma, colonic, *see also* Colon cancer
enhanced anti-tumor effect, multiple course radioimmunotherapy, bifunctional antibody, 911(ab)
I-131 monoclonal antibody F(ab')$_2$ fragments, radioimmunotherapy, 1035
interferon enhancement, radioimmunotherapy, 850(ab)
murine monoclonal antibodies, syngeneic and xenogeneic tumor models, 1028
Carcinoma, colorectal, *see also* Colorectal cancer
I-131 B72.3 monoclonal antibody, 852(ab)

immunoscintigraphy, Tc-99m monoclonal anti-CEA antibody, 535(le)
In-111 monoclonal antibodies, accumulation in non-tumored tissue, 1975
liver metastases, F-18 uracil PET, 888(ab)
metastatic, modulated fluorouracil chemotherapy, PET, 803(ab)
radiation dosimetry of Hybri-CEAker, 844(ab)
recurrent, radiation therapy evaluation, PET, 813(ab)

Carcinoma, medullary thyroid
different scintigraphic methods, 744(ab)
radioimmunoscintigraphy, I-131 anti-CEA monoclonal antibodies, Tl-201 scintigraphy, 1854

Carcinoma, ovarian, *see also* Ovarian cancer
anti-ovarian carcinoma antibody, I-131 PIP, Phase I evaluation, 777(ab)
I-131 HMFG1 monoclonal antibody, dosimetry and toxicity, 938(ab)

Carcinoma, prostatic
asymptomatic patients, role, routine bone scanning, 887(ab)
histological Gleason grading, radionuclide bone imaging findings, 752(ab)
hormone refractory, treatment, Sm-153 EDTMP, 755(ab)
painful bone metastases, Sr-89, 804(ab)

Carcinoma, thyroid, *see also* Carcinoma, medullary thyroid; Thyroid cancer
eosinophilic, follow-up, Tl-201 scintigraphy, 767(ab)
I-131 dosimetry, 935(ab)
I-131 whole-body scans, thyroglobulin measurement as replacement, 1766
sensitive hTg IRMA, 715(ab)
Tl-201 scintigraphy, magnetic resonance imaging, 1958
well-differentiated
utility of Tl-201, 744(ab)
validation of new protocol, 1585(ab)

Cardiomyopathy
Adriamycin-induced, I-125 MIBG, 832(ab)
blood-pool imaging, application, noncoronary heart disease, 10
changes in myocardial fatty acid and perfusion, hamsters, 1580(ab)
dilated, serial change, I-123 MIBG myocardial concentration, 792(ab)
doxorubicin-induced myocardial damage, cardiac adrenergic innervation, I-125 MIBG and metoprolol, 833(ab)
hypertrophic
active myocardial cell damage, In-111 antimyosin Fab, 782(ab)
I-123 MIBG, uptake and clearance, 792(ab)
regional abnormality, myocardial sympathetic nervous activity, 792(ab)
hypertrophic nonobstructive, exercise capacity, resting LV peak filling rate, 753(ab)
idiopathic dilated, myocardial oxygen consumption, 773(ab)
sympathetic nervous system, quantitative evaluation, PET, 792(ab)

Cardiotoxicity
cyclosporin A, correlation, histopathological finding, 834(ab)
doxorubicin, antimyosin cardiac imaging, 1970

Carotid artery
endarterectomy, SPECT quantitation, cerebral ischemia, 1412
internal, collateral circulation, brain SPECT, 878(ab)

Carotid disease, unilateral, hypercapnic blood flow reactivity, 789(ab)

Carrier, effect on reaction rates, 385(le)

Catecholamines, chemodectomas of head and neck region, I-123 MIBG scintigraphy, 1147

Cathepsin D, marker for tumor invasiveness, 1587(ab)

Catheter, heparin polyurethane angio-, platelet-thrombus formation rate, In-111 platelets, 891(ab)

Cell membrane, transport of pertechnetate, role of band-3 protein, Tc-99m erythrocytes, 2004

Central nervous system, murine lupus, Tc-99m HMPAO autoradiography, 884(ab)

Cerebellar diaschisis, crossed, mapping supratentorial lesions, 789(ab)

Cerebrovascular disease, brain blood flow, phase III evaluation, I-123 HIPDM SPECT, 879(ab)

Charcot joint disease, In-111 leukocyte/Tc-99m MDP bone and MRI, osteomyelitis, 549

Chelating agents
bifunctional, dual isotope pharmacokinetics, Lym-1, 823(ab)
chelated metallic radionuclides and, endotoxin testing, limulus amoebocyte lysate, 243
diaminedithiol bifunctional, synthesis, neutral technetium complexes, 806(ab)
macrocyclic bifunctional, Y-90 monoclonal antibody, therapy, 473
metal
attachment to a protein, stability constants, 1744(le)
protein attachment, stability constant determination, 480
P-NH_2-BZ-DOTA-3A, monoclonal antibody labeling, Y-90, 824(ab)
polymer, radiolabeling, 897(ab)
radioactive polychelates, antibody conjugates, preparation and characterization, 1592(ab)
transchelation reactions, Tc-99m ECD, 908(ab)

Chemodectomas, head and neck, I-123 MIBG scintigraphy, 1147

Chemohormonotherapy, sequential quantitative FDG/PET assessment, metabolic response, breast carcinoma, 746(ab)

Chemotherapy
disturbances in cerebral perfusion, HIV-1 seropositive asymptomatic subjects, 1601
head and neck cancer, F-18 FDG PET, 1586(ab)
malignant glioma, blood-brain barrier disruption, 1584(ab)
modulated fluorouracil, PET, metastatic colorectal carcinoma, 803(ab)
no-carrier-added C-11 labeling of busulfan, 1592(ab)
regional, F-18 uracil PET, 888(ab)
Tl-201 scintigraphy, bone sarcoma, 567

Chest, radiography, scintigraphy, suspected acute pulmonary embolism, 894(ab)

Chest syndrome, acute, rib infarction, sickle cell patients, 893(ab)

Children, *see* Pediatric patients

Cholecystokinin
antagonist MK-329, gastric emptying in cats, 1494
cholescintigraphy
Sphincter of Oddi dyskinesia, 848(ab)
gallbladder perforation, 1915
-induced bile reflux, Krishnamurthy-Bobba sign, 248(le)
-stimulated biliary scintigraphy, sphincter of Oddi dysfunction, 732(ab)

Chondroitin sulfate, Se-75 BISTAES and, binding determination, 946(ab)

Chondrolysis, secondary, slipped epiphysis, bone scintigraphy, 742(ab)

Chromium-51, urinary excretion from labeled erythrocytes, case of anti-Gerbich, *in vivo* cross-match, 2042

Chronic fatigue syndrome, Tc-99m HMPAO SPECT, 936(ab)

Cigarette smoking
chronic, upper gastrointestinal motor function, 801(ab)
delay of solid and liquid gastric emptying, mouth-cecum transit time, 847(ab)
exposure, pulmonary uptake, Tc-99m HMPAO, 773(ab), 894(ab)
perfusion lung scans, objective and reversible scintigraphic sign, 772(ab)
Tc-99m desferoxamine, measurements after aerosolization, 908(ab)

Cintichem research reactor, decommission, N37A(5)

Circulation, highlights, EANM Congress, N15A(10)

Cirrhosis, prognostic index, extrahepatic uptake, Tc-99m phytate, 436

Cobalt-57, cyanocobalamin capsules, radioactivity variations, 128(le)

Cobalt-57 bleomycin, administered dose and tumor dose, mice and men, 1784

Cocaine
amphetamine and, D1 and D2 dopamine ligand uptake, rat brain, 809(ab)
biodistribution of I-125 2′-iodococaine, inherent organ selective differences, mouse strains, 726(ab)
distribution of I-123 IMP, dog brain and lungs, 887(ab)
imipramine and, first pass extraction fraction, MIBG in heart, 726(ab)
-induced myocardial ischemia, Tl-201 imaging, 834(ab)
receptors, organ variations, 886(ab)
unnatural enantiomer, 886(ab)

Collagen, -vascular disease, ventilation and perfusion scans, 894(ab)

Collaterals
circulation, noninvasive quantification, myocardial blood flow, 271
coronary, noninvasive assessment, PET perfusion imaging, 259

Colles' fractures, regional bone mineral density changes, dual-photon absorptiometry, 1580(ab)

Collimation, narrow, depleted sources inappropriate to obese patients, 538(le)

Collimator
angulation error, effect on SPECT, 655
cone beam
cardiac SPECT imaging, 739(ab)
parallel beam and, ROC evaluation, 718(ab)
design optimization, ML estimation, Monte Carlo simulation, 728(ab)
dual sensitivity for SPECT, 870(ab)
fan beam
cardiac SPECT imaging, 1590(ab)
high-spatial resolution SPECT, brain imaging, 869(ab)
gold, Tc-99m MDP uptake, focal maxillofacial lesions, 856(ab)
optimization of design, acquisition parameters, cardiac Tl-201 studies, 870(ab)
parallel and converging ray, SPECT simulation and reconstruction, 719(ab)

parallel hole
actual and simulated tomographic reconstructions, 870(ab)
optimal design, 728(ab)
parallel hole, defective, SPECT, suggested approach, 1892(le)
rotating slant-hole
Tl-201 myocardial tomography, large number of projections, 1682
tomography, large number of projections, 1675
surgical detection probe system, characterization, 856(ab)
ultra-high resolution SPECT, radiopharmaceutical uptake, brain, 870(ab)
verification of hole angulation, SPECT imaging, 945(ab)
Colon
primary, recurrent colorectal cancer and, radioimmunoguided surgery, 851(ab)
transit scintigraphy, health and constipation, oral I-131 cellulose, 985
Colon cancer, *see also* Carcinoma, colonic
improved tumor uptake, I-125 monoclonal antibody, 852(ab)
metastases, radioimmunotherapy, nude mouse model, 765(ab)
xenografts
γ-interferon, CEA enhancer, 764(ab)
squamous transformation, radioimmunotherapy, 765(ab)
Colony-stimulating factor
granulocyte
adjunctive use, Y-90 monoclonal antibodies, 904(ab)
radioimmunotherapy, Y-90 monoclonal antibodies, 849(ab)
Colorectal cancer, *see also* Carcinoma, colorectal
in vivo fate of monoclonal antibody B72.3, 1133
recurrent, radioimmunoguided surgery, 851(ab)
Commentary
lines from the President, N20A(3), N33A(6), N26A(9), N26A(12)
low level ionizing radiation, N17A(7)
Common acute lymphocytic leukemia antigen, properties of human/mouse chimeric monoclonal antibody, 1077
Compton scatter
cold-lesion contrast, MLEM reconstruction, SPECT images, 869(ab)
dual-window correction, phantoms, 798(ab)
Monte Carlo simulation
nonuniform scattering media, 869(ab)
uniform scattering media, 869(ab)
SPECT dual-energy-window, 90
Computed tomography
compared to Tc-99m HMPAO SPECT, prognostication of recovery, stroke, 61
cone beam, improved SPECT attenuation compensation, 875(ab)
detection of talocalcaneal coalitions, magnification bone scintigraphy, 1797
diagnostic approaches, persons at risk, Huntington's disease, 740(ab)
Ga-67 SPECT, residual Hodgkin's disease, mediastinum, 793(ab)
radioiodine therapy of massive goiter, 846(ab)
regional spread of breast cancer, mammary lymphoscintigraphy, 745(ab)
SPECT and, volumetric correlation, radiolabeled monoclonal antibody distribution, 872(ab)
-SPECT fusion, complicated inflammatory disease, 871(ab)
SPECT image superimposition, transfer of RoI for quantification, 872(ab)
X-ray, SPECT and, chronic low back pain, 830(ab)
Computer
acceptance testing, 941(ab)
-assisted analysis, PET time-course data, 944(ab)
-based interactive educational technique, demonstration, PET, 944(ab)
computerized report generation with hypercard, 941(ab)
-controlled radiopharmaceutical dispensing system, reduction, personnel radiation exposure, 948(ab)
CRT display parameters, clinical interpretation, digital nuclear medicine images, 1589(ab)
current applications, nuclear medicine, N20A(2)
experience with Microvax digital image archive, 942(ab)
impact of local area networking, productivity, nuclear medicine departments, 856(ab)
interactive 3-D display of SPECT imaging, 871(ab)
interactive display station, acceptance and utility, 941(ab)
interpretation of thallium SPECT studies, neural network analysis, 1582(ab)
limitations of graphical analysis method, 862(ab)
model, nuclear medicine laboratory, 943(ab)
personal
low-cost nuclear image transfer system, 941(ab)
simulated stress thallium data, back propagation neural network, 1590(ab)
principal axes transformation, method for image registration, 1717
program for PET image alignment, cerebral metabolic rates, glucose, 2052
program for quantitative analysis, brain SPECT data, 1862
radiation dose calculations, evaluated nuclear structure data file, 948(ab)
single-screen immediate automated result reporting, image and graphic display, 942(ab)
software, tools for kinetic analysis, dynamic PET data, 943(ab)
ultra-high resolution laser printer, hardcopy, digital gamma camera images, 942(ab)
Connective tissue disease, quantitative and qualitative evaluation, esophageal motility disorder, multiple swallow test, 775(ab)
Conns syndrome, adrenal scintigraphy, adenoma *vs.* hyperplasia, 845(ab)
Constipation
colon transit scintigraphy, I-131 cellulose, 985
idiopathic, regional gut transit, encapsulated radiolabeled solid pellets, 775(ab)
Copper-PTSM
biodistribution, glutathione depletion, 910(ab)
cerebral perfusion imaging, generator-produced PET tracer, 351
localization, regional blood flow, dog kidney, 914(ab)
tumor blood flow measurement, 909(ab)
Copper-60 PTSM, small cyclotron production, PET blood flow measurements, 815(ab)
Copper-62
blood-pool imaging, radiopharmaceuticals, 727(ab)
pyruvaldehyde *bis*(*N*⁴-methylthiosemicarbazonato)copper(II), PET tracer evaluation, cerebral and myocardial perfusion, 1989
Copper-62 PTSM, generator-produced multi-purpose PET perfusion agent, 815(ab)
Coronary artery disease (CAD)
blinded evaluation of SESTAMIBI, myocardial perfusion studies, 827(ab)
comparative diagnostic efficacy, adenosine infusion, treadmill exercise SPECT thallium imaging, 733(ab)
left bundle branch block
specificity of Tl-201 SPECT, dipyridamole, 837(ab)
Tl-201 SPECT, 836(ab)
left main and left main equivalent disease, thallium SPECT, 763(ab)
left ventricular asynchrony, 838(ab)
left ventricular cavity, transient dilatation, intravenous dipyridamole, 1582(ab)
left ventricular dilatation, dipyridamole thallium scintigraphy, 723(ab)
left ventricular failure, stress-induced, pulmonary Tc-99m MIBI uptake, 1581(ab)
left ventricular function, global diastolic filling at rest, 753(ab)
new quantitative Tl-201 SPECT criteria, prior myocardial infarct, 812(ab)
noninvasive assessment of coronary collaterals, PET perfusion imaging, 259
regional sympathetic denervation, transient myocardial ischemia, cardiac tomography, 793(ab)
Tc-99m MIBI SPECT, planar gated imaging, 820(ab)
Tl-201 imaging, adenosine infusion, treadmill exercise, 733(ab)
Tl-201 scintigraphy, parallel distributed processing approach, 825(ab)
tomographic stress Tl-201 myocardial scintigrams, 1168
transient cavity dilatation, stress-redistribution TL-201 SPECT, 836(ab)
treadmill stress test, transesophageal atrial pacing, Tc-99m SESTAMIBI, 821(ab)
vascular territory, Tc-99m teboroxime, thallium scintigraphy, 827(ab)
Coronary occlusion, transient, risk area determination, isonitrile imaging, 784(ab)
Cryopreservation, inhibition of autoradiolysis, radiolabeled monoclonal antibodies, 84
Cushings syndrome
adrenal scintigraphy, adenoma *vs.* hyperplasia, 845(ab)
diagnostic accuracy and pitfalls, I-131 NP-59 imaging, 526
Cyanocobalamin capsules, cobalt-57, radioactivity variations, 128(le)
Cyclofoxy
determination of nonspecific tissue binding, K_D and B_{max}, 810(ab)
nonspecific brain tissue binding, 883(ab)
Cyclohexyl EDTA, derivatives, In-111 immunoconjugates, 896(ab)
Cyclosporin, -treated allogeneic kidney transplants, In-111 anti-lymphocyte and anti-MHC monoclonal antibodies, 851(ab)
Cyclosporin A, cardiotoxicity, correlation, histopathological finding, 834(ab)
Cyclotron
11 MEV proton, pre-synpatic dopaminergic tracers, electrophilic F-18, 901(ab)
small production of Cu-60 PTSM, PET blood flow measurements, 815(ab)
Cystography, single and two-stage radionuclide,

evaluation of reflux, 893(ab)
Cysts, hygroma, lymphoscintigraphy, 516

D

DB III, synthesis and characterization, radioimaging, 757(ab)
Dementia
AIDS, I-123 IMP SPECT, brain, 936(ab)
Alzheimer-type, mitochondrial encephalomyopathy, HMPAO-SPECT, 1740
anatomical correlation, SPECT and PET, 885(ab)
neuropsychological test scores, cerebral blood flow, 731(ab)
progressive, motor neuron disease, cerebral blood flow imaging, 688
visual inspection of FDG-PET images, validation studies, 740(ab)
Xe-133 and Tc-99m HM-PAO SPECT, 730(ab)
Dendritic cells, migration, gamma and UV-B irradiation, 820(ab)
Densitometry, bone, dual-energy X-ray absorptiometry, transiliac bone biopsies, 932(ab)
Deoxyglucose, sodium and, tissue concentration, myocardial infarction, 833(ab)
Department of Energy (DOE)
awards SNM member for lifetime achievement, N32A(9)
denial of request to close FFTF reactor, N31A(6)
epidemiologic research program, transfer to HHS, N28A(8)
Hanford environmental dose reconstruction project (HEDR), N22A(12)
ORNL stops production and distribution, yttrium-90, N18A(5)
radioisotope needs, preparation for future, N13A(3)
Secretary approves restart of HFIR, N22A(3)
SNM/ACNP testimony on 1991 Nuclear Medicine Budget, N37A(6)
Department of Transportation (DOT), NRC and, hazardous transport rules, N27A(11)
Desferoxamine, aluminum toxicity, altered biodistribution, Ga-67, 115
Diabetes
gastroparesis diabeticorum, intravenous erythromycin, gastric emptying, 1490
I.V. insulin injection, F-18 FDG PET, 933(ab)
osteomyelitis and pedal ulcers, In-111 leukocytes, 3-phase bone imaging, 890(ab)
quantitative and qualitative evaluation, esophageal motility disorder, multiple swallow test, 775(ab)
sn-1,2-Diacylglycerol, positron-labeled, phosphatidylinositol turnover measurement, PET, 738(ab)
Diaminedithiol
bifunctional chelate, synthesis, neutral technetium complexes, 806(ab)
Ga-67 label, synthesis, biological evaluation, 896(ab)
DIAMOX, brain SPECT, 936(ab)
Diet, post-fatty meal, gallbladder ejection fraction, DISIDA *vs.* US, 731(ab)
Dilatation, cardiac, supine exercise stroke volume, elderly, 838(ab)
Dipyridamole
adenosine as replacement, N25A(8)
distribution and regional washout, anatomic functional images, SPECT perfusion images, 872(ab)
-induced coronary hyperemia, pentoxifylline, 1020
-induced hyperemic stress, post-stenotic myocardial SQ30,217 kinetics, 785(ab)
-induced myocardial perfusion defects, ischemia, post-exercise fluorodeoxyglucose PET, 722(ab)
intravenous administration, transient dilatation, left ventricular cavity, 1582(ab)
left bundle branch block, improved specificity, Tl-201 SPECT, 837(ab)
myocardial perfusion imaging, Rb-82 PET, Tl-201 SPECT, 802(ab)
normal Tl-201 scan, long term follow-up, 837(ab)
Tc-99m MIBI, planar and SPECT imaging, first-pass angiocardiography, 821(ab)
thallium imaging
exercise and, automatic lung/heart ratios, 842(ab)
papillary muscle dysfunction, 124(le)
pentoxifylline effect, peripheral vascular disease, 734(ab)
ST segment depression, reversibility, 733(ab)
thallium scans
exercise, "left ventricular dilatation", 722(ab)
females, 733(ab)
transient left ventricular dilatation, 723(ab)
thallium SPECT, prognostic measures, cardiac risk, 732(ab)
vasodilation, thallium and echocardiographic imaging, adjunct bicycle exercise, 723(ab)
Discitis
calcific, bone scintigraphy, childhood, 234
In-111 leukocyte imaging, 711(ab)
Distinguished Educator Award, Thomas P. Haynie, N20A(7)
Diuresis
acute, renal function after captopril, 913(ab)
three-phase renography, detection, obstructive uropathy, 914(ab)
Diuretics, influence of therapy on clearances, post captopril, renovascular hypertension, 913(ab)
DNA, synthesis, utilization, labeled thymidine, 337
Dopa decarboxylase
activity in brain *in vivo*, 720(ab)
constrained evaluation in brain, F-18 FDOPA and PET, 884(ab)
Dopamine
blockade, C-11 methyl-benztropine, baboon brain, 780(ab)
D1 antagonist, C-11 SCH 39166 synthesis, PET, 737(ab)
D1 and D2 ligand uptake, amphetamine and cocaine effect, rat brain, 809(ab)
improved technique, investigation of pharmacological interventions, PET, 886(ab)
metabolism, striatal glucose, Parkinson's disease and Parkinsonism, 880(ab)
presynaptic neurons, trappable tracer, F-18 fluoro-MDL 72394, 902(ab)
radiolabeling of pre-synaptic dopaminergic tracers, electrophilic F-18, 11 MEV proton cyclotron, 901(ab)
reuptake sites, synthesis, F-18 GBR 12909 for human studies, 901(ab)
slow turn-over rate pool, 6-F-18 fluoro-L-dopa, rat and primate brain, 720(ab)
uptake inhibition, F-18 GBR 12909, 902(ab)
uptake inhibitors, I-125 and F-18-labeled ligands, 898(ab)
Dosimetry
administered dose and tumor dose, cobalt-57 bleomycin, mice and men, 1784
Auger electron, radiopharmacology and tissue localization, In-111 substances, 1591(ab)
biodistribution of I-131 anti-myeloid antibody, propylthiouracil effects, 1384
bone marrow, marrow-to-blood activity concentration ratio, 788(ab)
3-D dose computation, hepatic microsphere therapy, 784(ab)
dose heterogeneity, radiobiological response, radioimmunotherapy, 783(ab)
$F(ab')_2$ fragments *vs.* intact antibody, 1045
feasibility, radioimmunotherapy, micrometastases, 788(ab)
Hybri-CEAker, colorectal carcinoma, 844(ab)
I-123 IBZM, 844(ab)
I-131, thyroid carcinoma, 935(ab)
I-131 HMFG1
gamma camera, whole-body profile scanning, 945(ab)
ovarian and colorectal carcinoma, 938(ab)
importance of remaining body activity correction, radioimmunotherapy, 822(ab)
inhomogenous deposition, radiopharmaceuticals, cellular level, 1358
lacrimal gland, Tc-99m HMPAO, brain, 1237
monoclonal antibody image quantitation, buildup factor, 783(ab)
nonuniformity of tumor dose, radioimmunotherapy, 75
NRC seeks data, impact of lower dose limits, N32A(9)
obtaining S values for rectangular-solid tumors, rectangular-solid host organs, 845(ab)
photon sources, surface of human eye, 1591(ab)
quantitation in radioiodine therapy, metastatic thyroid cancer, 784(ab)
radiation absorbed dose, Tc-99m red blood cells, 378
radiation dose estimates, Tc-99m pertechnetate, blocked with potassium perchlorate, 822(ab)
radiation dose to bone marrow, backscattering, electron sources, 783(ab)
radiation dose to GI tract, blood and liver time-activity curves, 844(ab)
radioimmunotherapy, I-131- and Y-90-labeled anti-CEA antibody, 788(ab)
radiolabeled monoclonal antibodies, In-111 B72.3-GYK-DTPA, colorectal cancer, 787(ab)
reevaluation for FDG in human, 822(ab)
Tc-99m MAG3 and DTPA, I-131 hippuran, human subjects, 822(ab)
therapy dose calculations, I-131 treatment, Graves' disease, 519
tumor and organ, chimeric antibody, animal biodistribution data, 788(ab)
Doxorubicin
cardiotoxicity, antimyosin cardiac imaging, 1970
In-111 antimyosin scintigraphy, advanced breast cancer, 1965
-induced myocardial damage, cardiac adrenergic innervation, MIBG and metoprolol, 833(ab)
DTPA
ab-DTPA-In-111, molecular size and immunoreactivity, serum and supernatant, 906(ab)
modification of monoclonal antibody, polymer formation, immunoreactivity, 905(ab)

Dual-photon absorptiometry (DPA)
automatic image comparison, spine, 931(ab)
clinical practice, 1781
cyclic phosphate, etidronate and calcium therapy, osteoporosis, 752(ab)
depleted sources inappropriate to obese patients, narrow collimation, 538(le)
lumbar spine, limited precision, variations in soft-tissue background, 1774
measurement of body fat, 791(ab)
osteoporosis in women with eating disorders, 325
precision of regional bone mineral measurements, total-body scans, 43
reassessment for coverage, N15A(6)
regional bone mineral density changes, Colles' fractures, 1580(ab)
statistical artifact, low count rates, 537(le)
Duodenum, I-123 IMP administration, portosystemic shunting, superior mesenteric vein, 813(ab)

E

Eating disorders, *see also* specific type
caudate nuclei glucose hypermetabolism, 750(ab)
osteoporosis in women, 325
Echocardiograms, adjunctive role of nuclear medicine, cardiac pathology, 934(ab)
Echo-Doppler flowmetry, captopril renal scintigraphy, renal artery stenosis, 913(ab)
Ectomography, limited-angle tomography for the nineties, 1688
Edema, lymphoscintigraphy and lymphedema, lower extremities, 990
Editorials
advances in emission tomography, 628
antimyosin cardiac imaging, doxorubicin cardiotoxicity, 1970
art of progress, 123
axillary lymphoscintigraphy for breast cancer, 1835
best method for imaging focal infections, 413
cardiac substrate metabolism, regional heterogeneity, 1757
comparison of Tc-99m and I-123 nodules, 400
current and future use, tumor-localizing agents, 1658
diagnosing prosthetic joint infection, 1955
dual-photon absorptiometry, clinical practice, 1781
$F(ab')_2$ fragments *vs.* intact antibody, 1045
gastric emptying, 1499
generator-based PET perfusion tracers, 1641
"hot spot" imaging agents, acute myocardial infarction, 143
in vivo fate monoclonal antibody B72.3, 1143
internally admnistered isotopes for solid malignancy, 601
limited-angle tomography for the nineties, 1688
monoclonal antibodies and thrombus imaging, 1055
noncardiac applications, hexakis-(alkylisonitrile) Tc-99m complexes, 1166
nonspecifically-specific monoclonal antibodies, 1066
nuclear medicine investigation of neuroblastoma, 135
quantitative hepatobiliary scintigraphy, 1468
radionuclide angiocardiography, 1300
radionuclide imaging of joint imflammation, 684
red blood cells, 2044
regional myocardial blood flow, noninvasive quantification, collateral circulation, 271
registration of nuclear medicine images, 1227
residual mass and negative gallium scintigraphy, treated lymphoma, 369
rest reinjection of Tl-201, redistribution imaging, 1623
search for hot appendix, 316
serum thyroglobulin, management of thyroid cancer, 1771
SESTAMIBI and issue of tissue crosstalk, 1409
Sombreros Cientificos, 1986
splanchnic blood volume, importance, scintigraphic measurements, 160
systematic evaluation of primary brain tumors, 969
systemic radioisotopic therapy, primary and metastatic bone cancer, 1326
three-dimensional SPECT images, 1428
when magic bullets ricochet, 32
year's end, 2069
Education and Research Foundation Awards, N28A(6)
EHPG complexes, physicochemical and *in vivo* behavior, Fe-59, Ga-68 and In-111, 1662
Ejection fraction
gallbladder, post-fatty meal, 731(ab)
gated blood pool tomographic detection, streptokinase-treated patients, myocardial infarction, 842(ab)
left ventricular functional parameters, harmonic analysis, blood pool scans, 858(ab)
regional, variability, left ventricular function, 933(ab)
right, transfer function analysis, 1294
right ventricular, first-pass curve oscillations, 382(le)
Electrocardiogram
ambulatory monitoring, stress-redistribution thallium scintigraphy, 744(ab)
predictive value of ST segment depression, reversibility, dipyridamole thallium imaging, 733(ab)
Electroencephalography
bitemporal epidural, compared to PET, partial complex epilepsy, 710(ab)
Tc-99m HMPAO SPECT and psychometry, temporal lobe epilepsy, 881(ab)
Electrogastrogram, isotopic, characterization, gastric contractions, 775(ab)
Emission computed tomography
brain, resolution and count density requirements, 718(ab)
three-dimensional *vs.* two-dimensional quantitation, 729(ab)
variance reduction techniques, 728(ab)
Enalaprilat, scintigraphy, renovascular hypertension, 715(ab)
Enalaprit, -enhanced renography, renovascular hypertension, rat model, 501
Encephalitis, focal high uptake of HMPAO, brain perfusion studies, 1094
Encephalomyopathy, mitochondria, HMPAO-SPECT, Alzheimer-type dementia, 1740
Endarterectomy, carotid, SPECT quantitation, cerebral ischemia, 1412
Endocarditis, left sided, In-111 antifibrin monoclonal antibodies, rabbit model, 805(ab)
Endoprotheses, titanium, BMC measurement of femora, dual energy X-ray absorptiometry, 829(ab)
Endotoxin, testing with limulus amoebocyte lysate, radiopharmaceutical, chelated metallic radionuclides and chelating agents, 243
Environmental Protection Agency (EPA)
clean air legislation, N14A(6)
extension of NESHAP comment period, N34A(6)
radionuclide emission regulations, N29A(2)
Epiderpride, SPECT, dopamine D2 receptor, 882(ab)
Epilepsy
childhood-onset, Tc-99m HMPAO SPECT, 892(ab)
children treated by callosotomy, cerebral blood flow, SPECT, 893(ab)
complex partial, neuroimaging, seizure focus for surgical intervention, 1839
location of foci by HMPAO brain SPECT, correlation, site of lobectomy, 711(ab)
partial complex
mesial temporal sclerosis, PET and MRI, 880(ab)
PET compared to bitemporal epidural electroencephalography, 710(ab)
post-lobectomy epileptic patients, visual field defects, striate cortex hypometabolism, 881(ab)
presurgical evaluation
interictal SPECT scans, 879(ab)
intractable seizures, HIPDM-SPECT, 1280
temporal lobe, Tc-99m HMPAO SPECT, psychometry and EEG, 881(ab)
Epiphysis, slipped, secondary chondrolysis, bone scintigraphy, 742(ab)
Epithelium, lung, inhaled Tc-99m DTPA, urine excretion, 441
Erythrocytes
praise of red blood cells, 2044
radiolabeling with Tc-99m, pertechnetate transport across cell membrane, 2004
Erythromycin
bioavailability, food effects on small intestine, 846(ab)
intravenous, gastric emptying, gastroparesis diabeticorum and normals, 1490
parenteral, gastric emptying effect, symptomatic gastroparetic patients, 847(ab)
short and long term oral intake, gastric empyting, gastroparesis diabeticorum, 801(ab)
Escherichia coli, P-fimbriated, vesicoureteral reflux, acute pyelonephritis, 742(ab)
Esophageal cancer, gastric pull-up surgery, upright posture after meals, gastric emptying, 848(ab)
Esophagectomy, total, functional evaluation, gastric interposition, 775(ab)
Esophagus
dysmotility, radionuclide salivagram, 1588(ab)
motility disorders, quantitative and qualitative evaluation, multiple swallow test, 775(ab)
post-traumatic oralpharyngeal disorders, radionuclide evaluation, 774(ab)
radionuclide transit time
motility dysfunction, 775(ab)
motor dysfunction, compared to manometry, 1921
sclerotherapy for varices, portal hemodynamic changes, radionuclide imaging, 813(ab)
Estradiol, imageable, breast cancer detection, 937(ab)
Estrogens, bromine-77 bromovinyl steroidal and triphenylethylene, comparison of distribution, immature rat, 1534
Ethanol, aerosol ventilation scans, 894(ab)
Etidronate, cyclic phosphate and calcium therapy, dual-photon absorptiometry, osteoporosis,

752(ab)
European Association of Nuclear Medicine (EANM), Congress 1990, highlights, N15A(10)
Exercise
bicycle, thallium and echocardiographic imaging, dipyridamole vasodilation, 723(ab)
capacity, resting LV peak filling rate, hypertrophic nonobstructive cardiomyopathy, 753(ab)
dipyridamole thallium imaging
automatic lung/heart ratios, 842(ab)
"left ventricular dilatation", 722(ab)
gastric emptying, 800(ab)
maximal, iodophenylpentadecanoic acid-myocardial blood flow relationship, coronary occlusion, 99
osteoporosis in women with eating disorders, 325
supine, stroke volume, cardiac dilatation in elderly, 838(ab)
Tl-201
disease progression, coronary angioplasty, 836(ab)
restenosis after partial *vs.* total revascularization, coronary angioplasty, 763(ab)
Tl-201 tomography, extent of restenosis, multivessel PTCA, 843(ab)
treadmill
adenosine and Tl-201 imaging, coronary artery disease, 733(ab)
adenosine infusion, CAD detection, 733(ab)
perfusion and function at rest, Tc-99m SESTAMIBI, 1128
Extremities, lower, lymphoscintigraphy and lymphedema, 990
Eye
ocular melanoma, SPECT *vs.* planar immunoscintigraphy, Tc-99m F(ab′)$_2$ fragments, 854(ab)
radiation dosimetry for photon sources, 1591(ab)

F

Fab fragment
anti-P97, biodistribution and tumor targeting, immunoreactivity, 202
monoclonal anti-myosin Fab, target localization, isothiocyanatobenzyl-DTPA, 211
nonspecific polyclonal IgG, focal sites of inflammation, 1199
F(ab′)$_2$ fragments
I-131 monoclonal antibody, radioimmunotherapy, colon carcinoma, 1035
vs. intact antibody, isodose comparison, 1045
Familial inverted chorea, cerebral glucose metabolism, PET, 740(ab)
Fast Flux Test Facility, House denies DOE's request for closure, N31A(6)
Fat, body, measurement by dual photon absorptiometry, 791(ab)
Fatty acids
insulin and, myocardial glucose metabolism, FDG-PET, 802(ab)
iodinated methyl-branched, decreased myocardial uptake, inhibition of ATP synthesis, 708(ab)
myocardial, perfusion changes, cardiomyopathic hamsters, 1580(ab)
myocardial accumulation of I-125 BMIPP, relation to ATP concentration, 1818
simultaneously acquired modified, thallium images, small differences, 834(ab)
FDG-PET
hypometabolism assessment, temporal lobectomy, seizure, 710(ab)
reliability and utility, preoperative evaluation, seizure patient, 710(ab)
Ferrosomes
Fe-59 plasma and whole-body clearance, 717(ab)
superparamagnetic, MR imaging, lung parenchyma, 718(ab)
α-Fetoprotein, -16α-[F-18]fluoro-estradiol, age dependence, female rat serum, 910(ab)
Fetus, hepatic uptake of Tc-99m HMPAO, 237
Fever, prolonged, detection of focal lesions, Ga-67 citrate, 512
Fibrin, radioiodinated tissue plasminogen activator fragment, clot imaging, 903(ab)
Fibroblasts, accumulation of hexakis (2-methoxyisobutylisonitrile)technetium(I), mitochondrial and plasma membrane potentials, 1646
Fibromatosis, aggressive, scintigraphic evaluation, 1632
Filariasis, lymphangioscintigraphic patterns, 891(ab)
Filters
3-D post-reconstruction restoration, SPECT, 867(ab)
Fourier, resolution recovery and noise reduction, PET, 862(ab)
reconstruction, maximizing signal to noise ratios, PET cerebral blood flow subtraction, 865(ab)
selection, 3-D surface map variations, SPECT, 945(ab)
Wiener, regional myocardial perfusion, Tl-201 SPECT, 1230
First Impressions, 117, 239, 324, 429, 567, 1155, 1478, 1634
Fish, Boston Harbor winter flounder, use of radiopharmaceuticals, 736(ab)
Fluorine-18
angiotensin converting enzyme inhibitor, synthesis and biodistribution, 738(ab)
direct nucleophilic F-18 radio fluorination, improved anion exchange resin column, 1592(ab)
electrophilic, radiolabeling, pre-synaptic dopaminergic tracers, 901(ab)
-labeled inhalational anesthetics, 900(ab)
-labeled inhibitors, GABA reuptake, 786(ab)
-labeled ligands, dopamine uptake inhibitors, 898(ab)
muscarinic acetylcholine receptor ligands, 814(ab)
N-(4-fluorobenzyl)spiperone, synthesis, 901(ab)
PET
normal aging, whole brain and regional glucose metabolism, 771(ab)
total body and cross-sectional imaging, skeletal system, 780(ab)
proteins, novel method for labeling, 787(ab)
Fluorine-18 altanserine, PET, serotonin S2 receptors, 1584(ab)
Fluorine-18 captopril, synthesis and biodistribution, 738(ab)
Fluorine-18 catecholamines, PET, nucleophilic aromatic substitution reaction, 787(ab)
Fluorine-18 deoxyglucose
magnetic reonance, spinal cord tumor, 360
PET
advanced head and neck cancer, chemotherapy, 1586(ab)
image-guided phosphorus-31 magnetic resonance spectroscopy, brain tumors, 302
malignant pleural mesothelioma, 1585(ab)
metastatic melanoma, prior and after therapy, 804(ab)
preoperative staging, bronchiogenic carcinoma, 771(ab)
Fluorine-18 DFPA, brain tumor imaging, 888(ab)
Fluorine-18 6-FD, stability, production of radiotracer, 1076(le)
Fluorine-18 FDEX, F-18-labeled muscarinic acetylcholine receptor, 814(ab)
Fluorine-18 FDOPA, PET, constrained evaluation, dopa decarboxylase, 884(ab)
Fluorine-18 FES, age dependence in interaction, female rat serum, 910(ab)
Fluorine-18 flumazenil, mapping of cerebral benzodiazepine receptors, PET, 902(ab)
Fluorine-18 fluoride ion, PET, bone metabolic rates, 778(ab)
Fluorine-18 fluoroacetyl-D-glucosamine, cancer diagnosis, 1654
Fluorine-18 fluoroalkylbenzamides, aryl-substituted, PET D-2 studies, 737(ab)
Fluorine-18 fluorodeoxyglucose
brain metabolism, $GABA_A$ receptor antagonist, 878(ab)
Ga-67 and, malignant lymphoma, 888(ab)
global metabolism, variance in brain, 771(ab)
I-123 ortho-phenylpentadecanoic acid and, Tl-201 uptake, myocardial infarction, 803(ab)
micro-autoradiography, 885(ab)
nonuniformity in myocardial accumulation, normal fasted humans, 1749
PET
cancer therapy, 889(ab)
crossed cerebellar diaschisis, stroke, 770(ab)
differential diagnosis, lung tumor, 1927
I.V. insulin injection, diabetics, 933(ab)
residual or recurrent brain tumors, 800(ab)
residual or recurrent tumors, 803(ab)
residual or recurrent tumors, post-treatment changes, 937(ab)
soft-tissue masses, 746(ab)
Tl-201 SPECT and, brain tumors, 799(ab)
reevaluation of dosimetry in humans, 822(ab)
Fluorine-18 2-fluoro-2-deoxy-D-glucose, local cerebral glucose utilization by PET, 771(ab)
Fluorine-18 2-fluoro-2-deoxy-D-mannose, local cerebral glucose utilization by PET, 771(ab)
Fluorine-18 2-fluorodexetimide, one-pot radiosynthesis, 815(ab)
Fluorine-18 fluoro-dopa, estimation of kinetic parameters in brain, 865(ab)
6-[Fluorine-18]fluoro-L-dopa
blood-brain barrier transport, 1593(ab)
no-carrier-added regioselective preparation, 1247
slow turn-over rate pool, dopamine, rat and primate brain, 720(ab)
Fluorine-18 fluoroethylketanserin, S-2 receptor binding with PET, 780(ab)
Fluorine-18 fluorofatty acids, regional β-oxidation in the heart, 901(ab)
6-Fluorine-18 fluoro-L-fucose, PET tracer for glycoconjugates synthesis in tumors, 1997
Fluorine-18 fluoro-D-glucose, detection of tumor involvement, lymph nodes, 1831
Fluorine-18 fluoro-MDL 72394, trappable tracer, presynaptic dopamine neurons, 902(ab)
β-[Fluorine-18]fluoromethylene-*m*-tyrosine, synthesis of derivatives, 1593(ab)
Fluorine-18 fluoromisonidazole, imaging of

hypoxia in human tissues, 756(ab)
Fluorine-18 fluoropargyline, positron-labeled monoamine oxidase inhibitors, 1592(ab)
Fluorine-18 fluoropropyl-*N*-nordiprenorphine, sex-dependent differences, biodistribution and metabolism, 192
(3-Fluorine-18 fluoropropyl)putrescine, prostate tumor imaging, 707(ab)
Fluorine-18 fluorotyrosine, transport and protein incorporation, compartmental models, rat heart, 1590(ab)
L-[2-Fluorine-18] fluorotyrosine
pharmacokinetics and metabolism, brain and periphery, mice, 786(ab)
uptake in glioma, dynamic PET, 799(ab)
Fluorine-18 fluprepid, design and synthesis of PET ligands, dopamine D2 receptor, 786(ab)
Fluorine-18 FPMB, PET radiotracer, dopamine D-2 receptors, 787(ab)
Fluorine-18 GBR 12909
dopamine reuptake sites, 901(ab)
imaging and kinetic modeling, 720(ab)
tracer for dopamine uptake inhibition, 902(ab)
Fluorine-18 insulin, imaging of insulin receptors, 791(ab)
Fluorine-18 metaraminol, regional myocardial ischemia, sympathetic nervous system, 1352
Fluorine-18 methamphetamine, no-carrier-added, synthesis, analogs, 1592(ab)
6-Fluorine-18 methoxydopa, imaging in non-human primates, 720(ab)
Fluorine-18 NCQ 115, PET, 902(ab)
Fluorine-18 progestin, tumor uptake, mammary tumor transplants, 746(ab)
Fluorine-18 tetrahydrocannabinol, synthesis and distribution in mice, PET studies in baboon, 902(ab)
Fluorine-18 uracil
PET
liver metastases from colorectal carcinoma, 888(ab)
regional chemotherapy, 888(ab)
4-Fluorobenzylamine, conjugate of 2-nitroimidazole, potential hypoxia imaging agent, 815(ab)
Fluorodeoxyglucose
cardiac PET image, glucose loading effect, 840(ab)
correlation of uptake with tumor grade, musculoskeletal tumors, 756(ab)
kinetics, oxidative and glucose metabolism, normal heart, 774(ab)
PET
chemohormonotherapy, breast carcinoma, 746(ab)
caution, Alzheimer's disease, 740(ab)
derivation of indices, local lumped constant variation, 860(ab)
dipyridamole-induced myocardial perfusion defects, 722(ab)
early postoperative evaluation, brain tumors, 799(ab)
metabolic asymmetries, asymptomatic HIV seropositive subjects, 826(ab)
myocardial glucose metabolism, insulin and free fatty acid levels, 802(ab)
neuropsychological findings, head injury, 876(ab)
pediatric fossa brain tumors, 878(ab)
primary and metastatic breast cancer, 889(ab)
radiation defect differentiation, recurrent brain tumor, 799(ab)
schizophrenia, identical twins, 751(ab)
tissue viability, reinjection Tl-201 SPECT, 742(ab)
total body imaging, malignancies, 803(ab)
validation studies, dementia syndromes, 740(ab)
programmed infusion, approach, heart, 778(ab)
regional myocardial metabolism, quantification of patterns, 835(ab)
tumor and normal tissue uptake, serum glucose effects, breast carcinoma, 888(ab)
Fluoromisonidazole, kinetics, hypoxic and anoxic rat heart, 786(ab)
Fluorotamoxifen analogs, radiosynthesis, 903(ab)
Fluorouracil, modulated chemotherapy, PET, metastatic colorectal carcinoma, 803(ab)
Food, irradiation, perception problems, N11A(9)
Food and Drug Administration (FDA)
acceptance of nominations, Advisory Committee vacancies, N30A(7)
approval of three imaging agents, gastric emptying petition, N13A(2)
diagnostic I-131 study, criticism by radiation health experts, N13A(7)
reviewers' perspective, investigational new drug applications, 728(ab)
revitalization, N14A(6)
Fourier analysis
multiharmonic, improved detection, anterior left ventricular aneurysm, 1303
reconstruction coefficients, polar amplitude and phase images, gated SPECT, 1856
Frey, Kirk A., 1990 Tetalman Memorial Award, N23A(7)

G

Gadolinium, antagonism, marked alteration, normal biodistribution of Ga-67, 1844
Gadolinium-153 acetate, distribution of Gd^{3+}, dose and time-dependent differences, 898(ab)
Gadolinium-DTPA, enhanced MRI, reduction of infarct size, thrombolytic therapy, 717(ab)
Gallbladder
ejection fraction, post-fatty meal, DISIDA *vs.* US, 731(ab)
function, scintigraphy, extracorporeal shock wave lithotripsy, 1583(ab)
function before and after lithotripsy, 731(ab)
kinetics, 848(ab)
perforation, Niemeier classification, 1915
Gallium
scanning in metastatic or recurrent soft tissue sarcoma, 794(ab)
-transferrin complex, bicarbonate effect on stability, 903(ab)
Gallium-67
N-alkylated diaminedithiol, synthesis, biological evaluation, 896(ab)
altered biodistribution, aluminum toxicity, desferoxamine, 115
compared to Tl-201 scintigraphy, bone sarcoma, 567
complementary role of Tc-99m sulfur colloid, inflammation evaluation, 941(ab)
diagnosis of primary amyloid nephrotic syndrome, 292
distribution in sarcoidosis, recognition, distinctive patterns, 1909
F-18 FDG and, malignant lymphoma, 888(ab)
low and intermediate grade non-Hodgkin's lymphoma, 793(ab)
scintigraphy
lymphoma, 793(ab)
non-African Burkitt's lymphoma, 794(ab)
residual mass, treated lymphoma, 365, 369
SPECT
pediatric solid tumors, 168
residual Hodgkin's disease, mediastinum, 793(ab)
stable gadolinium antagonism, marked alteration, normal biodistribution of Ga-67, 1844
Gallium-67 citrate
arthrography, painful hip prosthesis, 830(ab)
detection of experimental abscess, 940(ab)
detection of focal lesions for anemia, proteinuria, prolonged fever, 512
experimental arthritis in rabbits, 781(ab)
localization of inflamation, Tc-99m proteins, 810(ab)
non-Hodgkin's lymphoma, gastrointestinal tract, 846(ab)
scintigraphy, aggressive fibromatosis, 1632
thymic uptake, adult *vs.* pediatric patients, 1746(le)
Gallium-68, trivalent metal complexes, physicochemical and *in vivo* behavior, 1662
Gallium-68 BAT-TECH
myocardial imaging agent, 1635
myocardial perfusion agent for PET, 727(ab)
Gallium-68 EDTA, PET, error analysis, blood-brain barrier, 860(ab)
Gallium-68 low-density lipoprotein, metabolism *in vivo*, 745(ab)
Gamma camera
complementary role of whole-body profile scanning, I-131 HMFG1 dosimetry, 945(ab)
digital, ultra-high resolution laser printer, 942(ab)
fast transmission technique, correction of attenuation, SPECT, 875(ab)
four-head rotating, single-photon emission computed tomograph, brain imaging, 603
full-field modular, 632
3-head rotating, high-resolution SPECT, normal brain perfusion, 880(ab)
implementation of holospectral imaging, 758(ab)
multiwire
count rate performance, 9.3-minute tantalum-178, 1723
mobile applications, automated portable W-178/Ta-178, 855(ab)
portable computerized, performance characteristics, 759(ab)
PET and, comparison, ASPECT system, 871(ab)
portable CdTe detection system, gastric emptying, 759(ab)
resolving time, pharmacokinetics data, radiation absorbed doses, 859(ab)
rotating slant-hole collimator
Tl-201 myocardial tomography, large number of projections, 1682
tomography, large number of projections, 1675
scintigraphy, *Strongyloides stercoralis*, 892(ab)
single crystal, first pass radionuclide angiography, acute myocardial infarction, 933(ab)
Starport, 536(le)
Gastric emptying
abnormal, head injury, 801(ab)
delayed, diagnosis, treatment assessment, 800(ab)
developments, 1499
erythromycin oral uptake, gastroparesis diabeticorum, 801(ab)
exercise effect, 800(ab)

intravenous erythromycin, gastroparesis diabeticorum and normals, 1490
parenteral erythromycin, symptomatic gastroparetic patients, 847(ab)
peripheral organ distribution volume, mammillary systems, 1702
petition
FDA approval, N13A(2)
Tc-99m sulfur colloid, N13A(2)
physical and psychological stress, 800(ab)
portable CdTe gamma detection system, 759(ab)
proximal and distal stomach, electromechanical activity, scintigraphy, 936(ab)
solid and liquid, delay by cigarette smoking, mouth-cecum transit time, 847(ab)
solid emptying promotion by MK-329 in cats, 1494
upright posture after meals, esophageal cancer, 848(ab)

Gastritis
chronic, C-14 urea breath test, 814(ab)
emphysemous, In-111 WBC, pancreatitis, 112

Gastroenterology, highlights of EANM Congress, N15A(10)

Gastroenteropathy, protein-losing, diagnostic value, In-111 transferrin, 814(ab), 847(ab)

Gastrointestinal tract
characterization of gastric contractions, isotopic electrogastrogram, 775(ab)
food effects on small intestine, drug bioavailability, 846(ab)
gastric interposition, functional evaluation, total esophagectomy, 775(ab)
late delayed imaging, bleeding studies, Tc-99m red blood cells, 814(ab)
non-Hodgkin's lymphoma, Ga-67 citrate, 846(ab)
prediction of radiation dose, blood and liver time-activity curves, 844(ab)
regional gut transit, idiopathic constipation, encapsulated radiolabeled solid pellets, 775(ab)
upper motor function, chronic smoking, 801(ab)

Gastroparesis diabeticorum, erythromycin oral uptake, gastric emptying, 801(ab)

Gated blood-pool studies, myocardial SPECT images, 3-D volume perspective view, 871(ab)

Gated heart studies
motion abnormalities, gated tomographic radionuclide ventriculograms, 824(ab)
stress MIBI imaging, coronary artery disease, planar gated with SPECT, 820(ab)

Gd(HP-DO3A), ongoing clinical trials, osmolal MR contrast medium, 1591(ab)

Gd(PAHIDA) complex, renal magnetic resonance imaging, 717(ab)

Gelatin, reusable gels for Ge-68 sources, 862(ab)

Generator
automated portable W-178/Ta-178, mobile applications, multiwire gamma camera, 855(ab)
-produced PET tracer cerebral perfusion imaging, Cu-PTSM, 351

Genetics, diagnostic approaches, persons at risk, Huntington's disease, 740(ab)

Germanium-68, reusable gels, 862(ab)

Glioma
epidermal growth factor receptor, murine monoclonal antibody, 849(ab)
L-[2-F-18] fluorotyrosine uptake, dynamic PET, 799(ab)
malignant
chemotherapy, blood-brain barrier disruption, 1584(ab)
grading of, Tl-201 SPECT, 826(ab)
recurrent malignant, I-125 brachytherapy, Tl-201/Tc-99m HMPAO SPECT, 826(ab)

Glomerular filtration rate (GFR)
ambulatory renal monitor, 1588(ab)
camera-based, volume of distribution estimation, Tc-99m DTPA, 915(ab)
comparison of methods for calculation, 424, 914(ab)
peripheral organ distribution volume, temporal behavior, mammillary systems, 1710
reduced, Tc-99m DTPA renal images, 913(ab)
renal plasma flow and, two-minute dynamic scintigraphy, 914(ab)
scintigraphic estimates, Tc-99m DTPA, children, 716(ab)
single plasma sample methods, 716(ab)
short transit times, renal transplants, 1588(ab)
Tc-99m DTPA, analysis of several common methods, 1211

Glucose
altered metabolism, brain, senescence accelerated mouse, 895(ab)
caudate nuclei hypermetabolism, eating disorders, 750(ab)
cerebral metabolism
drugs of abuse, 761(ab)
familial inverted chorea, PET, 740(ab)
rates, program for PET image alignment, 2052
chemistry of the unconscious, N24A(8)
distribution of I-123 IHA-16, esterification and oxidation, myocardium, 640
I-123 glucose analogues, heart imaging, 900(ab)
loading effect, FDG cardiac PET image quality, 840(ab)
local cerebral utilization by PET, 771(ab)
metabolism
functional recovery, myocardial revascularization, 773(ab)
regional variation, normal heart, 774(ab)
substrate level dependence, reperfused myocardium, 795(ab)
myocardial metabolism
anaerobic glycolysis, Tc-99m MIBI SPECT, 821(ab)
insulin and free fatty acid levels, FDG-PET, 802(ab)
planar imaging, residual viability after infarction, 842(ab)
resting state utilization in brain, memory performance, young and old subjects, 879(ab)
serum, tumor and normal tissue uptake of FDG, breast carcinoma, 888(ab)
spatial frequency pattern analysis, normals and schizophrenics, PET, 864(ab)
striatal, dopamine metabolism, Parkinson's disease and Parkinsonism, 880(ab)
uptake, ventricular performance, chronic hypobaric hypoxia, 1344
utilization, thoracic and abdominal organs, 778(ab)
whole brain and regional metabolism, normal aging, F-18 PET, 771(ab)

6-Glucose, regional myocardial metabolism, quantification of patterns, 835(ab)

Glutathione
depletion, Cu-PTSM biodistribution, 910(ab)
interaction of Tc-99m AM-PAO, 1115(le)
tumor blood flow measurement, copper-PTSM, 909(ab)

Glycoaldehyde, novel bioconjugation chemistry, 904(ab)

Glycoconjugate, synthesis in tumors, PET tracer, 6-F-18 fluoro-L-fucose, 1997

Goiter, massive, quantitative CT imaging, radioiodine therapy, 846

Gouty arthritis, acute, In-111 leukocyte scintigraphy, 682

Government Involvement in Nuclear Medicine, Chart, N26A(2)

Granulocytes, binding activity, Tc-99m Fab′ monoclonal antibody, imaging inflammatory lesions, 904(ab)

Graves' disease, I-131 treatment, therapy dose calculations, 519

H

Hanford nuclear site
radiation dose model, N22A(12)

Haynie, Thomas P.
honored as distinguished educator, N20A(7)
review of tenure as *Journal* editor, N22A(1)

Head and neck cancer, chemotherapy, F-18 FDG PET, 1586(ab)

Head injury
abnormal gastric emptying, 801(ab)
FDG-PET and neuropsychological findings, 876(ab)
traumatic
cerebellar hypometabolism, unusual patterns, 741(ab)
remote history, Tc-99m HMPAO SPECT, 936(ab)

Health and Human Services (HHS)
advisory committe on scientific integrity, N23A(3)
exceptions to anti-kickback statue, N30A(2)
opening of National Practitioner Data Bank, N29A(10)
role of nuclear medicine in health care, N30A(8)

Health Care Financing Administration (HCFA), physician's provider number, N28A(1)

Heart
allografts, perfusion abnormalities, PET, 841(ab)
apparent changes in geometry, SPECT TL-201 acquisition, complex phenomenon, 835(ab)
beta adrenergic receptor density, receptor-ligand affinity, 709(ab)
C-11 acetate kinetics and hemodynamic performance, 785(ab)
catheter left ventricular end diastolic pressure, SPECT *vs.* planar lung/heart ratios, 1582(ab)
chick cells, mitochondrial localization, Tc-99m MIBI, 748(ab)
chronic obstructive carotid disease, cerebral hemodynamics, 55
compartmental models, L-[2-^{18}F]fluorotyrosine transport, protein incorporation, 1590(ab)
congestive failure, β-adrenergic desensitization, MIBG, 726(ab)
coronary flow and ischemia, PCr/Pi ratio, 31P-MRS, 946(ab)
coronary occlusion, iodophenylpentadecanoic acid-myocardial blood flow relationship, exercise, 99
coronary thrombi detection, Tc-99m antifibrin monoclonal antibody, 804(ab)
dipyridamole-induced coronary hyperemia, pentoxifylline, 1020
diseases, asynchronous emptying and filling,

Hilbert transform, 858(ab)
dual-tracer autoradiography, Tc-99m MIBI and Tl-201, 832(ab)
first pass extraction fraction, MIBG, imipramine and cocaine, 726(ab)
functional images, radionuclide ventriculography, 825(ab)
gated cardiac blood-pool image sequences, fixed and variable temporal resolution methods, 38
glucose utilization, thoracic and abdominal organs, 778(ab)
graphical method for quantification, *beta* adrenoceptors, PET, 866(ab)
homogenates, muscarinic acetylcholine receptor ligands, 897(ab)
hypoxic and anoxic, fluoromisonidazole kinetics, 786(ab)
I-123 glucose analogues, 900(ab)
imaging, biorouting/performance, radiopharmaceuticals, 933(ab)
innervation, N25A(8)
ischemic neuronal injury, C-11 HED compared to I-131 MIBG, 725(ab)
kinetics of carbon-11 cocaine, 719(ab)
left-to-right shunt, improved method for evaluation, 753(ab)
-lung ratios, exercise and dipyridamole thallium imaging, 842(ab)
malignant pericardial effusion, phosphorus-32-colloidal chromic phosphate, 2034
mechanistic studies, C-11 *meta*-hydroxyephedrine, 707(ab)
metabolism of β-methyl-heptadecanoic acid, 1823
neuronal imaging, C-11 *meta*-hydroxyephedrine, false transmitter agent, 1328
noncoronary disease, blood-pool imaging, 10
normal, oxidative and glucose metabolism, C-11 acetate and FDG kinetics, 774(ab)
pathology, adjunctive role of nuclear medicine, MR images and echocardiograms, 934(ab)
perfusion tomography, determination of infarct size, 1590(ab)
PET
expected value of cash flows, economic analysis, 1893(le)
spatially dependent deadtime, 777(ab)
pitfalls of tissue fractionation, mitochondrial Tc-99m MIBI, 832(ab)
predictive value of ST segment depression, reversibiilty, dipyridamole thallium imaging, 733(ab)
pressure and volume loaded, metabolic performance, C-11 acetate PET, 773(ab)
prognostic measures of cardiac risk, quantitative indices, dipyridamole thallium SPECT, 732(ab)
programmed fluorodeoxyglucose infusion, approach, 778(ab)
pulmonary hypertension, 1
quantification of muscarinic receptors, modeling approach, PET, 709(ab)
rabbit, definition, myocardial viability, 934(ab)
reconstruction of Fourier coefficients, gated SPECT, 1856
regional β-oxidation, F-18 fluorofatty, 901(ab)
release of unexpected myocardial metabolite, radioiodinated BMIPP, 896(ab)
simulated images, multinomial model, concentration-level information, 858(ab)
SPECT
cone beam collimators, 739(ab)
fan beam collimators, 1590(ab)
image quality improvement, absolute quantitative accuracy, 738(ab)
three-dimensional simulation, horizontal motion, 870(ab)
substrate metabolism, regional heterogeneity, 1757(le)
supine exercise stroke volume, cardiac dilatation, elderly, 838(ab)
sympathetic innervation, C-11 hydroxyephedrine, distribution volume approach, 725(ab)
Tc-99m γ-pyrones, new class, Tc-99m cationic complexes, 908(ab)
Tl-201 studies, optimization, collimator design and acquisition parameters, 870(ab)
transient coronary occlusion, right ventricular function, 843(ab)
transplantation
absence of extraneuronal uptake, mIBG, 792(ab)
clinical utility, radionuclide ventriculography, 1933
risk stratification, In-111 antimyosin scintigraphy, 782(ab)
viability, PET, 1116(le)
wall motion, vessel patency and Q waves, PET viable from PET infarcted tissue, 774(ab)
***Heliobacter pylori*, validation, simplified C-14 urea breath test, 1940**
Hematoma
fracture, subperiosteal transplantation, healing, 781(ab)
giant, noninvasive imaging, 1577(le)
Hematoporphyrin analogs, radiolabeling with In-111 oxine, 768(ab)
Hemodialysis
access-site infection, In-111 leukocyte scintigraphy, 319
tumoral calcinosis, 1099
Hemodynamics
C-11 acetate kinetics, canine heart, 785(ab)
cerebral, chronic obstructive carotid disease, SPECT, 55
portal, sclerotherapy for esophageal varices, radionuclide imaging, 813(ab)
Hemorrhage, subarachnoid, vasospasm evaluation, Tc-99m HMPAO tomoscintigraphy, 972
Heparin, bonded polyurethane angio-catheter, platelet-thrombus formation rate, In-111 platelets, 891(ab)
Hepatectomy, liver metastases staging, immunoscintigraphy, Tc-99m monoclonal anti-CEA antibody, 1586(ab)
Hepatocytes, recognition and uptake, radiolabeled monoclonal antibodies, 755(ab)
Hevesy Award, Neils A. Lassen, N28A(5)
Hexadecylphosphocholine, radioiodinated analogs, tumor imaging agents, 708(ab)
Hexakis (2-methoxyisobutylisonitrile)technetium(I), mitochondrial and plasma membrane potentials, accumulation, mouse fibroblasts, 1646
High Level Radioactive Waste
Yucca Mountain HLRW site, NWTRB report, N31A(7)
Hilbert transform, asynchronous emptying and filling, heart diseases, 858(ab)
Hip
arthroplasty
evaluation of loosening, radionuclide and contrast arthrography, 712(ab)
periprosthetic In-111 leukocyte activity, Tc-99m sulfur colloid imaging, 1950
painful prosthesis, Ga-67 citrate arthrography, 830(ab)
prostheses, loosening, nuclear arthrography, 712(ab)
Histiocytoma
malignant fibrous
cold defect, Tc-99m methylene diphosphonate bone scan, 1104
uptake, In-111 leukocytes and Tc-99m sulfur colloid, 1548
HIV-1, *see also* Human immunodeficiency virus
seropositive asymptomatic subjects, disturbances, cerebral perfusion, 1601
HMPAO-SPECT
brain, localization of epileptic foci, site of temporal lobectomy, 711(ab)
resemblance to Alzheimer-type dementia, mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes, 1740
Hodgkin's disease, residual, radiographic methods, mediastinum, 793(ab)
Holmium-166 FHMA, antigen-induced arthritis, radiation synovectomy, 780(ab)
Holospectral imaging, implementation, gamma camera, 758(ab)
Homeostasis, splanchnic vascular capacity and capacitance, equilibrium blood-pool scintigraphy, 154
HPLC
analysis of Re-186 HEDP, 768(ab)
β-γ-γ flow-through detector, PET metabolites, 749(ab)
Human immunodeficiency virus, *see also* HIV-1
asymptomatic seropositive subjects
FDG/PET metabolic asymmetries, 826(ab)
Tc-99m D,L-HMPAO SPECT, 826(ab)
early stages in infection, Tc-99m HMPAO SPECT, 827(ab)
intestinal Kaposi's sarcoma, Tc-99m nanocolloid, 940(ab)
Huntington's chorea, early, iodoamphetamine uptake, SPECT, 937(ab)
Huntington's disease, diagnostic approaches for persons at risk, PET and CT, genetic testing and exam, 740(ab)
Hwang, Dah-Ren, 1990 Berson-Yalow Award, N19A(6)
Hydrazines, bifunctional aromatic, protein labeling, Tc-99m, 776(ab)
Hygroma, cystic, lymphoscintigraphy, 516
Hyperbilirubinemia, neonatal, differential diagnosis, Tc-99m BISIDA, 742(ab)
Hypercalcemia, periarticular tumoral calcinosis, hemodialysis, 1099
Hyperemia
adenosine-induced, left ventricular dilatation, SPECT thallium imaging, 837(ab)
coronary, dipyridamole-induced, pentoxifylline, 1020
dipyridamole-induced stress, post-stenotic myocardial SQ30,217 kinetics, 785(ab)
Hyperparathyroidism
lack of, periarticular tumoral calcinosis with hypercalcemia, hemodialysis, 1099
thyrotoxicosis and, bone scintigraphy, 840
Hyperplasia
prostate nodular, serum PSA and PAP level, adenocarcinoma prediction, 791(ab)
vs. adenoma, adrenal scintigraphy, Cushings and Conns syndrome, 845(ab)
Hypertension
ACE inhibitor, 1990 Berson-Yalow Award,

Dah-Ren Hwang, N19A(6)
chronic, cerebral blood flow, brain-dedicated SPECT, 882(ab)
permanently decreased renal blood flow, lithotripsy, 939(ab)
pulmonary
I-123 HIPDM lung imaging, 668
secondary to chronic thromboembolism, 1
renovascular
ACE inhibitor renography, 912(ab)
captopril-induced scintirenographic changes, 715(ab)
diuretic therapy, post captopril, 913(ab)
enalaprilat scintigraphy, 715(ab)
enalaprit-enhanced renography, rat model, 501
renal blood flow, Tc-99m DTPA, 1980
renal scintigraphy, artery stenosis, 674
Hyperthyroidism, management, iopanoic acid, 1180
Hyperventilation, distribution of Tc-99m D,L-HMPAO, 789(ab)
Hypometabolism, before and after temporal lobectomy, FDG-PET, seizure, 710(ab)
Hypotension, orthostatic and brain, autonomic failure, 877(ab)
Hypoxia
altitude, MIBG scintigraphic assessment, cardiac adrenergic activity, 34
chronic hypobaric, ventricular performance, glucose uptake, 1344
4-fluorobenzylamine conjugate of 2-nitroimidazole, 815(ab)
imaging in human tumors, F-18 fluoromisonidazole, 756(ab)
imaging of tissue, iodinated nitroimidazole, 756(ab)
imaging with I-125 azomycin acyclonucleosides, 900(ab)
myocardial uptake of I-123 MIBG, comparison with normoxia, 726(ab)

I

Imaging agents, *see also* specific type
"hot spot", acute myocardial infarction, 143
Imipramine, cocaine and, first pass extraction fraction, MIBG in heart, 726(ab)
Immunoglobulin G
Fc and Fab fragment localization, focal sites of inflammation, 1199
radiolabeled nonspecific, targeting, 32
rhenium labeling, generation, direct labeling methods, 905(ab)
Immunoreactivity, biodistribution and tumor targeting, radiolabeled anti-P97 Fab fragment, 202
Immunoscintigraphy
acute and chronic infection/inflammation, In-111 immunoglobulin, 819(ab)
colorectal carcinoma and recurrences, Tc-99m monoclonal anti-CEA antibody, 535(le)
detection of recurrent breast cancer, 734(ab)
human antimurine antibodies, 381(le)
human tumors transplanted in nude mice, radiolabeled anti-ras p21 monoclonal antibodies, 1520
inflammatory processes, Tc-99m monoclonal antigranulocyte antibody, 417
I-131 TNT-1 F(ab')$_2$, 735(ab)
ovarian cancer, In-111 OV-TL 3 F(ab')$_2$ monoclonal antibody, 1802
planar, SPECT or, Tc-99m F(ab')$_2$ fragment and ocular melanoma, 854(ab)
Tc-99m granulocytes antibody, inflammatory bowel diseases, 1586(ab)
Tc-99m monoclonal antibody BW 250/183, compared to radiocolloid scanning, solid tumors and systemic disorders, 1588(ab)
Tc-99m monoclonal anti-CEA antibody, liver metastases staging, before partial hepatectomy, 1586(ab)
Tc-99m NCA-95/CEA antibodies, bone marrow, 751(ab)
thrombus detection and thrombolysis, 832(ab)
venous thrombosis, Tc-99m T2G1S antifibrin monoclonal antibody, 782(ab)
Impotence, detection of venous leakage, Xe-133 corporeal clearance, prostaglandin E1, 762(ab)
Indium-111
ab-DTPA-, molecular size and immunoreactivity, serum and supernatant, 906(ab)
anti-lymphocyte and anti-MHC monoclonal antibodies, rejecting and cyclosporin-treated allogeneic kidney transplants, 851(ab)
antimyosin, triphenyl tetrazolium chloride comparison, myocardial infarction, 231
biotin and streptavidin-conjugated antibodies, imaging of tumor, 1791
minimal transchelation, benzyl-EDTA chelate, 218
multiwindow imaging, multi-contrast liver phantom, 943(ab)
radiolabeling of new polymer chelates, 897(ab)
radiopharmacology and tissue localization, Auger electron dosimetry, 1591(ab)
recombinant tissue plasminogen activator, rabbit thrombosis model, 805(ab)
spaced-poly-L-lysine-DTPA-antibody synthesis, 906(ab)
trivalent metal complexes, physicochemical and *in vivo* behavior, 1662
Indium-111 antibodies, validation of quantitative SPECT, 873(ab)
Indium-111 anti-CEA antibody, interferon-induced changes in pharmacokinetics, 852(ab)
Indium-111 antifibrin monoclonal antibody
left sided endocarditis vegetations, rabbit model, 805(ab)
thrombus imaging, 1048
Indium-111 antimyosin
cardiac imaging, doxorubicin cardiotoxicity, 1970
detection of experimental abscess, 940(ab)
different stages of myocardial infarction, compared to Tc-99m pyrophosphate imaging, 136
myocardial necrosis, left ventricular function, 841(ab)
myocardial uptake, acute subendocardial infarction, 1851
rheumatic myocarditis, 841(ab)
scintigraphy
doxorubicin therapy, advanced breast cancer, 1965
predictive value, ischemic events after first myocardial infarction, 782(ab)
risk stratification, heart transplant, 782(ab)
serum myosin light chain I comparison, myocardial infarction, 714(ab)
TlCl-201 myocardial SPECT and, acute myocardial infarction, 783(ab)
Indium-111 antimyosin Fab
active myocardial cell damage, hypertrophic cardiomyopathy, 782(ab)
imaging of soft-tissue sarcoma, 23
Indium-111 B72.3-GYK-DTPA, radiation dosimetry model, colorectal cancer, 787(ab)
Indium-111 biotin derivatives, improved immunotargeting, 903(ab)
Indium-111 chloride
experimental arthritis in rabbits, 781(ab)
scintigraphy, bone marrow imaging, myelodysplasia and aplastic anemia, 752(ab)
Indium-111 DPTA-IgG, imaging of infection/inflammation 890(ab)
Indium-111 DTPA-labeled monoclonal antibodies, liver uptake of In-111, labeling parameters, antibody dose, 1084
Indium-111 granulocytes
scintigraphy, brain abscess diagnosis, 1121
splenic pooling, inflammatory bowel disease, scintigraphy, 1470
wound healing, kinetics, antiflammatory and antimicrobial agents, 890(ab)
Indium-111 immunoconjugates, cyclohexyl EDTA derivatives, 896(ab)
Indium-111 immunoglobulin G, Tc-99m human polyclonal IgG, focal site of infection, rats, 2022
Indium-111 leukocytes
complementary role of Tc-99m sulfur colloid, inflammation evaluation, 941(ab)
detection of experimental abscess, 940(ab)
emphysemous gastritis in pancreatitis, 112
experimental arthritis in rabbits, 781(ab)
infectious localization, oncology patient, 819(ab)
In-111 nonspecific polyclonal IgG comparison, canine osteomyelitis model, 811(ab)
multifocal skeletal uptake, infection *vs.* tumor metastasis, 1543
orthopedic implant sepsis, 712(ab)
osteomyelitis, 2029
periprosthetic activity, total hip arthroplasty, Tc-99m sulfur colloid imaging, 1950
scintigraphy
acute gouty arthritis, 682
hemodialysis access-site infection, 319
Tc-99m MDP bone and magnetic resonance imaging, neuropathic osteoarthropathy, osteomyelitis, 549
Tc-99m sulfur colloid and, uptake, malignant fibrous histiocytoma, 1548
three-phase bone scanning and, acetabulum, porous-coated hip arthroplasty, 274
vs. Tc-99m albumin colloid WBC, osteomyelitis, 890(ab)
vertebral osteomyelitis/discitis, 711(ab)
Indium-111 low-density lipoprotein
atherosclerotic disease, lipoprotein biodistribution, 343
metabolism *in vivo*, 745(ab)
Indium-111 lymphocytes, distribution after IL-2 administration, 1585(ab)
Indium-111 monoclonal antibodies
accumulation in non-tumored tissue, colorectal carcinoma, 1975
localization, pulmonary human sarcoma xenografts, 1378
metabolism in tumor and normal tissue, athymic mouse, 1510
preload of metal iron, enhanced tumor targeting, 851(ab)
Indium-111 monoclonal antibody antiferritin immunoconjugates, linker-modulated biodistribution, nude mice, 823(ab)
Indium-111 OV-TL F(ab')$_2$ monoclonal antibody
immunoscintigraphy of ovarian cancer, 1802

ovarian cancer, 734(ab)
Indium-111 oxine
hematoporphyrin analogs, 768(ab)
labeled lymphocytes, *in vivo* traffic, automated apheresis, 999
Indium-111 oxine leukocytes, Tc-99m HM-PAO leukocytes or, intraabdominal sepsis, 311
Indium-111 platelets
platelet-thrombus formation rate, heparin polyurethane angio-catheter, 891(ab)
splenic dynamics, idiopathic thrombocytopenic purpura, 383(le)
Indium-111 polyclonal IgG, scintigraphic detection, bone and joint infections, 403
Indium-111 polyclonal nonspecific IgG
In-111 leukocytes and
canine osteomyelitis model, 811(ab)
scintigraphy, 811(ab)
scintigraphy, febrile neutropenic patients, 819(ab)
Tc-99m monoclonal antigranulocyte antibody comparison, imaging focal infection, 811(ab)
Indium-111 transferrin, diagnostic value, protein-losing gastroenteropathy, 814(ab), 847(ab)
Infant, brief separation from monkey mother, mother's metabolic brain activity, 887(ab)
Infarction
cerebral, dependence on SPECT/IMP results, time post onset after infarction, 878(ab)
myocardial, *see* Myocardial infarction
Infection
acute and chronic, In-111 immunoglobulin, immunoscintigraphy, 819(ab)
delineation of sites, Tc-99m polyclonal immunoglobulin, Tc-99m antigranulocyte monoclonal antibody, 890(ab)
focal
Tc-99m monoclonal antigranulocyte antibody, In-111 nonspecific IgG, 811(ab)
Tc-99m polyclonal IgG, hydrazino nicotinamide derivative, 819(ab)
highlights of EANM Congress, N15A(10)
imaging focal infections, best method, 413
imaging with In-111 DPTA-IgG, 890(ab)
In-111 nonspecific polyclonal human IgG, scintigraphic detection, bone and joint infections, 403
intracranial, after neurological procedures, Tc-99m BW 250/183 antigranulocyte antibody scintigraphy, 818(ab)
localization in oncology patient, In-111 leukocyte imaging, 819(ab)
localization of lesions in humans, Tc-99m polyclonal immunoglobulins, 758(ab)
prosthetic joint, 1955
Tc-99m HIG, 811(ab)
Tc-99m human polyclonal IgG, imaging in rats, 2022
Tc-99m sulfur colloid, periprosthetic In-111 leukocyte activity, total hip arthroplasty, 1950
tumor metastasis, multifocal skeletal uptake of labeled leukocytes, 1543
urinary tract, DMSA scan, 893(ab)
Inflammation
acute and chronic, In-111 immunoglobulin, immunoscintigraphy, 819(ab)
florid inflammatory lesions, subtraction/reverse subtraction imaging, monoclonal anti-granulocyte antibody and nanocolloid, 1587(ab)
focal sites, Fc and Fab fragments, nonspecific polyclonal IgG, 1199
imaging of lesions, Tc-99m Fab' monoclonal antibody, granulocyte binding activity, 904(ab)
imaging with In-111 DPTA-IgG, 890(ab)
immunoscintigraphy, Tc-99m monoclonal antigranulocyte antibody, 417
inflammatory bone lesions, double tracer subtraction/reverse subtraction imaging, 1589(ab)
joint, radionuclide imaging, 684
localization with Tc-99m proteins, 810(ab)
scintigraphic detection of foci, radiolabeled proteins, 810(ab)
sepsis, 1746(le)
Tc-99m HIG, 811(ab)
Inflammatory bowel disease, immunoscintigraphy, Tc-99m granulocyte antibody, 1586(ab)
Inflammatory disease, SPECT-CT fusion, 871(ab)
In memoriam, Kriss, Joseph P., 704
Institute of Medicine (IOM)
brain symposium, developments, cerebral imaging, N32A(9)
election of SNM member, N28A(8)
Insulin
brain glucose metabolism, PET during euglycemic clamps, Pima Indians, 879(ab)
free fatty acid levels and, myocardial glucose metabolism, FDG-PET, 802(ab)
I.V. injection in diabetics, F-18 FDG PET, 933(ab)
receptor, imaging, F-18 insulin, 791(ab)
type A resistance, defect, liver insulin receptors, 791(ab)
Interferon
enhancement of radioimmunotherapy, colon carcinoma, 850(ab)
-induced changes in pharmacokinetics, In-111 anti-CEA antibody, 852(ab)
γ-Interferon, enhancer of CEA, colon cancer xenografts, 764(ab)
Interleukin 2, distribution of In-111 lymphocytes, 1585(ab)
International Atomic Energy Agency (IAEA), WHO and, promotion of nuclear procedures, developing countries, N27A(11)
International Commission on Radiological Protection (ICRP), proposal of revised limits for radiation workers, N25A(9)
Intestine, small, food effects, drug bioavailability, 846(ab)
Investigational new drug applications, FDA reviewers' perspective, 728(ab)
Iodination, methyl-branched fatty acid, decreased myocardial uptake, inhibition of ATP synthesis, 708(ab)
Iodine-123
receptor ligands, N18A(8)
SPECT
correction of overestimation, cerebral blood flow, 790(ab)
quantitation, 874(ab)
quantitation linearity, brain, 769(ab)
Tc-99m and
simultaneous SPECT in brain, PRISM scanner, 877(ab)
thyroid nodules, pathologic findings, 393, 400
Iodine-123 E2, imageable, breast cancer detection, 937(ab)
Iodine-123 epiderpride, SPECT, dopamine D2 receptors in man, 779(ab)
Iodine-123 glucose analogues, heart imaging, 900(ab)
Iodine-123 HIPDM
lung imaging, pulmonary vein-banded pulmonary hypertension, 668
SPECT
brain blood flow, cerebrovascular disease, 879(ab)
human pancreas scintigraphy, 1015
Iodine-123 hippuran, Tc-99m red blood cells and Tc-99m macroaggregated albumin, excretion into breast milk, 978
Iodine-123 hippurate, Tc-99m MAG_3 and, renal scintigraphy and clearance, 1811
Iodine-123 IBF, selective dopamine D-2 receptor imaging agent, I-125 IBF, 648
Iodine-123 IBZM
kit formulation, 899(ab)
radiation dosimetry, 844(ab)
SPECT, dopamine D-2 receptors, humans, 573
Iodine-123 IHA-16, glucose effect on distribution, esterification and oxidation, myocardium, 640
Iodine-123 IMP
brain SPECT, clinical significance, pediatric patients, 878(ab)
cocaine effect on distribution, dog brain and lungs, 887(ab)
deposition, effects of visual stimulation, 875(ab)
duodenal administration, portosystemic shunting, superior mesenteric vein, 813(ab)
increased accumulation, bronchial carcinoid tumor, 240
N-isopropyl-P-, cerebral blood flow, SPECT, 750(ab)
SPECT
AIDS dementia, brain, 936(ab)
correction for extraction fraction, cerebral blood flow, 868(ab)
crossed cerebellar diaschisis, stroke, 770(ab)
ocular melanoma, 375
spinocerebellar degeneration, 881(ab)
validation studies, cerebral blood flow tracer, 1364
unusually high and focal uptake, early Huntington's chorea, SPECT, 937(ab)
Iodine-123 iodo-2'-deoxyuridine, autoradiographic validation, brain tumors, 766(ab)
Iodine-123 iodolisuride, SPECT, D2 receptor imaging, 770(ab)
L-3-Iodine-123 iodo-α-methyl tyrosine
brain tumor recurrences, 766(ab)
SPECT studies of brain tumors, 281
Iodine-123 iodo-*m*-tyrosine, brain SPECT, synthesis, preliminary evaluation, 796(ab)
Iodine-123 IPA, SPECT, brain tumor analysis, 899(ab)
Iodine-123 IPPA, recognition of viable myocardium, transmural myocardial infarction, 1582(ab)
Iodine-123 IQNB, localization, SPECT, Alzheimer's patients, 729(ab)
Iodine-123 ISP, SPECT, dopamine D2 receptors, 885(ab)
Iodine-123 IVM, metabolic marker for myocardial ischemia, 833(ab)
Iodine-123 MIBG
absence of extraneuronal uptake, cardiac transplantation, 792(ab)
aerosol, dynamic lung scanning, sympathoadrenal system, 772(ab)
cardiac adrenergic activity, response to altitude hypoxia, 34
MRI, functioning paragangliomas, 935(ab)
myocardial concentration, serial change, dilated cardiomyopathy, 792(ab)
myocardial uptake in rats, chronic hypoxia,

comparison with normoxia, 726(ab)
pitfalls, skeletal assessment, neuroblastoma, 129
regional sympathetic denervation, transient myocardial ischemia, coronary artery disease, 793(ab)
scintigraphy, chemodectomas, head and neck region, 1147
uptake and clearance, hypertrophic cardiomyopathy, 792(ab)
Iodine-123 NCQ 298, D-2 dopamine receptors, 796(ab)
Iodine-123 ortho-phenylpentadecanoic acid, F-18 FDG and, Tl-201 uptake, myocardial infarction, 803(ab)
Iodine-123 prenalterol, SPECT, myocardial β-adrenergic receptor studies, 899(ab)
Iodine-123 QNB, compared to Tc-99m ECD blood flow, dynamic SPECT, 707(ab)
Iodine-123 Ro 16-0154, SPECT investigations, benzodiazepine receptors, 1007
Iodine-123 sodium iodide, radiochemical purity and reaction yields, 947(ab)
Iodine-123 TISCH, D-1 dopamine receptor imaging ligand, 708(ab)
Iodine-124 antibodies, PET, quantitative imaging, 864(ab)
Iodine-124 ICR12, PET, proto-oncogene expression, breast cancer, 777(ab)
Iodine-124 monoclonal antibody, PET, ovarian cancer metastases, 764(ab)
Iodine-124 NCL-6-I, PET radiotracer for adrenal, 947(ab)
Iodine-125
brachytherapy, recurrent malignant glioma, Tl-201/Tc-99m HMPAO SPECT, 826(ab)
-labeled ligands, dopamine uptake inhibitors, 898(ab)
neopterin radioimmunoassay evaluation, 714(ab)
sigma receptor ligands, synthesis, biodistribution studies, 797(ab)
Iodine-125 anti-epidermal growth factor receptor, monoclonal antibody, cytotoxicity, 845(ab)
Iodine-125 azomycin acyclonucleoside, hypoxia imaging, 900(ab)
Iodine-125 BMIPP, myocardial accumulation, relation to ATP concentration, 1818
Iodine-125 DEX, ligand for detection of atropine effects, central muscarinic receptors, 886(ab)
Iodine-125 epidermal growth factor, anti-EGF-R Mab 425 and, biodistribution, tumor xenografts, 1587(ab)
Iodine-125 epiderpride, interaction with dopamine receptors, rat brain, 809(ab)
Iodine-125 IBF, selective dopamine D-2 receptor imaging agent, 648
Iodine-125 IBZ, dopamine D2 receptors, 882(ab)
Iodine-125 IDEX, characterization, 898(ab)
Iodine-125 IMEL, binding to melatonin receptor, rat brain, 883(ab)
Iodine-125 IMP, metabolism in cultured rat liver cells, 910(ab)
Iodine-125 iodobenzovesamicol, presynaptic cholinergic marker, 797(ab)
Iodine-125 2′-iodococaine, inherent organ selective differences, biodistribution, mouse strains, 726(ab)
Iodine-125 iodo-2′-deoxyuridine, autoradiographic validation, brain tumors, 766(ab)
Iodine-125 iododexetimide, characterization of binding, muscarinic cholinegic receptors, 725(ab)
Iodine-125 iothalamate
comparison of methods, calculation, glomerular filtration rate, 914(ab)
glomerular filtration rate, 424
Iodine-125 MIBG
adrenoceptors in rats, 1253(le)
Adriamycin-induced cardiomyopathy, 832(ab)
cardiac adrenergic innervation, doxorubicin-induced myocardial damage, metoprolol, 833(ab)
neuroblastoma, alternative therapeutic radiolabel, 804(ab)
neuroblastoma treatment, 1479
Iodine-125 monoclonal antibodies
biotinylated, cold avidin, antibody guided surgery, 853(ab)
improved tumor uptake, colon cancer model, 852(ab)
Iodine-125 NCQ 298, D-2 dopamine receptors, 796(ab)
Iodine-125 NRLU-10, kinetic studies, bismuth-212-NRLU-10 toxicity, LS174T multicell spheroids, 1527
Iodine-125 TNT-1, localization of inflammation, Tc-99m proteins, 810(ab)
Iodine-131
anti-βHCG antibodies, testicular tumors, 854(ab)
chimeric monoclonal antibodies, body distribution, 850(ab)
diffuse liver uptake, 1575(le)
dosimetry, thyroid carcinoma, 935(ab)
evaluation of remote radioiodination system, radioimmunotherapy, 508
external exposure rates, thyroid cancer therapy, 845(ab)
FDA's diagnostic study, criticism by radiation health experts, N13A(7)
Graves' disease, therapy dose calculations, 519
low level ionizing radiation, N18A(7)
nasal activity, 52
normal residual thyroid tissue, differentiated thyroid cancer, 744(ab)
SPECT, quantitation in phantoms, human tumors, 1945
whole-body scans, replacement by thyroglobulin measurement, thyroid carcinoma, 1766
Iodine-131 antibodies, imaging and treatment, B-cell lymphoma, 1257
Iodine-131 anti-CEA antibody
dosimetric considerations, radioimmunotherapy, 788(ab)
radioimmunoscintigraphy, Tl-201 scintigraphy, medullary thyroid carcinoma, 1854
Iodine-131 anti-fibrin T2G1s monoclonal antibody, thrombus imaging, 1048
Iodine-131 anti-myeloid antibody, propylthiouracil effects on biodistribution, dosimetry, 1384
Iodine-131 B1 antibody, therapy of B-cell lymphoma xenografts, 765(ab)
Iodine-131 cellulose, colon transit scintigraphy, health and constipation, 985
Iodine-131 3F8, neuroblastoma treatment and diagnosis, 742(ab)
Iodine-131 hippuran, Tc-99m MAG3 and DTPA, dosimetry, human subjects, 822(ab)
Iodine-131 HMFG1
diagnostic and therapeutic efficacy, ovarian and colorectal carcinoma, dosimetry, 938(ab)
dosimetry, gamma camera, whole-body profile scanning, 945(ab)
Iodine-131 IMP, metabolism in cultured rat liver cells, 910(ab)
Iodine-131 Lym-1, treatment of B cell malignancies, 723(ab)
Iodine-131 MIBG
C-11 HED comparison, ischemic neuronal injury, heart, 725(ab)
first pass extraction fraction, imipramine and cocaine, heart, 726(ab)
monoclonal antibody uptake or, neuroblastoma xenografts, 741(ab)
perivesicle pheochromocytoma, 1669
scans and biochemical analyses, pheochromocytoma, 745(ab)
SPECT, quantitation in phantoms, human tumors, 1945
Iodine-131 monoclonal antibody
B72.3, colorectal carcinoma, 852(ab)
$F(ab')_2$ fragments, radioimmunotherapy, colon carcinoma, 1035
quantification of uptake, liver metastases, SPECT, 873(ab)
radioimmunotherapy of B-cell lymphoma, 852(ab)
Iodine-131 NP-59, diagnostic accuracy and pitfalls of imaging, 526
Iodine-131 OIH
spectrum of scintigraphic findings, lymphoceles, renal transplant, 940(ab)
Tc-99m MAG3 or, parenchymal retention, transplanted kidneys, 716(ab)
Iodine-131 PIP, anti-ovarian carcinoma antibody, Phase I evaluation, 777(ab)
Iodine-131 TNT-1 $F(ab')_2$, immunoscintigraphy, 735(ab)
Iodine-131 TNT-1 monoclonal antibody, pharmacokinetic evaluation in humans, 853(ab)
Iodine-131 toluidine-blue, scintigraphy, localization, parathyroid pathology, 790(ab)
Iodoamphetamine, redistribution, autoradiographic analysis, brain ischemia, 660
Iodocyanopindolol, beta adrenergic receptor density, receptor-ligand affinity, heart, 709(ab)
Iodoethylspiperone, central dopamine D-2 receptors, 796(ab)
Iodophenylpentadecanoic acid, -myocardial blood flow relationship, maximal exercise, coronary occlusion, 99
Ionophores, mitochondrial metabolic inhibitors, Tc-MIBI accumulation, chick myocytes, 736(ab)
Iopanoic acid, management of hyperthyroidism, 1180
15-(Ortho-^{123}/^{131}I phenyl)-pentadecanoic acid, 15-(para-^{123}/^{131}I phenyl)-pentadecanoic acid or, tracer kinetics, animals and man, 1608
Iron, preload for enhanced tumor targeting, In-111 monoclonal antibody, 851(ab)
Iron-59, trivalent metal complexes, physicochemical and *in vivo* behavior, 1662
Iron-59 plasma, whole-body clearance, ferrosomes, 717(ab)
Irradiation
food, perception problems, N11A(9)
gamma and UV-B, migration, rat dendritic cells and lymphocytes, 820(ab)
Irridium-191m, generator eluates, Os-191 impurity, pH adjustment agents, 523
Ischemia
brain, autoradiographic analysis, iodoamphetamine redistribution, 660
cerebral, SPECT quantitation, carotid endarterectomy, 1412
low flow, Tc-99m MIBI compared to Tl-201 uptake, 713(ab)
myocardial, *see* Myocardial ischemia

Isothiocyanatobenzyl-DTPA, derivatized monoclonal antimyosin Fab, target localization, 211
Isotopes, internally administered, solid malignancy, 601

J

Jaw, bone scans, orthopan display technique and normal values, 871(ab)
Joint
infection, scintigraphic detection, In-111 nonspecific polyclonal human IgG, 403
inflammation, radionuclide imaging, 684
sacroiliac, increased uptake, bone scintigraphy for low back pain, 712(ab)

K

Kidney
accelerated renal clearance, Tc-99m antimyosin Fab′, 833(ab)
ambulatory renal monitor, glomerular filtration rate, 1588(ab)
blood flow, Tc-99m DTPA, renovascular hypertension, 1980
captopril renal scintigraphy, echo-Doppler flowmetry, renal artery stenosis, 913(ab)
Cu(PTSM) localization, regional blood flow, 914(ab)
depth, renographic estimation, relative renal function, 1576(le)
diagnosis of primary amyloid nephrotic syndrome, utility, gallium imaging, 292
error analysis and mean transit times, split renal function, DTPA renography, 940(ab)
excretion characteristics of isomers, L,L and D,D of Tc-99m ethylenedicysteine, 806(ab)
glomerular filtration rate
comparison of methods for calculations, 424
renal plasma flow, two-minute dynamic scintigraphy, 914(ab)
Tc-99m DTPA and I-125 iothalamate clearance, 914(ab)
impaired renal function, kit preparation, Tc-99m MAG_3, 1568
magnetic resonance imaging, Gd(PAHIDA) complex, 717(ab)
measurement of skin-to-kidney distance, quantitative renography, children, 287
peripheral organ distribution volume, mammillary systems, 1702, 1710
permanently decreased renal blood flow, hypertension, lithotripsy, 939(ab)
pharmacokinetics of Tc-99m MAG_3 in humans, 1285
predicting and/or refining response, Lasix stimulation, factor analysis, 913(ab)
rejecting and cyclosporin-treated allogeneic transplants, In-111 anti-lymphocyte and anti-MHC monoclonal antibodies, 851(ab)
renal blood flow, 1990 Hevesy Award, Neils A. Lassen, N28A(5)
renal failure, transplantation, radionuclide first pass study and sulfur colloid, 912(ab)
renal function after captopril, acute diuresis, 913(ab)
renal scintigraphy, renovascular hypertension secondary to artery stenosis, 674
renal transplants
blood flow, pediatric patients, 580
blood flow assessment, inter-operator errors, 911(ab)
renovascular disease detection, captopril renography, renal transplant, 716(ab)
renovascular hypertension, enalaprit-enhanced renography, rat model, 501
scintigraphy and clearance, Tc-99m MAG_3 and I-123 hippurate, renal disorders, 1811
Tc-99m DTPA
reduced glomerular filtration rate, 913(ab)
renal clearance, background correction, 430
transplant
intraperitoneal urine leak, radionuclide imaging, 1206
lymphocele, scintigraphic findings, 1627
parenchymal retention, I-131 OIH or Tc-99m MAG3, 716(ab)
scintigraphic findings, lymphoceles, 940(ab)
short transit times, glomerular filtration rate, 1588(ab)
unified single-injection, two-sample renal clearance, both children and adults, 912(ab)
Kinetic models, concentration of benzodiazepine receptors, 709(ab)
Krishnamurthy-Bobba sign, scintigraphic cholecystokinin-induced bile reflux, 248(le)
Kriss, Joseph P., in memoriam, 704

L

Lacrimal gland, dosimetry, Tc-99m HMPAO, brain, 1237
Lactic acidosis, mitochondrial encephalomyopathy, HMPAO-SPECT, Alzheimer-type dementia, 1740
Laser, paper-based images, bone scans, 857(ab)
Lassen, Neils A., 1990 Hevesy Award, N28A(5)
Lead, collimator walls, calculation of coherent scattering, 140 keV photons, 856(ab)
Lead carbonate, advantages, high-resolution PET imaging, 749(ab)
Learning disorders, Tc-99m HMPAO SPECT, brain, children, 741(ab)
Leg
occlusive arterial disease, exercise whole-body thallium scintigraphy, 1443
xenon imaging, 939(ab)
Leiomyosarcoma, gallium scanning, 794(ab)
Lesions, focal, detection with Ga-67 citrate, anemia and proteinuria, 512
Leukemia
chronic myelogenous, splenic accumulation, Tc-99m methylene diphosphonate, 1552
radiation discharges and cancer mortality, no link, N11A(11)
Leukocytes
febrile neutropenic patients, In-111 polyclonal nonspecific IgG scintigraphy, 819(ab)
Tc-99m HMPAO, early diagnosis, acute abdominal sepsis, 1743(le)
Ligands
AH5183, SPECT, cholinergic denervation in brain, 885(ab)
assessment of presynaptic cocaine receptors, 719(ab)
bifunctional amide thiolate, Tc-99m Fab, radioimmunodetection, 747(ab)
binding kinetics in PET, effects, neuroreceptor clustering, 709(ab)
C-11 citalopram and C-11 fluoxetine, serotonin uptake site, 883(ab)
dopamine D1 receptor
I-123 (R+)TISCH, 708(ab)
preparation of C-11 SCH 39166, PET, 737(ab)
(R+) and S(-)TISCH, 899(ab)
dopamine D1 and D2, amphetamine and cocaine effect, rat brain uptake, 809(ab)
dopamine D2 receptor
F-18 N-(4-fluorobenzyl)spiperone, PET, 901(ab)
F-18 NCQ 115 PET, 902(ab)
kit formulation, I-123 IBZM, 899(ab)
functionalized tripodal hexadentate, Tc-99m radiopharmaceutical applications, 897(ab)
I-125 DEX, detection of atropine effects, central muscarinic receptors, 886(ab)
monoclonal antibody percolation through tumors, modeling analysis, 1191
muscarinic acetylcholine receptor
F-18 label, 814(ab)
heart homogenates, 897(ab)
muscarinic receptor, characterization, I-125 IDEX, 898(ab)
pentadentate amine-phenol, Tc-99m complexes, 947(ab)
PET, F-18 fluprepid, dopamine D2 receptor, 786(ab)
receptor, modeling alternatives, C-11 tropanyl benzilate binding to muscarinic cholinergic receptors, 709(ab)
sigma receptor, I-125, biodistribution, 797(ab)
Limulus amoebocyte lysate, endotoxin testing, radiopharmaceutical, chelated metallic radionuclides and chelating agents, 243
Lipoprotein
biodistribution, In-111 LDL, atherosclerotic disease, 343
metabolism, Ga-68 and In-111 labeled LDL, 745(ab)
Liposomes, *see also* Ferrosomes
labeling with Tc-99m, 806(ab)
Lithotripsy
extracorporeal shock wave
before and after, hepatic kinetics, 849(ab)
gallbladder kinetics, 848(ab)
scintigraphy, gallbladder function, 1583(ab)
piezoelectric biliary extracorporeal shockwave, gallbladder function before and after, 731(ab)
post-biliary, hepatobiliary imaging, 935(ab)
Liver
blood and, time-activity curves, GI tract radiation dose, 844(ab)
cellular proliferation, [2-C-11]thymidine and PET, 847(ab)
C-11 ethanol PET, 849(ab)
C-11 palmitic acid, β-methyl heptadecanoic acid distribution, 848(ab)
defect in insulin receptors, type A insulin resistance, 791(ab)
diffuse uptake of I-131, 1575(le)
function studies, clinical evaluation, Tc-99m GSA, 1583(ab)
hepatic arterial and portal venous blood flow, nonlinear regression based deconvolution method, fractional distribution, 859(ab)
hepatic microsphere therapy, 3-D dose computation, 784(ab)
hepatic venoocclusive disease, lung uptake of sulfur colloid, 372
hepatobiliary imaging, post-biliary lithotripsy, 935(ab)
I-125 and I-131 IMP metabolism, 910(ab)
In-111 spaced-poly-L-lysine-DTPA-antibody synthesis, 906(ab)
intravenously injected radiolabeled antibody, micronucleus assay, 844(ab)
kinetics, pre- and post-ESWL, 849(ab)
large telangiectatic focal nodular hyperplasia, presentation with normal radionuclide studies, 2037
metabolism of β-methyl-heptadecanoic acid, 1823

metastases
antibody uptake, autoradiography, 855(ab)
F-18 uracil PET, colorectal carcinoma, 888(ab)
monoclonal antibody localization, critical factors, 754(ab)
uptake of I-131 monoclonal antibodies, SPECT, 873(ab)
metastases staging before partial hepatectomy, immunoscintigraphy, Tc-99m monoclonal anti-CEA antibody, 1586(ab)
multi-contrast phantom, In-111, multiwindow imaging, 943(ab)
normal, binding site analysis, antibodies 96.5 and 9.2.27, 755(ab)
quantitative hepatobiliary scintigraphy, 1468
sincalide-augmented quantitative hepatobiliary scintigraphy, Sphincter of Oddi manometry, 1462
transplant
Tc-99m DISIDA, biliary stenosis early detection, 732(ab)
Tc-99m DISIDA hepatobiliary studies, biopsies, 731(ab)
uptake of In-111, administration of In-111 DTPA-labeled monoclonal antibodies, 1084
uptake of Tc-99m HM-PAO, 237
volume determination, Tc-99m sulfur colloid SPECT, preoperative transplant recipients, 874(ab)

Lobectomy
radioisotopic pulmonary, 594
temporal
epileptic foci localization, HMPAO brain SPECT, 711(ab)
hypometabolism assessment with FDG-PET, seizure, 710(ab)

Low-Level Radioactive Waste Policy Amendments Act (LLRWPAA), status of states, N22A(5)

Lung
allograft transplant rejection, Tc-MAA quantitative scintigraphy, 722(ab)
aspiration and esophageal dysmotility, radionuclide salivagram, 1588(ab)
bronchial carcinoid tumor, increased accumulation, I-123 IMP, 240
cancer
mediastinal staging, "fusion" of CT and radiolabeled antibody SPECT, 798(ab)
mediastinal lymph node metastases, Tl-201 SPECT, 889(ab)
cardiac cath left ventricular end diastolic pressure, SPECT *vs.* planar lung/heart ratios, 1582(ab)
cocaine effect, I-123 IMP distribution, 887(ab)
disease, blood-pool imaging, noncoronary heart disease, 10
dynamic scanning, I-123 MIBG aerosol, sympathoadrenal system, 772(ab)
embolism and single perfusion defect, angiography, 296
epithelial transport, inhaled Tc-99m DTPA, urine excretion, 441
fibrosis, Tc-99m HMPAO and Tc-99m DTPA aerosol clearance, 772(ab)
-heart ratios, exercise and dipyridamole thallium imaging, 842(ab)
highlights of EANM Congress, N15A(10)
hypertension, 1
increased uptake, Tc-99m sulfur colloid liver-spleen scans, hepatic venoocclusive disease, 372
leg Xe imaging, 939(ab)
localization of pulmonary sarcoma xenografts, In-111 monoclonal antibodies, 1378
metastases, monoclonal antibody localization, critical factors, 754(ab)
mucociliary clearance and transport, global and regional assessment, 543
parenchyma, superparamagnetic ferrosomes, MRI, 718(ab)
pulmonary vein-banded pulmonary hypertension, I-123 HIPDM lung imaging, 668
radioisotopic pulmonary lobectomy, 594
segmental scan defects, prefusion reduction correlates, mean pulmonary artery pressure, 721(ab)
significance of flip-flop pattern, reversed V/Q mismatch, 895(ab)
smoker's, perfusion scans, 772(ab)
suspected malignant pulmonary lesions, Tl-201 SPECT, 766(ab)
Tc-99m HMPAO diffusion of uptake, cigarette smokers, 894(ab)
Tc-99m MIBI uptake, indicator for stress-induced LV failure, coronary artery disease, 1581(ab)
transplants, pre- and post-operative evaluation, ventilation-perfusion imaging, 721(ab)
tumor, differential diagnosis with PET, T6
unilateral generalized perfusion defects, diagnostic significance, 721(ab)
uptake of Tc-99m HMPAO, cigarette smoke exposure, 773(ab)
ventilation and perfusion abnormalities, ventilation perfusion imbalance, pulmonary atresia or extreme tetralogy of Fallot, 1276

Lupus, murine, Tc-99m HMPAO autoradiography, 884(ab)

Lym-1
anti-lymphoma antibody, dual isotope pharmacokinetics, new bifunctional chelating agent, 823(ab)
intratumor localization of monoclonal antibodies, autoradiography, 1059

Lymphadenectomy, use of Tc-99m monoclonal antibody, melanoma, 1586(ab)

Lymphangioscintigraphy, patterns in filariasis, 891(ab)

Lymphedema, lymphoscintigraphy and, lower extremities, 990

Lymph nodes
detection of tumor involvement, 2-deoxy-2[^{18}F] fluoro-D-glucose, 1831
mediastinal metastases in lung cancer, Tl-201 SPECT, 889(ab)

Lymphoceles
scintigraphic findings, renal transplant, 1627
spectrum of scintigraphic findings, renal transplant, 940(ab)

Lymphocytes
adoptively transferred autologous, homing patterns, brain tumors, 818(ab)
In-111 oxine, *in vivo* traffic, automated apheresis, 999
migration, gamma and UV-B irradiation, 820(ab)

Lymphoma
B-cell
imaging and treatment, 1257
radioimmunotherapy, I-131 MB-1 monoclonal antbody, 852(ab)
xenografts, I-131 B1 antibody therapy, 765(ab)
Ga-67 scintigraphy, 793(ab)
malignant, F-18 FDG and Ga-67, 888(ab)
non-African Burkitt's, Ga-67 scintigraphy, 794(ab)
non-Hodgkin's
Ga-67 citrate, gastrointestinal tract, 846(ab)
low and intermediate grade, Ga-67 and Tl-201, 793(ab)
radioimmunotherapy, 724(ab)
successful radioimmunotherapy, monoclonal antibody, 724(ab)
treated, residual mass, negative gallium scintigraphy, 365

Lymphoscintigraphy
axillary, breast cancer, 1835
cystic hygroma, 516
lymphedema and, lower extremities, 990
mammary, regional spread, breast cancer, 745(ab)

M

Magnetic field, -induced human movement, spectamine flow analysis, 761(ab)

Magnetic resonance imaging: ***See*** **Nuclear magnetic resonance**

Magnetic resonance spectroscopy, P-31, FDG-PET, brain tumors, 302

Malaria, antigen detection, rat monoclonal immunoradiometric assay, 1587(ab)

Malemide, radioiodinated, radioimmunoconjugator, no-carrier-added preparation, 906(ab)

Malformation, peripheral arteriovenous, intraarterial injection, Tc-99m MAA, 1557

Malignancy
soft tissue tumors, Tl-201 scintigraphy, 889(ab)
solid, internally administered isotopes, 601
total body imaging, FDG-PET, 803(ab)

Mallinckrodt Fellowship, Martha J. Senneff, N24A(6)

Malpractice, medical, data bank, N28A(2)

Mammary cancer, *see also* Breast cancer
transplants, tumor uptake, F-18 progestin, 746(ab)

Mammary gland, lymphoscintigraphy, regional spread, breast cancer, 745(ab)

Mammillary systems, peripheral organ distribution volume, 1702
early kinetics, 859(ab)

Manometry
radionuclide esophageal transit study
esophageal motor dysfunction, 1921
motility dysfunction, 775(ab)
Sphincter of Oddi, sincalide-augmented quantitative hepatobiliary scintigraphy, 1462

Manpower Summit, shortage of radiologic and sonographic technologists, N30A(2)

Marijuana, synthesis and distribution, F-18 tetrahydrocannabinol PET, 902(ab)

Marine animals, applications of radiopharmaceuticals, 831(ab)

McCune-Albright syndrome, patterns of scintigraphic abnormalities, 1474

Meckel's diverticulum, First Impressions, 1083

Mediastinum
improved staging in lung cancer, "fusion" of CT and radiolabeled antibody SPECT, 798(ab)
radiographic methods, residual Hodgkin's disease, 793(ab)

Medicare
fiscal year 1991 budget, N15A(6)
technical component payment cap proposal, N23A(3)

Melanoma

melanocyte-stimulating hormone, conjugation, monoclonal anti-T-cell antibody, 854(ab)
metastatic, prior and after therapy, F-18 deoxyglucose PET, 804(ab)
mouse, tumor imaging and biodistribution, non-specific proteins, 853(ab)
ocular
I-123 IMP and SPECT imaging, 375
SPECT *vs.* planar immunoscintigraphy, Tc-99m F(ab')$_2$ fragments, 854(ab)
Tc-99m monoclonal antibody, use in patients before lymphadenectomy, 1586(ab)
Memory, performance, resting state brain glucose utilization, young and old subjects, 879(ab)
Menstruation, osteoporosis in women with eating disorders, 325
Mesothelioma
gallium scanning, 794(ab)
malignant pleural, F-18 deoxyglucose PET, 1585(ab)
Metaiodobenzylguanidine, mechanisms of β-adrenergic desensitization, congestive heart failure, 726(ab)
Metal, chelates, attachment to a protein, stability constants, 480, 1744(le)
Metastasis
bone
radioimmune imaging of marrow, primary breast cancer, 1450
samarium-153 EDTMP, clinical effects, 586
Sr-89, prostatic and breast carcinoma, 804(ab)
colon cancer, radioimmunotherapy, nude mouse model, 765(ab)
colorectal carcinoma, modulated fluorouracil chemotherapy, PET, 803(ab)
hepatic and pulmonary, monoclonal antibody localization, critical factors, 754(ab)
liver
antibody uptake, autoradiography, 855(ab)
F-18 uracil PET, colorectal carcinoma, 888(ab)
uptake of I-131 monoclonal antibodies, SPECT, 873(ab)
localization of pulmonary human sarcoma xenografts, In-111 monoclonal antibodies, 1378
mediastinal lymph node, lung cancer, Tl-201 SPECT, 889(ab)
melanoma, prior and after therapy, F-18 deoxyglucose PET, 804(ab)
osseous spinal, accuracy, bone scintigraphy, 931(ab)
ovarian cancer, I-124 monoclonal antibody PET, 764(ab)
prostate and breast cancer, Sr-89 therapy, bone marrow scanning, 938(ab)
skeletal, bone scan abnormalities, breast cancer, 387
soft tissue osteogenic sarcoma, scintigraphy, 679
soft tissue sarcoma, gallium scanning, 794(ab)
thyroid cancer, quantitation, radioiodine therapy, 784(ab)
tumor, infection, multifocal skeletal uptake of labeled leukocytes, 1543
Methoxy phenyl isothiocyanate, activated, conjugation technique, radiodinated proteins, 907(ab)
β-Methyl heptadecanoic acid
distribution, C-11 palmitic acid, human liver, 848(ab)
metabolism in perfused rat heart and liver, 1823
Metoprolol, cardiac adrenergic innervation, MIBG, doxorubicin-induced myocardial damage, 833(ab)
Micro-autoradiography, F-18 fluorodeoxyglucose, 885(ab)
Micrometastases, dosimetry feasibility, radioimmunotherapy, 788(ab)
Milk, breast, excretion of radioactivity, 978
Mineralization, rat tibial bone repair, technetium uptake, 2011
Mitochondria
encephalomyopathy, HMPAO-SPECT, Alzheimer-type dementia, 1740
localization of Tc-99m MIBI, electron probe X-ray microanalysis, chick heart cells, 748(ab)
metabolic inhibitors and ionophores, Tc-MIBI accumulation, chick myocytes, 736(ab)
oxidative substrate flux, myocardial blood flow, chronically ischemic myocardium, 840(ab)
plasma membrane potentials and, hexakis (2-methoxyisobutylisonitrile)technetium(I) accumulation, mouse fibroblasts, 1646
Tc-MIBI, pitfalls of tissue fractionation, 832(ab)
Mitral stenosis, cardiac blood-pool imaging, 10
MK-329, gastric emptying in cats, 1494
Monoamine oxidase
inhibitors, positron-labeled, 1592(ab)
synthesis of β-[F-18]fluoromethylene-*m*-tyrosine derivatives, 1593(ab)
Monoclonal antibodies
antibody-guided tumor detection, avidin-biotin system, CEA-positive patients, 735(ab)
anti-CEA, anti-idiotype second antibody, enhanced clearance, 854(ab)
anti-fibrin GC4, thrombus imaging, 1048
antimyosin Fab, target localization, isothiocyanatobenzyl-DTPA, 211
anti-T-cell, conjugation to melanocyte-stimulating hormone, melanoma, 854(ab)
B72.3
in vivo fate, 1143
in vivo fate, colorectal cancer, 1133
Tc-99m bato-isothiocyanates labeling, 747(ab)
beta camera for static and dynamic imaging, charged-particle emitting radionuclides, biologic samples, 2058
biotinylated, tumor targeting, ovarian cancer and streptavidin, 735(ab)
bismuth-labeled, cell survival curves, SQ20B cell irradiation, 788(ab)
cold antibody titration, HAMA, 854(ab)
different antigenic natures of CA-125 antigen, apparently healthy individuals, 895(ab)
distribution in man, mathematical modeling, 1589(ab)
human/mouse chimeric, common acute lymphocytic leukemia antigen, 1077
I-125 anti-epidermal growth factor receptor, cytotoxicity, 845(ab)
I-131 labeled chimeric, body distribution, 850(ab)
I-131 TNT-1 F(ab')$_2$, immunoscintigraphy, 735(ab)
image quantitation, buildup factor, 783(ab)
In-111 B72.3-GYK-DTPA, radiation dosimetry model, colorectal cancer, 787(ab)
In-111 DTPA-labeled, liver uptake, 1084
In-111 OV-TL 3 F(ab')$_2$, 735(ab)
In-111 spaced-poly-L-lysine-DTPA-antibody synthesis, 906(ab)
labeling with Y-90, P-NH$_2$-BZ-DOTA-3A chelate agent, 824(ab)
localization in hepatic and pulmonary metastases, critical factors, 754(ab)
modeling analysis of distribution in tumors, binding site barrier, 851(ab)
murine
epidermal growth factor receptor, glioma, 849(ab)
erroneous Ca-125 values, HAMA in serum, 715(ab)
syngeneic and xenogeneic tumor models, 1028
nonantigen-specific tissue localization, 1438(le)
nonspecifically-specific, 1066
novel bioconjugation chemistry, 904(ab)
percolation through tumors, modeling analysis, 1191
polymer formation to DTPA modification, immunoreactivity, 905(ab)
radiohalogenation, N-succinimidyl-5-(tri-*n*-butylstannyl)pyridine-3-carboxylate, 776(ab)
radioiodination, ATE and Bolton-Hunter methods, 757(ab)
radiolabeled
hepatocyte recognition and uptake, 755(ab)
inhibition of autoradiolysis, cryopreservation, 84
nonuniform distribution in tumor, 1252(le)
volumetric correlation, SPECT and CT images, 872(ab)
radiolabeled anti-P97 Fab fragment, immunoreactivity, biodistribution, 202
radiolabeled anti-ras p21, immunoscintigraphy, human tumors transplanted in nude mice, 1520
radiolabeled reagents, preparation and comparative evaluation, 906(ab)
radiolabeling of fragments, Tc-99m, one-vial kit, 905(ab)
Re-186, urinary catabolites, 823(ab)
reactive with TAG-72, radioimmunotherapy, 765(ab)
reduction-mediated Tc-99m labeling, 692
status, N15A(12)
successful radioimmunotherapy, lymphoma, 724(ab)
SV2-61r, overexpression, c-*erb*B-2 proto-oncogene, 850(ab)
Tc-99m single chain antibody Fv fragment, characterization and biodistribution, 776(ab)
thrombus imaging, 1055
TNT-1
diffusion and binding, multicellular tumor spheroids, 758(ab)
Lym-1 and, autoradiography, 1059
uptake, 1434(le)
uptake by neuroblastoma xenografts, MIBG comparison, 741(ab)
Monte Carlo
attenuation correction in SPECT, transmission studies, build-up functions, 493
BaF$_2$ detectors, UW SP3000 TOF PET system, 863(ab)
estimation, collimator design optimization, ML estimation, 728(ab)
simulation, high resolution anthroporomorphic phantom, 729(ab)
simulation of Compton scatter distribution function, uniform scattering media, 869(ab)
nonuniform scattering media, 869(ab)
Multiple sclerosis, PET metabolic findings, 741(ab)
Muscle
blood flow response to functional electrical stimulation, spinal cord injury, xenon-in-saline wash-out method, 818(ab)
papillary, dysfunction, dipyridamole-thallium

imaging, 124(le)
Musculoskeletal tumors, correlation of FDG uptake, tumor grade, 756(ab)
Myelodysplasia, bone marrow imaging, MRI and In-111 chloride scintigraphy, 752(ab)
Myocardial infarction
acute
beta-adrenergic blockade, radionuclide ventriculography, 557
In-111 antimyosin and TlCl-201 SPECT, 783(ab)
oxidative and glycolytic metabolic tissue, dynamic PET, 774(ab)
single gamma camera first pass radionuclide angiography, 933(ab)
age of, quantitative assessment, antimyosin images, 782(ab)
alterations in global and regional left ventricular function, gated tomographic radionuclide ventriculography, 753(ab)
C-14 deoxyglucose accumulation, 835(ab)
delayed recovery, thallium perfusion, successful PTCA, 763(ab)
detection of ischemia, Tl-201 reinjection *vs.* redistribution, 743(ab)
determination of infarct size, cardiac perfusion tomography, 1590(ab)
F-18 FDG and I-123 oPPA, Tl-201 uptake, comparative study, 803(ab)
highlights of EANM Congress, N15A(10)
new quantitative Tl-201 SPECT criteria, 812(ab)
nuclear imaging, Tc-99m glucaric acid, 785(ab)
perfusion, mental stress, Tc-99m MIBI, 934(ab)
predictive value of In-111 antimyosin scintigraphy, ischemic events, 782(ab)
predictors of delayed redistribution, early "fixed" defects, exercise SPECT thallium imaging, 764(ab)
quantification of size, gated Tc-99m MIBI tomography SPECT, 832(ab)
reduction of infarct size, thrombolytic therapy, Gd-DTPA enhanced MRI, 717(ab)
residual ischemia, Tc-99m exercise first pass ventriculography, 840(ab)
residual viability, planar imaging, myocardial glucose metabolism, 842(ab)
serum myosin light chain I, compared to In-111 antimyosin monoclonal antibody, 714(ab)
streptokinase-treated patients, gated blood pool tomographic detection, ejection fraction, 842(ab)
thrombolytic therapy, Tc-99m MIBI SPECT, myocardial salvage, 839(ab)
tissue concentration, deoxyglucose and sodium, 833(ab)
transmural, recognition of viable myocardium, I-123 IPPA, 1582(ab)
Myocardial ischemia
after infarction, Tl-201 reinjection *vs.* redistribution, 743(ab)
cocaine-induced, Tl-201 imaging, 834(ab)
coronary flow, PCr/Pi ratio, 31P-MRS, 946(ab)
detection of viable myocardium, coronary disease, Tl-201 injection, 743(ab)
dipyridamole-induced perfusion defects, post-exercise fluorodeoxyglucose PET, 722(ab)
disease progression in previously normal vessels, coronary angioplasty, 836(ab)
dual-tracer autoradiography, Tc-99m MIBI and Tl-201, 832(ab)
during PTCA, perfusion imaging, 840(ab)
early net myocardial extraction, C-11 acetate, oxidative substrate flux, 842(ab)
initial and delayed post-exercise images, Tc-99m SESTAMIBI, 828(ab)
metabolic marker, I-123 IVM, 833(ab)
myocardial preservation, trifluoperazine, 796(ab)
neuronal injury, C-11 HED compared to I-131 MIBG, 725(ab)
nonuniformity in myocardial accumulation, F-18 fluorodeoxyglucose, normal fasted humans, 1749
occlusive and pacing-induced ischemic stress, SQ30,217 kinetics, 785(ab)
predictive value of In-111 antimyosin scintigraphy, first myocardial infarction, 782(ab)
reversible, reinjection Tl-201 SPECT, delayed imaging, 743(ab)
silent, quantitative SPECT thallium imaging, 812(ab)
sympathetic nervous system, F-18 metaraminol, 1352
Tc-99m MIBI exercise first pass ventriculography, SPECT myocardial perfusion, infarction, 840(ab)
transient, regional sympathetic denervation, coronary artery disease, 793(ab)
wall motion analysis, 3-D gated radionuclide ventriculograms, 838(ab)
Myocarditis, rheumatic, In-111 monoclonal antimyosin antibody, 841(ab)
Myocardium
accumulation of I-125 BMIPP, relation to ATP concentration, 1818
acute infarction
evaluation of residual viability, 225
"hot spot" imaging agents, 143
adenosine-SPECT Tl-201 imaging, 723(ab)
β-adrenergic receptor studies, I-123 prenalterol SPECT, 899(ab)
attenuation correction, misalignment, transmission and emission PET, 736(ab)
blood flow
dysfunctioning collateral-dependent myocardium, 843(ab)
iodophenylpentadecanoic acid, exercise with coronary occlusion, 99
N-13 ammonia PET, factor analysis, 802(ab)
noninvasive quantification, collateral circulation, 271
O-15 water *vs.* N-13 ammonia, 1431(le)
optimal dynamic SPECT data acquisition protocols, 718(ab)
validation, N-13 ammonia, 1335
C-11 acetate, compartmental model, delineation, 777(ab)
chick cells, metabolic inhibition, Tc-99m MIBI kinetics, 464
chronically ischemic, mitochondrial oxidative substrate flux, blood flow, 840(ab)
clearance kinetics, Tc-99m SQ30217, 1183
count density, stress *vs.* adenosine Tl-201 SPECT studies, 837(ab)
Cu-62 pyruvaldehyde *bis*(*N*⁴-methylthiosemicarbazonato)copper(II), tracer for PET, 1989
decreased uptake of iodinated methyl-branched fatty acid, inhibition of ATP synthesis, 708(ab)
doxorubicin-induced damage, cardiac adrenergic innervation, MIBG and metoprolol, 833(ab)
extraction of Tc-99m-labeled BATO derivatives, SQ30217 and SQ32014, thallium, 67
fatty acid and perfusion changes, cardiomyopathic hamsters, 1580(ab)
Ga-68 BAT-TECH
biodistribution, 1635
perfusion agent, PET, 727(ab)
gated SPECT images, 3-D volume perspective view, 871(ab)
glucose metabolism
I-123 IHA-16, esterification and oxidation, 640
insulin and free fatty acid levels, FDG-PET, 802(ab)
infarction
In-111 antimyosin antibody, 136
In-111 antimyosin images, triphenyl tetrazolium chloride, 231
ischemic *vs.* normal, Rb-82 and O-15 water, PET, 802(ab)
limited perfusion reserve, left ventricular hypertrophy, 255
metabolic fate of N-13 ammonia, human and canine blood, 163
metabolic rate of oxygen, O-15 water and PET, 736(ab)
necrosis, left ventricular function, In-111 antimyosin, 841(ab)
nonuniformity in accumulation, F-18 fluorodeoxyglucose, normal fasted humans, 1749
O-15 water PET, factor analysis, without blood pool scan, 861(ab)
oxidative metabolism
chest pain and normal coronary arteries, PET, 713(ab)
three-dimensional assessment, PET-derived C-11 acetate kinetics, 1876
tracer, C-11 acetate, 1581(ab)
oxygen consumption
idiopathic dilated cardiomyopathy, 773(ab)
three-dimensional functional images, positron tomography, 2064
perfusion
bull's eye polar map, Tl-201 SPECT, 808(ab)
cations, Tc-99m, 907(ab)
defect and severity, Tc-99m RP-30 and Tl-201 SPECT, 735(ab)
defects, Tl-201 SPECT reversibility bull's eye, 1240
left ventricular wall motion, Tc-99m MIBI and angina, 457
Mallinckrodt Fellowship, Martha J. Senneff, N24A(6)
multicenter trial, Tc-99m teboroxime, 827(ab)
N-13 ammonia PET, error analysis, 862(ab)
preliminary evaluation, SPECT and PET, 1581(ab)
prone imaging, TL-201 SPECT, 812(ab)
radial long-axis tomography, Tl-201 SPECT, 808(ab)
Rb-82 PET, α2 receptor agonists, 841(ab)
Rb-82 PET, Tl-201 SPECT, 802(ab)
SESTAMIBI, blinded evaluation, 827(ab)
SESTAMIBI, function, 820(ab)
SESTAMIBI, quantitation, 858(ab)
SPECT, probability of coronary lesion, 797(ab)
three-dimensional SPECT, 808(ab)
Tl-201 SPECT, Wiener filtering, 1230
ventricular function and, gated MIBI perfusion tomograms, 859(ab)
perfusion scintigraphy, late redistribution predictors, viability, 764(ab)
planar Tc-99m SESTAMIBI perfusion, quantitative analysis, modified background

subtraction, 1400
potential imaging agents, cationic Tc-99m complexes, 748(ab)
preservation after low flow ischemia, trifluoperazine, 796(ab)
radioactivity, correction for underestimation, partial volume defect in PET, 737(ab)
redistribution of Tc-99m SESTAMIBI, 1059
regional anaerobic glycolysis, PET, "non-critical" coronary artery disease, 821(ab)
regional metabolism, quantification of patterns, 835(ab)
release of unexpected metabolite, radioiodinated BMIPP, 896(ab)
reperfused
substrate level dependence, glucose metabolism, 795(ab)
sustained metabolic abnormalities, 795(ab)
reperfusion injury
dual radiolabeled antimyosin imaging, membrane stabilizing agent, 805(ab)
Tc-99m glucarate, 795(ab)
revascularization, functional recovery, glucose and oxidative metabolism, 773(ab)
serial changes in perfusion, tomographic Tc-99m SESTAMIBI, reperfusion therapy in infarction, 1269
stress-induced Tl-201 perfusion defects, reversibility, 1761
stunned
antimyosin uptake, 795(ab)
inotropic stimulation, blood flow and oxidative metabolism, 713(ab)
persistence of perfusion, functional reserve capacity, 794(ab)
sympathetic nervous activity, regional abnormality, hypertrophic cardiomyopathy, 792(ab)
target localization, monoclonal antimyosin Fab, isothiocyanatobenzyl-DTPA, 211
Tc-99m(III), nonreducible perfusion tracer, 834(ab)
Tc-99m new imaging agents, 747(ab)
Tc-99m SESTAMIBI SPECT processing, interobserver and intraobserver reproducibility, 1582(ab)
timing of SPECT imaging, stress Tl-201 studies, 813(ab)
tissue viability, PET assessment, 801(ab)
Tl-201 scintigraphy, 1168, 1390
Tl-201 tomography, rotating slant-hole collimator, large number of projections, 1682
tracer kinetics in animals and man, double-labeled $^{123}/^{131}$I, oPPA and pPPA, 1608
uptake of I-123 MIBG, chronic hypoxia, comparison with normoxia, 726(ab)
uptake of In-111 antimyosin, acute subendocardial infarction, 1851
viability definition, rabbit heart, 934(ab)
viability evaluation, Tl-201 reinjection method, 743(ab)
viable
I-123 IPPA, transmural myocardial infarction, 1582(ab)
ischemia and coronary disease, Tl-201 injection, 743(ab)
wall thickening, quantitation, Tc-99m MIBI, 173
Myocytes, Tc-MIBI accumulation, mitochondrial metabolic inhibitors, ionophores, 736(ab)
Myosin light chain I, serum, myocardial infarction, compared to In-111 antimyosin monoclonal antibody, 714(ab)

N

Naloxone, cerebral blood flow, complex partial seizures, 710(ab)
National Cancer Institute (NCI), radiation discharges and cancer mortality, no link, N11A(11)
National Emission Standards for Hazardous Air Pollutants (NESHAP), sixty-day stay, N27A(10)
National Institutes of Health (NIH), SPECT conference, N30A(7)
National Nuclear Data Center (NNDC), radiation dose calculations, evaluated nuclear structure data file, 948(ab)
NCQ 298, D2 dopamine receptors, 796(ab)
Necrosis, myocardial, left ventricular function, In-111 antimyosin, 841(ab)
Neonate, hyperbilirubinemia, differential diagnosis, Tc-99m DISIDA, 742(ab)
Neoplasms, childhood, thallium scintigraphy, 938(ab)
Neopterin, I-125 radioimmunoassay, 714(ab)
Nerve, heart neuronal imaging, C-11 *meta*-hydroxyephedrine, false transmitter agent, 1328
Neuroblastoma
controversy, nuclear medicine investigation, 135
I-125 MIBG, 1479
alternative therapeutic radiolabel, 804(ab)
skeletal studies, pitfalls, 129
treatment and diagnosis, I-131 3F8, 742(ab)
xenografts, MIBG and monoclonal antibody uptake, 741(ab)
Neurons
heart imaging, C-11 *meta*-hydroxyephedrine, false transmitter agent, 1328
motor neuron disease, progressive dementia, cerebral blood flow imaging, 688
presynaptic dopamine, trappable tracer, F-18 fluoro-MDL 72394, 902(ab)
Neuropathic osteoarthropathy, In-111 leukocyte/Tc-99m MDP bone and MRI, osteomyelitis, 549
Neuropsychiatric illness, C-11 NMSP PET, dopamine and serotonin receptors, 809(ab)
Neuropsychology, correlates, PET, AIDS, 1584(ab)
Neuroreceptors
concentration from single SPECT or PET image, estimation, 865(ab)
effects of clustering, ligand binding kinetics, PET, 709(ab)
Neurotransmitter, cardiac adrenergic activity, MIBG assessment, altitude hypoxia, 34
Niemeier classification, gallbladder perforation, T4
Nitrogen-13 ammonia
metabolic fate in human and canine blood, 163
PET, error analysis, myocardial perfusion calculations, 862(ab)
regional myocardial blood flow
O-15 water and, 1431(le)
PET, factor analysis, 802(ab)
validation, 1335
Nitroimidazole, iodinated, imaging of hypoxic tissue, 756(ab)
2-Nitroimidazole, 4-fluorobenzylamine conjugate, potential hypoxia imaging agent, 815(ab)
Norepinephrine, -induced left ventricular dysfunction, 1580(ab)
Nose, nasal radioiodine activity, 52
Nuclear magnetic resonance
adjunctive role of nuclear medicine, cardiac pathology, 934(ab)
bone marrow imaging, myelodysplasia, aplastic anemia, 752(ab)
diagnosis of pulmonary embolism, 721(ab)
F-18 deoxyglucose imaging, spinal cord tumor, 360
Fe-59 plasma, whole-body clearance, ferrosomes, 717(ab)
Gd-DTPA enhanced, reduction of infarct size, thrombolytic therapy, 717(ab)
Gd(PAHIDA) complex, kidney, 717(ab)
I-123 MIBG, functioning paragangliomas, 935(ab)
In-111 leukocyte/Tc-99m MDP, osteomyelitis, neuropathic osteoarthropathy, 549
MRI, correction of PET data, atrophy effects, 816(ab)
osmolal MR contrast medium, ongoing clinical trials, Gd(HP-DO3A), 1591(ab)
P-31, perfusion and oxygenation of 9L tumor, BCNU treatment, 717(ab)
PCr/Pi ratio, coronary flow, ischemia, 946(ab)
PET and, mesial temporal sclerosis, partial complex epilepsy, 880(ab)
postive and negative oral contrast, 946(ab)
principal axes transformation, method for image registration, 1717
regional spread of breast cancer, mammary lymphoscintigraphy, 745(ab)
SPECT and, CNS systemic lupus erythematosus, brain, 876(ab)
superparamagnetic ferrosomes, lung parenchyma, 718(ab)
three-dimensional cortical surface display-PET and analysis, 865(ab)
three-dimensional surface MR image, combination of PET, 817(ab)
Tl-201 scintigraphy and, thyroid carcinoma, 1958
white blood cell scintigraphy and, chronic osteomyelitis, 711(ab)
Nuclear medicine
adjunctive role, cardiac pathology, MR images and echocardiograms, 934(ab)
computerized report generation with hypercard, 941(ab)
departments
cost effectiveness, 857(ab)
impact of local area networking, productivity, 856(ab)
experience with Microvax digital image archive, 942(ab)
fully computerized laboratory, model, 943(ab)
inauguration of technology school, different approach to recruitment, 948(ab)
quantitation, 1986
tracer analysis, peripheral organ distribution volume, mammillary systems, 1702
Nuclear Medicine Technologist Certification Board (NMTCB), recognition of ARRT and ASCP certifications, N30A(5)
Nuclear Medicine Week 1990
fifth annual, N26A(4), N30A(5)
Nuclear Regulatory Commission (NRC)
ACUI meeting, first time in two years, N23A(10)
amendment of licensee reporting requirements, N27A(10)
application by Utah, additional waste disposal authority, N26A(4)
Barry Siegal appointed Chairman of ACMUI, N37A(6)
DOT and, hazardous transport rules, N27A(11)
exemption of very low-level radioactive waste, N24A(9)
funding plans for decommissioning by labs,

N31A(7)
interim rule, medical use of radionuclides, N20A(11)
legislation on dual regulation of licensees pending, N29A(2)
new member, N15A(6)
petition to change 10 CFR Part 35, N15A(6)
QA regulations, N15A(6)
quality assurance rule, N22A(4)
radiation doses for nuclear power workers, decline of, N25A(11)
seeks data on impact of lower dose limits, N32A(9)
set up of Fellows program, N31A(8)
training and experience, N15A(6)
Nuclear Waste Technical Review Board (NWTRB), Yucca Mountain HLRW site, N31A(7)

O

Oak Ridge National Laboratory
resumption of medical radioisotope production, N30A(8)
stops production and distribution, yttrium-90, N18A(5)
Obsessive-compulsive disorder
cerebral blood flow, SPECT, 750(ab)
metabolic activity, N24A(8)
Tc-99m D,L-HMPAO SPECT, 750(ab)
Obstructive carotid disease, chronic, cerebral blood volume SPECT, DIAMOX cerebral blood flow SPECT, 877(ab)
Oncology, highlights of EANM Congress, N15A(10)
Oralpharyngeal disorders, post-traumatic, radionuclide evaluation, 774(ab)
Orthopedics, implant sepsis, In-111 leukocyte and Tc-99m sulfur colloid imaging, 712(ab)
Osmium-191, impurity in Ir-191m generator eluates, biologic behavior, pH adjustment agents, 523
Osteocalcin, serum measurements, prostate carcinoma, skeletal deposits, 1486
Osteomyelitis
canine model, In-111 nonspecific polyclonal IgG, In-111 leukocytes, 811(ab)
chronic, MRI and white blood cell scintigraphy, 711(ab)
chronic recurrent multifocal, Tc-99m MDP bone imaging, 938(ab)
diabetics with pedal ulcers, In-111 leukocytes, 3-phase bone imaging, 890(ab)
indium white blood cells scan, 2029
In-111 leukocyte/Tc-99m MDP bone and MRI, neuropathic osteoarthropathy, 549
suspected, systemic evaluation, algorithm, 932(ab)
Tc-99m albumin colloid WBC *vs.* In-111 WBC, 890(ab)
vertebral, In-111 leukocyte imaging, 711(ab)
Osteoporosis
dual-photon absortiometry, cyclic phosphate, etidronate and calcium therapy, 752(ab)
women with eating disorders, 325
Ovarian cancer, *see also* Carcinoma, ovarian
immunoscintigraphy, In-111 OV-TL 3 F(ab')^2 monoclonal antibody, 1802
In-111 OV-TL 3 F(ab')$_2$, 734(ab)
intraperitoneal radioimmunotherapy, Y-90 GKY-DTPA-B72.3 antibody, 724(ab)
metastases, I-124 monoclonal antibody PET, nude rat model, 764(ab)
tumor targeting, biotinylated monoclonal antibodies, streptavidin, 735(ab)
Oxamniquine, acute schistosomiasis treatment, scintigraphy, 1583(ab)
Oxygen
CMR_{O2} measurement in PET, weighted integration, CBV correction, 861(ab)
consumption in brain
direct determination, PET, 882(ab)
myocardium, 3-D positron tomography, 2064
metabolism
functional recovery, myocardial revascularization, 773(ab)
regional variation, normal heart, 774(ab)
metabolism and blood flow, inotropic stimulation, stunned myocardium, 713(ab)
myocardial consumption, idiopathic dilated cardiomyopathy, 773(ab)
perfusion of rat 9L tumor after BCNU treatment, P-31 NMR metabolic activation, 717(ab)
Oxygen-15
extraction fraction in tumors, tissue heterogeneity, 756(ab)
residual activity, calculated cerebral blood flow, PET, 861(ab)
Oxygen-15 butanol
PET, cerebral blood flow, human subjects, 884(ab)
routine, automated synthesis, positron tomography, 1727
Oxygen-15 water
cerebral blood flow, test-retest comparison, face matching task, 760(ab)
factor analysis and dynamic PET, without blood pool scan, 861(ab)
PET
myocardial metabolic rate, 736(ab)
noninvasive LV time-activity curve, input function, 778(ab)
Rb-82 and, ischemic *vs.* normal myocardium, 802(ab)
regional chemotherapy, F-18 uracil, 888(ab)
reproducibility, resting cerebral blood flow, 887(ab)
separation of blood time activity curves, labeled metabolites, quantitative tracer PET studies, 708(ab)
simultaneous measurement of CMRO2 and CBF, slow inhalation, dynamic PET, 760(ab)
threshold level, cerebral blood flow, functional activation, 760(ab)
vs. N-13 ammonia, regional myocardial blood flow, 1431(le)

P

Pain
chest, impaired myocardial metabolism, PET, 713(ab)
low back, bone scintigraphy, increased sacroiliac joint uptake, 712(ab)
relief, simple kit for preparation, Re-186 HEDP, 898(ab)
Palmitate, uptake assay, tritium release, heart, 910(ab)
Pancreas
C-11 ethanol PET, 849(ab)
cancer, blood flow imaging by PET, 847(ab)
scintigraphy, I-123 HIPDM SPECT, 1015
Pancreatitis, emphysemous gastritis, In-111 WBC, 112
Panic disorder, treated and untreated, cerebral blood flow, 880(ab)
Paragangliomas, functioning, detection, I-123 MIBG MRI, 935(ab)
Parathyroid
adenoma, technetium-thallium scintigraphy, 935(ab)
highlights of EANM Congress, N15A(10)
pathology, Tl-201 and I-131 toluidine-blue scintigraphy, 790(ab)
scintigraphy, energy spectral analysis method, Tc-99m or Tl-201, 855(ab)
sensitivity of TC/TL imaging, simultaneous dual isotope acquisition technique, 1583(ab)
Tc-99m SESTAMIBI, 790(ab)
Parenchyma
lung, superparamagnetic ferrosomes, MRI, 718(ab)
retention of I-131 OIH or Tc-99m MAG3, transplanted kidneys, 716(ab)
transit times, evaluation, obstructive uropathy, 761(ab)
Parkinson's disease, Parkinsonism and, striatal glucose, dopamine metabolism, 880(ab)
Pediatric patients
acute pyelonephritis, vesicoureteral reflux, P-fimbriated *E. coli*, 742(ab)
calcific discitis, bone scintigraphy, 234
childhood neoplasms, thallium scintigraphy, 938(ab)
clinical significance, I-123 IMP SPECT, 878(ab)
epileptic children treated by callosotomy, cerebral blood flow, SPECT, 893(ab)
fossa brain tumors, FDG-PET, 878(ab)
glomerular filtration rate, scintigraphic estimates, Tc-99m DTPA, 716(ab)
measurement of skin-to-kidney distance, quantitative renography, 287
renal tranplants, blood flow, 580
solid tumors, Ga-67 SPECT studies, 168
unified single-injection, two-sample renal clearance, 912(ab)
ventilation perfusion imbalance, pulmonary atresia, extreme tetralogy of Fallot, 1276
Pelvis, elimination of "hot" bladder artifacts, SPECT, 1872
Penis
blood flow, Xe-133 washout, 246(le)
detection of venous leakage, Xe-133 corporeal clearance, prostaglndin E1, 762(ab)
plethysmography, combined radioisotope, xenon washout, 762(ab)
Pentobarbital, norepinephrine-induced left ventricular dysfunction, 1580(ab)
Pentose phosphate, radiation-induced activation of pathway, rat brain, 844(ab)
Pentoxifylline
dipyridamole-induced coronary hyperemia, 1020
hemodynamic responses and thallium sensitivity, dipyridamole thallium imaging, peripheral vascular disease, 734(ab)
pH, adjustment agents, biologic behavior, Os-191 impurity in Ir-191m generator eluates, 523
Phagocytosis, malignant fibrous histiocytoma, uptake, In-111 leukocytes and Tc-99m sulfur colloid, 1548
Phantoms
dual-window Compton-scatter correction, multiplier dependency, 798(ab)
high resolution anthroporometric, Monte Carlo simulation, 729(ab)
Pheochromocytoma
C-11 HED PET, 745(ab)
I-131 MIBG scans and biochemical analyses, 745(ab)
pentavalent Tc-99m (V)-DMSA uptake, Sipple's

syndrome, 106
perivesicle, I-131 MIBG imaging, 1669
Phosphate, technetium uptake, rat tibial bone repair, 2011
Phosphatidylinositol, measurement of turnover, positron-labeled sn-1,2-diacylglycerol, PET, 738(ab)
Phospholipid analogs, radioiodinated, tumor imaging agents, 708(ab)
Phospholipid ether, radioiodinated, tumor visualization, 332
Phosphorus-31
magnetic resonance spectroscopy, FDG-PET, brain tumors, 302
NMR metabolic activation, perfusion and oxygenation of 9L tumor, BCNU treatment, 717(ab)
Phosphorus-32-colloidal chromic phosphate, treatment of choice, malignant pericardial effusion, 2034
Photons, 140 keV, calculation of coherent scattering, Pb collimator walls, 856(ab)
Placenta, localization in abdominal pregnancy, Tc-99m red blood cells, 1106
Planar imaging
dipyridamole Tc-99m MIBI, first-pass angiocardiography, 821(ab)
immunoscintigraphy, SPECT or, Tc-99m $F(ab')_2$ fragment and ocular melanoma, 854(ab)
myocardial glucose metabolism and perfusion, residual viability, acute myocardial infarction, 842(ab)
SESTAMIBI and issue of tissue crosstalk, 1409
SPECT or, cardiac cath left ventricular end diastolic pressure, 1582(ab)
Tc-99m MIBI scintigrams, quantitative analysis, 828(ab)
Tc-99m MIBI SPECT, coronary artery disease diagnosis, 820(ab)
Tc-99m SESTAMIBI perfusion, quantitative analysis, modified background subtraction, 1400
Plantar fasciitis, three-phase bone scintigraphy, 932(ab)
Plasma
C-11 flumazenil metabolism, 897(ab)
glomerular filtration rate, 424
membrane potentials, hexakis (2-methoxyisobutylisonitrile)technetium(I) accumulation, mouse fibroblasts, 1646
single sample methods
glomerular filtration rate, 716(ab)
Tc-99m MAG_3 clearance, 912(ab)
Plasminogen activator
fragment, radioiodination, clot imaging, 903(ab)
tissue
acitve-site mutant, human clot labeling, 187
In-111, rabbit thrombosis model, 805(ab)
Platelets
Tc-99m monoclonal antibody
acute pulmonary emboli, 805(ab)
in vivo visualization, occlusive arterial thrombi, 713(ab)
partially occlusive thrombi, 805(ab)
Tc-99m synthetic peptides, thrombus imaging, 757(ab)
-thrombus formation rate, heparin bonded polyurethane angio-catheter, In-111 platelets, 891(ab)
Plethysmography, penile, combined radioisotope, xenon washout, 762(ab)
Pneumonia, lower-lobe, hyperfusion, positive end-expiratory pressure, 124(le)
Pneumonitis, interstitial, regional function, radionuclide method, 772(ab)
Polyazacycloalkane-N-acetic DOTA, bismuth complexes of bifunctional DTPA's, 824(ab)
Positron
improved anion exchange resin column, direct nucleophilic F-18 radio fluorination, 1592(ab)
-labeled monoamine oxidase inhibitors, 1592(ab)
Positron emission tomography (PET)
1990 Aebersold Award, Marcus E. Raichle, N26A(5)
1990 Berson-Yalow Award to Dah-Ren Hwang, N19A(6)
accuracy for detecting Alzheimer's disease, 730(ab)
activity-time measurements, high resolution TOF systems, 863(ab)
advances in emission tomography, 628
aryl-substituted F-18 fluoroalkylbenzamides, D-2 studies, 737(ab)
behavioral activation, normal aging and Alzheimer's, 730(ab)
blood-brain barrier permeability, error analysis, Ga-68 EDTA, 860(ab)
blood flow and exchangeable volume of water distribution, breast tumors, 746(ab)
blood flow imaging of pancreatic cancer, 847(ab)
booklet available, N28A(7)
brain applications, N21A(8)
brain glucose metabolism, insulin effect, 879(ab)
C-11 acetate
FDG kinetics, oxidative and glucose metabolism in normal heart, 774(ab)
metabolic performance, pressure and volume loaded heart, 773(ab)
three-dimensional assessment, myocardial oxidative metabolism, 1876
C-11 carfentanil, opiate *mu* receptors, Alzheimer's disease, 770(ab)
C-11 compounds, contribution of labeled carbon dioxide, 909(ab)
C-11 ethanol, pancreas and liver imaging, 849(ab)
C-11 HED, pheochromocytoma, 745(ab)
C-11 MHED, neuronal heart agent, 831(ab)
C-11 NMSP, dopamine and serotonin receptors, neuropsychiatric illness, 809(ab)
C-11 putrescine, human prostate, 762(ab)
C-11 SCH 39166 synthesis, potential D1 dopamine antagonist, 737(ab)
C-11 thymidine
accumulation, primary and metastatic brain tumors, 1585(ab)
hepatic cellular proliferation, 847(ab)
ring-2 and methyl positions, 794(ab)
C-11 tropanyl benzilate, cerebral muscarinic receptors, 779(ab)
C-11 YM-09151-2, D2-dopamine receptor-specific binding, brain, 779(ab)
C-15 water, compared to Tc-99m SPECT, regional cerebral blood flow, 1595
cardiac
3D interpolation algorithms, 1590(ab)
spatially dependent deadtime, 777(ab)
cardiac viability, 1116(le)
cerebral blood flow subtraction, optimal reconstruction filters, 865(ab)
cerebral glucose metabolism, familial inverted chorea, 740(ab)
cerebral oxygen consumption, direct determination, 882(ab)
clinical function following stroke, 1574(le)
clinical studies, expert system, 944(ab)
CMR_{O2} measurement, weighted integration, CBV correction, 861(ab)
combination display, three-dimensional brain surface MR image, 817(ab)
comments needed for Office of Health Technology Assessment, N29A(1)
complex partial epilepsy
bitemporal epidural electroencephalography, preoperative evaluation, 710(ab)
role of neuroimaging, surgical intervention, 1839
concentration of benzodiazepine receptors, 709(ab)
continuous-slice PENN-PET scanner, volume imaging capability, 617
correction for deadtime loss, 2-D modular detectors, 864(ab)
correction for motion distortion, dynamic monitoring, patient position, 816(ab)
correction of data, effects of atrophy, MRI, 816(ab)
Cu-60 PTSM, small cyclotron production, blood flow measurements, 815(ab)
Cu-62 PTSM, production and evaluation, 815(ab)
Cu-62 pyruvaldehyde *bis*(N^4-methylthiosemicarbazonato)copper(II), tracer for cerebral and myocardial perfusion, 1989
demonstration, computer-based interactive educational technique, 944(ab)
design and use of tomographs, 1732
diagnostic approaches, persons at risk, Huntington's disease, 740(ab)
differential diagnosis of lung tumor, T6
Duke experience in 1000 clinical studies, 944(ab)
dynamic
L-[2-F-18] fluorotyrosine uptake, glioma, 799(ab)
software tools, kinetic analysis, 943(ab)
estimation of relative regional neuroreceptor concentration, 865(ab)
F-18
normal aging, whole brain and regional glucose metabolism, 771(ab)
total body and cross-sectional imaging, skeletal system, 780(ab)
F-18 altanserine, serotonin S2 receptors, 1584(ab)
F-18 catecholamines, nucleophilic aromatic substitution reaction, 787(ab)
F-18 deoxyglucose
image-guided phosphorus-31 magnetic resonance spectroscopy, brain tumors, 302
malignant pleural mesothelioma, 1585(ab)
metastatic melanoma, prior and after therapy, 804(ab)
preoperative staging, bronchiogenic carcinoma, 771(ab)
F-18 FDG
advanced head and neck cancer, chemotherapy, 1586(ab)
asymptomatic HIV seropositive subjects, 826(ab)
cancer therapy, 889(ab)
caution, Alzheimer's disease, 740(ab)
chemohormonotherapy, breast carcinoma, 746(ab)
crossed cerebellar diaschisis, stroke, 770(ab)
derivation of indices, local lumped constant variation, 860(ab)

differentiation, residual or recurrent tumors, 803(ab)
dipyridamole-induced myocardial perfusion defects, 722(ab)
early postoperative evaluation, brain tumors, 799(ab)
glucose loading effect, 840(ab)
I.V. insulin injections, diabetics, 933(ab)
myocardial glucose metabolism, insulin and free fatty acid levels, 802(ab)
neuropsychological findings, head injury, 876(ab)
pediatric fossa brain tumors, 878(ab)
primary and metastic breast cancer, 889(ab)
radiation defect differentiation, recurrent brain tumor, 799(ab)
reinjection, Tl-201 SPECT, 742(ab)
residual or recurrent brain tumors, 800(ab)
residual or recurrent tumors, post-treatment changes, 937(ab)
schizophrenia, identical twins, 751(ab)
soft-tissue masses, 746(ab)
Tl-201 SPECT and, brain tumors, 799(ab)
total body imaging, malignancies, 803(ab)
validation studies, dementia syndromes, 740(ab)
F-18 FDOPA, constrained evaluation, dopa decarboxylase, 884(ab)
F-18 flumazenil, mapping, cerebral benzodiazepine receptors, 902(ab)
F-18 fluoride ion, bone metabolic rates, 778(ab)
F-18 2-fluoro-2-deoxy-D-glucose
detection of tumor involvement, lymph nodes, 1831
F-18 2-fluoro-2-deoxy-D-mannose, cerebral glucose utilization, 771(ab)
6-F-18 fluoro-L-fucose, glycoconjugate synthesis in tumors, 1997
F-18 FPMB, dopamine D-2 receptors, 787(ab)
F-18 NCQ 115, 902(ab)
F-18 tetrahydrocannabinol, synthesis and distribution, 902(ab)
F-18 uracil, liver metastases from colorectal carcinoma, 888(ab)
frontal lobe function, regional cerebral blood flow, 750(ab)
functional brain images, correlation methods, alignment, 1220
generator-based perfusion tracers, 1641
generator-produced tracer, cerebral perfusion imaging, Cu-PTSM, 351
graphical method for quantification, *beta* adrenoceptors, heart, 866(ab)
heart, expected value of cash flows, economic analysis, 1893(le)
highlights of EANM Congress, N15A(10)
highlights of the SNM Meeting, N17A(8)
high-resolution, advantages, lead carbonate, 749(ab)
I-124 antibodies, quantitative imaging, 864(ab)
I-124 ICR12, proto-oncogene expression, breast cancer, 777(ab)
I-124 monoclonal antibody, ovarian cancer metastases, 764(ab)
I-124 NCL-6-I, radiotracer for adrenal, 947(ab)
image analysis and observer bias, 864(ab)
image restoration, Bayesian method, 748(ab)
impaired myocardial metabolism, chest pain and normal coronary arteries, 713(ab)
improved technique, investigation of pharmacological interventions, 886(ab)
ligand binding kinetics, effects, neuroreceptor clustering, 709(ab)
ligand design and synthesis, F-18 fluprepid, dopamine D2 receptor, 786(ab)
Mallinckrodt Fellowship, Martha J. Senneff, N24A(6)
measurement noise in plasma curves, model parameter estimates, tracer kinetic studies, 861(ab)
metabolic findings
multiple sclerosis, 741(ab)
optimizing therapy management, unresectable bronchiogenic carcinoma, 766(ab)
metabolites, β-γ-γ flow-through detector, HPLC analysis, 749(ab)
modulated fluorouracil chemotherapy, metastatic colorectal carcinoma, 803(ab)
MRI and, mesial temporal sclerosis, partial complex epilepsy, 880(ab)
MRI-3D-dimensional cortical surface display, 865(ab)
myocardial tissue viability, 801(ab)
N-13 ammonia
error analysis, myocardial perfusion calculations, 862(ab)
regional myocardial blood flow, factor analysis, 802(ab)
validation, regional myocardial blood flow, 1335
neural-network classifier, Alzheimer's disease, 817(ab)
neuropsychologic correlates of AIDS, 1584(ab)
noise and resolution performance, 864(ab)
O-15 butanol, cerebral blood flow, human subjects, 884(ab)
O-15 water
cerebral blood flow, face matching task, 760(ab)
cerebral blood flow, threshold level, 760(ab)
factor analysis, without blood pool scan, 861(ab)
myocardial metabolic rate, 736(ab)
noninvasive LV time-activity curve, input function, 778(ab)
reproducibility, resting cerebral blood flow, 887(ab)
simultaneous measurement, CMRO2 and CBF, 760(ab)
oxidative and glycolytic metabolic tissue, acute infarction, 774(ab)
ovarian cancer metastases, I-124 monoclonal antibody, nude rat model, 764(ab)
paired images, mathematical realignment, pixel-by-pixel subtraction, 816(ab)
partial volume defect, correction for underestimation, myocardial radioactivity, 737(ab)
perfusion abnormalities, cardiac allografts, 841(ab)
perfusion imaging, noninvasive assessment, coronary collaterals, 259
phosphatidylinositol turnover measurement, positron-labeled sn-1,2-diacylglycerol, 738(ab)
preliminary evaluation of myocardial perfusion, 1581(ab)
preparation of C-11 SCH 39166, 737(ab)
principal axes transformation, method for image registration, 1717
production of radionuclides, high-current electrostatic accelerator, targetry, 943(ab)
progestin receptors, breast carcinoma, 746(ab)
program for image alignment, calculated differences, cerebral metabolic rates for glucose, 2052
prostate tumor imaging, 707(ab)
pseudo-Poisson noise model, 863(ab)
quantification of muscarinic receptors, heart, modeling approach, 709(ab)
quantitative tracer studies, separation of blood time activity curves, labeled metabolites, 708(ab)
radial elongation, depth-of-interaction measurement resolution, 749(ab)
radiation therapy evaluation, recurrent colorectal carcinoma, 813(ab)
radioisotope delivery systems, N37A(5)
Rb-81, tumor perfusion, 1307
Rb-82
disruption, hyperosmotic blood-brain barrier, 810(ab)
α2 receptor agonists, myocardial perfusion, 841(ab)
replacement for Tl-201, N25A(8)
Tl-201 SPECT and, myocardial perfusion imaging, 802(ab)
Rb-82 and O-15 water, ischemic *vs.* normal myocardium, 802(ab)
reconstruction, correlated structural images, 748(ab)
regional chemotherapy, liver metastases, F-18 uracil, 888(ab)
regional myocardial anaerobic glycolysis, Tc-99m MIBI SPECT, 821(ab)
registration of nuclear medicine images, 1227
reimbursement, N15A(6)
rotating γ-camera and, comparison, ASPECT system, 871(ab)
scanners, functional brain mapping, metric for activation detectability, 817(ab)
SDIO to fund project, N30A(7)
simultaneous resolution recovery, noise reduction, Fourier filtering, 862(ab)
spatial frequency pattern analysis, normals and schizophrenics, 864(ab)
SPECT and, anatomical correlation, dementia, 885(ab)
SPECT studies of brain tumors, L-3-[I-123] iodo-α-methyl tyrosine, 281
SP-3000 time-of-flight
Monte Carlo investigation, 863(ab)
performance improvements, 863(ab)
spatial frequency pattern analysis, normals and schizophrenics, 864(ab)
S-2 receptor binding, F-18 fluoroethylketanserin, 780(ab)
sympathetic nervous system, cardiomyopathy, 792(ab)
synthesis and investigation, N,N,N′,N′-tetrakis-(2-hydroxy-3,5-dimethylbenzyl)-ethylene, 768(ab)
synthesis of [F-18]N-(4-fluorobenzyl)spiperone, 901(ab)
thorax, 939(ab)
three-dimensional functional images, myocardial oxygen consumption, 2064
time-course data, computer-assisted analysis, 944(ab)
transmission and emission, misalignment, attentuation correction effects in myocardium, 736(ab)
utilization of labeled thymidine, 337
viable from infarcted tissue, vessel patency and Q waves, cardiac wall motion, 774(ab)
whole body imaging evaluation, 749(ab)
without a cyclotron, N25A(8)
Positron tomography, O-15 butanol, routine, automated synthesis, 1727
Posture, upright, gastric emptying, esophageal cancer, 848(ab)
Potassium perchlorate, Tc-99m pertechnetate,

radiation dose estimates, 822(ab)
Pregnancy, abdominal, placental localization, Tc-99m red blood cells, 1106
Pressure, positive end-expiratory, hyperfusion, lower-lobe pneumonia, 124(le)
Probe, beta sensitive intraoperative, 759(ab)
Propylthiouracil, biodistribution of I-131 anti-myeloid antibody, dosimetry, 1384
Prostaglandin E1, venous leakage, Xe-133 corporeal clearance, 762(ab)
Prostate
carcinoma, serum osteocalcin measurements, skeletal deposits, 1486
C-11 putrescine PET, 762(ab)
metastatic cancer, Sr-89 therapy, bone marrow scanning, 938(ab)
tumor imaging, PET, N-(3-[F-18] fluoropropyl)putrescine, 707(ab)
Prostate specific antigen
liquid-phase two-site sandwich radioimmunometric assay, 714(ab)
prostate acid phosphatase and, prostate adenocarcinoma prediction, prostate nodular hyperplasia, 791(ab)
Prostectomy, radical, adenocarcinoma recurrence, bone scans and PSA levels, 751(ab)
Prosthesis
diagnosing joint infection, 1955
In-111 leukocyte activity, total hip arthroplasty, Tc-99m sulfur colloid, 1955
painful hip, Ga-67 citrate arthrography, 830(ab)
Protein
attachment by metal chelates, stability constant determination, 480
dose and volume effects, intraperitoneal antibody delivery, 850(ab)
labeling with Tc-99m, bifunctional aromatic hydrazines, 776(ab)
-losing gastroenteropathy, diagnostic value, In-111 transferrin, 814(ab), 847(ab)
non-specific, tumor imaging and biodistribution, mouse melanoma, 853(ab)
novel method for labeling, F-18, 787(ab)
radioiodination, conjugation technique, activated methoxy phenyl isothiocyanate, 907(ab)
radiolabeled, scintigraphic detection, inflammation foci, 810(ab)
synthesis rate, L-[1-11C]tyrosine validation, four compartment model, 861(ab)
Protein A, preparation of streptavidin-biotinylated antibodies, revelance, complex size to tissue uptake, 904(ab)
Proteinuria, detection of focal lesions, Ga-67 citrate, 512
Proto-oncogenes
c-*erb*B-2, overexpression, detection by SV2-61r monoclonal antibody, 850(ab)
I-124 ICR12 PET, breast cancer, 777(ab)
Psychiatric disorders, 1990 Aebersold Award, Marcus E. Raichle, N26A(5)
Psychometry, Tc-99m HMPAO SPECT and EEG, temporal lobe epilepsy, 881(ab)
PTCA, *see* Angioplasty, coronary
Pulmonary embolism
acute, chest radiograph, scintigraphy, 894(ab)
diagnosis with MRI, 721(ab)
leg Xe imaging, 939(ab)
postatelectatic ventilation-perfusion mismatch, 1397
single perfusion defect and, angiography, 296
Tc-99m monoclonal antibody, activated platelets, 805(ab)
Purpura, idiopathic thrombocytopenic, splenic dynamics, In-111 platelets, 383(le)
Pyelonephritis, acute, vesicoureteral reflux, P-fimbriated *E. coli*, 742(ab)

Q

Quality assurance
ACMUI meeting, first in two years, N23A(10)
reissuance of rule by NRC, N22A(4)

R

Raclopride, N-alkyl fluorination, molecular conformation, electron distribution, 727(ab)
Radiation
defect differentiation from recurrent brain tumor, FDG-PET images, 799(ab)
discharges, cancer mortality and, no link, N11A(11)
health experts' criticism of methodology and presentation, FDA's diagnostic I-131 study, N13A(7)
-induced activation, pentose phosphate pathway, rat brain, 844(ab)
ionizing, BEIR V report, higher risk estimates, N13A(4)
low level ionizing, Newsline Commentary, N17A(7)
protection, radiobiology and, self-study test, 1661, 1692
synovectomy, Ho-166-FHMA, antigen-induced arthritis, 780(ab)
therapy for recurrent colorectal carcinoma, PET evaluation, 813(ab)
workers, revised exposure limits, ICRP, N24A(9)
Radiation dose
calculations, evaluated nuclear structure data file, National Nuclear Data File, 948(ab)
decline for nuclear power workers, N25A(11)
obtaining S values for rectangular-solid tumors, rectangular-solid host organs, 845(ab)
pharmacokinetics data, resolving time, gamma camera, 859(ab)
Radioactive waste
disposal, LLRW compact status, N22A(5)
very low-level, exemption by NRC, N24A(9)
Radioactivity, myocardial, correction for underestimation, partial volume defect in PET, 737(ab)
Radioaerosols, utility of Tc-99m DTPA inhalational scans, artifically ventilated patients, 46
Radiochemicals
purity and reaction yields, I-123 sodium iodide solutions, 947(ab)
serum and supernatant, molecular size and immunoreactivity, Ab-DTPA-In-111, 906(ab)
Radiochemistry, determination of stability constants, metal chelates attached to protein, 480
Radiocolloids
phosphorus-32-colloidal chromic phosphate, malignant pericardial effusion, 2034
scanning compared to immunoscintigraphy, solid tumors and systemic disorders, Tc-99m mAb BW 250/183, 1588(ab)
Radiogallium, uptake in sarcoidosis, distinction of patterns, AIDS, 895(ab)
Radiography
chest, scintigraphy, suspected acute pulmonary embolism, 894(ab)
plane, immunoscintigraphy, bone marrow, 751(ab)
Radiohalogenation, N-succinimidyl-5-(tri-*n*-butylstannyl)pyridine-3-carboxylate, monoclonal antibodies, 776(ab)
Radioimaging, synthesis and characterization of DB III, 757(ab)
Radioimmunoassay
CA-15-3, breast cancer, radiologic and clinical evaluations, 938(ab)
neopterin I-125 evaluation, 714(ab)
Radioimmunoconjugator, radioiodinated maleimide, no-carrier-added preparation, 906(ab)
Radioimmunodetection, bifunctional amide thiolate ligands, Tc-99m Fab, 747(ab)
status, NI5A(12)
Radioimmunoimaging
highlights of EANM Congress, N15A(10)
Quo vadis, 1439(le)
Tc-99m NCA antibodies, bone marrow, breast cancer, 751(ab)
tumor imaging, 1436(le)
Radioimmunoscintigraphy
I-131 anti-CEA monoclonal antibodies, Tl-201 scintigraphy, medullary thyroid carcinoma, 1854
nonspecific uptake, 1438(le)
Radioimmunotherapy
adjunctive use of G-CSF, Y-90 monoclonal antibodies, 904(ab)
B-cell lymphoma, I-131 MB-1 monoclonal antibody, 852(ab)
bismuth complexes of bifunctional DTPA's, polyazacycloalkane-N-acetic DOTA, 824(ab)
buthionine sulfoximine as radiosensitizer, 853(ab)
dosimetric considerations, I-131- and Y-90-labeled anti-CEA antibody, 788(ab)
dosimetry feasibility, micrometastases, 788(ab)
evaluation of remote radioiodination system, 508
granulocyte colony-stimulating factor, Y-90 monoclonal antibodies, 849(ab)
human colon cancer metastases, nude mouse model, 765(ab)
I-131 monoclonal antibody $F(ab')_2$ fragments, human colon carcinoma grafted in nude mice, 1035
interferon enhancement, colon carcinoma, 850(ab)
intraperitoneal, Y-90-GKY-DTPA-B72.3 antibody, ovarian cancer, 724(ab)
intravenously injected radiolabeled antibody, micronucleus assay, liver cells, 844(ab)
monoclonal antibodies reactive with TAG-72, 765(ab)
multiple course, enhanced anti-tumor effect, bifunctional antibody, 911(ab)
non-Hodgkin's lymphoma, 724(ab)
nonuniformity of tumor dose, 75
NR-LU-10, model system, breast carcinoma, 852(ab)
pharmacokinetics data and radiation absorbed doses, resolving time, gamma camera, 859(ab)
pretreatment imaging techniques, 942(ab)
radiobiological response, dose heterogeneity, 783(ab)
Re-186 antibodies and $F(ab)'_2$ fragments, chemistry of, animals and man, 823(ab)
remaining body activity correction, calculation of dose, 822(ab)
squamous transformation, colon cancer xenografts, 765(ab)
status, N15A(12)
successful, monoclonal antibody, lymphoma, 724(ab)
Y-90 monoclonal antibody, multifocal cancer,

911(ab)
Radioiodination
BMIPP, release, unexpected myocardial metabolite, 896(ab)
management of hyperthyroidism, iopanoic acid, 1180
monoclonal antibodies, ATE and Bolton-Hunter methods, 757(ab)
nasal activity, 52
phospholipid analogs, tumor imaging agents, 708(ab)
phospholipid ether, tumor visualization, 332
proteins, conjugation technique, activated methoxy phenyl isothiocyanate, 907(ab)
quantitation, metastatic thyroid cancer, 784(ab)
remote system, evaluation, radioimmunotherapy, 508
Radioisotopes
delivery systems, PET, N37A(5)
medical, resumption of production at HFIR, N30A(8)
needs evaluated by DOE, preparation for future, N13A(3)
penile plethysmography, penile blood flow, xenon washout, 762(ab)
pulmonary lobectomy, 594
Radiolabeled Blood Elements, international society formed, N29A(1)
Radiology Relative Value Scale, exemption, N14A(6)
Radiometallic nuclides, novel bioconjugation chemistry, 904(ab)
Radionuclides
angiocardiography, 1300
charged-particle emitting
beta camera, static and dynamic imaging, 2058
improved imaging detector, 1589(ab)
clean air legislation, N14A(6)
detection of primary pulmonary osteogenic sarcoma, 1110
emission regulations by EPA, N29A(2)
esophageal transit study, motor dysfunction, compared to manometry, 1921
first pass study and sulfur colloid, renal failure, transplantation, 912(ab)
imaging, intraperitoneal urine leak, renal transplant, 1206
imaging of joint inflammation, 684
medical use of, interim rule, NRC, N20A(11)
portal hemodynamic changes, sclerotherapy, esophageal varices, 813(ab)
post-traumatic oralpharyngeal disorders, 774(ab)
production for PET, high-current electrostatic accelerator, targetry, 943(ab)
regional function of chronic interstitial pneumonitis, 772(ab)
use in immunodetection, immunotherapy, N15A(12)
xenon-127m, applications in nuclear medicine, 489
Radiopharmaceuticals
applications in marine animals, 831(ab)
biorouting/performance, pharmacologic alterations, cardiac imaging, 933(ab)
bone-seeking, nonosseous uptake, 931(ab)
chelated metallic radionuclides and chelating agents, endotoxin testing, limulus amoebocyte lysate, 243
computer-controlled dispensing system, reduction, personnel radiation exposure, 948(ab)
copper-62, blood-pool imaging, 727(ab)
cyclosporin A cardiotoxicity, correlation, histopathological finding, 834(ab)
evaluation of Boston Harbor winter flounder, 736(ab)
factors in variable quality of Tc-99m HMPAO images, brain, 118
inhomogenous deposition, cellular level, 1358
in-house labeled, automated quality control, 946(ab)
plasma free fraction, concentration-dependence, tracer kinetic modeling, 809(ab)
praise of red blood cells, 2044
reactor production and specialty handling, Curie quantities, beta emitters, 947(ab)
sex-dependent differences, *N*-(3-[F-18]fluoropropyl)-*N*-nordiprenorphine, 192
uptake in brain, ultra-high resolution SPECT collimator, 870(ab)
Radiopharmacology, tissue localization, In-111 substances, Auger electron dosimetry, 1591(ab)
Radiosynthesis, fluorotamoxifen analogs, 903(ab)
Radiotherapeutic agents, auger electron emitting Adriamycin analogues, 900(ab)
Radiotracers
non-invasive imaging, experimental arthritis, rabbits, 781(ab)
selective, cholinergic synaptic vesicle, Alzheimer's disease, 797(ab)
Raichle, Marcus E., 1990 Aebersold Award, N25A(5)
Reactor, restart at Oak Ridge National Laboratory, N22A(3)
Reagents, radiolabeled, monoclonal antibody labeling, 906(ab)
Receiver operating characteristics (ROC)
cone beam and parallel beam collimators, 718(ab)
iterative maximum likelihood-EM reconstruction, SPECT, 739(ab)
Receptors
α2 agonists, Rb-82 PET, myocardial perfusion, 841(ab)
benzodiazepine
cerebral mapping, F-18 flumazenil PET, 902(ab)
concentration, C-11 Ro 15-1788/PET/tracer kinetics, 709(ab)
I-123 Ro 16-0154 SPECT, 1007
primate brain, SPECT, 779(ab)
beta adrenergic
congestive heart failure, MIBG, 726(ab)
density and receptor-ligand affinity, rat heart, 709(ab)
central muscarinic, I-125 DEX ligands, atropine effects, 886(ab)
cocaine
molecular probe, radioiodinated tropeines, 899(ab)
organ variations, 886(ab)
presynaptic, ligands, 719(ab)
dopamine, I-125 epiderpride, rat brain, 809(ab)
dopamine and serotonin, C-11 NMSP PET, neuropsychiatric illness, 809(ab)
dopamine D-1
imaging, I-123 (R$^+$)TISCH, 708(ab)
preparation of C-11 SCH 39166, PET, 737(ab)
(R$^+$) and S(-)TISCH, 899(ab)
dopamine D-2
aryl-substituted F-18 fluoroalkylbenzamides, PET, 737(ab)
binding in brain, C-11 YM-09151-2 PET, 779(ab)
C-11 and I-125 IBZ, 882(ab)
C-11 NMB, 882(ab)
C-11 raclopride and C-11 NMSP comparison, 1583(ab)
epiderpride, SPECT, 882(ab)
F-18 FPMB, PET radiotracer, 787(ab)
F-18 N-(4-fluorobenzyl)spiperone, PET, 901(ab)
I-123 epiderpride SPECT, 779(ab)
I-123 IBZM in humans, SPECT, 573
I-123 iodolisuride SPECT, 770(ab)
I-123 ISP SPECT, 885(ab)
I-123-/I-125- and unlabelled NCQ 298, 796(ab)
I-125 IBF, 648
iodoethylspiperone, 796(ab)
kit formulation, I-123 IBZM, 899(ab)
ligand, F-18 NCQ 115 PET, 902(ab)
N-C-11 methyl-benperidol, 2015
PET ligand design and synthesis, F-18 fluprepid, 786(ab)
SPECT, primate brain, 883(ab)
epidermal growth factor, glioma, murine monoclonal antibody, 849(ab)
$GABA_A$, antagonist, F-18 FDG brain metabolism, 878(ab)
insulin
defect in liver, type A insulin resistance, 791(ab)
imaging, F-18 insulin, 791(ab)
melatonin, I-125 IMEL binding, rat brain, 883(ab)
muscarinic
C-11 tropanyl benzilate PET, brain, 779(ab)
heart, PET, 709(ab)
muscarinic acetylcholine, ligands, heart homogenates, 897(ab)
muscarinic cholinergic
characterization, I-125 iododexetimide binding, 725(ab)
C-11 tropanyl benzilate binding, modeling alternatives, 709(ab)
opiate, quantification, C-11 diprenorphine binding, 866(ab)
opiate *mu*, C-11 carfentanil and PET, Alzheimer's disease, 770(ab)
progestin, breast carcinoma, PET, 746(ab)
scintigraphy, radioiodinated somatostatin analogue, 1501
serotonin S2
F-18 altanserine PET, 1584(ab)
F-18 fluoroethylketanserin PET, 780(ab)
sigma, ligands, I-125, 797(ab)
Red blood cells
label, Tc-99m enzyme inhibitor, 892(ab)
praise of, 2044
Reflux
single and two-stage radionuclide cystography, 893(ab)
vesicoureteral, acute pyelonephritis, P-fimbriated *E. coli*, 742(ab)
Regional wall motion
automatic quantitative assessment of abnormalities, gated tomographic radionuclide ventriculograms, 824(ab)
cardiac analysis, vessel patency and Q waves, PET viable from PET infarcted tissue, 774(ab)
cardiac LV, comparison of expert images, 825(ab)
3-D surface rendered gated radionuclide ventriculograms, cine slice analysis, coronary angiography, 838(ab)
left ventricular wall motion and myocardial perfusion, Tc-99m MIBI at stress and rest, angina, 457

planar imaging of myocardial glucose metabolism, residual viability, acute myocardial infarction, 842(ab)
radial long-axis tomography, Tl-201 SPECT, myocardial perfusion, 808(ab)
segmental myocardial wall thickening, quantitation, Tc-99m MIBI, 173
significance of fill-in after Tl-201 reinjection, delayed imaging, 1617
Relative Value Scale, SNM/ACNP government relations update, N14A(6)
Renin, plasma assays, renovascular hypertension, 912(ab)
Renography
ACE inhibitor, renovascular hypertension, 912(ab)
captopril, renovascular disease detection, renal transplant, 716(ab)
DTPA, split renal function, mean transit times, 940(ab)
enalaprit-enhanced, renovascular hypertension, rat model, 501
estimation of relative renal function, influence, kidney depth, 1576(le)
quantitative, skin-to-kidney distance, children, 287
three-phase diuretic, detection, obstructive uropathy, 914(ab)
Reperfusion, acute myocardial infarction, evaluation of residual viability, 225
Resource-Based Relative Value Scale (RBRVS), cost-containment, plan in Congress, N13A(1), N14A(6)
Rhabdomyosarcoma, gallium scanning, 794(ab)
Rhenium, -labeled antibodies, generation, direct labeling methods, 905(ab)
Rhenium-186
antibodies and F(ab)′$_2$ fragments, radioimmunotherapy, animals and man, 823(ab)
kit for pain of metastatic breast cancer, N26A(8)
whole monoclonal antibody and F(ab′)$_2$ fragment, radioimmunotherapy, solid tumors, 724(ab)
Rhenium-186 DMSA, pentavalent, tumor therapy agent, 768(ab)
Rhenium-186 HEDP
HPLC analysis, 768(ab)
simple kit for preparation, 898(ab)
Rhenium-186 monoclonal antibodies, fragments and, urinary catabolites, 823(ab)
Rib, infarction in sickle cell patients, acute chest syndrome, 893(ab)
RP-30, *see* Tc-99m SESTAMIBI
Rubidium-81, PET, tumor perfusion, 1307
Rubidium-82
PET
disruption, hyperosmotic blood-brain barrier, 810(ab)
O-15 water and, ischemic *vs.* normal myocardium, 802(ab)
α2 receptor agonists, myocardial perfusion, 841(ab)
replacement for Tl-201, N25A(8)
Tl-201 SPECT and, myocardial perfusion imaging, 802(ab)
PET for the heart, expected value of cash flows, economic analysis, 1893(le)

S

Salivagram, radionuclide, detection, pulmonary aspiration and esophageal dysmotility, 1588(ab)
Salmonella, food irradiation, perception problems, N11A(9)
Samarium-153 EDTMP
bone tumors, clinical and clinicopathologic response, 1316
clinical and clinicopathologic effects, 586
hormone refractory prostate carcinoma, 755(ab)
uptake and retention, metabolically active calcific tissues, 767(ab)
Sarcoidosis
Ga-67 distribution, recognition, distinctive patterns, 1909
myocardial, diagnosis, Tc-99m MIBI or Tl-201 SPECT, 839(ab)
radiogallium uptake, distinction of patterns, AIDS, 895(ab)
Sarcoma
bone, Tl-201 scintigraphy, 567
Ewing's, bone scintigraphy, 755(ab)
intestinal Kaposi's, Tc-99m nanocolloid, HIV-infected patients, 940(ab)
localization of pulmonary xenografts, In-111 monoclonal antibodies, 1378
primary pulmonary osteogenic, radionuclide detection, 1110
soft-tissue, In-111 monoclonal antimyosin Fab fragments, 23
soft-tissue osteogenic, metastases, scintigraphy, 679
Scanner
autoradiographic image digitization, analysis system, 758(ab)
continuous-slice PENN-PET, volume imaging capability, 617
PRISM, simultaneous Tc-99m and I-123 SPECT, brain, 877(ab)
QCT scanner STRATEC SCT 900 precision, bone mineral measurement, 856(ab)
Scatter
attenuation correction and, SPECT, density maps and Monte Carlo simulated scatter functions, 1560
coherent, calculation of, Pb collimator walls, 856(ab)
Compton, *see* Compton scatter
correction on quantification, effect, holospectral imaging, 729
correction techniques, evaluation and comparison, 873(ab)
degradation factor, activity quantitation, SPECT, 739(ab)
high resolution brain SPECT, spatial system response, 739(ab)
out-of-plane, detection and compensation, SPECT, 798(ab)
response function, functional description, compensation in SPECT, 873(ab)
Schistosomiasis, acute, scintigraphy, oxamniquine treatment, 1583(ab)
Schizophrenia
identical twins, PET-FDG imaging, 751(ab)
spatial frequency pattern analysis in PET, 864(ab)
Schwannoma, gallium scanning, 794(ab)
Scintigraphy
acute schistosomiasis, oxamniquine treatment, 1583(ab)
adrenal, adenoma *vs.* hyperplasia, Cushings and Conns syndrome, 845(ab)
aggressive fibromatosis, 1632
blood pool, scrotal variocele, 911(ab)
bone
accuracy, osseous spinal metastasis, 931(ab)
calcific discitis, childhood, 234
Ewing's sarcoma, 755(ab)
hyperparathyroidism, thyrotoxicosis, 845(ab)
increased sacroiliac joint uptake, low back pain, 712(ab)
magnification, talocalcaneal coalitions, 1797
regional perfusion, blood pool images, 831(ab)
secondary chondrolysis, slipped epiphysis, 742(ab)
soft tissue abnormalities, serendipitous findings, 932(ab)
bone fracture healing, ultrasonic stimulation, 781(ab)
bone scan abnormalities, skeletal metastases, breast cancer, 387
captopril renal, echo-Doppler flowmetry, renal artery stenosis, 913(ab)
cerebral perfusion defects, vestibular disorders, 876(ab)
chest radiography, suspected acute pulmonary embolism, 894(ab)
cholecystokinin-induced bile reflux, Krishnamurthy-Bobba sign, 248(le)
cholecystokinin-stimulated biliary, sphincter of Oddi dysfunction, 732(ab)
colon transit, health and constipation, oral I-131 cellulose, 985
combined, acute bone marrow infarction, sickle cell disease, 893(ab)
continuous bedside monitoring, right ventricular function, 1581(ab)
detection of bone and joint infections, In-111 nonspecific polyclonal human IgG, 403
different methods, medullary carcinoma, 744(ab)
diffusion-convection model, absolute organ perfusion, 825(ab)
dipyridamole thallium, transient left ventricular dilatation, 723(ab)
dynamic, absolute organ perfusion, compartment analysis, 860(ab)
electromechanical activity, proximal and distal stomach, 936(ab)
enalaprilat, renovascular hypertension, 715(ab)
equilibrium blood-pool, splanchnic vascular capacity, capacitance, 154
exercise whole-body thallium, diagnosis and evaluation, occlusive arterial disease in legs, 1443
extracorporeal shock wave lithotripsy, gallbladder function, 1583(ab)
Ga-67
lymphoma, 793(ab)
non-African Burkitt's lymphoma, 794(ab)
residual mass, treated lymphoma, 365, 369
gamma camera, *Strongyloides stercoralis,* 892(ab)
glomerular filtration rate, Tc-99m DTPA, children, 716(ab)
I-123 MIBG, chemodectomas, head and neck region, 1147
I-131 toluidine-blue, localization, parathyroid pathology, 790(ab)
importance of measurements, splanchnic blood volume, 160
In-111 antimyosin
doxorubicin therapy, advanced breast cancer, 1965
predictive value, ischemic events after first myocardial infarction, 782(ab)
risk stratification, heart transplant, 782(ab)
In-111 chloride, bone marrow imaging, myelodysplasia and aplastic anemia, 752(ab)
In-111 granulocyte, brain abscess diagnosis, 1121
In-111 granulocyte splenic pooling, inflamma-

tory bowel disease activity, 1470
In-111 leukocytes
acute gouty arthritis, 682
hemodialysis access-site infection, 319
In-111 nonspecific polyclonal IgG, In-111 leukocytes and, 811(ab)
In-111 polyclonal nonspecific IgG, febrile neutropenic patients, 819(ab)
inflammation foci, radiolabeled proteins, 810(ab)
lymphocele, renal transplant, 1627
myocardial perfusion, late redistribution predictors, viability, 764(ab)
pancreas, I-123 HIPDM SPECT, 1015
parathyroid, energy spectral analysis method, Tc-99m or Tl-201, 855(ab)
patterns of abnormalities, McCune-Albright syndrome, 1474
patterns on bone scan, acute and chronic brucellosis, 830(ab)
pharmacokinetics of Tc-99m MAG_3 in humans, 1285
quantitative hepatobiliary, 1468
receptor, radioiodinated somatostatin analogue, 1501
renal
angiotensin converting enzyme, renal artery stenosis, 1847
renovascular hypertension secondary to artery stenosis, 674
Tc-99m MAG_3 and I-123 hippurate, renal disorders, 1811
role in trauma, 931(ab)
sensitivity and non-specificity, detection, very small phantom lesions, 857(ab)
sincalide-augmented quantitative hepatobiliary, sphincter of Oddi manometry, 1462
smoker's lung, perfusion scans, 772(ab)
spectrum of findings, lymphoceles, renal transplant, 940(ab)
Tc-MAA, pulmonary allograft transplant rejection, 722(ab)
Tc-99m BW 250/183 antigranulocyte antibody, intracranial infection, neurological procedures, 818(ab)
Tc-99m MIBI, quantitative analysis method, 828(ab)
TC/TL, parathyroid, 1583(ab)
technetium-thallium, parathyroid adenoma, 935(ab)
thallium-201, stress-redistribution, ambulatory ECG monitoring, 744(ab)
three-phase bone
fractures of scaphoid, 831(ab)
plantar faciitis, 932(ab)
stress injury, anterior iliac crest, 1554
Tl-201
bone sarcoma, 567
childhood neoplasms, 938(ab)
coronary artery disease, parallel distributed processing approach, 825(ab)
differentiation of malignant from benign mass abnormalities, breast, 767(ab)
follow-up, eosinophilic thyroid carcinoma, 767(ab)
I-131 anti-CEA monoclonal antibodies, medullary thyroid carcinoma, 1854
magnetic resonance imaging, thyroid carcinoma, 1958
malignant soft tissue tumors, 889(ab)
myocardium, 1168
Tc-99m teboroxime and, vascular territory, 827(ab)
Tl-201 myocardial, 1390
two-minute dynamic, renal plasma flow, glomerular filtration rate, 914(ab)
uncommon soft-tissue osteogenic sarcoma metastases, 679
Scintillation, detector, simple method for estimation, energy resolution, 855(ab)
Scintillation camera, spectral changes, intrinsic count rate tests, 2074(le)
Scintilympphangiography, sequential mediastinal, intraperitoneal injection, Tc-99m albumin colloid, 897(ab)
Sclerosis, amyotrophic lateral, Tc-99m HMPAO SPECT, brain, 818(ab)
Sclerotherapy, portal hemodynamic changes, esophageal varices, radionuclide imaging, 813(ab)
Scrotum, variocele, blood pool scintigraphy, 911(ab)
Seascale, radiation discharges and cancer mortality, no link, N11A(11)
Seizure
complex partial
naloxone effects, cerebral blood flow, 710(ab)
role of neuroimaging, surgical intervention, 1839
hypometabolism assessment with FDG-PET, before and after temporal lobectomy, 710(ab)
intractable, presurgical evaluation, HIPDM-SPECT, 1280
postictal switch, cerebral blood flow, HMPAO SPECT, 711(ab)
preoperative evaluation, reliability and utility, FDG-PET, 710(ab)
Selenium-75 BISTAES, chondroitin sulfate and, binding determination, 946(ab)
Senescence, accelerated mouse, altered glucose metabolism, brain, 895(ab)
Senneff, Martha J., Mallinckrodt Fellowship, N24A(6)
Sepsis
abdominal, early diagnosis, Tc-99m HMPAO leukocyte scan, 1743(le)
inflammation imaging, 1746(le)
intraabdominal, Tc-99m HMPAO leukocytes, In-111 oxine leukocytes, 311
orthopedic implant, In-111 leukocyte and Tc-99m sulfur colloid imaging, 712(ab)
Serotonin
blockade, C-11 methyl-benztropine, baboon brain, 780(ab)
uptake site, C-11 citalopram and C-11 fluoxetine, 883(ab)
Serum
age dependence, α-fetoprotein-16α-[F-18]fluoroestradiol, 910(ab)
molecular size and immunoreactivity, ab-DTPA-In-111, 906(ab)
Sex differences, *N*-(3-[F-18]fluoropropyl)-*N*-nordiprenorphine, biodistribution and metabolism, 192
Shunt
cardiac left-to-right, improved method for evaluation, 753(ab)
portosystemic, superior mesenteric vein, I-123 IMP duodenal administration, 813(ab)
Sickle cell disease
combined scintigraphic identification, acute bone marrow infarction, 893(ab)
rib infarction, acute chest syndrome, 893(ab)
Siegal, Barry, appointed Chairman of NRC's ACMUI, N37A(6)
Sincalide, -augmented quantitative hepatobiliary scintigraphy, sphincter of Oddi manometry, 1462
Single photon emission computed tomography (SPECT)
activity quantitation, restoration filtering, scatter degradation factor, 739(ab)
adenosine, Tl-201 myocardial imaging, 723(ab)
advances in emission tomography, 628
AH5183 as ligand, cholinergic denervation, brain, 885(ab)
ASPECT-dedicated, physical performance, brain, 769(ab)
attenuation compensation, cone beam CT, 875(ab)
attenuation correction, build-up functions, 493
benzodiazepine receptor in primate brain, 779(ab)
brain
accurate modeling, spatial system response, 739(ab)
cerebral blood flow, chronic hypertension, 882(ab)
collateral circulation, trial balloon occlusion, 878(ab)
data, program for quantitative analysis, 1862
error, uniformity correction algorithm, 700(le)
lateral view, 872(ab)
perfusion, annular single crystal camera, 1456
cardiac
attenuation scan misalignment, 875(ab)
cone beam collimators, 739(ab)
fan beam collimators, 1590(ab)
image quality improvement, absolute quantitative accuracy, 738(ab)
cerebral blood flow, epileptic children treated by callosotomy, 893(ab)
cerebral blood volume, DIAMOX cerebral blood flow SPECT, cerebral vascular reserve, 877(ab)
cerebral hemodynamics, chronic obstructive carotid disease, 55
clinical function following stroke, 1574(le)
collimator angulation error, 655
comparison of I-123 QNB kinetics, blood flow, Tc-99m ECD, 707(ab)
complex partial epilepsy, role of neuroimaging, surgical intervention, 1839
cone beam, two orbits, brain, 770(ab)
correction of attenuation, fast transmission technique, gamma camera, 875(ab)
CT and, volumetric correlation, radiolabeled monoclonal antibody distribution, 872(ab)
CT fusion, complicated inflammatory disease, 871(ab)
CT image superimposition, transfer of RoI for quantification, 872(ab)
cutaway three-dimensional volume perspective, internal organ activity, 808(ab)
defective parallel-hole collimator, suggested approach, 1892(le)
diagnosis of Budd-Chiari syndrome, 109
DIAMOX, brain, 936(ab)
dipyridamole Tc-99m MIBI, first-pass angiocardiography, 821(ab)
dipyridamole-thallium, prognostic measures, cardiac risk, 732(ab)
dopamine D2 receptor, primate brain, 883(ab)
dual-energy-window Compton correction, 90
dual isotope, N24A(8)
dual sensitivity collimation, 870(ab)
dynamic transaxial, efficient sampling, 719(ab)
electronically collimated, 178
elimination of "hot" bladder artifacts, pelvis, 1872

estimation of relative regional neuroreceptor concentration, 865(ab)
filter design for iterative Chang method, attenuation correction, 739(ab)
four-head rotating gamma camera, new apparatus, brain imaging, 603
"fusion" of CT and radiolabeled antibody, improved mediastinal staging, lung cancer, 798(ab)
Ga-67
  pediatric solid tumors, 168
  residual Hodgkin's disease, mediastinum, 793(ab)
gated, reconstruction, Fourier coefficients, 1856
gated myocardial, 3-D volume perspective view, 871(ab)
gated Tc-99m MIBI tomography, myocardial infarct size, 832(ab)
highlights of the SNM Meeting, N17A(8)
high resolution, normal brain perfusion, 3-head rotating gamma camera, 880(ab)
high-spatial resolution, fan beam collimators, brain imaging, 869(ab)
HIPDM brain imaging, presurgical evaluation, intractable seizures, 1280
HMPAO, brain perfusion patterns, sleep apnea and Alzheimer's disease, 877(ab)
I-123, correction of overestimation, cerebral blood flow, 790(ab)
I-123 epiderpride, dopamine D2 receptors in man, 779(ab)
I-123 HIPDM
  brain blood flow, cerebrovascular disease, 879(ab)
  human pancreas scintigraphy, 1015
I-125 IBF, selective dopamine D-2 receptor imaging agent, 648
I-123 IMP
  AIDS dementia, brain, 936(ab)
  clinical significance, pediatric patients, 878(ab)
  correction for extraction fraction, cerebral blood flow, 868(ab)
  crossed cerebellar diaschisis, stroke, 770(ab)
  ocular melanoma, 375
  spinocerebellar degeneration, 881(ab)
  validation studies, cerebral blood flow tracer, 1364
I-123 iodoamphetamine, early Huntington's chorea, 937(ab)
I-123 iodolisuride, D2 receptor imaging, 770(ab)
L-3-[I-123]iodo-α-methyl tyrosine, brain tumors, 281
I-123 iodo-*m*-tyrosine, synthesis, brain, 796(ab)
I-123 IPA, brain tumor analysis, 899(ab)
I-123 ISP, dopamine D2 receptor, 885(ab)
I-123 prenalterol, myocardial β-adrenergic receptor studies, 899(ab)
I-123 Ro 16-0154, benzodiazepine receptors, 1007
I-131 concentration in phantoms, human tumors, 1945
I-131 monoclonal antibodies, uptake, liver metastases, 873(ab)
image reconstruction, iterative ML-EM algorithm, 867(ab)
imaging of CNS D-2 dopamine receptors, I-123 IBZM in humans, 573
IMP, time post onset after cerebral infarction, 878(ab)
In-111 antimyosin and TlCl-201, acute myocardial infarction, 783(ab)
information theoretic performance approximations, maximum likelihood object classification, projection data, 798(ab)
interactive three-dimensional region of interest analysis, HMPAO, brain, 2046
interictal scans, pre-surgical evaluation, epilepsy, 879(ab)
iterative cone beam reconstruction algorithm, geometric point response correction, 867(ab)
iterative maximum likelihood-EM reconstruction, ROC methods, 739(ab)
localization of R,R-I-123 IQNB, Alzheimer's patients, 729(ab)
maximum value reprojection, 1590(ab)
MLEM reconstruction, Compton scattering, cold-lesion contrast, 869(ab)
MRI and, CNS systemic lupus erythematosus, brain, 876(ab)
myocardial perfusion, probability, coronary lesion, 797(ab)
neuropsychological test scores, cerebral blood flow, dementia, 731(ab)
NIH holds conference, N30A(7)
N-isopropyl-P [I-123] IMP, cerebral blood flow, 750(ab)
optimal dynamic data acquisition protocols, myocardial blood flow studies, 718(ab)
out-of-plane scatter detection, compensation, 798(ab)
perfusion studies, anatomic functional images, distribution and regional washout, 872(ab)
PET and, anatomical correlation, dementia, 885(ab)
planar immunoscintigraphy or, ocular melanoma, Tc-99m $F(ab')_2$ fragments, 854(ab)
preliminary evaluation of myocardial perfusion, 1581(ab)
quantification of cerebral ischemia, carotid endarterectomy, 1412
quantitation with iodine-123, 874(ab)
quantitative, validation, In-111 antibodies, 873(ab)
ratio of rCBV to rCBF, 1433(le)
recommendations of Nuclear Medicine Subcommittee, N18A(3)
reconstructing truncated projections, cardiac fan beam and cone beam tomography, 867(ab)
reconstruction and compensation techniques, improvement, quantitative accuracy, 866(ab)
regional cerebral blood flow studies
  crack users and control subjects, 876(ab)
  obssessive-compulsive disorder, 750(ab)
reimbursement, N15A(6)
scatter compensation, functional description, scatter response function, 873(ab)
simulation and reconstruction, parallel and converging ray collimation geometries, 719(ab)
SNM Highlights, Image of the Year, N20A(8)
subtraction images and sector analyses, changes in tracer uptake, brain, 874(ab)
table-top, multi-bar cylindrical detector, 769(ab)
Tc-99m D,L-HMPAO
  asymptomatic HIV+drug abusers, 826(ab)
  obsessive-compulsive disorder, 750(ab)
Tc-99m and I-123
  quantitation linearity, brain, 769(ab)
  simultaneous imaging in brain, PRISM scanner, 877(ab)
Tc-99m ECD or Xe-133, regional cerebral blood flow, mild perfusion abnormalities, 817(ab)
Tc-99m glucaric acid, myocardial infarction, 785(ab)
Tc-99m HEXAMIBI, pediatric brain tumor, 2040
Tc-99m HMPAO
  amyotrophic lateral sclerosis, brain, 818(ab)
  amytal distribution, intra-arterial sodium amytal test, 818(ab)
  brain, learning or behavior disorders, 741(ab)
  childhood-onset epilepsy, 892(ab)
  chronic fatigue syndrome, 936(ab)
  compared to C-15 O_2 PET, regional cerebral blood flow, 1595
  early stages, HIV infection, 827(ab)
  kinetic model, blood flow, 868(ab)
  localization of epileptic foci, site of temporal lobectomy, 711(ab)
  postictal switch, cerebral blood flow, 711(ab)
  prognostication of recovery, stroke, 61
  psychometry and EEG, temporal lobe epilepsy, 881(ab)
  remote history, traumatic head injury, 936(ab)
  reversible cerebrovascular disease, acetazolamid, 789(ab)
  triple tracer kinetics, 881(ab)
Tc-99m MIBI
  coronary artery disease, chest pain at rest, 714(ab)
  coronary artery disease diagnosis, planar gated imaging, 820(ab)
  early or delayed, intercomparison, 945(ab)
  myocardial salvage, acute infarction, 839(ab)
  regional myocardial anaerobic glycolysis, PET, 821(ab)
Tc-99m MIBI exercise first pass ventriculography, myocardial ischemia after acute infarction, 840(ab)
Tc-99m MIBI or Tl-201, diagnosis, myocardial sarcoidosis, 839(ab)
Tc-99m RBC and Tc-99m HMPAO, cerebral blood flow, 790(ab)
Tc-99m RP-30 and Tl-201, myocardial perfusion defect, severity, 735(ab)
Tc-99m SESTAMIBI
  interobserver and intraobserver reproducibility, 1582(ab)
  issue of tissue crosstalk, 1409
  reproducibility, blood flow quantification, 821(ab)
  right ventricular regional perfusion, polar map display, 839(ab)
Tc-99m TEBO, feasibility of perfusion imaging, Tl-201 and coronary arteriography, 1581(ab)
thallium, computer interpretation, neural network analysis, 1582(ab)
three-dimensional display
  advantages and problems, 1428
  interactive, 807(ab), 871(ab)
  mathematical phantom of human torso, 868(ab)
  myocardial perfusion scans, 808(ab)
  post-reconstruction restoration filtering, 867(ab)
  simulation, horizontal motion and the heart, 870(ab)
  stationary, design study and brain imaging, 769(ab)
  surface map variations, filter selection and threshold, 945(ab)
  volume rendering, 807(ab), 1421
Tl-201
  adenosine infusion and treadmill exercise, CAD detection, 733(ab)
  apparent changes, cardiac geometry, 835(ab)
  artifactual defects, orbit-related variation,

718(ab)
bull's eye polar map, perfusion defects, 808(ab)
color washout slices, anatomic information, 812(ab)
detectability, thyroid cancer metastases, 147
grading of malignant glioma, 826(ab)
inappropriate motion correction, breast attenuation, 1591(ab)
left bundle branch block, 836(ab)
left bundle branch block, dipyridamole, 837(ab)
left main and left main equivalent disease, 763(ab)
left ventricular dilatation, adenosine-induced hyperemia, 837(ab)
left ventricular wall motion, myocardial perfusion, 457
mediastinal lymph node metastases, lung cancer, 889(ab)
meta-diagnosis, experienced reader interpretation, 836(ab)
methods and results, brain tumors, 965
motion effect, 934(ab)
myocardial perfusion defects, reversibility bull's eye, 1240
new criteria, prior myocardial infarct, 812(ab)
preoperative, astrocytoma, 825(ab)
prone imaging, myocardial perfusion, 812(ab)
radial long-axis tomography, regional myocardial perfusion, 808(ab)
Rb-82 PET and, myocardial perfusion imaging, 802(ab)
regional myocardial perfusion, Wiener filtering, 1230
reinjection, FDG-PET tissue viability, 742(ab)
reinjection, reversible ischemia, 743(ab)
silent myocardial ischemia, 812(ab)
stress-redistribution, prone imaging, 812(ab)
stress-redistribution, transient cavity dilatation, 836(ab)
Tc-99m flood source, transmission and emission data simultaneously, 798(ab)
timing of imaging, myocardial stress studies, 813(ab)
tissue characterization, pulmonary lesions, 766(ab)
Tl-201 exercise, predictors of delayed redistribution, early "fixed" defects, 764(ab)
Tl-201/Tc-99m HMPAO, detection of recurrent malignant glioma, I-125 brachytherapy, 826(ab)
tolerance of perfusion imaging to patient motion, 841(ab)
ultra-high resolution, collimator, radiopharmaceutical uptake in brain, 870(ab)
verification of hole angulation, collimators, 945(ab)
visual stimulation effects, I-123 IMP deposition, 875(ab)
Xe-133, disturbances in cerebral perfusion, HIV-1 seropositive asymptomatic subjects, 1601
Xe-133, Tc-99m HMPAO and, dementia, 730(ab)
X-ray CT and, chronic low back pain, 830(ab)

Sipple's syndrome, pentavalent Tc-99m (V)-DMSA uptake, pheochromocytoma, 106

Skeleton
assessment in neuroblastoma, pitfalls, I-123 MIBG scans, 129
biodistribution, rare-earth carboxylate complexes, 767(ab)
total body and cross-sectional imaging, F-18 PET, 780(ab)

Sleep, apnea, brain perfusion patterns, HMPAO SPECT, 877(ab)

Sn(II) complex, macromolecular, preparation, Tc-99m radiopharmaceuticals, 907(ab)

Society of Nuclear Medicine (SNM)
associate director recertified, N23A(3)
1990 Aebersold Award, Marcus E. Raichle N25A(5)
1990 Berson-Yalow Award, Dah-Ren Hwang, N19A(6)
1990 Hevesy Award, Neils A. Lassen, N28A(5)
1990 Tetalman Award, Kirk A. Frey, N23A(7)
committee develops training guides, N38A(6)
Distinguished Educator Award, Thomas P. Haynie N20A(7)
DOE award for lifetime achievement, N32A(9)
Education and Research Foundation, N28A(6)
election results, N31A(8)
government relations update, N14A(6)
Mallinckrodt Fellowship, Martha J. Senneff, N24A(6)
member elected to Institute of Medicine, N28A(8)
relocation of national office, N24A(4)
should Presidency be for two-year term, N33A(6)
technologist section election results, N31A(8)
37th Annual Meeting, N13A(5), N17A(8)
Work-in-Progress rules of submission, 33A(10)

Sodium, deoxyglucose and, tissue concentration, myocardial infarction, 833(ab)

Somatostatin analogue, radiodinated, receptor scintigraphy, 1501

Sonography, gallbladder perforation, 1915

SPECT, *see* Single photon emission computed tomography

Spectamine, flow analysis, voluntary and magnetic field-induced human movement, 761(ab)

Spermatozoan, migration and transport, radiolabeled cells, 910(ab)

Spheroids, LS174T multicell, I-125 NRLU-10 kinetic studies, bismuth-212-NRLU-10 toxicity, 1527

Sphincter of Oddi
dysfunction, CCK-stimualted biliary scintigraphy, 732(ab)
dyskinesia, CCK-cholescintigraphy, 848(ab)
manometry, sincalide-augmented quantitative hepatobiliary scintigraphy, 1462

Spinal cord
injury, muscle blood flow, electrical stimulation, 818(ab)
tumor, magnetic resonance, F-18 deoxyglucose, 360

Spine
automatic image comparison, dual-photon absorptiometry, 31(ab)
lumbar
bone mineral density, dual-energy X-ray absorptiometry, 1156
dual-photon absorptiometry, limited precision, 1774

Spiperone, analogs, separation, dopaminergic and serotonergic properties, 728(ab)

Spleen
accumulation of Tc-99m methylene diphosphonate, transfusion-dependent patient, chronic myelogenous leukemia, 1552
dynamics of In-111 platelets, idiopathic thrombocytopenic purpura, 383(le)
In-111 granulocyte splenic pooling, inflammatory bowel disease, scintigraphy, 1470
normal, binding site analysis, antibodies 96.5 and 9.2.27, 755(ab)

SQ30,217
kinetics, occlusive and pacing-induced ischemic stress, 785(ab)
post-stenotic kinetics, adenosine and dipyridamole-induced hyperemic stress, 785(ab)
SQ32014 and, Tc-99m-labeled, myocardial extraction, 67

Stark Bill, fate of, N18A

Stenosis, renal artery, renovascular hypertension, renal scintigraphy, 674

Stomach, proximal and distal, electromechanical activity, scintigraphy, 936(ab)

Stomach cancer, quantitation and distribution, TAG-72 and CEA, 755(ab)

Strategic Defense Initiative Organization (SDIO), funding of PET projects, N30A(7)

Streptavidin
-biotinylated antibodies using protein A, revelance, complex size to tissue uptake, 904(ab)
-conjugated antibodies, In-111 biotin, imaging of tumor, 1791
radioactive, tumor targeting and biotinylated mAb, ovarian cancer, 735(ab)

Streptokinase, -treated patients with myocardial infarction, gated blood pool tomographic detection, ejection fraction, 842(ab)

Stress
-induced LV failure, pulmonary Tc-99m MIBI uptake, coronary artery disease, 1581(ab)
injury of anterior iliac crest, three-phase radionuclide bone imaging, 1554
mental, post infarction myocardial perfusion, Tc-99m MIBI, 934(ab)
physical and psychological, gastric emptying, 800(ab)

Stroke
acute, regional cerebral hematocrit, blood flow, 1584(ab)
clinical function, 1574(le)
crossed cerebellar diaschisis, I-123 IMP SPECT, F-18 FDG PET, 770(ab)
posterolateral thalamic, cortical metabolism, 880(ab)
prognostication of recovery, computed tomography, Tc-99m HM-PAO SPECT, 61

Strongyloides stercoralis, gamma camera scintigraphy, 892(ab)

Strontium-89
metastatic prostate and breast cancer, bone marrow scanning, 938(ab)
multiple painful bone metastases, prostatic and breast carcinoma, 804(ab)

N-Succinimidyl-5-(tri-*n*-butylstannyl)pyridine-3-carboxylate, radiohalogenation of monoclonal antibodies, 776(ab)

Supernatant, molecular size and immunoreactivity, ab-DTPA-In-111, 906(ab)

Surgery, radioimmunoguided, primary colon and recurrent colorectal cancer, 851(ab)

Sympathetic nervous system
myocardial activity, regional abnormality, hypertrophic cardiomyopathy, 792(ab)
quantitative evaluation by PET, cardiomyopathy, 792(ab)
regional myocardial ischemia, F-18 metaraminol, 1352

Sympathoadrenal system, dynamic lung scanning, I-123 MIBG aerosol, 772(ab)

Synovectomy, radiation, Ho-166-FHMA, antigen-induced arthritis, 780(ab)

Systeme International, transition, N19A(1)

Systemic lupus erythematosus, brain SPECT and MRI, 876(ab)

T

TAG-72
quantitation and distribution, stomach cancer, 755(ab)
reactive monoclonal antibodies, radioimmunotherapy, 765(ab)
Tantalum-178, count rate performance, multiwire gamma camera, 1723
Teboroxime NDA, N14A(2)
Technetium-96, preparation, long-lived stand-in for Tc-99m, 909(ab)
Technetium-99m
cationic complexes, Tc-99m γ-pyrones, 908(ab)
cationic myocardial perfusion imaging agents, initial human experience, 907(ab)
distribution and regional washout, anatomic functional images, SPECT perfusion images, 872(ab)
enzyme inhibitor, red blood cell label, 892(ab)
I-123 and, simultaneous SPECT in brain, PRISM scanner, 877(ab)
increased flexibility, N14A(2)
iodine-123 and, thyroid nodules, pathologic findings, 393, 400
labeling of fragment E1, thrombus imaging, 776(ab)
labeling of protein, bifunctional aromatic hydrazines, 776(ab)
large telangiectatic focal nodular hyperplasia, presentation with normal radionuclide studies, 2037
liposome labeling method, 806(ab)
neutral lipophilic complex, regional cerebral blood flow, 1370
new myocardial imaging agents, 747(ab)
preparation of Tc-96, 909(ab)
radiolabeling
monoclonal antibody fragments, one-vial kit, 905(ab)
new polymer chelates, 897(ab)
radiopharmaceuticals
functionalized tripodal hexadentate ligand, 897(ab)
preparation, Sn(II)complex, 907(ab)
single chain antibody Fv fragment, characterization and biodistribution, 776(ab)
Sn complexes, 806(ab)
SPECT, quantitation linearity, brain, 769(ab)
-thallium scintigraphy, parathyroid adenoma, 935(ab)
Tl-201 or, energy spectral analysis method, parathyroid scintigraphy, 855(ab)
uptake in rat tibial bone repair, 2011
Technetium-99m(III), nonreducible perfusion tracer, 834(ab)
Technetium-99m alanyltriglycine, isomers of D and L, labeling and biodistribution, 907(ab)
Technetium-99m albumin colloid, intraperitoneal injection, sequential mediastinal scintilymphangiography, 897(ab)
Technetium-99m albumin colloid WBC, *vs.* In-111 WBC, detection of osteomyelitis, 890(ab)
Technetium-99m albumin macroaggregated, excretion into breast milk, 978
Technetium-99m anti-AFP, initial clinical evaluation, 850(ab)
Technetium-99m antibody fragments, stability and immunoreactivity, direct labeling method, 905(ab)
Technetium-99m antifibrin monoclonal antibody, coronary thrombi detection, 804(ab)
Technetium-99m antigranulocyte monoclonal antibody
immunoscintigraphy, inflammatory processes, 417
In-111 nonspecific IgG comparison, imaging focal infection, 811(ab)
scintigraphy, intracranial infection, neurological procedures, 818(ab)
subtraction/reverse substraction imaging, florid inflammatory lesions, 1587(ab)
Tc-99m polyclonal immunoglobulin and, delineation, infection sites, 890(ab)
Technetium-99m antimyosin Fab', accelerated renal clearance, 833(ab)
Technetium-99m BATO, SQ30217 and SQ32014, comparative myocardial extraction, thallium, 67
Technetium-99m BATO-isothiocyanates, B72.3 monoclonal antibody, 747(ab)
Technetium-99m complexes
cationic, potential myocardial imaging agents, 748(ab)
lipophilic, mimicry of rCBF, 807(ab)
neutral, synthesis, diaminedithiol bifunctional chelate, 806(ab)
hexakis-(alkylisonitrile), noncardiac applications, 1166
pentadentate amine-phenol ligands, 947(ab)
Technetium-99m desferoxamine, measurements after aerosolization, 908(ab)
Technetium-99m DISIDA
correlation with biopsies, liver transplant patients, 731(ab)
differential diagnosis, neonatal hyperbilirubinemia, 742(ab)
efficacy in early detection, biliary stenosis, liver transplanted children, 732(ab)
hepatobiliary imaging, post-biliary lithotripsy, 935(ab)
Technetium-99m DMSA
scintigraphy, aggressive fibromatosis, 1632
urinary tract infection, 893(ab)
Technetium-99m DTPA
aerosol clearance, idiopathic pulmonary fibrosis, 772(ab)
comparison of methods, calculation, glomerular filtration rate, 914(ab)
error analysis of mean transit times, split renal function, renography, 940(ab)
glomerular filtration rate, 424
analysis of several common methods, 1211
inhalational scans
urine excretion, lung epithelial transport, 441
utility, artificially ventilated patients, 46
kit preparation of Tc-99m MAG_3, patients with impaired renal function, 1568
noninvasive measurement, renal blood flow, renovascular hypertension, 1980
renal clearance, effect, background correction, 430
renal images, reduced glomerular filtration rate, 913(ab)
scintigraphic estimates, glomerular filtration rate, children, 716(ab)
spectrum of scintigraphic findings, lymphoceles, renal transplant, 940(ab)
Tc-99m desferoxamine, measurements after aerosolization, 908(ab)
Tc-99m MAG3 and, I-131 hippuran, dosimetry in human subjects, 822(ab)
volume of distribution estimation, camera-based GFR, 915(ab)
Technetium-99m ECD
blood flow, compared to I-123 QNB kinetics, SPECT, 707(ab)
transchelation reactions, 908(ab)
Xe-133 comparison, SPECT, regional cerebral blood flow, 817(ab)
Technetium-99m erythrocytes, role of band-3 protein, pertechnetate transport across cell membrane, 2004
Technetium-99m L,L-ethylenedicysteine
alternative to Tc-99m MAG_3, 908(ab)
D,D isomers and, renal excretion characteristics, 806(ab)
Tc-99m MAG3 and, comparison, human volunteers, 762(ab)
Technetium-99m Fab, bifunctional amide thiolate ligands, radioimmunodetection, 747(ab)
Technetium-99m Fab' chelator conjugate, hydrolysis product characterization, 905(ab)
Technetium-99m $F(ab')_2$ fragments, SPECT *vs.* planar immunoscintigraphy, ocular melanoma, 854(ab)
Technetium-99m Fab' monoclonal antibody, imaging inflammatory lesions, granulocyte binding activity, 904(ab)
Technetium-99m galactosylated albumin, new kit formulation, clinical evaluation, 846(ab)
Technetium-99m galactosyl-neoglycoalbumin, receptor-binding radiopharmacokinetic model, 909(ab)
Technetium-99m glucarate, myocardial reperfusion injury, 795(ab)
Technetium-99m glucaric acid, nuclear imaging, myocardial infarction, 785(ab)
Technetium-99m granulocytes, immunoscintigraphy, inflammatory bowel diseases, 1586(ab)
Technetium-99m GSA, clinical evaluation, liver function studies, 1583(ab)
Technetium-99m HEXAMIBI, SPECT, pediatric brain tumor, 2040
Technetium-99m HIG, infection and inflammation, 811(ab)
Technetium-99m HMPAO
autoradiography, central nervous system, murine lupus, 884(ab)
brain death determination, 2075(le), 2076(le)
brain SPECT, triple tracer kinetics, 881(ab)
detection of experimental abscess, 940(ab)
diffusion of pulmonary uptake, cigarette smokers, 894(ab)
flow and rate constants, compartmental model, brain, 868(ab)
focal high uptake, brain perfusion studies, 1094
hepatic uptake, 237
interaction with glutathione, 1115(le)
labeled white blood cells, detection, acute appendicitis, 1588(ab)
lacrimal gland dosimetry, brain, 1237
leukocytes, compared to In-111 oxine leukocytes, intraabdominal sepsis, 311
leukocyte scan, early diagnosis, acute abdominal sepsis, 1743(le)
mapping of supratentorial lesions, crossed cerebellar diaschisis, 789(ab)
preparation, 127(le), 1892(le)
pulmonary uptake, cigarette smoke exposure, 773(ab)
SPECT
amyotrophic lateral sclerosis, brain, 818(ab)
brain perfusion patterns, sleep apnea and Alzheimer's disease, 877(ab)
childhood-onset epilepsy, 892(ab)
chronic fatigue syndrome, 936(ab)
compared to C-15 O_2 PET, regional cerebral blood flow, 1595
detection of recurrent malignant glioma, I-

125 brachytherapy, 826(ab)
distribution of amytal, intra-arterial sodium amytal test, 818(ab)
early stages, HIV infection, 827(ab)
interactive three-dimensional region of interest, brain, 2046
kinetic model, blood flow, 868(ab)
learning or behavior disorders, children, 741(ab)
postictal switch, cerebral blood flow, 711(ab)
prognostication of recovery, stroke, 61
psychometry and EEG, temporal lobe epilepsy, 881(ab)
remote history, traumatic head injury, 936(ab)
reversible cerebrovascular disease, acetazolamid, 789(ab)
Tc-99m DTPA aerosol clearance and, idiopathic pulmonary fibrosis, 772(ab)
Tc-99m red blood cells and, cerebral blood flow, SPECT, 790(ab)
tomoscintigraphy, evaluation of vasospasm, subarachnoid hemorrhage, 972
variable quality of images of brain, radiopharmaceutical factors, 118
Xe-133 and, SPECT, dementia, 730(ab)

Technetium-99m D,L-HMPAO
aqueous solutions, radiolytically induced dissociation, 806(ab)
distribution, hyperventilation effects, 789(ab)
distribution in brain volume, neuroanatomy, 937(ab)
SPECT
asymptomatic HIV+drug abusers, 826(ab)
obsessive-compulsive disorder, 750(ab)

Technetium-99m isonitriles, replacement for Tl-201, N25A(8)

Technetium-99m MAA
intraarterial injection, peripheral arteriovenous malformation, 1557
pulmonary allograft transplant rejection, 722(ab)

Technetium-99m MAG_3
clearance, single plasma sample technique, 912(ab)
pharmacokinetics in humans, 1285
I-123 hippurate and, renal scintigraphy and clearance, 1811
I-131 OIH or, parenchymal retention, transplanted kidneys, 716(ab)
kit formulation
high purity and stability, 907(ab)
patients with impaired renal function, 1568
Tc-99m L,L-ethylenedicysteine and alternative, 908(ab)
comparison, human volunteers, 762(ab)
Tc-99m DTPA and, I-131 hippuran, dosimetry in human subjects, 822(ab)

Technetium-99m MDP
bone imaging, chronic recurrent multifocal osteomyelitis, 938(ab)
compared to Tl-201 scintigraphy, bone sarcoma, 567
experimental arthritis in rabbits, 781(ab)
-In-111 leukocyte bone and magnetic resonance imaging, neuropathic osteoarthropathy, osteomyelitis, 549
uptake by gold collimated miniature Cd-Te probe, focal maxillofacial lesions, 856(ab)

Technetium-99m methylene diphosphonate
bone scan, cold defect, malignant fibrous histiocytoma, 1104
splenic accumulation, transfusion-dependent patient, chronic myelogenous leukemia, 1552

Technetium-99m MIBI
accumulation in chick myocytes, mitochondrial metabolic inhibitors, ionophores, 736(ab)
compared to Tl-201 uptake, low flow ischemia, 713(ab)
diagnosis of coronary artery disease, planar gated with SPECT imaging, 820(ab)
dipyridamole, planar and SPECT imaging, first-pass angiocardiography, 821(ab)
exercise first pass ventriculography, SPECT myocardial perfusion, infarction, 840(ab)
fast labeling, microwave oven heating method, 839(ab)
left ventricular wall motion and myocardial perfusion, angina, compared to Tl-201 SPECT, 457
metabolic inhibition, kinetics, chick myocardial cells, 464
mitochondrial
pitfalls of tissue fractionation, 832(ab)
plasma membrane potentials and, mouse fibroblasts, 1646
mitochondrial localization, electron probe X-ray microanalysis, chick heart cells, 748(ab)
noncardiac applications, 1166
post infarction myocardial perfusion, mental stress, 934(ab)
pulmonary uptake, indicator for stress-induced LV failure, coronary artery disease, 1581(ab)
regional myocardial perfusion, ventricular function, gated MIBI perfusion tomograms, 859(ab)
risk area determination, transient coronary occlusion, 784(ab)
scintigrams, quantitative analysis method, 828(ab)
segmental myocardial wall thickening, 173
SPECT
coronary artery disease, chest pain at rest, 714(ab)
early or delayed, intercomparison, 945(ab)
gated tomography, myocardial infarct size, 832(ab)
myocardial salvage, acute infarction, 839(ab)
regional myocardial anaerobic glycolysis, PET, 821(ab)
Tl-201 and, dual-tracer autoradiography, heart, 832(ab)
Tl-201 SPECT or, diagnosis, myocardial sarcoidosis, 839(ab)

Technetium-99m monoclonal antibody
activated platelets
acute pulmonary emobli, 805(ab)
occlusive arterial thrombi, 713(ab)
partialy occlusive thrombi, 805(ab)
immunoscintigraphy compared to radiocolloid scanning, solid tumors and systemic disorders, 1588(ab)
melanoma, use in patients before lymphadenectomy, 1586(ab)
reduction-mediated, 692
thrombi imaging, rabbit jugular vein, 747(ab)

Technetium-99m monoclonal anti-CEA antibody
immunoscintigraphy
colorectal carcinoma and recurrences, 535(le)
liver metastases staging, before partial hepatectomy, 1586(ab)
tumor diagnosis, 1586(ab)

Technetium-99m MRP20, brain perfusion agent, 760(ab)

Technetium-99m nanocolloid, HIV-infected patients, intestinal Kaposi's sarcoma, 940(ab)

Technetium-99m NCA antibodies, radioimmunoimaging, bone marrow, breast cancer, 751(ab)

Technetium-99m NCA-95/CEA antibodies, immunoscintigraphy of bone marrow, 751(ab)

Technetium-99m pertechnetate, blocked with potassium perchlorate, radiation dose estimates, 822(ab)

Technetium-99m phytate, extrahepatic uptake, prognostic index, cirrhosis, 436

Technetium-99m platelets, fluid shear, 820(ab)

Technetium-99m polyclonal IgG, hydrazino nicotinamide derivative, focal infection sites, 819(ab), 2022

Technetium-99m polyclonal immunoglobulin
localization of infectious lesions in humans, 758(ab)
Tc-99m antigranulocyte monoclonal antibody and, delineation, infection sites, 890(ab)

Technetium-99m protein
inflammation localization, 810(ab)
urinary excretion, patients receiving Tc-99m red blood cells, 896(ab)

Technetium-99m γ-pyrones, Tc-99m cationic complexes, 908(ab)

Technetium-99m pyrophosphate, compared to In-111 antimyosin antibody, stages of myocardial infarction, 136

Technetium-99m red blood cells
excretion into breast milk, 978
late delayed imaging, gastrointestinal bleeding studies, 814(ab)
penile blood flow, combined radioisotope plethysmography, 752(ab)
placental localization in abdominal pregnancy, 1106
radial long-axis tomography, Tl-201 SPECT, myocardial perfusion, 808(ab)
radiation absorbed dose, 378
Tc-99m HM-PAO and, cerebral blood flow, SPECT, 790(ab)
urinary excretion of Tc-99m protein, 896(ab)

Technetium-99m SESTAMIBI
blinded evaluation, myocardial perfusion studies, 827(ab)
ischemic heart disease, initial and delayed post-exercise images, 828(ab)
issue of tissue crosstalk, 1409
myocardial imaging, treadmill stress test, transesophageal atrial pacing, 821(ab)
myocardial perfusion and function, 820(ab)
myocardial perfusion scans, 858(ab)
myocardial redistribution, 1069
NDA N14A(2)
parathyroid imaging, 790(ab)
perfusion and function at rest, treadmill exercise, 1128
planar myocardial perfusion, quantitative analysis, modified background subtraction, 1400
SPECT
interobserver and intraobserver reproducibility, 1582(ab)
myocardial perfusion defect, severity, 735(ab)
reproducibility, blood flow quantification, 821(ab)
right ventricular regional perfusion, polar map display, 839(ab)
tomographic, serial changes, myocardial perfusion, 1269

Technetium-99m SQ30217, myocardial clearance kinetics, 1183

Technetium-99m sulfur colloid
complementary role following In-111 WBC or Ga-67, inflammation evaluation, 941(ab)
gastric emptying petition, N19A(2)

In-111 leukocytes and, uptake, malignant fibrous histiocytoma, 1548
liver-spleen scans, increased lung uptake, hepatic venoocclusive disease, 372
orthopedic implant sepsis, 712(ab)
radionuclide first pass study, renal failure, transplantation, 912(ab)
SPECT, determination of liver volume, preoperative transplant recipients, 874(ab)
total hip arthroplasty, periprosthetic In-111 leukocyte activity, 1950
Technetium-99m synthetic peptides, thrombus imaging, activated platelets, 757(ab)
Technetium-99m T691, uptake and retention, cerebral blood flow, 885(ab)
Technetium-99m TBI, visualization, suppressed thyroid tissue, 1163
Technetium-99m teboroxime
multicenter trial, 827(ab)
thallium scintigraphy and, vascular territory, 827(ab)
vascular territory, coronary angiography, 828(ab)
Technetium-99m T2G1S antifibrin monoclonal antibody, venous thrombosis, immunoscintigraphy, 782(ab)
Technetium-99m (V)-DMSA, uptake in pheochromocytoma, Sipple's syndrome, 106
Telluride, -cadmium, Tc-99m MDP, focal maxillofacial lesions, 856(ab)
Testicular tumors, I-131 anti-βHCG antibodies, 854(ab)
Tetalman Memorial Award, Kirk A. Frey, N23A(7)
N,N,N′,N′-Tetrakis-(2-hydroxy-3,5-dimethylbenzyl)-ethylene, synthesis and investigation, PET, 768(ab)
Tetralogy of Fallot, pulmonary ventilation and perfusion abnormalities, ventilation perfusion imbalance, children, 1276
Thallium, -dipyridamole imaging, papillary muscle dysfunction, 124(le)
Thallium-201
adenosine, stress, comparative myocardial count density, 837(ab)
cardiac, optimization, collimator design and acquisition parameters, 870(ab)
cardiac SPECT, Tc-99m flood source, transmission and emission data silmultaneously, 798(ab)
caution in use of 167-KEV peak, 1589(ab)
cocaine-induced myocardial ischemia, 834(ab)
comparative myocardial extraction, Tc-99m BATO derivatives, 67
dipyridamole
exercise, "left ventricular dilatation", 722(ab)
exercise and, automatic lung/heart ratios, 842(ab)
normal scan, long term follow-up, 837(ab)
ST segment depression, reversibility, 733(ab)
testing in females, 733(ab)
dipyridamole-induced coronary hyperemia, pentoxifylline, 1020
dipyridamole scintigraphy, transient left ventricular dilatation, 723(ab)
dipyridamole SPECT, prognostic measures, cardiac risk, 732(ab)
echocardiographic imaging, dipyridamole vasodilation, adjunct bicycle exercise, 723(ab)
exercise imaging
disease progression, coronary angioplasty, 836(ab)
restenosis after partial *vs.* total revascularization, coronary angioplasty, 763(ab)
feasibility of SPECT perfusion imaging, Tc-99m TEBO, 1581(ab)
F-18 FDG and I-123 oPPA uptake, myocardial infarction, 803(ab)
injection, viable myocardium detection, ischemia, 743(ab)
intravenous adenosine infusion, treadmill exercise, coronary artery disease, 733(ab)
I-131 toluidine-blue scintigraphy and, localization, parathyroid pathology, 790(ab)
low and intermediate grade non-Hodgkin's lymphoma, 793(ab)
myocardial imaging, adenosine-SPECT, 723(ab)
myocardial perfusion defects, stress-induced, reversibility, 1761
myocardial tomography, rotating slant-hole collimator, large number of projections, 1682
normal residual thyroid tissue, differentiated thyroid cancer, 744(ab)
perfusion in infarcted myocardium, successful PTCA, delayed recovery, 763(ab)
predictors of delayed redistribution, early "fixed" defects, exercise SPECT, 764(ab)
Rb-82 PET as replacement, N25A(8)
redistribution at 24 hours, compared to 2 and 4 hours post-injection, 763(ab)
reinjection method, evaluation, myocardial viability, 743(ab)
reinjection *vs.* redistribution, detection of ischemia, myocardial infarction, 743(ab)
rest reinjection, redistribution imaging, 1623
reversibility, computerized quantitative assessment, 874(ab)
scintigraphy
bone sarcoma, 567
childhood neoplasms, 938(ab)
coronary artery disease, parallel distributed processing approach, 825(ab)
differentiation of malignant from benign mass abnormalities, breast, 767(ab)
follow-up, eosinophilic thyroid carcinoma, 767(ab)
I-131 anti-CEA monoclonal antibodies, medullary thyroid carcinoma, 1854
magnetic resonance imaging, thyroid carcinoma, 1958
malignant soft tissue tumors, 889(ab)
myocardial, 1168, 1390
stress-redistribution, ambulatory ECG monitoring, 744(ab)
Tc-99m teboroxime and, vascular territory, 827(ab)
whole-body, occlusive arterial disease in legs, 1443
sensitivity, pentoxifylline effect, peripheral vascular disease, 734(ab)
significance of fill-in after reinjection, delayed imaging, regional wall motion, 1617
simultaneously acquired modified fatty acid, small differences, 834(ab)
SPECT
adenosine infusion and treadmill exercise, CAD detection, 733(ab)
apparent changes, cardiac geometry, 835(ab)
artifactual defects, orbit-related variation, 718(ab)
bull's eye polar map, perfusion defects, 808(ab)
color washout slices, anatomic information, 812(ab)
computer interpretation, neural network analysis, 1582(ab)
detectability, thyroid cancer metastases, 147
detection of recurrent malignant glioma, I-125 brachytherapy, 826(ab)
effect of motion, 934(ab)
false positive, women, 836(ab)
F-18 FDG PET and, brain tumors, 799(ab)
grading of malignant glioma, 826(ab)
inappropriate motion correction, breast attenutation, 1591(ab)
left bundle branch block, 836(ab)
left main and left main equivalent disease, 763(ab)
left ventricular dilatation, adenosine-induced hyperemia, 837(ab)
left ventricular wall motion, myocardial perfusion, 457
mediastinal lymph node metastases, lung cancer, 889(ab)
meta-diagnosis, experienced reader interpretation, 836(ab)
methods and results, brain tumors, 965
myocardial perfusion defects, reversibility bull's eye, 1240
myocardial perfusion defect, severity, 735(ab)
new criteria, prior myocardial infarct, 812(ab)
preoperative, astrocytoma, 825(ab)
prone imaging, myocardial perfusion, 812(ab)
prone imaging, stress-redistribution, 812(ab)
radial long-axis tomography, regional myocardial perfusion, 808(ab)
Rb-82 PET and, myocardial perfusion imaging, 802(ab)
regional myocardial perfusion, Wiener filtering, 1230
reinjection, FDG-PET tissue viability, 742(ab)
reinjection, reversible myocardial ischemia, 743(ab)
silent myocardial ischemia, 812(ab)
stress-redistribution, transient cavity dilatation, 836(ab)
Tc-99m MIBI, myocardial sarcoidosis, 839(ab)
timing of imaging, myocardial stress studies, 813(ab)
tissue characterization, pulmonary lesions, 766(ab)
tolerance of perfusion imaging, patient motion, 841(ab)
stress, back propagation neural network, personal computer, 1590(ab)
Tc-99m isonitriles as replacement, N25A(8)
Tc-99m MIBI and
dual-tracer autoradiography, heart, 832(ab)
low flow ischemia, 713(ab)
Tc-99m or, energy spectral analysis method, parathyroid scintigraphy, 855(ab)
-technetium scintigraphy, parathyroid adenoma, 935(ab)
tomography
comparison, adenosine infusion, 722(ab)
extent of restenosis, multivessel PTCA, 843(ab)
well-differentiated thyroid carcinoma, 744(ab)
Therapeutic nuclear medicine, systemic radioisotopic therapy, primary and metastatic bone cancer, 1326
Thorax, PET imaging, 939(ab)
Three Mile Island, radiation discharges and cancer mortality, no link, N11A(11)
Thrombi
coronary, Tc-99m antifibrin monoclonal antibody, 804(ab)
detection and thrombolysis, immunoscintigraphy, 832(ab)
formation rate, heparin bonded polyurethane angio-catheter, In-111 platelets, 891(ab)

imaging with monoclonal antibodies, 1055
occlusive arterial, *in vivo* visualization, Tc-99m monoclonal antibody against activated platelets, 713(ab)
partially occlusive, Tc-99m monoclonal antibody, activated platelets, 805(ab)
radiolabeled GC4 and T2G1s fibrin-specific monoclonal antibodies, 1048
Tc-99m labeling of fragment E1, 776(ab)
Tc-99m MH-1 monoclonal antibody, rabbit jugular vein, 747(ab)
Tc-99m synthetic peptides, reactive with activated platelets, 757(ab)
Thromboembolism, chronic, pulmonary embolism, 1
Thrombolysis
acute myocardial infarction, evaluation of residual viability, 225
fast labeling of Tc-99m MIBI, microwave oven heating method, 839(ab)
reduction of infarct size, Gd-DTPA enhanced MRI, 717(ab)
Tc-99m MIBI SPECT, myocardial salvage, thrombolytic therapy, 839(ab)
thrombus detection, immunoscintigraphy, 832(ab)
Thrombosis
deep venous, detection, blood pool and blood flow venography, 838(ab)
In-111 tissue plasminogen activator, 805(ab)
venous, immunoscintigraphy, Tc-99m T2G1S antifibrin monoclonal antibody, 782(ab)
Thymus, uptake of Ga-67 citrate, adult *vs.* pediatric patients, 1746(le)
Thyroglobulin
measurement in post-surgical follow-up, I-131 whole-body scans, thyroid carcinoma, 1766
serum, management of thyroid cancer, 1771
Thyroid
carcinoma, *see* Carcinoma, thyroid
metastases, detectability, Tl-201 SPECT, 147
nodules, comparison, Tc-99m and I-123, 393, 400
normal residual tissue, differentiated thyroid cancer, Tl-201 and I-131, 744(ab)
peripheral organ distribution volume, mammillary systems, 1702
visualization of suppressed tissue, Tc-99m TBI, 1163
Thyroid cancer, *see also* Carcinoma, thyroid
differentiated, normal residual tissue, Tl-201 and I-131, 744(ab)
I-131 external exposure rates, 845(ab)
management, serum thyroglobulin, 1771
metastatic, quantitation, radioiodine therapy, 784(ab)
non-hospitalized patients, single doses 50-400 mCi, 784(ab)
Thyroid-stimulating hormone, chemiluminescent label, clinical sensitivity, 714(ab)
Thyrotoxicosis, hyperparathyroidism and, bone scintigraphy, 845(ab)
Tin, technetium complexes, 806(ab)
Titanium, endoprostheses, BMC measurement of femora, dual energy X-ray absorptiometry, 829(ab)
TlCl-201, In-111 myocardial SPECT and, acute myocardial infarction, 783(ab)
TNT-1, intratumor localization of monoclonal antibodies, autoradiography, 1059
Tomography
high resolution ASP, small animals, 769(ab)
limited-angle, 1688
rotating slant-hole collimator, large number of projections, 1675
Tl-201, extent of restenosis, multivessel PTCA, 843(ab)
Tomoscintigraphy, Tc-99m HMPAO, evaluation of vasospasm, subarachnoid hemorrhage, 972
Tracers
kinetic studies
measurement noise in plasma curves, model parameter estimates, 861(ab)
proposal, unified symbols and nomenclature, 860(ab)
Transferrin, -gallium complex, bicarbonate effect on stability, 903(ab)
Transplantation
heart
absence of extraneuronal uptake, mIBG, 792(ab)
clinical utility, radionuclide ventriculography, 1933
risk stratification, In-111 antimyosin scintigraphy, 782(ab)
kidney
cyclosporin, In-111 anti-lymphocyte and anti-MHC monoclonal antibodies, 851(ab)
parenchymal retention, I-131 OIH or Tc-99m MAG3, 716(ab)
short transit times, glomerular filtration rate, 1588(ab)
liver
Tc-99m DISIDA, biliary stenosis early detection, 732(ab)
Tc-99m DISIDA hepatobiliary studies, biopsies, 731(ab)
lung
allograft transplant rejection, Tc-MAA quantitative scintigraphy, 722(ab)
post-operative evaluation, ventilation-perfusion imaging, 721(ab)
pre-operative evaluation, ventilation-perfusion imaging, 721(ab)
mammary tumor, tumor uptake, F-18 progestin, 746(ab)
preoperative liver transplant recipients, determination of liver volume, Tc-99m sulfur colloid SPECT, 874(ab)
renal
blood flow, pediatric patients, 580
intraperitoneal urine leak, radionuclide imaging, 1206
lymphocele, scintigraphic findings, 1627
renovascular disease detection, captopril renography, 716(ab)
scintigraphic findings, lymphoceles, 940(ab)
renal failure, radionuclide first pass study, sulfur colloid, 912(ab)
subperiosteal, fracture site hematoma, fracture healing, 781(ab)
Trauma, role of scintigraphy, 931(ab)
Trifluoperazine, myocardial preservation, low flow ischemia, 796(ab)
Triphenylethylene, estrogens, bromine-77 bromovinyl steroids, distribution, 1534
Triphenyl tetrazolium chloride, compared to In-111 antimyosin images, myocardial infarction, 231
Tritium, release, palmitate uptake assay, heart, 910(ab)
Tropeines, radioiodinated, molecular probe, cocaine receptor, 899(ab)
Tumoral calcinosis, periarticular, hypercalcemia, hemodialysis, 1099
Tumor-associated antigens
TAG-72
colorectal cancer, 1133
reactive monoclonal antibodies, radioimmunotherapy, 765(ab)
TAG-72 and CEA, quantitation and distribution, stomach cancer, 755(ab)
Tumor-localizing agents, current and future use, 1658
Tumors
imaging, bispecific antibody conjugates, radiolabeled tracers, 757(ab)
invasiveness, cathepsin D as marker, 1587(ab)
multicellular spheroids, diffusion and binding, monoclonal antibody TNT-1, 758(ab)
normal tissue and, metabolism of In-111 monoclonal antibody, athymic mouse, 1510
obtaining S values for rectangular-solid tumors, rectangular-solid host organs, 845(ab)
residual or recurrent, differentiation, F-18 FDG PET, 803(ab)
solid
Ga-67 SPECT studies, children, 168
radioimmunotherapy, Re-186 whole mAb and fragment, 724(ab)
visualization, radioiodinated phospholipid ether, 332

U

Ulcer
peptic, C-14 urea breath test, 814(ab)
pedal, osteomyelitis, In-111 leukocytes and bone scans for diabetics, 890(ab)
Ultrasound
duplex, renovascular hypertension, 912(ab)
fracture healing, scintigraphic evaluation, 781(ab)
placental localization in abdominal pregnancy, Tc-99m red blood cells, 1106
Ureteropelvic junction, obstruction, detection by new quantitative method, 761(ab)
Urinary tract, infection, DMSA scan, 893(ab)
Urine
excretion of inhaled Tc-99m DTPA, lung epithelial transport, 441
excretion of Tc-99m protein, patients receiving Tc-99m red blood cells, 896(ab)
intraperitoneal leak, after renal transplant, radionuclide imaging, 1206
Uropathy
obstructive
detection, three-phase diuretic renography, 914(ab)
evaluation, parenchymal transit times, 761(ab)
Utah, application to NRC, additional waste disposal authority, N26A(4)

V

Variocele, scrotal, blood pool scintigraphy, 911(ab)
Vasospasm, evaluation with Tc-99m HMPAO tomoscintigraphy, subarachnoid hemorrhage, 972
Vein
jugular, thrombi imaging, Tc-99m MH-1 monoclonal antibody, 747(ab)
pulmonary, hypertension, I-123 HIPDM lung imaging, 668
superior mesenteric, portosystemic shunting, I-123 IMP duodenal administration, 813(ab)
Venography
blood flow, detection, deep venous thrombosis, 838(ab)
gonadal, blood pool scintigraphy, scrotal varicocele, 911(ab)

Ventilation
artificial, utility, Tc-99m DTPA inhalational scans, 46
perfusion imbalance, pulmonary atresia or extreme tetralogy of Fallot, 1276
perfusion scans and, collagen-vascular disease, 894(ab)
positive end-expiratory pressure, hyperfusion, lower-lobe pneumonia, 124(le)
scans with aerosol, improvement with ethanol, 894(ab)
significance of flip-flop pattern, reversed V/Q mismatch, 895(ab)
single perfusion defect and pulmonary embolism, angiography, 296
Ventilation-perfusion
postatelectatic mismatch, simulation, pulmonary embolus, 1397
post-operative evaluation, lung transplant patients, 722(ab)
pre-operative evaluation, lung transplant patients, 721(ab)
Ventricular function
contractility in acute myocardial infarction, single gamma camera first pass radionuclide angiography, 933(ab)
glucose uptake, chronic hypobaric hypoxia, 1344
left
alterations in global and regional function, acute myocardial infarction, 753(ab)
asynchrony, quantitative assessment, 838(ab)
detection of aneurysm, multiharmonic Fourier analysis, 1303
dilatation during adenosine-induced hyperemia, SPECT thallium imaging, 837(ab)
ejection fraction, harmonic analysis of blood pool scans, 858(ab)
exercise capacity, hypertrophic nonobstructive cardiomyopathy, 753(ab)
function during pacing, activation sequence, 752(ab)
global diastolic filling at rest, coronary artery disease, 753(ab)
hypertrophy, limited myocardial perfusion reserve, 255
myocardial necrosis, In-111 antimyosin, 841(ab)
norepinephrine-induced dysfunction, 1580(ab)
regional wall motion, comparison of expert images, 825(ab)
stress-induced failure, pulmonary Tc-99m MIBI uptake, 1581(ab)
variability, regional ejection fraction, 933(ab)
left dilatation
exercise, dipyridamole thallium scans, 722(ab)
transience, dipyridamole-thallium scintigraphy, 723(ab)
regional myocardial perfusion, gated MIBI perfusion tomograms, 859(ab)
right
continuous scintigraphic bedside monitoring, 1581(ab)
ejection fraction, first-pass curve oscillations, 382(le)
regional perfusion, Tc-99m SESTAMIBI SPECT, 839(ab)
transient coronary occlusion, 843(ab)
systolic and diastolic, transient coronary flow interruption, 754(ab)
Tc-99m SESTAMIBI, perfusion and function at rest, treadmill exercise, 1128
transfer function analysis, right ventricular ejection fraction, 1294
transient dilatation of LV cavity, dipyridamole admninistration, coronary artery disease, 1582(ab)
Ventriculography, Tc-99m MIBI exercise first pass, SPECT myocardial perusion, infarction, 840(ab)
Ventriculography, radionuclide
beta-adrenergic blockade, acute myocardial infarction, 557
cardiac blood-pool imaging, applications, noncoronary heart disease, 10
cardiac functional images, 825(ab)
clinical utility, cardiac transplantation, 1933
gated SPECT, reconstruction, Fourier coefficients, 1856
left ventricular functional parameters, errors in determination, 698(le)
motion abnormalities, automatic quantitative assessment, 824(ab)
post-extrasystolic potentiation, LV pressure data, list-mode, 824(ab)
three-dimensional surface gated, wall motion analysis, coronary angiography, 838(ab)
Vestibular disorders, cerebral perfusion defects, 876(ab)
Virus, radiation discharges and cancer mortality, no link, N11A(11)
Volume, left ventricular, calculation using count-based ratio method, multigated radionuclide angiography, 450

W

Waste, board reports on Yucca Mountain HLRW site, N31A(7)
Water, exchangeable volume and blood flow, breast tumors, PET, 746(ab)
Welch, Michael J., ACS Award for nuclear chemistry, 38A(6)
West Valley, NY, radiation discharges and cancer mortality, no link, N11A(11)
White blood cells
MRI and, chronic osteomyelitis, 711(ab)
Tc-99m HMPAO, detection, acute appendicitis, 1588(ab)
Women
false positive SPECT thallium studies, 836(ab)
osteoporosis and eating disorders, 325
World Federation of Nuclear Medicine and Biology, 5th Congress, N28A(12)
World Health Organization (WHO), IAEA and, promotion of nuclear procedures, developing countries, N27A(11)
Wound healing, In-111 granulocytes, kinetics, antiflammatory and antimicrobial agents, 890(ab)

X

Xenografts
B-cell lymphoma, therapy, I-131 B1 antibody, 765(ab)
colon cancer
γ-interferon, CEA enhancer, 764(ab)
squamous transformation, radioimmunotherapy, 765(ab)
neuroblastoma, MIBG and monoclonal antibody uptake, 741(ab)
pulmonary sarcoma, localization, In-111 monoclonal antibodies, 1378
tumor, biodistribution, I-125 EGF and anti-EGF-R mAb 425, 1587(ab)
Xenon-127, penile blood flow, combined radioisotope plethysmography, 762(ab)
Xenon-133
corporeal clearance, venous leakage, prostaglandin E1, 762(ab)
disturbances in cerebral perfusion, HIV-1 seropositive asymptomatic subjects, 1601
follow-up of regional cerebral blood flow, children from birth to 18 years, 892(ab)
inhaled, bone dynamics, 781(ab)
leg imaging, 939(ab)
muscle blood flow, electrical stimulation, spinal cord injury, 818(ab)
Tc-99m ECD comparison, SPECT, regional cerebral blood flow, 817(ab)
Tc-99m HMPAO and, SPECT, dementia, 730(ab)
washout, penile blood flow, 246(le)
Xenon-127m, applications in nuclear medicine, 489
X-ray, Ga-67 SPECT, residual Hodgkin's disease, mediastinum, 793(ab)

Y

Young Investigator Award, cardiovascular nuclear medicine, criteria, 34A(10)
Yttrium-90
monoclonal antibody labeling, P-NH_2-BZ-DOTA-3A chelate agent, 824(ab)
ORNL stops production and distribution, N18A(5)
radiolabeling of new polymer chelates, 897(ab)
Yttrium-90 anti-CEA antibody, dosimetric considerations, radioimmunotherapy, 788(ab)
Yttrium-90 GKY-DTPA-B72.3 antibody, intraperitoneal radioimmunotherapy, ovarian cancer, 724(ab)
Yttrium-90 monoclonal antibody
adjunctive use of G-CSF, radioimmunotherapy, 904(ab)
intravenous administration, reactive adenocarcinoma, 725(ab)
radioimmunotherapy
granulocyte colony-stimulating factor, 849(ab)
multifocal cancer, 911(ab)
therapy, new macrocyclic bifunctional chelating agent, 473
Yttrium-90 monoclonal antibody antiferritin immunoconjugates, linker-modulated biodistribution, nude mice, 823(ab)
Yucca Mountain, HLRW site, NWTRB report, N31A(7)

Z

ZCE-025 monoclonal antibody, radiation dosimetry of Hybri-CEAker, colorectal carcinoma, 844(ab)